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Abstract 
 
Background:  
Resting heart rate (RHR) is an easily accessible clinical parameter. In spite of the well-
established association between resting heart rate and mortality in men and women, potential 
links between the marker and more specific cardiovascular diseases (CVDs) have not yet been 
explored. No previous research has used clinically collected RHR measurements from primary 
care settings. Normal RHR values have not been firmly established, although this is crucial in 
clinical practice and promotion of personalised health care. 
 
Objectives: 
The main objectives of this PhD are to:  
 Examine the association between RHR and the onset of specific fatal and non-fatal 
cardiovascular diseases  
 Examine the association between RHR and the prognosis of people with coronary 
artery disease (CAD)  
 Investigate the association between RHR and the onset and prognosis of atrial 
fibrillation 
 Describe the establishment of a consented clinical cohort resource of patients with CAD 
(4C)  
 Compare electronic health records (EHR) processes and data with the 4C consented 
clinical cohort 
 
Methods: 
I used CALIBER, a linked electronic health records (EHR) platform that links primary and 
secondary care data, myocardial infarction disease registry and mortality data. Additionally, to 
establish a clinical cohort of people with CAD, I consented, recruited and collected 
anthropometric and biomarker data including RHR from patients attending chest pain clinics 
and angiography labs in London. 
 
Results: 
RHR was associated with myocardial and arrhythmic disorders, but not with coronary disease 
or peripheral arterial disease. An average RHR of >70bpm in the general population was 
associated with increased hazards of specific CVDs and mortality particularly in men and 
should not be considered as normal. Additionally, increased RHR was strongly associated with 
higher risk of cardiovascular outcomes not currently considered as primary endpoints in trials, 
such as heart failure. Finally, higher HR is strongly associated with atrial fibrillation in men, but 
not in women.  
 
Conclusions: 
   4 
 
EHR provides a wealth of primary care data, so far unexplored that give insight into associations 
of heart rate with CVDs in healthy and CAD populations. Average RHR of >70bpm in the 
general male population is associated with increased myocardial and arrhythmic disorders risk, 
but not with coronary disease. Disaggregation of CVDs into its constituent phenotypes 
contributes to our understanding of disease mechanisms with implications for clinical practice 
and interpretation of clinical trials. 
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Overview and aims of this PhD 
 
The aims of this PhD are to determine the association of resting heart rate (RHR) with:  
 
 The onset of specific fatal and non-fatal cardiovascular diseases using a platform of 
linked electronic health records (CALIBER platform) 
 The prognosis of people with coronary artery disease (CAD)  using CALIBER data 
 The onset and prognosis of atrial fibrillation using CALIBER data 
 To describe the establishment of a consented clinical cohort of patients with CAD (4C) 
that records parameters such as quality of life, genetic variants and diagnostic imaging 
 Compare linked electronic health records processes and data with the 4C consented 
clinical cohort 
 
An overview of these objectives and the overall PhD structure is illustrated in Figure 1 at the 
end of this section. Below, a more detailed description of each chapter is presented. 
 
Heart rate mechanisms of action 
Resting heart rate is an easily accessible clinical parameter increasingly recorded by healthy 
people monitoring personal fitness with mobile devices and phone applications. Heart rate 
affects the human system on many levels. It is an indirect metabolic marker and “decides” how 
much energy the body is consuming. It is controlled by the central nervous system (CNS) and 
an increase in heart rate is accompanied by autonomic imbalance (increase of sympathetic and 
a decrease of the parasympathetic activity). HR reduction also plays a pivotal role at the cellular 
level. Experimental studies demonstrate several vascular responses accounting for the 
detrimental effects of accelerated heart rate 1. From vascular risk factors to endothelial function, 
coronary blood flow to atherosclerotic plaque development, plaque rupture, and myocardial 
infarction, heart rate affects several stages of the cardiovascular disease continuum2-4 (Chapter 
1).  
 
Literature findings 
In addition, a significant amount of epidemiological data support the predictive value of resting 
heart rate on several fatal and non-fatal, cardiovascular and no cardiovascular events5. The 
first data on the adverse role of heart rate was reported as early as 1945 by Levy et al. when 
they investigated the association between elevated heart rate and increased  risk of mortality3. 
They found that cardiovascular death was much more frequent among subjects with transient 
tachycardia defined as persistent heart rate over 100 beats per minute (bpm), than it was 
among subjects with a heart rate of less than 100 bpm, however this association was not 
statistically significant. Since then, a large part of the literature devoted on heart rate has 
identified associations between the marker and the experience of cardiovascular diseases. 
These associations were observed in the general healthy population but also in hypertensive 
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patients as well as in patients with clinically evident coronary artery disease. 6-9 The most 
commonly investigated cardiovascular diseases (besides fatal cardiovascular events) 
examined by literature as having affected by increased heart rate are coronary diseases (stable 
angina, myocardial infarction), cardiac diseases such as heart failure, and vascular diseases 
particularly stroke.  
 
Although Cardiovascular Diseases and more specifically coronary disease are not a single 
unified condition but rather a set of different syndromes under which a wide range of 
atherosclerotic and non-atherosclerotic mechanisms might lie, they are collapsed by literature 
and treated as pooled, unified phenomena with a common root. For this indicator, aggregate 
analytical methods and techniques have been proposed and implemented. Furthermore, 
clinical research so far has presented conflicting evidence regarding the types of CVDs that 
heart rate is associated with. To that effect, the mechanistic implications of increased heart rate 
and its underlying processes remain speculative. Furthermore, normal heart rate values have 
not been firmly established and as a result clinical practice underrates the use of heart rate as 
marker of diseases and collects it in non-routine patterns. Additionally, the prognostic value of 
heart rate in patients with stable coronary artery disease has drawn limited attention. A recent 
trial conducted in sCAD population with left ventricular ejection fraction >40% (SIGNIFY) on the 
prognosis of heart rate and future cardiovascular events, altered the so far established belief 
that heart rate is strongly correlated with coronary artery disease, which consequently questions 
the atherosclerotic nature of the underlying mechanism. All available literature has been 
presented in Chapter 2.  
 
To address these issues of the lack of specificity of cardiovascular diseases in current literature, 
this PhD thesis sets out to investigate all the potential associations between heart rate and 
incidence and prognosis of a number of different cardiovascular diseases and cardiac 
endpoints such as different phenotypes of CAD (stable/unstable angina, Myocardial Infarction), 
cerebrovascular diseases (Ischaemic, subarachnoid stroke, Transient Ischaemic Attack), 
Abdominal Aortic Aneurysm, heart failure and mortality from sudden or unheralded death in 
different populations (healthy, sCAD, atrial fibrillation).  
 
Data from CALIBER: A linked electronic health records platform 
To explore the above aims, the linked electronic health records platform CALIBER will be used. 
CALIBER is a platform that links primary and secondary care, disease registry and mortality 
data. Heart rate data for the exploration of my research questions will be provided by primary 
care and this is the first time that heart rate is assessed using general population data from a 
primary care source (Chapter 3). Each association will be individually approached, while major 
attention will be given to identification of effect heterogeneity (i.e. potential differential 
responses of cardiovascular mechanisms to the different levels of heart rate values). This will 
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be of utmost importance since potential heterogeneity in responses to heart rate levels might 
indicate dissimilar underlying mechanisms of action. 
 
Heart rate associations with CVDs in various populations 
One of the aims of this thesis is to identify potential correlations of heart rate with initial 
presentations of different cardiovascular diseases (Chapter 4). Intrinsically, the term “initial 
presentation” refers to the first manifestation of these diseases (first symptomatic presentation), 
hence the analysis will exclusively include population free of any cardiovascular disease, or 
prior manifestation or history. This thesis will attempt to estimate the prognostic ability of heart 
rate on people with established stable coronary artery disease using linked electronic health 
records data (EHR) from the general primary and secondary care in UK and will allow for more 
precise investigations with higher resolution not only among different CVDs but also between 
the two genders (Chapter 5). Another crucial outcome that obtained particular attention by this 
thesis is the rhythm disorder atrial fibrillation. Associations of resting heart rate with the 
incidence and prognosis of atrial fibrillation have been examined in Chapter 6.  
 
In addition to heart rate, a variety of risk factors established or suspected to contribute to 
cardiovascular disease mechanisms will be investigated with an emphasis on markers and 
environmental factors that potentially modify the effect of heart rate on the different 
cardiovascular endpoints, (e.g. smoking).  Moreover, by treating heart rate as a marker with 
distinctive levels and not simply as a continuous factor (i.e. effect varying according to where 
in the heart rate distribution one is), heart rate levels previously considered as “normal” will be 
approached as an independent entity that requires further investigation. Statistical approaches 
that were applied to explore these associations mainly entail Cox proportional hazard models 
and imputation techniques to account for the large missing values proportion. 
 
Establishment of a consented clinical cohort of people with CAD(4C cohort)- Comparison with 
EHR 
 Due to the nature of the linked electronic health records data nature, data on quality of life or 
genetic information was not available. Therefore, to gather this type of information I recruited 
patients to assemble a clinical consented cohort of people with suspected or established 
coronary artery disease and chest pain. More specifically, I approached, consented and 
collected anthropometric measurements, biomarkers and blood samples from patients 
attending the chest pain clinic and angiography lab of Heart hospital in London (Chapter 7). 
Later on, the two different approaches (i.e. using linked electronic health records routinely 
recorded by primary and secondary settings and consented cohort data have been compared 
and contrasted and will be presented in Chapter 8.  
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Figure 1. Flow chart of PhD individual studies examining associations of heart rate with CVDs 
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1. Heart rate measurement, physiology and trials of heart 
rate lowering 
 
The purpose of this chapter is to describe the biomarker heart rate, from its definition, to the 
ways of measurement, normal limits and main mechanisms of effect on a cellular and 
pathophysiological level. Additionally, I will describe the main conditions and medications 
affecting heart rate with a focus on drug trials that aim at lowering heart rate and their 
implications in acute myocardial infarction, stable coronary artery diseased and heart failure 
populations after using beta-blockers, nondihydropyridine calcium antagonists and ivabradine.  
 
1.1. Heart rate definition and normal values 
 
1.1.1. Definition 
 
Heart rate is the number of heartbeats per unit of time, typically expressed as beats per minute 
(bpm). Heart beats nearly 100,000 beats per day, or about 37 million beats per year and 3 
billion in an average lifetime. Heart rate can vary as the body's need to absorb oxygen and 
excrete carbon dioxide changes, such as during physical exercise, sleep or illness. Because 
an individual has a constant blood volume, one of the physiological ways to deliver more oxygen 
to an organ is to increase heart rate to permit blood to pass by the organ more often. According 
to an interesting theory, yet to be proven, living beings are born with a predefined number of 
heart beats. Those with a particularly high heart rate use up their quota of energy more quickly 
and therefore have a lower life expectancy than those with a lower heart rate.10, 11 
 
Heart rate in animals 
Among mammals, it has been observed that the calculated number of heart beats in a lifetime 
is remarkably constant, despite a 40-fold difference in life expectancy. Life and energy available 
are equally important in evolution, and the intrinsic concept can be interpreted as the less 
energy needed, the longer the lifespan. Azbel stressed the concept that smaller animals have 
a higher heart rate and shorter lifespan than do larger animals, with a 35-fold difference in heart 
rate and a 20-fold difference in lifespan, and suggested that life expectancy is predetermined 
by the basic energetics of living cells and that the inverse relationship between longevity and 
heart rate reflects an epiphenomenon in which heart rate is a marker for or a determinant of 
metabolic rate and energetic needs 12. 
 
1.1.2. Sinus rhythm and normal heart rate range 
 
Sinus rhythm-definition and criteria 
Sinus rhythm refers to any cardiac rhythm where depolarisation of the cardiac muscle begins 
at the sinus node13 and is identified by the presence of correctly-oriented P waves on the 
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electrocardiogram (ECG). The term normal sinus rhythm (NSR) is sometimes used to denote 
a specific sinus rhythm where all other measurements on the ECG also fall within designated 
normal limits, giving rise to the characteristic appearance of the ECG when the electrical 
conduction system of the heart is functioning normally.14 The ECG criteria used to define normal 
sinus rhythm are14:  
 
 Normal heart rate (classically 60 to 100 beats per minute for an adult). 
 Regular rhythm, with less than 0.16 second variation in the shortest and longest 
durations between successive P waves. 
 The sinoatrial node should pace the heart – therefore, P waves must be round, all the 
same shape, and present before every QRS complex in a ratio of 1:1. 
 Normal P wave axis (+15 to +75 degrees) 
 Normal PR interval, QRS complex and QT interval. 
 QRS complex positive in leads I, II, aVF and V3-V6, and negative in lead aVR 
 
Abnormal sinus rhythm ranges 
Other types of sinus rhythm include sinus tachycardia, sinus bradycardia.The current definition 
of sinus tachycardia is a heart rate >100 beats per minute (bpm), while sinus bradycardia is 
said to exist in the adult when the sinus node discharges at a rate <60 bpm.15 In epidemiological 
studies in general populations or hypertensive cohorts, no increased risk of mortality was 
generally found for the lower extreme of heart rate. Only in the Chicago Heart Association Study 
were low heart rates (<60 bpm) related to an increase in sudden death.16 However, in that 
study, subjects with bradyarrhythmias at ECG were not excluded, and, thus, the excess in 
mortality could be explained by subjects with bradycardia having important brady-arrhythmias. 
In the elderly subjects of the CASTEL study in which all individuals with brady-arrhythmias at 
standard ECG were excluded, a better prognosis in the subjects with heart rate <64 bpm than 
in those with heart rates between 64 and 80 bpm was found.17 This suggests that there is not 
an increase in risk of mortality for the lower extreme of heart rate, provided the subject has 
been checked for possible sinoatrial dysfunction. 
 
Is there a valid normal heart rate range? 
The fundamental issue before examining the role of heart rate in the general population is to 
establish what we mean by “normal” heart rate values in humans. To begin with, resting heart 
rate (RHR) is defined as the heart rate when a person is awake, in a neutrally temperate 
environment, and has not undergone any recent exertion or stimulation, such as stress or even 
surprise. The heart rate in neonates is 130–140 bpm and falls throughout childhood to reach 
adult levels of 50–75 bpm, which is considered normal at the age of 20.18  
 
Spodick et al19 attempted to redefine the normal limits of heart rate on the basis of the results 
obtained in a population of subjects aged 50 to 80 years. By the addition of 2 SD to the mean 
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heart rate value, Spodick et al. found upper normal limits of 93 bpm  for resting heart rate in the 
men and of 95 bpm in the women, which are above those found to be associated with an 
increased risk of mortality by most investigators.20, 21 Moreover, the Spodick approach implies 
the existence of a normal distribution for heart rate in the general population and identified the 
level of 50 bpm as the lowest normal limit of heart rate, but there is no indication from the 
literature that a heart rate below that limit is really hazardous in the absence of sinoatrial 
dysfunction.  
 
However, the normal range of a clinical variable can be established according to different 
criteria. For parameters such as most biochemical indexes, the standard deviation is calculated 
to identify the upper normal limit of the variable. This statistical approach does not appear 
suitable for clinical variables such as heart rate in which the relationship with the level of risk is 
a continuous one. Heart rate normal range was set arbitrarily when heart rate was not yet 
regarded as a risk factor for cardiovascular disease, probably with the main purpose of 
distinguishing between a disease state (fever, thyrotoxicosis, anemia, congestive heart failure, 
etc.) and a normal state.22  
 
Heart rate variations 
Heart rate is also supposed to continue to decrease with age, especially in the higher age 
groups, although there is a lack of consensus on this assumption. 23, 24Some of the biological 
explanations for this phenomenon is fibrosis of the sinus atrial (SA) node, decreased adrenergic 
sensitivity and responsiveness to autonomic CV reflex. 25 It is widely accepted that resting heart 
rate is higher in women than in age matched men. 26 Of course, heart rate in humans changes 
in response to physiological conditions in order to maintain cardiac output and preserve 
perfusion to the vital organs. Other sources of variability will be described later on. 
Nevertheless, whether or not the aforementioned heart rate ranges are validated as normal and 
what are the acceptable heart rate above which the risk of adverse events increases, remains 
unclear. 
 
Although there is no firm evidence that allow us to establish new normal limits for 
resting heart rate, it seems clear that the traditional 100 bpm value of tachycardia is 
not appropriate to define the threshold below which heart rate can be considered safe. 
The epidemiological studies that I will present in Chapter 2 clearly demonstrate that 
the association between heart rate and the cardiovascular mortality risk occurs for 
levels well below the 100 bpm value, while for specific cardiovascular endpoints this 
threshold has not been yet examined.  
 
1.2. How to measure resting heart rate 
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1.2.1. Guidelines and standards 
 
In view of the lack of evidence related to definition and standardised assessment of heart rate, 
a consensus meeting in Padova, Italy, sponsored by the European Society of Hypertension in 
2005, reviewed and evaluated the available evidence to make recommendations for optimal 
methods of heart rate description. According to this Consensus Panel of the European Society 
of Hypertension, studies reporting heart rate data should also provide information related to a. 
resting period before measurement, b. environmental conditions, c. method of measurement, 
d. number of measurements, e. duration of measurement, f. body position, g. nature of the 
observer 27. All the above parameters will be described in the present chapter. 
 
1.2.2. Heart rate measurement in everyday life 
 
The measurement of heart rate is used by medical professionals to assist in the diagnosis and 
tracking of medical conditions. It is also used by individuals, athletes or people trying to 
measure their fitness levels and are interested in monitoring their heart rate to gain maximum 
efficiency from their training, using various devices such as activity trackers (fitbits), 
smartphones, pedometers, accelerometers, etc. Wearable heart rate monitors for athletes were 
available in 1981.28Wearable fitness tracking devices, including wireless heart rate monitoring 
that integrated with commercial-grade fitness equipment found in gyms, were available in 
consumer-grade electronics by at least the early 2000s. 
 
1.2.3. Preparation for heart rate measurement 
 
Heart rate fluctuates during the day due to activity, stress, caffeine, medications, and other 
factors that might influence it. Heart rate at rest is the lowest that heart rate would go during the 
day. Ideally, one has to measure it when they first wake up in the morning, before any activity.  
In recent years, the international scientific societies have often focused on the methods of 
measurement of blood pressure, while no specific guidelines have been given for the 
assessment of heart rate. Whereas blood pressure is usually measured in the sitting position, 
there is no general agreement on the body position for heart rate measurement in the literature, 
with studies using sitting heart rate, and some other using supine heart rate. Venous pooling of 
the blood in the lower extremities while the patient is sitting decreases the sympatho-inhibition 
exerted by the cardiopulmonary baroreceptors.29 Consequently, a higher heart rate is generally 
recorded in sitting than in supine patients with a 1–2bpm higher heart rate to be expected in 
the sitting posture. A period of 30 s appears to be sufficient to obtain a reliable estimate of heart 
rate because the duration of 30–40 cardiac cycles can be averaged out.  In the majority of the 
studies available in the literature concerning heart rate measured in clinical settings and CVD 
risk, the heart rate was measured after a 5 min rest by the patient.29 A period of rest is necessary 
for stabilization of the hemodynamic parameters. It is suggested that international guidelines 
should also be developed for the measurement of heart rate. This would allow a better between-
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studies comparison and a stratification of the individual risk according to heart rate levels, giving 
a greater practical impact to this clinical parameter. 29 
 
In clinical practice, heart rate is measured using the palpation method, the more precise 
electrocardiogram (ECG) or automated blood pressure devices. 
 
1.2.4. Methods of heart rate measurement 
 
Palpation 
One way for someone to determine heart rate is to manually take their pulse. Heart rate is 
measured by finding the pulse of the body and counting the number of times the heart beats in 
one minute. This pulse rate can be measured at any point on the body where an artery's 
pulsation is transmitted to the surface - often as it is compressed against an underlying structure 
like bone - by pressuring it with the index and middle finger.29 The thumb should not be used 
for measuring another person's heart rate, as its strong pulse may interfere with discriminating 
the site of pulsation. The two most common locations used to take a pulse are at the radial 
artery in the wrist and the carotid artery in the neck. The radial artery is the easiest to use to 
check the heart rate. However, in emergency situations the most reliable arteries to measure 
heart rate are carotid arteries. This is important mainly in patients with atrial fibrillation, in whom 
heart beats are irregular and stroke volume is largely different from one beat to another. In 
those beats following a shorter diastolic interval left ventricle doesn't fill properly, stroke volume 
is lower and pulse wave is not strong enough to be detected by palpation on a distal artery like 
the radial artery.  
 
Automated blood pressure device 
Blood pressure devices (e.g. Omron device) help to monitor blood pressure and identify 
hypertension in everyday life and in clinical practice. It is an accurate technique in monitoring 
not only blood pressure but also heart rate and is able to detect irregular heartbeat. It is 
suggested by their manufacturers to carry out repeated home blood pressure readings 
throughout the day to obtain a representative picture of the blood pressure and heart rate in 
order to allow identification of average daytime measurements. An upper arm monitor is 
supposed to give more accurate readings. The alternative, the wrist monitor, needs more care 
as the cuff around the wrist has to be placed at the level of the heart to give an accurate reading. 
In that case, a computer chip changes the reading because heart rate and blood pressure 
measurements are different at the wrist compared to the upper arm. 
 
ECG-RR interval 
A more precise method of determining pulse involves the use of an electrocardiograph, or ECG 
(also abbreviated EKG). Continuous electrocardiograph monitoring of the heart is routinely 
done in many clinical settings, especially in critical care medicine. On an ECG the heart rate is 
measured using the R wave to R wave interval (RR interval). Additionally pulse oximeters 
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measure heart rate by pulse detection. Heart rate monitors allow measurements to be taken 
continuously and can be used during exercise when manual measurement would be difficult or 
impossible (such as when the hands are being used).29 Various commercial heart rate monitors 
are also available. Some monitors, used during sport, consist of a chest strap with electrodes. 
The signal is transmitted to a wrist receiver for display. In several heart rate studies that will be 
presented in the next chapters of this PhD, the heart rate was measured from a standard 
electrocardiogram. Although this is an accurate method of computing the resting heart rate, it 
might be a further source of between study variability.29 In the Chicago studies, the heart rate 
was higher in member of the Western Electric population, in whom it was measured by pulse, 
than it was in members of the Heart Association or the People Gas Company populations, in 
whom it was calculated from the electrocardiogram.21 However, in the only study which 
compared the two methods, Erikssen et al.30 found the same values (61.2bpm) for heart rates 
measured by cardiac auscultation for 1 min and calculated from the electrocardiogram (as the 
average of nine R–R intervals), and a good correlation between the data provided by the two 
methods (r = 0.89, P < 0.001).29 
 
In this PhD, the assumption that blood pressure was measured using these devices 
will be also applied for heart rate measurements in the sense that heart rate 
measurements taken on the same day as blood pressure measurements, will be 
hypothesized to be recorded using automated blood pressure devices. This hypothesis 
will be also tested in Chapter 3. 
 
1.2.5. Duration of measurements and clinical visits 
 
There is scarce information on the duration of heart rate measurements in the vast majority of 
studies. However, the longer time of measurement, the greater the measurement precision. In 
a large majority of the studies, the reported heart rate values are based on a single 
measurement during one visit. Only a few authors calculated heart rate from more than one 
measurement3, 31, 32 and only two performed more than one visit.3, 31 The heart rate tends to 
decline progressively during a visit33 and this decline is steeper during the second visit.33  
 
In the present PhD, due to the nature of the data that comes from GP practices without reporting 
of the heart rate measurement method, I will not be able to give clear accounts related to the 
precise way that heart rate was recorded, the site of the palpation if this was the method used 
or details on any electronic device e.g. for blood pressure measurement that offered heart rate 
assessment as well. 
 
1.3. Sources of heart rate variation  
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Despite the fact that resting heart rate is an easily measurable cardiovascular parameter, it is 
a highly variable physiologic phenomenon which can be influenced by a large variety of stimuli 
such as physical, psychological, and environmental factors. Methodological issues have often 
been neglected by the investigators even when heart rate was one of the major variables to 
measure.  
 
Nature of the observer and technique 
In most studies, heart rate was measured by a doctor, but in some it was measured by a 
technician34, however the majority did not mention the observer. In some studies automatic 
instrumentation was used.32 It is known that the alarm reaction at the time of measurement may 
vary according to the type of observer. Little or no reaction should be expected when the heart 
rate is measured with an automatic device.29 
 
Ambulatory vs office measurements 
In addition, the reproducibility of heart rate proved to be better for ambulatory than for office 
heart rate.35 These findings suggest that heart rate measured out of the clinic might be a better 
prognostic indicator than traditional measurement in the hospital setting. Unfortunately, little 
data do exist on the clinical significance of heart rate recorded with ambulatory monitoring 
devices or collected at home. In a study performed with continuous electrocardiographic 
recording in a population of elderly participants, the risk of death increased by 14% for each 5 
bpm increase in mean 24-h heart rate.36 However, in that study no comparison with clinic heart 
rate was provided. The same limitation applies to the analysis by Hozawa et al.37 These authors 
found a 17% increase in the risk of mortality for a 5 bpm increase in home heart rate, but, as 
mentioned above, also that study failed to compare the predictive power of out-of-office heart 
rate with that of clinic heart rate.5 A simultaneous analysis of clinic heart rate and out of-office 
heart rate was provided in a subset of 807 participants enrolled in the Syst-Eur study 38. In that 
study, 24-h ambulatory heart rate was recorded intermittently using ambulatory blood pressure 
monitoring devices. The positive relationship between clinic heart rate and the incidence of fatal 
end points found in the main study was confirmed in the ambulatory monitoring subgroup 38. 
However, ambulatory heart rate failed to provide prognostic information over and above clinic 
heart rate.5 On the other hand, in the PAMELA study neither in-office nor out-of-office heart rate 
were significant predictors of cardiovascular or all-cause mortality 39. Overall, available data do 
not show that there is an advantage of heart rate measured out of the office over clinic heart 
rate, but the available evidence is still limited and more research is needed.5 
 
Time of measurement 
Other influences on the heart rate variability reflect the interaction with physiologic factors. With 
regard to these factors, it is known that the heart rate during sleep is substantially lower than 
that during daytime.33 Whether and to what extent the heart rate varies during daytime hours 
remains controversial. With 24 h recordings in ambulant patients, some authors40 found higher 
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heart rate levels during morning hours, whereas others33 reported similar values during the 
morning and the afternoon, but in these studies the heart rate obviously was influenced by 
subjects activities. In 13 normotensive subjects confined to bed Casiglia et al41  found heart 
rates 5 beats/min higher in the afternoon than in the morning. The clinic heart rate was also 
generally found to be higher when measured in the afternoon rather than in the morning30, 42, 
indicating that, to obtain comparable results, heart rates should be measured at the same time 
of the day. 
 
Hereditary parameters 
Heredity also plays a substantial role in the inter-individual variation of resting heart rate, 
accounting for 26–32% of heart rate variation in prior studies. 43, 44 Large twin studies with 
electrocardiogram (ECG) data report even higher heritability estimates up to 55–63%. 45, 46 
Candidate gene approaches have identified multiple loci associated with heart rate 44, 47, 48 but 
the results have been inconsistent and difficult to replicate. Genome-wide genotyping arrays of 
single-nucleotide polymorphisms (SNPs) assay common variation in the human genome and 
can identify genetic variants with modest influences on a complex trait such as heart rate, as 
shown by two recent genome-wide association studies (GWAS) that identified common 
variation at or near MYH6, GJA1 and CD34 associated with heart rate.49, 50 These chromosomal 
loci identified in a genome-wide study may represent novel risk factors for cardiovascular 
disease outcomes. This knowledge may also have an impact on clinical care (i) by identifying 
novel factors that cause pathologic heart rate states (such as sick sinus syndrome or other 
arrhythmias), (ii) by identifying factors that influence cardiac structure or function (e.g. stroke 
volume) and thereby modulate heart rate (since cardiac output = heart rate × stroke volume) or 
(iii) by improving our understanding of the physiologic basis of heart rate regulation. Genetic 
determinants of heart rate could alter the function of the sinus node (the dominant pacemaker 
in the normal heart) either directly through altered pacemaking activity 51or indirectly through 
sympathetic or parasympathetic inputs to the heart. Besides a direct effect on sinus node 
function, effects on cardiac structure, either developmental or through remodeling and function 
could underlie the observed associations.52 
 
In this PhD I was unable to account for some variability sources such as physical 
activity, observer bias, time of the day since no heart rate variability measurements 
recorded by ambulatory devices have been reported in the data, nor specific details 
regarding the time and technicians/clinicians that recorded these data have been 
noted. Genetic variations and heart rate are out of this PhD scope. 
 
1.4. Mechanistic considerations-Higher heart rate effects 
 
1.4.1. Heart rate physiology 
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Initiation of heart rate and products 
Heart rate could be described as a sort of language in which the centre is represented by the 
heart which communicates with the periphery (the body). The heart is in contact with virtually 
every cell of the body through the shear stress of the endothelium. The initiation of the heart 
rate by spontaneous sinoatrial node depolarization is determined by membrane currents, 
particularly the hyperpolarization-activated pacemaker current I(f), and by calcium release from 
the sarcoplasmic reticulum. In this I(f) current which was first described almost 30 years ago53 
“f” stands for “funny” because of the unusual properties of I(f) relative to other systems known 
at the time. Each time the heart beats, it expels around 90 mL of blood into the aorta, which 
creates a kind of shock wave (stress) which is propagated peripherally. Local shear stress (the 
tangential force in the direction of blood flow generated by flow velocity over the vascular 
surface.54) is sensed by endothelial receptors and induces endothelial gene expression and 
has multiple functions such as promotion of dilatation by stimulating constitutive nitric oxide 
(NO) synthase, which produces NO55. This mechanism, not only does the heart contract to 
drive the circulation, but it also sends out signals to keep the arteries open and relaxed, i.e. it 
contributes to the maintenance of vascular tone. If the heart rate increases then so does shear 
stress, along with the production of NO. This in turn produces vasodilatation, allowing more 
blood to reach peripheral tissue, accelerating metabolism and producing a relative increase in 
energy consumption and heat loss. It follows that heart rate is an indirect metabolic marker and 
hence of how much energy the body is consuming.  
 
Heart rate and autonomic system 
The central nervous system (CNS) controls the heart rate by varying impulse traffic in 
sympathetic and parasympathetic nerve fibers terminating in the sinoatrial node 56. Heart rate 
is the result of the intrinsic automaticity of the sinoatrial node and the modulating influence of 
the autonomic nervous system (ANS).57 The ANS is generally conceived to have two major 
branches—the sympathetic system, associated with energy mobilization, and the 
parasympathetic system, associated with vegetative and restorative functions.56 Normally, the 
activity of these branches is in dynamic balance. There is a well-documented circadian rhythm 
such that sympathetic activity is higher during daytime hours and parasympathetic activity 
increases at night. In healthy individuals, average heart rate is greater during the day, when 
energy demands are higher, than at night, when energy demands are lower. Thus, the system 
has a local energy minimum or attractor for daytime and another for night time. Hence, the 
system always tries to minimize the energy requirements of the organism.58  
 
Increase in heart rate is accompanied by autonomic imbalance (increase of sympathetic and a 
decrease of the parasympathetic activity). Empirically, there is a large body of evidence to 
suggest that autonomic imbalance, in which typically, the sympathetic system is hyperactive 
and the parasympathetic system is hypoactive, is associated with various pathological 
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conditions.  Beside other effects stimulation of sympathetic nervous system can cause 
myocardial apoptosis as well as sudden cardiac death 59 58.  
 
Heart rate and energy consumption 
In order to function, heart requires high availability of energy in the form of adenosine 
triphosphate (ATP) - the primary source of energy in the heart that is used for electrical 
excitation, contraction, relaxation, and recovery of the resting electrochemical gradients across 
membranes. It stores only small quantities of ATP, just sufficient to power a few beats60  Heart 
rate might suddenly increase its output up to six-fold, thus requiring a huge amount of energy 
(hence ATP) and the low ATP levels are then counterbalanced by a higher level of creatine 
phosphate. In humans, the heart beats an average of 100,800 times per day, which 
corresponds to approximately 36.8x106 times per year, or 29x108 heart beats in a lifetime 
(average 80 years). The cost of each heart beat is approximately 300 mg of ATP.  
 
Oxygen consumption 
To produce ATP, the myocardium needs oxygen and it has been calculated that the basal 
oxygen consumption/body atom is approximately 10 molecules of oxygen/lifetime, which, 
referred to HR, corresponds to 10-8 molecules of oxygen per heart beat.61 Hence, heart rate is 
among the factors that have important effect on myocardial oxygen consumption. It is the most 
easily measured of the variables and clearly has the most direct relationship to the rate of 
myocardial energy use.12 It has been suggested that lowering heart rate may favorably increase 
the ischemic threshold and improve cardiac performance and this is of high significance, as a 
number of cardiovascular drugs alter heart rate as I will present in the following sections.62 
During each cardiac cycle the energy or work performed is converted into heat during relaxation 
of the heart. With increased heart rate more energy is wasted to perform internal work when 
more contractions are performed per unit time 63 64. These effects count tremendously more in 
the failing heart. The work is much decreased, whereas much more internal energy is generated 
which consecutively decreases efficiency. Therefore, when heart disease is present, in 
particular heart failure, heart rate becomes an important marker for inefficient myocardial 
oxygen consumption. These findings support the concept that lower energy consumption 
prolongs life. According to detailed calculations a heart rate reduction of 10 bpm can save about 
5 kg of ATP per lifetime in humans. 65 Even though the above are crudely estimated, they point 
to the pivotal role of HR reduction at the cellular level.66 
 
1.4.2. Heart rate and pathology 
 
Oxygen delivery to the heart mainly occurs during diastole, and the fraction of the cardiac cycle 
occupied by diastole increases as HR decreases. Therefore, HR reduction improves diastolic 
perfusion time and myocardial perfusion. Any increase in HR could be deleterious, as it further 
reduces diastolic perfusion, increases stealing from the ischaemic zone, and impairs the flow 
at the ischaemic obstruction, which further compromises coronary flow, hence reduction in HR 
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under these circumstances is highly beneficial. Increasing HR by atrial pacing in patients with 
CAD produces coronary constriction, further impairs oxygen supply.67 In patients with stable 
CAD, most episodes of ambulatory or exercise-induced myocardial ischaemia are preceded by 
an increase in HR.68 Some epidemiologic studies have argued that he likelihood of developing 
ischemia is related to the baseline HR.69 The frequency of ischaemic episodes in patients with 
CAD is related to their mean HR, in particular, patients with HR >80 bpm experience ischaemia 
almost twice as often as those with HR <70 bpm.70 The main suggested pathological 
mechanisms are summarized in Figure 1.1. 
 
Plaque disruption 
Increased HR and haemodynamic forces may play a role in plaque disruption. Plaque rupture 
has been suggested as the main pathophysiological mechanism underlying acute coronary 
syndromes and the progression of coronary atherosclerosis71 and in particular it was shown 
that elevated heart rate is associated with coronary plaque disruption in ACS patients.72 The 
role of haemodynamic forces, i.e. HR, has been investigated in 106 patients who underwent 
two coronary angiographic procedures within 6 months.73 This study identified positive 
associations between plaque rupture, left ventricular muscle mass >270 g, and a mean HR >80 
bpm, and a negative association with HR-reducing medication.  
 
Tensile stress 
Elevated tensile stress (described above) is thought to induce direct endothelial injury and to 
increase endothelial permeability to LDL and to circulating inflammatory mediators. Very high 
HR (>120 bpm) by reducing the diastolic phase reduces the stroke volume and the cardiac 
output. Tachycardia (close to 100 bpm) increases the tensile stress and may promote 
endothelial injury and wall stiffness. In chapter 5, the effect of different levels of heart rate on 
adverse cardiovascular events in people with coronary artery disease will be thoroughly 
investigated. 
 
1.4.2.1. Experimental evidence 
 
Overall, there are several theories about what causes elevated heart rate and why high heart 
rate is associated with adverse events. As I mentioned above, heart rate may be a reflection of 
autonomic nervous system abnormalities74. It has also been suggested that heart rate plays a 
more direct role in the pathogenesis of certain disease states and progression of 
atherosclerosis.  
 
Animal studies 
More direct evidence of the importance of heart rate on the progression of coronary 
atherosclerosis comes from animal studies.  In primates with similar blood pressure, serum lipid 
levels, and body weight profiles, atherosclerotic lesions in the group with low heart rates were 
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approximately one third the size of the lesions found in the group with high heart rates. 75Beere 
et al 75 investigated the role of HR reduction in monkeys fed with an atherogenic high cholesterol 
diet for 6 months. These animals underwent sinus node ablation and compared with eight 
animals which had the same operation without sinus node ablation. The average lesion area in 
the low heart rate subgroup was one third that of the high heart rate subgroup, while the 
coronary arterial plaque area was found, on average, to be more than twice as large in monkeys 
with naturally high heart rates (mean 159 bpm) than in those with slower heart rates (mean 133 
bpm). Kaplan et al.76 have shown that monkeys with habitual high resting heart rate have twice 
as extensive lesions in the coronary arteries as animals with low resting heart rate. In a more 
recent study Kaplan et al. observed an attenuated progression of atherosclerosis through heart 
rate reduction by propranolol in primates. Heart rate was an important predictor of the size of 
coronary artery lesions in saturated- fat-fed monkeys with high resting heart rates versus those 
with low resting heart rates77. Moreover, decreasing the heart rate with propranolol in primates 
was associated with reduction in the progression of atherosclerosis, independent of total or 
high-density lipoprotein cholesterol concentration77. Further evidence for the link between heart 
rate and atherosclerosis has come from the measurement of changes in endothelial function 
and markers of inflammation. Increasing heart rate by 10% by electrical pacing in hypertensive 
rats significantly enhanced cardiac oxidative stress and activated pathways implicated in 
cardiac hypertrophy and cardiac remodeling, without any increase in blood pressure.78 Guth et 
al.22 evaluated the beneficial effect of intravenous atenolol on exercise-induced regional 
myocardial ischaemia and contractile dysfunction in dogs with single-vessel coronary stenosis. 
The regional dysfunction was reduced with atenolol but the improvement was prevented when 
HR was kept constant with atrial pacing. Evidence from heart rate reduction with ivabradine, a 
heart rate lowering medication that I will describe in the following sections, reduced oxidative 
stress, improved endothelial function, and prevented atherosclerosis in apolipoprotein E-
deficient mice.79 All the above evidence in animals, show towards the fact that HR reduction 
may play an important role in cardiovascular diseases. 
 
Studies in humans 
Experimental data have demonstrated that elevated heart rate has a role in the development 
of atherosclerosis and plaque disruption coronary artery endothelial dysfunction in experimental 
studies.80, 81 It has been also speculated that heart-rate-induced alterations in the velocity and 
direction of blood flow may be a contributing factor in the pathogenesis of coronary artery 
atherosclerosis. A relatively high heart rate may indicate increased sympathetic activity, 
reduced vagal activity, or both. In experimental studies 82, 83 these factors have been shown to 
lower the threshold for ventricular fibrillation. In the presence of acute myocardial ischemia, a 
high heart rate produces a greater and more prolonged decrease in the ventricular fibrillation 
threshold84. High heart rate may also exert a negative effect on cardiac performance by 
increasing myocardial oxygen demand85 as we previously described. In an epidemiological 
study, increased heart rate in patients with restricted coronary blood flow causes an increase 
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in myocardial ischemia and complications including pain, larger infarction, and arrhythmias83. 
An increase in myocardial oxygen demand may potentiate ischemia at a given level of coronary 
atherosclerosis85. Heart rate and double product (heart rate multiplied by systolic blood 
pressure) correlate well with myocardial oxygen consumption during exercise in patients with 
angina pectoris, while reduction of myocardial oxygen consumption raises the threshold for 
myocardial ischemia at a fixed level of coronary blood supply. 62 
 
In summary, it has been experimentally suggested that high heart rate is of importance 
in the development and progression of atherosclerosis, myocardial ischemia, acute 
ischemic events, and sudden cardiac death, and that a reduction in heart rate has 
beneficial effects.86 However, these suggestions have been largely derived by animal 
research and not by general, large scale population-based epidemiological studies. 
The present PhD will seek to explore associations of heart rate with coronary artery 
diseases and subsequent atherosclerotic events. 
 
1.5. Factors affecting heart rate 
 
1.5.1.  Cardiac conditions affecting heart rate 
 
This subchapter will present the most common cardiac conditions that affect the resting heart 
rate. Among the main conditions affecting heart rate are atrial fibrillation, thyroid diseases and 
anxiety. Abnormal heart rhythms (arrhythmias) are caused by problems with the electrical 
system that regulates the steady heartbeat and the heart rate can then be too slow or too fast. 
Finally structural disorders of the heart muscle such as cardiomyopathy and congenital 
abnormalities can damage the heart muscle or valves and influence the heart rate. The 
proportion of patients with structural or valve disorders in the CALIBER cohorts analyzed was 
small, hence they were not excluded from the final population.  
 
 
 
 
 
 
 
 
 
Figure 1.1. Potential mechanisms between higher heart rate and cardiovascular diseases (adaptation from Fox et al.87) 
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Some of the conditions that cause rhythm disorders are: 
 
i. Atrial fibrillation 
In atrial fibrillation, the heartbeat is irregular and rapid due to disorganized signals from the 
heart’s electrical system. The atrium may beat as often as 300 times a minute, about four times 
faster than normal and has been linked with several adverse cardiovascular and 
cerebrovascular events. In large rate versus rhythm control trials in patients with atrial 
fibrillation, heart rate reduction tended toward improved survival when compared with a rhythm 
control strategy.88 Atrial fibrillation is a pathological cardiac arrhythmia, and the optimal degree 
of heart rate reduction required for its treatment is unknown. 89  
 
ii. Ventricular fibrillation 
In ventricular fibrillation, the heartbeat is fast causing the ventricles to spasm and heart rate is 
unable to pump the blood out of heart. Sometimes, a blockage of the heart arteries can lead to 
this type of arrhythmia and often leads to sudden cardiac arrest.  
 
iii. Long QT Syndrome  
This syndrome is a disorder of the electrical system, commonly genetically transmitted. People 
with long QT syndrome are at increased risk for ventricular fibrillation.  
 
iv. Heart block 
Increased 
Heart Rate
↑ pulsatile 
shear stress
endothelial 
dysfunction
development of 
atherosclerosis ↑ myocardial O2 
requirement
↓ diastolic 
duration
↓ coronary 
perfusion time 
imbalance of 
oxygen supply 
& demand
plaque rupture
↑ myocardial 
ischemia / 
infarction
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One of the disorders that decrease heart rate is heart block that happens when electrical 
signals from atria cannot travel to the ventricles. The heart then beats too slowly, decreasing 
the amount of oxygen that gets to the body and brain.  
 
v. Sinus node disease 
Sick sinus syndrome is not a disease, but a group of signs or symptoms that show the heart’s 
natural electrical pacemaker, the sinus node, is not working properly. In this syndrome, the 
heart rate can alternate between slow (bradycardia) and fast (tachycardia). Severe sinus 
bradycardia may be a feature of sinus node disease, and in turn related to underlying 
cardiovascular disease and ageing.  
 
vi. Heart Valve disorders 
Finally, congenital diseases of the heart such as heart valve disorders affect the heart rate 
causing usually an increase of rhythm.  
 
Associations of atrial fibrillation with heart rate and future cardiovascular events in healthy or 
CAD people have been also under-examined. This PhD will seek to examine these potential 
associations. 
 
Experimental studies in lowering heart rate and arrhythmia events 
Experimental studies suggest that heart rate modulation can reduce the risk of life-threatening 
arrhythmias during ischemic episodes; the beneficial effect of beta-blockade in this context may 
be mediated primarily by heart rate reduction.90 Improvement of survival after reduction of  heart 
rate has been shown in atrial fibrillation patients in the post-myocardial infarction or heart failure 
setting with some beta-blockers such as carvedilol.91 More studies on heart rate lowering 
medication and its effect will be shortly presented in the next subsection. 
 
1.5.2. Non-cardiac conditions affecting heart rate 
 
Among the non-cardiac conditions that can result in heart rate changes is hypertension. 
Individuals with hypertensive disease, usually have higher values of heart rate than healthy 
controls. Furthermore, when the body’s immune system becomes compromised for example, 
with injury, anemia, or infection, changes in heart rate although usually temporary, can occur. 
Particularly if septic shock sets in, the heart rate naturally gets more rapid to meet oxygen 
demands. In stressful situations such as panic episodes or generalized anxiety disorder, the 
body naturally responds with a faster pulse. The same applies for fear, another type of anxiety, 
which prompts the flight response and releases hormones that make the heart pump faster. 
Fever or a sudden increase in temperature also affects heart rate and quicken the pulse. In 
dehydration situations the heart naturally works harder to maintain the normal cardiac output 
and hence the heart rate increases. 
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Thyroid diseases 
One of the differences between patients with hyperthyroidism and hypothyroidism is in the 
pulse-rate.  
Experimental observations in the 1960s’s suggest that this was a result from a direct effect of 
circulating thyroxine on the heart and not, as has been generally accepted, from an increase in 
sympathetic stimulation of the heart arising from potentiation of the cardiac actions of 
catecholamines by excess thyroxine.92 Other thyroid disorders such as Hashimoto’s disease 
also called chronic lymphocytic thyroiditis, is a form of chronic inflammation of the thyroid gland. 
These types of thyroid disorders decrease heart rate.93  
 
Inflammatory syndromes 
Systemic inflammatory response syndrome (SIRS) is an inflammatory syndrome that among 
its criteria for diagnosis established in 1992 as part of the American College of Chest 
Physicians/Society of Critical Care Medicine Consensus Conference 94 is heart rate greater 
than 90 bpm. Other autoimmune diseases such as rheumatoid arthritis or infiltrative diseases 
such as amyloidosis might lead to a decrease of heart rate.  
 
Stress 
It has been also suggested that psychosocial stress associated with an increase in heart rate 
can trigger the onset of acute myocardial infarction, in addition to sudden cardiac death. This 
has been documented in the literature, and one example of an increase in attacks of sudden 
death occurred during the San Francisco earthquake in 1994.95 During the earthquake, there 
was a seven-fold increase in the risk of sudden cardiac death reported by hospitals in the 
region. Elevated heart rate during mental stress may play a key role in the development of 
sudden cardiac death. It is well known that the incidence of sudden cardiac death among 
patients with hypertension, myocardial infarction, or congestive heart failure is reduced by beta-
blockers96. These observations are supported by results from the Betablocker Cholesterol 
lowering Asymptomatic Plaque Study (BCAPS), a randomized trial that showed that 
administration of a beta-blocker reduces the rate of progression of carotid artery intima 
thickness in asymptomatic subjects97.  
 
1.5.3. Other factors affecting heart rate 
 
Although it has been established that the maximal heart rate declines with age,98 whether the 
resting heart rate increases or declines with advancing age remains controversial. The majority 
of studies30 reported a slight decrease in heart rate with increasing age. Surprisingly, among 
multivariate analyses that removed all confounders, the decrease was the same (0.13 
beats/year) in the study by Erikssen et al 30 in the Harvest study and in the Belgian population 
study. Some studies21  found little or no change in heart rate related to age, whereas in one 
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study85 a positive association was reported. Overall, these data indicate that age affects heart 
rate only to a slight extent.29 A large body of evidence shows that the heart rate is higher in 
women than it is in men. This sex-related difference has been found both in economically 
advanced countries and in undeveloped countries.29 According to the results of the 
Framingham study 85, the difference increases with advancing age, which was not observed in 
other studies29, 34. 
 
Other factors have also been found associated with heart rate. Smoking was correlated 
positively to heart rate in the Chicago studies 16 and the Paris Prospective study 23, but in other 
studies it was unrelated to (the Harvest study and the Belgian population study), or even 
correlated negatively to heart rate (the Tecumseh study and the Mirano study). Slight negative 
correlations were found between heart rate and alcohol consumption (in the Tecumseh, Harvest 
and Mirano studies) or coffee consumption (in the Tecumseh and  Mirano studies), but they 
disappeared in multivariate analyses. A close inverse correlation between physical fitness and 
heart rate has long been recognized, and was demonstrated by experimental and epidemiologic 
studies99, 100 at any age in both sexes. In Section 1.4 I will also present conditions and 
medications linked with heart rate and result to an increase or decrease of the marker. 
 
1.6. Trials of drugs affecting heart rate and impact on CVD outcomes 
 
As discussed before, myocardial ischemia results from an imbalance between myocardial 
perfusion and myocardial oxygen demand. Most episodes of myocardial ischemia, whether 
induced by exertion or detected during ambulatory monitoring, usually are found to be preceded 
by an increase in heart rate.101, 102 Lowering heart rate, is a well-established strategy for 
management of stable angina pectoris.103 The most common medications affecting heart rate 
are presented in Table 1.4. Two widely used types of antianginal drugs (b-blockers and non-
dihydropyridine calcium channel blockers) have heart rate–lowering action104; much of the anti-
ischemic benefit of b-blockade has been related to heart rate lowering.22 
 
1.6.1. Beta-blockers and Nondihydropyridine calcium antagonists 
 
It is well known that the incidence of sudden cardiac death among patients with myocardial 
infarction, stable coronary artery disease or congestive heart failure is reduced by beta-
blockers,96 extensively known for their heart rate lowering effects. These observations are 
supported by results from the Betablocker Cholesterol lowering Asymptomatic Plaque Study 
(BCAPS), a randomized trial that showed that administration of a beta-blocker reduces the rate 
of progression of carotid artery intima thickness in asymptomatic subjects.97 Further evidence 
from clinical trials are presented below: 
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Table 1.4. Medications affecting heart rate 
Drugs that increase heart rate   Drugs that decrease heart 
rate 
Drug Category   
Sympathomimetics (BNF: 2.7)  Sympatholytic drugs 
Inotropic sympathomimetics (BNF: 2.7.1)  Beta-adrenoceptor blocking 
drugs (BNF: 2.4) 
Vasoconstrictor Sympathomimetics (BNF: 2.7.2)  Vasodilators 
Bronchodilators  Calcium Channel Blockers 
(BNF: 2.6.2) 
Adrenoceptor Agonists (BNF: 3.1.1)  Long-acting nitrates (BNF: 
2.6.1) 
Antimuscarinic Bronchodilators (BNF: 3.1.2)  Cardiac Glycosides (BNF: 2.1. 
(Positive Inotropic Drugs)) 
Theophylline (BNF: 3.1.3)  Anti-Migraine drugs (BNF: 
4.7.4) 
Thyroid Hormone Replacement (BNF: 6.2)  Antiarrhythmics (BNF: 2.3.2) 
Antidepressant drugs (BNF: 4.3)  Others 
Tricyclic and related antidepressant drugs (BNF: 
4.3.1) 
 Ivabradine (BNF: 2.6.3 (Other 
anti-anginal drugs)) 
Selective serotonin re-uptake inhibitors (BNF: 4.3.3)   
Stimulants- Illicit Drugs (BNF: 4.4 (CNS 
Stimulants)) 
  
 
 
Evidence from trials on post MI patients 
 
 Beta-blockers 
The majority of the information available on the effect of β-blockers on heart rate and mortality 
outcomes is obtained from old trials evidence on post myocardial infarction patients. A meta-
analysis of 29 trials in which patients were assigned to early treatment with β-blockers revealed 
a 13% reduction in overall mortality.105 The reduction in heart rate obtained with β-blockers 
ranged from 10.5% to 22.8%, and a benefit was obtained only if the heart rate was reduced by 
14 bpm or more.106 For a heart rate reduction of less than 8 bpm, no benefit at all could be 
achieved. In addition, this meta-analysis showed that if patients' heart rate was <55 bpm, only 
little effect was shown by beta-blocking therapy.106 Data from 26 large trials in post myocardial 
infarction patients followed for long periods who received beta-blocker therapy on 5 through 28 
days after the infarction showed a 23% mortality reduction among treated patients.105 In 
particular, β-blockers proved effective in reducing sudden death and death due to pump 
failure.105, 107, 108 Again, benefit from therapy in terms of both reinfarction and all-cause mortality 
was proportional to heart rate reduction.106  
   38 
 
 
 Nondihydropyridine calcium antagonists 
The way in which a drug slows the heart rate may be important in determining the outcome of 
heart rate slowing. If the disappointing effects of β-blockers in hypertension are due to their 
unfavorable effects on the lipid profile, the use of drugs that reduce blood pressure and heart 
rate without altering plasma lipids should provide better results in hypertensive patients with 
high heart rate. This could be obtained with nondihydropyridine calcium antagonists, which 
have shown to be neutral on the metabolic profile.124,125 Phenylalkylamines for example, such 
as verapamil have a central action that decreases the sympathetic outflow and reduce heart 
rate.128 Consequently, nondihydropyridine calcium antagonists reduced the risk of cardiac 
events and the death rate in post MI patients, but only in patients with no signs of heart 
failure.109, 110A meta-analysis of trials stratified according to whether calcium antagonists 
increased or decreased heart rate showed that for dihydropyridine calcium antagonists, there 
was a trend toward increased mortality, whereas for verapamil and diltiazem, the trend was 
toward a small decrease in mortality.111 The Multicenter Diltiazem Postinfarction Trial and the 
Danish Verapamil Infarction Trial II showed a reduction in the combined end point of death or 
reinfarction in patients without clinical signs of congestive heart failure.109, 110 Finally, a recent 
meta-regression analysis performed by Cucherat112 to determine the extent to which heart rate 
reduction induced by the various beta-blockers and Nondihydropyridine channel blockers 
modifying heart rate affects the reduction of mortality and morbidity observed in randomized 
placebo-controlled trials in patients with myocardial infarction.106 A significant relationship was 
found between resting heart rate reduction and the clinical benefit caused by these drugs, 
including reduction in cardiac death, all-cause mortality, sudden death and nonfatal MI 
recurrence. A 30% reduction in the relative risk of cardiac death was observed for each 10 bpm 
reduction in the heart rate.  
 
The findings of these trials confirm that the beneficial effect of beta-blockers and calcium 
channel blockers in post MI patients is proportionally related to the reduction of resting heart 
rate.  
 
Evidence from trials on CAD patients 
In patients with stable coronary artery disease, it has been shown that reduction of angina and 
of the underlying ischemia determined by heart rate–lowering drugs is related to reduction of 
heart rate.113, 114In the ASIS study, propranolol caused a greater reduction of heart rate than 
diltiazem and was more effective in relieving both symptomatic and asymptomatic ischemic 
episodes.115 Beta-blockers and nondihydropyridine calcium antagonists however, might have 
negative effects especially presented in patients with left ventricular dysfunction (heart failure). 
Therefore, a pure heart rate lowering drug, ivabradine, has been developed and will be 
described later on in this section. 
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Trials on heart failure patients 
Beta-blockers, have been shown to be effective also in patients with congestive heart failure.116, 
117 Pooled results from carvedilol trials in subjects with congestive heart failure reported a 
marked reduction in mortality with the use of this β-blocker.118 Mortality reduction was higher in 
patients with a high heart rate. The mechanism by which β-blockers improve left ventricular 
function is still uncertain. Several mechanisms have been proposed including improved cardiac 
myocyte metabolism and reduction in apoptosis, a reduction in heart rate, a reduction in atrial 
and ventricular arrhythmias, or a reduction in myocardial ischemia and/or hibernation.119 The 
Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Failure demonstrated similar 
heart rate reductions at doses of extended-release metoprolol above and below the median.120 
Importantly, similar relative risk reductions in all-cause mortality were observed in that study 
between patients receiving high and low doses, supporting the concept that it is heart rate 
reduction that may be more important than absolute dose in maximizing clinical benefit.106 
Finally, an analysis of the CIBIS II trial showed that both low baseline heart rate and a marked 
heart rate reduction caused by β-blocker administration were significantly associated with a 
better prognosis in patients with heart failure.121 The hypothesis that heart rate reduction was 
the main mechanism by which β-blockers improve outcome in congestive heart failure was 
tested in a randomized, double-blind, parallel group study comparing chronic higher-rate (80 
bpm) with lower-rate (60 bpm) pacing in pacemaker-dependent patients with symptomatic left 
ventricular systolic dysfunction receiving β-blockers. 73 Mean left ventricular end-diastolic (P = 
.03) and systolic (P =.006) volumes increased with higher-rate vs lower-rate pacing, whereas 
left ventricular ejection fraction declined with the former compared to the latter. These findings 
suggest that heart rate reduction is the main mechanism of beta-blockers’ effect in patients with 
congestive heart failure.106 
 
Prescribed beta-blocker medication has been considered in my analyses of heart rate 
associations with CVDs in healthy, CAD and atrial fibrillation populations, as a potential 
confounding factor and in sensitivity analyses restricted to people who did not had 
prescribed beta-blockers. 
 
1.6.2. Ivabradine 
 
So far I described the most common medications that have an effect on heart rate and are quite 
commonly prescribed in clinical practice. However, lowering agents may have multiple other 
actions on the heart and on other organs and tissues.103 Some of these may cause undesirable 
adverse effects in some patients, for instance beta-blockers and non-dihydropyridine calcium 
channel blockers have negative inotropic effects, can, affect intracardiac conduction, and may 
cause hypotension.103, 104 
 
Mechanisms of action 
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Ivabradine, is the first specific heart rate lowering agent and acts by inhibiting If, an ionic current 
involved in pacemaking activity in the sinoatrial node. If contributes a depolarizing current that 
drives spontaneous diastolic depolarization to trigger a subsequent action potential, and 
modulation of If is important in physiological regulation of heart rate. 122 Ivabradine has no 
appreciable action at other receptors or channels in the cardiovascular system. The heart-rate-
lowering action of ivabradine has been compared directly with β-blockers in experimental 
studies in healthy animals and in models of CAD and heart failure. Ivabradine reduces 
myocardial oxygen demand and simultaneously improves oxygen supply, by prolonging 
diastole and thus allowing increased coronary flow and myocardial perfusion.123 As beta-
blockers additionally reduce myocardial contractility, it might be predicted that β-blocking 
treatment would reduce myocardial oxygen demand more than ivabradine.106 However, it has 
been experimentally shown (in animals) that for all parameters of regional myocardial ischemia 
measured, the effect of ivabradine was as great or greater than that of propranolol.124  
 
Overall, compared with β-blockade, ivabradine produces a form of heart rate lowering that more 
closely resembles the physiological situation and that does not perturb a series of mechanisms 
involved in ensuring efficient myocardial performance at different beating rates. However, it 
should be emphasized that β-blockade has effects other than heart rate reduction, which might 
be beneficial in some clinical situations. For example, elevated heart rate can reflect a 
generalized increase in sympathetic tone, which can induce adverse effects unrelated to heart 
rate. In this case, heart rate lowering with ivabradine is unlikely to produce the full range of 
benefits potentially achievable with β-blockade. On the other hand, ivabradine can be 
appropriate in some patients with contraindications to β-blockers resulting from such additional 
effects.  
 
Evidence from trials in people with CAD 
The evidence available on associations of heart rate reduction with ivabradine and 
cardiovascular diseases have been exclusively provided by trials on coronary artery diseased 
populations. The most important and up-to date findings on ivabradine in a CAD population with 
heart failure (left ventricular ejection fraction <40% have been showed by a large clinical trial 
(BEAUTIFUL trial).125 The BEAUTIFUL study 125 randomized 10,917 patients with coronary 
disease and left ventricular dysfunction to receive ivabradine or a placebo, to test whether 
reducing the heart rate would reduce cardiovascular mortality and morbidity. A subgroup of 
patients with a heart rate >70 bpm was shown to have a 46% increased risk of MI and 38% 
increased risk of coronary revascularization. Further analysis showed that for every 5 bpm 
increase in heart rate, there were increases in cardiovascular death (8%, P=0.0005), admission 
to hospital with heart failure (16%), admission to hospital with MI (7%), and coronary 
revascularization (8%).These findings suggest that addition of ivabradine to standard treatment 
including β-blockers can improve outcome in CAD patients with heart failure. The effects of 
ivabradine were analysed in a subgroup of patients with a heart rate of >70bpm. Ivabradine 
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treatment did not affect the primary composite outcome, cardiovascular death, or admission to 
hospital for new-onset or worsening heart failure, but reduced secondary end points: admission 
to hospital for fatal and nonfatal myocardial infarction and coronary revascularization. All the 
available clinical trials using ivabradine and examining associations of heart rate reduction with 
cardiovascular diseases are presented in Table 1.5. Ivabradine was not available in CALIBER 
dataset, hence it has not been used in the analytic process. 
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Table 1.5 Trials examining associations of ivabradine and other heart rate lowering medications with CVD prognosis in people with sCAD 
Author/year 
n
u
m
b
e
r 
o
f 
p
a
ti
e
n
ts
 
Trial arms 
Population 
Duration of 
follow-up 
P
ri
m
a
ry
 e
n
d
p
o
in
t 
Main results 
In
te
rv
e
n
ti
o
n
 
C
o
n
tr
o
ls
 
The International 
Collaborative Study 
Group 1984108 
144 Intravenous timolol Placebo MI - Infarct size 
The timolol group had 
reduced infarct size 
The Multicentre 
Diltiazem Postinfarction 
Trial Research Group 
1988110 
2466 Diltiazem Placebo Past MI 25 months Mortality, reinfarction 
The Diltiazem group had 11% 
reduction in cardiac death or 
nonfatal reinfarction, but no 
difference in overall mortality.  
Stone 1990115 50 
Propranolol, or 
diltiazem, or 
nifedipine 
Placebo  
Stable angina and a 
high frequency of 
asymptomatic ischemic 
episodes 
1.5 months Ischaemia episodes 
The propranolol group had 
fewer ischemia episodes . 
Danish Study Group 
1990109 
1775 Verapamil Placebo MI without heart failure 18 months 
Death, composite of 
death or reinfarction 
The verapamil group had 
4.1% lower mortality and 
5.1% lower composite rate 
Packer 1996118 1094 Carvedilol Placebo Chronic heart failure 6 months 
Death or hospitalization 
for cardiovascular 
reasons 
The carvedilol group 
had27%reduction in risk of 
hospitalization for 
cardiovascular causes and a 
38% reduction in the 
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hospitalization/ death 
composite 
Van Der Vring 1999114 335 
3 arms: Mibefradil, 
Diltiazem or 
amlodipine 
Placebo or 
one of the 
other arms 
Stable angina with 
myocardial ischaemia 
produced at ETT under 
b-blocker medication 
14 days 
Duration of exercise, 
onset of ischaemia, time 
to onset of angina, time 
to onset of ischaemia 
The mibefradil group had the 
largest anti-ischaemic effect 
and improved time to 
ischaemia by 29.8s than 
amlodipine. No difference 
between diltiazem and 
amlodipine. Further reduction 
of heart rate was associated 
with better anti-ischaemic 
effects 
Lechat 2001121 2539 Bisoprolol  Placebo  Chronic heart failure 2 months 
Mortality and 
hospitalization for heart 
failure 
The bisoprolol group had 
reduced mortality in patients 
with sinus rhythm (RR= 0.58) 
but not in patients with atrial 
fibrillation (RR=1.16). 
Reductions were also 
observed for cardiovascular 
mortality and hospitalization 
for heart failure. 
Wikstrand 2002120 3991 -Metoprolol CR/XL Placebo Heart failure 3 months 
Total mortality, 
composite of all-cause 
mortality and all-cause 
hospitalization (time to 
first event) 
The metoprolol group had 
reduction risks of 38% for 
total mortality, 45% for 
sudden death and 54% for 
hospitalizations for heart 
failure. 
Borer126 2003 360 Ivabradine Placebo Chronic stable angina - 
Time to 1-mm ST-
segment depression and 
Angina attacks decreased 
from 4.14±5.59 attacks per 
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time to limiting angina 
during ETT 
week at baseline  to 
0.95±2.24 attacks per week 
Fox 2008127 
(BEAUTIFUL)* 
5,438 Ivabradine Placebo 
Coronary Artery 
Disease and Heart 
Failure 
19 months 
(median) 
Composite of 
cardiovascular death, 
admission to hospital for 
acute myocardial 
infarction, and admission 
to hospital for new onset 
or worsening heart 
failure. 
Heart rate reference level: 
<70bpm 
Increased risk of MI, HF, 
revascularization and CV 
death for <70 vs. >70bpm 
heart rate. 
Fox128 2014 (SIGNIFY)* 19,102 Ivabradine Placebo 
Coronary Artery 
Disease (activity-limiting 
angina) 
27.8 months 
(median) 
Composite of death from 
cardiovascular causes or 
nonfatal myocardial 
infarction. 
No effect difference on the 
primary endpoint between 
>75 vs. <75bpm heart rate 
* Studies that used specific heart rate values for comparisons of hazards; ETT, Exercise Tolerance Test; MI, Myocardial Infarction 
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1.7. Cardiovascular diseases 
 
In this section I will describe the main outcomes explored in this PhD in relation to resting heart 
rate. These outcomes include diseases that affect the coronary, cerebral and peripheral arterial 
beds. The incidence of specific cardiovascular diseases in the CALIBER population by age and 
sex is illustrated in Figure 1.2.129 
 
Figure 1.2 Age and sex distribution of 60 155 events in men and 54 704 in women representing the initial presentation of a 
wide range of CVDs. CHD indicates coronary heart disease; CVD, cardiovascular disease; NOS, not otherwise specified; and 
SCD, sudden cardiac death. 
 
 
 
1.7.1. Coronary diseases (stable angina/myocardial infarction) 
 
Definition 
The term "coronary artery disease" (CAD) or “coronary heart disease” (CHD) encompasses a 
range of diseases that result from atheromatous changes in coronary vessels. In the past, CHD 
was thought to be a simple, inexorable process of artery narrowing, eventually resulting in 
complete vessel blockage (and MI). However, in recent years the explanatory paradigm has 
changed because it was realized that a whole spectrum of coronary plaques exists – from stable 
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(lipid-poor, thick fibrous cap) to unstable (lipid-rich, thin fibrous cap) 130 Angina results when 
myocardial perfusion is insufficient to meet the myocardial metabolic demand. 
 
Clinical evidence 
Framingham estimates traditionally predict total CHD, which includes angina pectoris, 
recognized and unrecognized myocardial infarction, coronary insufficiency (unstable angina), 
and CHD deaths.131 The inclusion of unstable angina and unrecognized myocardial infarction 
(defined by electrocardiography) probably gives estimates of hard CHD that are somewhat 
higher than combined end points reported in several clinical trials.132, 133 Another clinical trial134 
specified acute coronary events, including unstable angina, acute myocardial infarction, and 
coronary death, as the primary end point. This combined end point probably corresponds 
closely to the Framingham study’s definition of hard CHD. Definitions of coronary end points 
assume critical importance when risk cut points are defined to select patients for specific 
therapies.131 
 
Clinical evidence exists from ambulatory electrocardiographic (ECG) monitoring in patients with 
stable CAD that increases in heart rate are associated with episodes of myocardial ischemia.87 
For example, in one study, 89% of participants were preceded by an increase in heart rate of 
≥10 bpm.135 In another trial described before, the BEAUTIFUL trial,125 the relative risk of 
cardiovascular death was increased by 34% in patients with heart rate ≥70 bpm compared with 
those whose heart rate was <70 bpm, and the rate of cardiovascular death increased 
progressively with baseline heart rate. The effect of heart rate on myocardial ischemia underlies 
the use of heart-rate-reducing drugs, such as β-blockers, in the treatment of stable angina 
pectoris. In US guidelines, a target resting heart rate of 55–60 bpm is recommended in patients 
with stable angina.22 In experimental animals23 and in patients24 the anti-ischemic benefits of 
beta-blockers were eliminated if the heart rate reduction was prevented by electrical pacing. 
On the other hand, studies of placebo and active control treatment studies using a prototype 
agent of ivabradine (zatebradine) in angina patients has revealed no antianginal or anti-
ischemic activities of the drug in spite of reductions in both rest and exercise  heart rate.136, 137 
The implication of these findings is that HR reduction alone may play a small role, if any, in the 
antianginal actions of drugs such as beta-blockers and calcium blockers.138 In a recent clinical 
trial of people with angina and ejection fraction >40%, the addition of ivabradine to standard 
background therapy to reduce the heart rate did not improve the primary outcome which was 
composite of death from cardiovascular causes or nonfatal myocardial infarction. Beta-blockers 
are effective at reducing angina and are usually preferred as initial therapy. The non-inferiority 
of ivabradine compared with atenolol was demonstrated when ivabradine induced a similar or 
greater improvement in exercise capacity than beta-blockers for a comparatively smaller 
reduction in HR.139  
 
Evidence from Genome-Wide association studies 
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In contrast to the above trial findings, genome-Wide association studies (GWAS) failed to 
identify associations of heart rate loci with coronary artery disease (CAD) or MI. However, a 2-
stage meta-analysis of GWAS in up to 181,171 individuals showed that heart rate–increasing 
alleles were associated with prolonged PR duration and reduced QT duration independent of 
heart rate, as well as with both reduced and prolonged QRS duration. None of the heart rate 
loci showed evidence of association with the risk of coronary artery disease or myocardial 
infarction.140 
 
In this PhD, associations of stable angina and myocardial associations with heart rate will be 
examined in healthy, CAD and atrial fibrillation populations. 
 
1.7.2. Cardiac diseases 
 
1.7.2.1.  Heart failure 
 
Definition 
Heart failure is defined as the inability of the myocardium to adequately supply circulation with 
blood at normal enddiastolic filling pressures provided that normal venous return exists. 
Neuroendocrine mechanisms like an increase of the sympathetic activity and increased activity 
of the renin-angiotensin-aldosterone (RAA) system are activated and contribute to a 
progression of ventricular dysfunction. 4 
 
Clinical importance 
Heart failure is a frequent cause of hospitalization, and it is estimated in Europe to be 
responsible for 1 million hospitalizations per year. Increased resting heart rate has recently 
received attention regarding its ability to be an independent prognostic factor in paints with 
heart failure.141 As the natural history of patients with CAD includes the possible occurrence of 
acute myocardial infarction, progression towards heart failure, and death from a cardiovascular 
origin, heart rate reduction represents a potential approach to improving the prognosis of 
patients with heart failure.142 A number of factors support the benefit that may be derived from 
heart rate reduction in heart failure. It is well established that heart rate is a regulating factor in 
myocardial oxygen demand. Factors that can affect myocardial oxygen demand include wall 
stress, which is dependent on preload and afterload, myocardial contractility, and heart rate.142 
As reported many years ago by Holmberg and Varnauskas,143 myocardial oxygen uptake 
increases as a product of heart rate and systolic blood pressure in a linear fashion. On the other 
hand, the level of heart rate reflects the interactions of the adrenergic drive and vagal tone. The 
autonomic nervous system plays an important role in the development of atherosclerosis and 
is known to be an acute trigger of sudden cardiac death that accounts for a high proportion of 
heart failure-related mortality142.  
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1.7.3. Stroke, peripheral vascular disease 
 
Definition 
Stroke is a result of restricted blood flow to an area of brain tissue, e.g. due to a blood clot or a 
bleed. The blood deprivation causes a cell death. The most common types of stroke are the 
ischaemic (when the artery that supplies blood to the brain is blocked) and haemorrhagic (when 
a blood vessel bursts and bleeds into  your brain, damaging brain tissue and starving some of 
your brain cells of blood and oxygen). An additional form of stroke is the transient ischaemic 
attack (TIA) that occurs when there is a temporary blockage in the blood supply to the brain.  
 
All the aforementioned types of strokes will be individually explored in relation to heart 
rate in the present PhD. 
 
Clinical importance 
As heart rate is a parameter reflecting heart function, and adverse effects of resting heart rate 
include an increased susceptibility to cardiac events, the adverse cardiovascular events such 
as heart failure of increased heart rate could be predominantly present in CAD and general 
populations.144 However, as elevated sympathetic nervous activity is also present in patients 
with vascular diseases at other locations and other adverse effects of heart rate such as 
atherosclerotic plaque rupture and endothelial dysfunction are systemic, it is possible that the 
detrimental effects of an elevated heart rate could affect patients with clinical manifest vascular 
disease. In a post hoc analysis of the ONTARGET/TRANSCEND trials, associations between 
baseline and average heart rate in trial with stroke were evaluated. They found that associations 
between baseline heart rate and stroke were significant in crude analyses and after adjusting 
for age and sex alone, but not after adjusting for other prognostic factors, while in-trial heart 
rate was significantly associated with stroke even after multivariate adjustment.145 Associations 
between heart rate and other vascular diseases such as peripheral arterial disease or 
abdominal aortic aneurysm have not yet been explored and the question whether there is a 
differential effect of heart rate on specific separate vascular or (cerebro)vascular diseases. This 
PhD seeks to explore these cerebral and peripheral vascular phenotypes individually and with 
higher resolution among genders. 
 
1.8. Conclusions 
 
Heart rate is the number of heartbeats per unit of time, typically expressed as beats per minute 
(bpm). Heart rate limit was set arbitrarily when heart rate was not yet regarded as a risk factor 
for cardiovascular disease, probably with the main purpose of distinguishing between a disease 
state. In clinical practice, heart rate is measured using the palpation method, the more precise 
electrocardiogram (ECG) or automated blood pressure devices. HR reduction plays a pivotal 
   49 
 
role at the cellular level. Heart rate is affected by specific medication types such as 
sympathomimetics, bronchodilators and anti-depressives that increase heart rate and 
sympatholytics, vasodilators and glycosides that decrease it. Among the heart rate lowering 
medications, ivabradine acts by inhibiting If, an ionic current involved in pacemaking activity in 
the sinoatrial node. The findings of clinical trials confirm that the beneficial effect of beta-
blockers, calcium channel blockers and ivabradine in post MI patients or heart failure patients 
is proportionally related to the reduction of resting heart rate. The most commonly investigated 
cardiovascular diseases (besides fatal cardiovascular events) examined by literature as having 
affected by increased heart rate are coronary diseases (stable angina, myocardial infarction), 
cardiac diseases such as heart failure, and vascular diseases particularly stroke. This PhD will 
expand the range of cardiovascular diseases assessed by published epidemiological studies 
and will further explore associations of heart rate with coronary, cerebral and vascular 
endpoints individually examined. 
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2. Associations of heart rate and cardiovascular diseases: 
literature findings  
 
 
In this chapter I summarize the main findings of published cohort studies concerning the 
association of resting heart rate with cardiovascular diseases in three different populations: 
healthy, patients with coronary artery disease and patients diagnosed with atrial fibrillation. The 
main objectives of this literature review are: 
 
 To identify cohort studies on resting heart rate and incidence of CVDs (fatal or non 
fatal) in healthy populations (free from initial atherosclerotic disease at the time of entry 
in the study) 
 To identify cohort studies on resting heart rate and CVDs experience (fatal or non fatal) 
in populations with stable coronary artery disease 
 To detect cohort studies on resting heart rate and a)the onset of atrial fibrillation in 
general poulations and b) the experience of subsequent CVD events in atrial fibrillation 
populations. 
 
The start of follow-up in these studies should be designated by the heart rate measurement at 
baseline and the end by the experience of one of fatal or non fatal cardiovascular outcome or 
all-cause mortality. In each section I start describing the search strategy that I conceived and 
implemented to retrieve relevant studies. I used the PICO tool, a helpful structured approach 
for developing questions about interventions (population, intervention (or risk factor of interest), 
comparison and outcome), adjusted to the form of questions at the present PhD. This approach 
divides each question into four components: 1) population (the population under study, in this 
case healthy, CAD or atrial fibrillation), 2) intervention (heart rate), 3) comparators (different 
levels of heart rate), 4) outcome (risk of cardiovascular diseases)146. I then list the main studies 
found and analyze the knowledge gaps in the field of interest and the methodological limitations 
of previous studies. I finish by summarizing key issues that need to be addressed to advance 
knowledge in order to answer the research questions of interest. 
 
2.1. Heart rate and onset of CVDs in initially healthy populations 
 
2.1.1. Search strategy 
 
Eligibilty criteria 
Studies with subjects who had history of prior cardiovascular disease were excluded. 
Populations not in sinus rhythm, or populations contained children or adolescent subjects were 
also excluded. Studies examining heart rate measurements not taken at a resting state (during 
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exercise or from ambulatory devices) were also excluded, as well as studies that were using 
heart rate variability, or fetal heart rate or infant heart rate in their titles or abstracts. 
 
Literature search 
To identify all the appropriate published literature, I initially focused on the PICO componentsof 
each individual research question and determined which were searchable and which could be 
spread out into multiple terms (e.g. for the exposure-heart rate split into: heart 
rate/classification, heart rate/drug effects, heart rate/etiology, etc.). Once I had determined all 
of the specific concepts (the main term was heart rate (pulse rate as synonym)) and to the study 
outcomes I combined the terms with the Boolean operators, AND, OR or NOT to optimize my 
search in Pubmed, Medline and google scholar. I used both a comprehensive list of relevant 
terms and Medical Subject Heading (MeSH) terms to construct my search. I also used 
truncation (wildcards) in the form of the symbol “*”  to identify terms of similar syntax (e.g. 
“ischaem* ). Finally, I used free text to search studies in google scholar. This type of search 
has limited specificity but high sensitivity. The detailed step-by-step research strategy that I 
used to identify all relevant studies on resting heart rate and CVDs in healthy populations is 
presented in Table 2.1.  The final query used in search strategy yielded 1,209 studies. The 
abstracts of these studies then were retrieved and of the ones that were relevant, the whole 
paper was downloaded. I identified 19 cohort studies that met my search criteria. These are 
listed in Table 2.2.  
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Table 2.1 Search strategy used to identify studies on association between heart rate and onset of CVD 
Concepts Boolean 
operator 
# search Terms and queries used No. of 
studies 
found 
Risk factor 
(Heart rate) 
OR #1 ((((((“heart rate"[MeSH Terms] OR pulse rate[Title]) NOT variability[Title]) NOT infant*[Title]) NOT fet*[Title])) NOT 
exercise[Title] 
10,520 
 #2 (("pulse"[MeSH Terms] OR pulse rate[Title])) 599 
Population  
OR #3 Search incidence of cardiovascular disease*[Title/Abstract] 9274 
 #4 Search (cardiovascular disease NEXT onset[Title/Abstract]) OR CVD NEXT onset[Title/Abstract] Schema: all 0 
Endpoints 
AND #5 (((((“coronary artery disease”[MeSH Terms] OR coronary heart disease[Title/Abstract]) OR angina 
pectoris[Title/Abstract]) OR stable angina[Title/Abstract]) OR unstable angina[Title/Abstract]) OR 
angina[Title/Abstract] 
127,207 
OR #6 ((((((((("myocardial infarction"[MeSH Terms]] OR Ischaem* OR STEMI[Title/Abstract]) OR non 
STEMI[Title/Abstract]) OR nSTEMI[Title/Abstract]) OR acute coronary syndrome[Title/Abstract]) OR heart 
attack[Title/Abstract]) OR heart failure[Title/Abstract]) OR syncope[Title/Abstract] OR 
syncope/cardiac[Title/Abstract] OR syncopy[Title/Abstract]) 
232,803 
OR #7 ("stroke"[MeSH Terms] OR "stroke"[All Fields]) OR cerebrovascular disease[Title/Abstract] 205,117 
OR #8  (((abdominal aortic aneurysm) OR peripheral arterial disease) OR peripheral ischaemia) OR peripheral vascular 
disease 
92,979 
 #9 ((cardiac arrest) OR sudden cardiac death) OR death 592,057 
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Final Query 
used 
 #1 OR #2 AND #3 
OR #4 AND #5 OR 
#6 OR #7 OR #8 
OR #9 
(((((((heart rate[Title]) OR pulse rate[Title]) NOT variability[Title]) NOT infant*[Title]) NOT fet*[Title])) NOT 
exercise[Title]) AND ((((((coronary artery disease[Title/Abstract]) OR coronary heart disease[Title/Abstract]) OR 
angina pectoris[Title/Abstract]) OR stable angina[Title/Abstract]) OR unstable angina[Title/Abstract]) OR 
angina[Title/Abstract])) OR (((((((myocardial infarction[Title/Abstract] OR STEMI[Title/Abstract]) OR non 
STEMI[Title/Abstract]) OR nSTEMI[Title/Abstract]) OR acute coronary syndrome[Title/Abstract]) OR heart 
attack[Title/Abstract]) OR heart failure[Title/Abstract]) OR syncope[Title/Abstract] OR 
syncope/cardiac[Title/Abstract] OR syncopy[Title/Abstract]))) OR ((stroke) OR cerebrovascular 
disease[Title/Abstract])) OR ((((abdominal aortic aneurysm) OR peripheral arterial disease) OR peripheral 
ischaemia) OR peripheral vascular disease)) OR (((cardiac arrest) OR sudden cardiac death) OR death OR 
mortality) 
1,209 
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2.1.2. Studies of heart rate and onset of CVDs  
 
Zero out of nineteen of the cohort studies identified were based on the use of linked electronic 
health records to define heart rate.Twelve studies  were conducted used data collected in 
1960’s, 1970’s or 1980’s, one in 1940’s and two in 1990’s and the study periods terminated 
around ten or twenty years ago. The sample size varied, with only two being of a 105 size 
(Tverdal, Hsia). The majority of the studies were conducted in USA (5 studies) and the rest in 
Europe (apart from 3 in Asia) and only one in UK included 7,735 subjects. 
 
The majority of studies focused on all-cause mortality, cardiovascular and non-cardiovascular 
death, with one reporting on sudden cardiac death and myocardial infarction.147 None  
disaggregated the composite endpoints (e.g. disagreggate CHD into stable and unstable 
angina and myocardial infarction). Studies were restricted to the investigation of coronary 
diseases. None specifically reported on cerebral, abdominal or peripheral arterial disease 
associations with heart rate.  
 
In terms of the heart rate levels used to analyse their research questions, only 3 studies used 
the 70-79bpm level which represents average heart rate values in the population.148-150 
 
The studies found did not explore potential differences between genders. One of the two largest 
studies, including 129,000 patients was restricted to post-menopausal women (Hsia)151 and 
only four reported a sex related comparison in heart rate associations152-155 with cardiovascular 
mortality and all-cause mortality outcomes that showed positive and graded relationship 
between heart rate and mortality from CVD, IHD, stroke, and death from any cause both in men 
and women. The shape of the associations that could provide information on thresholds above 
or below which the risk of cardiovascular events is increased or decreased was described only 
by the same study of mortality outcomes.152  
 
Overall,  I identified 19 cohort studies (no trials identified), the majority characterized by limited 
sample size in the majority that did not allow for further subgroup analyses, or specific 
cardiovascular endpoints examination. None of the studies used primary care data to collect 
heart rate or linked electronic health records in the data collection process. A clear need for a 
study of large sample size and high resolution that will explore specific cardiovascular 
phenotypes with sufficient power for gender comparisons is apparent. 
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Table 2.2 Summary of cohort studies examining associations of resting heart rate with the onset of CVDs in healthy populations 
Design and methods Endpoints Results 
Author 
 
Country 
 
Data 
sources 
Year of 
study 
initiation 
Sample 
size 
 
Age 
 
Gender 
 
Mortality 
only 
outcome
s 
N of 
non-
fatal 
specific 
disease
s 
Descriptio
n of shape 
of 
associatio
n 
Estimate
s 
reported 
for 70-
79bpm 
Test for 
sex 
interaction 
Reported comparison and main findings 
 
P
o
p
u
la
ti
o
n
 
s
u
rv
e
y
 
E
H
R
 
Kannel et 
al.(1987)85 
USA ● ○ 1948 5,209 
35-
95 
Both ● 0 ○ ○ ɵ 
Per 1bpm increase 
Finding: No evidence of threshold or association was found. 
Gillum et al. 
(1991)153 
USA ● ○ 1971 5,995 
45-
74 
Both ● 0 ○ ○ ● 
Reference level: <74bpm. 
Finding: High risk of all-cause and CVD death for HR>84bpm for 
both sexes (in white people), risk for CHD only present in men  
Shaper et al 
(1993)148 
UK ● ○ 1969 7,735 
40-
59 
Males ● 0 ○ ● ○ 
Reference level: <90 
Findings: high statistically significant  risk of IHD morbidity and 
mortality and SCD for ≥90bpm but not for 70-to -89 
Mensink et 
al. (1997)19 
Germany ● ○ 1982 4,756 
40-
80 
Both ● 0 ○ ○ ɵ 
Per 20bpm increase 
Findings: Men: all-cause and CVD mortality HazR=1.7 and 1.7 
Women: HazR=1.4 and HazR=1.3 respectively 
Benetos et 
al.154 (1999) 
 
France 
 
● ○ 1970 19,386 
40-
69 
Both ● 0 ○ ○ ● 
Reference level: 60-80bpm 
In men increased risk for CV, all-cause and non-CV death and 
CAD events for HR>100bpm. No stroke risk 
Women: insignificant increased risk for CVD & stroke. 
Greenland 
et al. (1999) 
USA ● ○ 1967 33,781 
18-
74 
Both ● 0 ○ ○ ○ 
Per 12 bpm increase associated with increased risk of CHD, CVD 
mortality in men but not consistently in all ages for women 
Palatini et 
al. (1999)156 
Italy ● ○ 1983 1,938 >65 Both ● 0 ○ ○ ○ 
Reference level 1st quintile (non-specific values) 
Elder Men/women (for all-cause mortality, 5th quintile: 
RR=1.21/1.13), Cardiovascular mortality: RR=1.55/1.08 
Kristal-
Boneh et al. 
(2000)157 
Israel ● ○ 1985 3,527 43 Males ● 0 ○ ○ ○ 
Reference level: 70-79bpm 
For >90bpm: All-cause mortality RR=2.23 
CVD mortality: RR=2·02. 
For 80-89bpm no effect was found 
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Seccarecci
a et al. 
(2001)149 
Italy ● ○ 1984 2,533 
40-
69 
Males ● 0 ○ ● ○ 
Reference level: <60bpm 
For≥90 bpm: All-cause HazR = 2.67 
CVD mortality: HazR=2.54 
Non-CVD mortality :HazR=2.87 
Jouven et 
al. (2001)147 
France ● ○ 1967 7,746 
42-
53 
Males 
MI fatal, 
SCD 
2 ○ ○ ○ 
For 1 SD increase of HR: Sudden death: HazR=1.28 (1.06-1.61) 
Fatal MI: HazR=1.05 (0.95-1.16) (multivariable) 
Fujiura et al 
(2001) 
Japan ● ○ 1977 573 
40-
64 
Males ● 0 ○ ● ○ 
Reference level: 60-69bpm 
For>90bpm:  mortality risk :RR=2.68 
Okamura et 
al. (2004) 
Japan ● ○ 1981 8,800 30 Both stroke 1 ○ ○ ○ 
For 11bpm increase: CHD+HF, non-CV and all-cause death: 
insignificant for both men/women. 
For highest quartile (HR>74bpm vs <60bpm), CHD+HF 
HazR=3.99 in younger men. HR not associated with 
cerebral infarction, cerebral haemorrhage 
Tverdal et 
al. (2008)152 
Norway ● ○ 1985 
379,84
3 
40-
45 
Both ● 0 ● ○ ● 
In HR>95bpm vs <80bpm and every 10bpm: SCD insignificant 
In HR >95bpm vs <65bpm: Stroke death insignificant in both 
sexes, CVD and IHD death significant only in men 
Hsia et al. 
(2009)151 
USA ● ○ 1993 
129,13
5 
50-
79 
Wome
n 
stroke 1 ○ ○ ○ 
Reference level 1st quintile (<62bpm) 
For HR>76bpm: MI or coronary death: HazR=1.68 
Stroke: HazR=1.23 
For HR 71-76bpm (4th quintile), HazR=1.21  
Cooney et 
al. (2010) 
Finland ● ○ 1972 21,853 
25-
74 
Both ● 0 ○ ○ ɵ 
For each 15 bpm: CVD, CHD and total mortality significant in 
men/women, MI (non-fatal)+CHD death insignificant for men 
>90bpm vs <60bpm was associated with a 2-fold increased risk of 
CVD mortality in men and 3-fold increased risk in women 
Jensen et 
al. (2012) 
Denmark ● ○ 1976 6,518 
56.
2 
Males ● 0 ○ ○ ○ 
For every 10bpm HR: CVD mortality: HazR=1.21. 
All-cause  HazR=1.15 
Jensen et 
al. (2013)158 
 
Denmark 
 
● ○ 1970 2,798 63 No ● 0 ○ ○ ○ 
Reference level: <50bpm 
5th quintile(>90bpm):All-cause mortality risk: HazR=3.06 
Nanchen et 
al. (2013)159 
Netherland
s 
● ○ 1993 4,768 ≥55 Both HF 1 ○ ○ ɵ 
Per 10 bpm in men, risk of HF: HazR=1.14 (1.03–1.27) 
No association found in women 
Opdahl et 
al. (2014) 
USA ● ○ 2000 6,814 
45-
84 
Both HF 1 ○ ○ ● 
Per 1bpm: Heart failure incidence: HR=1.04(1.02-1.06), 
Quartile analysis reference level: <57bpm 
For >69bpm (4th quartile): HR=3.76 (2.00–7.07). 
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Risk consistent for 2nd, 3rdquartiles. 
CALIBER 
study 
UK  ● 1997 
196,50
8 
>30 Both ● 11 ● ● 
In UCD no 
associatio
n with 
women 
was found 
Reference level: <60bpmHeart rates >80bpm have an increased 
risk of heart failure and unheralded coronary death and a risk of 
sudden cardiac death for heart rate >90bpm. No association with 
CAD endpoints, cerebrovascular, or peripheral vascular diseases. 
Apparent threshold for effect on SCD with the linear association 
confined to heart rate values >85bpm. 
Abbreviations: HER, electronic health records; HazR, Hazard Ratio; HR, heart rate; Q, quintile; CAD, coronary artery disease; CVD, cardiovascular disease; MI, myocardial infarction; HF, heart failure; AF, atrial 
fibrillation; SCD, sudden cardiac death; In test sex interaction: ● denotes tested and women had similar results as men; ɵ denotes weaker associations in women; ○ denotes no testing 
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2.2. Heart rate and cardiovascular diseases in populations with CHD 
 
In this sub-chapter I present the search strategy and findings of studies looking at the 
association of resting heart rate with cardiovascular diseases in patients with coronary artery 
disease. The start of follow-up in these studies should be designated by the heart rate 
measurement after a diagnosis of stable coronary heart disease and the end by the experience 
of one of fatal or non fatal cardiovascular outcome or all-cause mortality. Eligibility of studies 
was based on whether their population did not suffer from stable coronary artery disease (alone 
or with co-morbidities), or if they exclusively had an acute coronary event in less than a month. 
Systematic reviews or meta-analytic studies, as well as studies that examined heart rate 
variability associations with CVDs since these studies do not explore associations of a resting 
heart rate at baseline but the change in heart rate values over time, or finally their populations 
contained children or adolescent subjects (or fetal subjects) were also excluded. 
 
2.2.1. Search strategy 
 
Eligibility criteria 
Studies with healthy subjects or studies with an acute ischaemic event at baseline or less than 
a month before the study entry and initiation of follow-up were excluded. Populations not in 
sinus rhythm, or populations contained children or adolescent subjects were also excluded. 
Studies examining heart rate measurements not taken at a resting state (during exercise or 
from ambulatory devices) were also excluded, as well as studies that were using heart rate 
variability, or fetal heart rate or infant heart rate in their titles or abstracts. No restriction criteria 
were set regarding language or date of publication.  
 
Literature search 
Similarly as in the first section, to identify all the appropriate published literature, I initially 
focused on the PICO componentsof each individual research question and determined which 
were searchable and which could be spread out into multiple terms and I combined them with 
the Boolean operators, AND, OR or NOT to optimize my search in Pubmed, Medline and google 
scholar. The search for the exposure heart rate was identical in all literature searches. I used 
both a comprehensive list of relevant terms and Medical Subject Heading (MeSH) terms to 
construct my search. I also used truncation (wildcards) in the form of the symbol “*”  to identify 
terms of similar syntax (e.g. “ischaem* ). Finally, I used free text to search studies in google 
scholar. Web crawling was implemented, cross references from original articles (backward and 
forward citations) and systematic reviews were also searched and assessed, whereas grey 
literature (conference proceedings and symposiums’) was handsearched. The strategy used is 
presented in Table 2.3.  The final query used in search strategy yielded 1,209 studies. The 
abstracts of these studies then were retrieved and of the ones that were relevant, the whole 
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paper was downloaded. I identified 19 cohort studies that met my search criteria. These are 
listed in Table 2.4.  
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Table 2.3 Search strategy used to identify studies on association between heart rate and prognosis of CVDs in people with CAD  
Concepts 
Boolean 
operator 
Searc
h Query 
Items 
found 
Risk factor 
 
#1 
((((((“heart rate"[MeSH Terms] OR pulse rate[Title]) NOT variability[Title]) NOT infant*[Title]) NOT fet*[Title])) 
NOT exercise[Title] 
10,520 
Population 
AND #2 coronary artery disease 129031 
OR 
#3 
Search (((stable[Title]) AND coronary artery disease[Title]) OR coronary heart disease[Title]) OR coronary 
artery disease[MeSH Terms] 
55112 
 #4 Search coronary heart disease[MeSH Terms] 507623 
Endpoints 
 
#5 
Search (((cardiovascular diseases[Title]) OR coronary artery disease[Title/Abstract]) OR coronary heart 
disease[Title/Abstract]) OR ischaemic disease[Title/Abstract] 
2872 
OR #6 Search (heart failure[Title/Abstract]) OR heart attack[Title/Abstract] 108486 
OR #7 Search mortality[Title/Abstract] 118582 
OR #8 Search sudden cardiac death[Title/Abstract] 10195 
OR #9 Search atrial fibrillation[Title/Abstract] 43259 
OR #10 Search (stable angina[Title/Abstract]) OR angina pectoris[Title/Abstract] 21014 
 #11 Search ((myocardial infarction[Title/Abstract]) OR ischaemic[Title/Abstract]) OR ischaemi*[Title/Abstract] 181708 
  #12 Search (#1 AND #2 or #3 AND #4 AND #5 OR #6 OR #7 OR #8 #9 OR #10 OR (#11 OR #12)) 237689 
Final Query 
used 
 
#13 
Search ((((((((((#1) AND #2) OR #3)) OR #4) AND #5)) OR (#6 OR #7 OR #8 OR #9 OR #10 OR #11) 
8583 
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2.3. Studies on heart rate and prognosis of CAD  
 
Of the 8,583 studies identified, 12 were eligible and are presented in Table 2.4. Among the 
cohort studies identified that assessed resting heart rate association with CVDs, a multicentre 
cohort of Bangalore et al.160  examines the association of heart rate lowering medication (beta-
blockers) with the prognosis of cardiovascular events in CAD populations. In chapter 1 we also 
observed 3 RCTs that examined associations of resting heart rate lowering via ivabradine 
intake with CVDs (Table 1.4). One of them, BEAUTIFUL study by Fox et al.125 uses data from 
this RCT to assess in a subgroup of patients with CAD and left ventricular systolic dysfunction 
the impact of the effect of heart rate on cardiovascular outcomes directly and not through the 
use of ivabradine as proxy of heart rate lowring. This study is also included in Table 2.4. 
 
None of the studies was based on the analysis of linked (or non-linked) electronic health records 
collected from baseline to follow-up. Contemporary studies were exclusively conducted in 
populations included in angiography registries 161-165 and clinical trials.125, 145, 166-168 None 
explored associations in the general population (most severe cases admitted in hospitals or 
recorded in registries) or a systematic level (ascertainment bias/Berkson’s fallacy). The latter 
might result in a spurious negative correlation between specific characteristics of the CAD (e.g. 
people that have more severe chest pains or lower LVEF tend to get admitted for coronary 
procedures that people with CAD in the general population). As a result, angiography registries 
contain data exclusively colected for research purposes and is confined to high risk patients or 
patients admitted for acute coronary syndromes or referred for specific cardiovascular 
procedures. Consequently, the external validity of their findings is potentially compromised, 
while the applicability and generalizability of this data on the general population is under 
question. 
 
Apart from the latent differential effects in clinical trials and research-selective populations, 
limitations stemming from their inclusion criteria confinining their population generalisability. To 
be more specific, approximately half of the studieswere conducted among patients who had 
specific comorbidities. In BEAUTIFUL study by Fox et. al. in 2008125, included people with signs 
of heart failure (reduced left ventricular ejection fraction). Kolloch in 2008166 studied people with 
CAD and hypertension, Anselmino in 2010163 people with CAD and diabetes, and Jensen in 
2013168 patients with stable and unstable coronary disease after PCI. Only Diaz et al. explored 
heart rate associations with CVDs in CAD patients without other comorbidities161. 
 
Only three studies assessed specific cardiovascular endpoints (Kolloch (N=22,192), Diaz 
(N=24,959), Lonn (N=31,531)). Composite cardiovascular endpoints have been extensively 
studied. None investigated atrial fibrillation as an incident event in people with CAD.   
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No study described the shape of the association between heart rate and CVDs to identify risk 
thresholds. Gender differences in heart rate associations with cardiovascular events have not 
been sufficiently explored. Specifically, only one study investigated interactions with sex 166 
since its sample size allowed to, however not at a baseline heart rate analysis. Finally, current 
evidence is largely indirectly derived  from evaluations of heart rate lowering medication on 
cardiovascular endpoints and not on the study of associations with heart rate measurements 
126, 128, 160. Table 2.2.2 (b) lists these studies.  
 
Two of the largest published studies conducted in populations with CAD show conflicting 
results. The BEAUTIFUL study that analysed patients’ outcomes based on a heart rate division 
of >70bpm vs <70bpm found that heart rate >70bpm resulted in statistically significant higher 
risk of cardiovascular death, heart failure, MI and coronary revascularisation in people with 
reduced LVSF125. Although the risk for coronary outcomes was higher in the groups with heart 
rate above 70 bpm, they found no evidence of a strong gradient for risk for higher heart rates. 
The SIGNIFY trial conducted in 2014 by Fox et. al. assessed ivabradine (a pure heart rate 
lowering agent) efficacy and effectiveness in people with CAD and a normal LVSF128. The 
investigators found that there was no significant difference between the ivabradine group and 
the placebo group in the incidence of death from cardiovascular causes and nonfatal 
myocardial infarction. Ivabradine was associated with an increase in the incidence of the 
primary end point among patients with more severe angina but not among those with less 
severe. 
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Table 2.4 Literature review of studies examining resting HR and prognosis in people with stable coronary artery disease. 
Author/year Country 
Year of 
data 
collection 
No of 
patients 
C
lin
ic
a
l 
tr
ia
l 
(A
n
g
io
g
ra
p
h
y
) 
R
e
g
is
tr
y
 
EHR 
Comorbidities 
in addition to 
CAD at 
baseline 
Heart rate 
classifications 
G
e
n
d
e
r 
c
o
m
p
a
ri
s
o
n
 
>1 disease 
outcomes A
tr
ia
l 
F
ib
ri
lla
ti
o
n
 
Shape of 
association 
Findings 
Cohort studies 
Diaz169 
 
Canada 
1975-
1979 
24,959 ○ ● ○ ○ 
5th Quintile 
(>83bpm) vs 
1st (<62bpm): 
○ 
Hospitalization for: 
HF, MI, SA, stroke 
○ ○ 
Reference level: 
<62bpm (1st quintile) 
For 5th Q (>83bpm): No 
significant 
association with HF, 
MI, SA, stroke 
Aboyans162 
 
France 
1998-
2002 
1,022 ○ ● ○ ○ 
10bpm HR 
increase 
○ 
Stroke/death/ 
MI/stroke/TIA 
composite 
○ ○ 
For 10bpm HR 
increase, no 
association with 
stroke/death endpoint 
and mild with 
MI/stroke/death 
Anselmino163 
Multicentre 
(25 
European 
countries) 
2003-
2004 
2,608 ○ ● ○ Diabetes 
10bpm RHR 
increase 
○ 
Composite of all-
cause mortality, 
MI, and stroke 
○ ○ 
10bpm RHR increase 
mildly associated with 
all-cause 
mortality/MI/stroke 
 
Ruiz Ortiz164 
2010 
Spain 
2000-
2004 
1,264 ○ ● ○ ○ 
1bpm HR 
increase, or 
>70bpm vs 
<70bpm or 
highest 
quartile 
(>74bpm vs 
<60bpm) 
○ 
Composite of 
mortality, ACS, 
need for coronary 
revascularization, 
stroke, or 
admission for HF 
○ ○ 
For 1bpm HR increase, 
or >70bpm vs <70bpm 
or highest quartile 
(>74bpm vs <60bpm) 
no association of RHR 
with the rate of major or 
coronary events or total 
mortality 
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ó Hartaigh165 Germany 
1997-
2000 
3,316 ○ ● ○ ○ 
Quartiles (4th 
>84bpm vs 1st 
<64bpm) and 
10bpm 
increase 
○ 
All-cause and CVD 
mortality 
○ ● 
Reference level: 
<64bpm (1st quartile) 
>84 bpm or 10bpm 
increase in HR 
associated with overall 
and CVD mortality 
Bangalore160 
2012 
44 countries 
across 6 
major 
regions 
(Latin/North 
America, 
Europe, 
Asia, the 
Middle East, 
and 
Australia) 
2003-
2004 
16,315 ○ ● ○ Hypertension - ○ Stroke, MI ○ ○ 
Heart rate lowering 
medication (ß-blocker) 
use associated with 
increased risk of CV 
events and death 
Bemelmans170 Netherland 
1996-
2009 
4,272 ○ ● ○ PAD, AAA 
Quartiles (Q5 
>82bpm vs 
Q1 <51bpm), 
10 bpm 
increase 
○ 
MI, stroke, 
vascular death, all-
cause mortality 
○ ○ 
Reference level: 
<51bpm (1st quartile) 
No association between 
an increase 
of 10 bpm RHR or Q5 in 
MI or stroke risk, 
associations with all-
vascular events and 
death 
Clinical trials 
   65 
 
 
Fox125  2008 
(BEAUTIFUL) 
International, 
multicentre 
2004-
2006 
5,438 ● ○ ○ LVSD 
>70bpm vs 
<70bpm 
○ 
Hospitalization for: 
MI, HF, 
revascularization, 
death 
○ ○ 
Reference level: 
<70bpm 
For heart rate >70bpm, 
increased risk of MI, 
HF, revascularization 
and CV death 
Kolloch166 
Multicentre 
(United 
States, 
Australia, 
New 
Zealand 
Germany, 
Canada, 
Mexico, Italy, 
France, 
Spain, Israel 
and South 
Africa 
1998- 22,192 ● ○ ○ Hypertension - ○ 
Composite of all-
cause death, non-
fatal MI, or non-
fatal stroke 
○ ● 
Baseline heart rate 
associated with 
adverse outcomes with 
a linear relationship 
(Not specified HR 
values) 
 
Ho167 J.E 
multicentre 
1998-
1999 
9,580 ● ○ ○ ○ 
>70bpm vs 
<70bpm 
○ 
Composite of CHD 
death, nonfatal MI, 
resuscitated 
cardiac 
arrest, or stroke. 
○ ○ 
Reference level: 
<70bpm 
For >70bpm, HF risk: 
HR=2.30 
Mild association with MI 
and stroke 
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Jensen 
Switzerland, 
Denmark, 
Austria, Italy 
2007-
2008 
2,029 ● ○ ○ 
Stable/ 
unstable 
population 
after PCI 
<60, 60-69, 
70-79, 80-89, 
>90bpm 
○ 
Composite of CVD 
death/MI 
○ ○ 
Reference level: 
<60bpm 
For HR >90bpm the risk 
of CVD death and MI 
composite: HR=6.2 
Lonn145 multicentre - 31,531 ● ○ ○ 
Peripheral or 
CBV disease 
with diabetes 
and end 
organ 
damage 
Quintiles, HR 
ranges:<50, 
50–59, 
60–69, 70–
79, 80–89, 
90–99 and 
>100bpm, 
also <70bpm 
vs >70bpm 
○ 
Composite of: 
death from CV 
causes, MI, stroke, 
or hospitalization 
for HF and all-
cause mortality 
○ ○ 
Reference levels: 
<50bpm and <70bpm 
Continuous relationship 
between MVE and HR 
with no observed 
threshold. MVE, CV 
death, stroke, CHF, and 
all-cause death 
increased across heart 
rate quintiles. No 
association between MI 
and HR 
Present PhD 
CALIBER 
 
UK 
1997-
2010 
51,703 ○ ○ ● ○ 
<60, 60-69, 
70-79, 80-89, 
>90bpm, per 
10 
continuous, 
quintiles 
● 
SA, MI, AF, HF, 
SCD, PAD, Stroke 
CVD death, All-
cause mortality 
● ● 
Reference level: 
<60bpm 
For >90bpm increased 
risk for HF 
(HazR=2.96), SCD 
(HazR=1.30) and AF 
(HazR=2.04) 
Abbreviations: HER, electronic health records; HazR, Hazard Ratio; HR, heart rate; Q, quintile; CAD, coronary artery disease; CVD, cardiovascular disease; MI, myocardial infarction; HF, heart 
failure; AF, atrial fibrillation; SCD, sudden cardiac death;PAD, peripheral arterial disease; SA, stable angina 
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In summary, available literature findings come from trials and registries and are conducted for 
research specific purposes, are confounded by comorbidities, with insufficient sample sizes 
and underreporting of potential differential effects among subgroups. Opposing findings of trials 
conducted in research-recruited populations or through drug treatment administration analysis, 
complex the mechanistic inferences that were established so far pointing out the endothelial 
dysfunction pathway. The criteria set at the search strategy stage and the findings of Table 2.4 
enhance the contribution of our study in the sense that this is the first attempt to assess CVD 
prognosis in a general sample of CAD people that includes less severe cases of coronary 
disease that ranges from mild symptoms to severe cases that undergo procedures and is highly 
representative and potentially avoid overestimation of effects. The need for use of clinically 
relevant heart rate levels, collected from a primary care seeting of GP practices with sufficient 
indivual sizes that allow risk assessment for heart rate values previously regarded as normal 
and were so far dismissed from inclusion in the alarming categories, is apparent. An additional 
benefit of the use of Linked electronic health records, is the provision of insights into the 
pathophysiological mechanisms of disease progression in a stable CAD population. 
 
2.4.  Heart rate and atrial fibrillation incidence in healthy populations 
 
Similar search process and tools as in the revious sections were followed to retrieve studies 
exploring ithe association of resting heart rate with i) the incidence of atrial fibrillation and ii)the 
risk assessment of patients with atrial fibrillation (AF) for subsequent cardiovascular and 
coronary diseases. Specifically, exposure (heart rate) search was identical to the two previous 
searches. Additional search terms for outcomes (atrial fibrillation) were added. The start of 
follow-up should be the date of heart rate measurement and the end the date of atrial fibrillation 
experience (regardless of cardiovascular events prior to the atrial fibrillation event) in order to 
explore heart rate associations and AF onset. To assess heart rate associations with CVD 
prognosis of patients with AF, the initiation of follow-up should coincide with a heart rate 
measurement in people with AF and the end of follow-up with the first experience of a 
cardiovascular event (fatal or non-fatal). The detailed research strategy I used to identify all 
relevant studies is presented below in Table 2.5. 
 
2.4.1. Search strategy 
 
Eligibility criteria 
For the objective (i) studies with subjects who had history of prior cardiovascular disease were 
excluded. Populations not in sinus rhythm, or populations contained children or adolescent 
subjects were also excluded. Studies examining heart rate measurements not taken at a resting 
state (during exercise or from ambulatory devices) were also excluded, as well as studies that 
were using heart rate variability, or fetal heart rate or infant heart rate in their titles or abstracts. 
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For the objective (ii) similar criteria were set with the difference that patients should have been 
diagnosed with AF before the time of heart rate measurement. 
 
Literature search 
In this sub-chapter I present the search strategy and findings of cohort studies looking at the 
association of resting heart rate with incidence of atrial fibrillation in healthy population and 
subsequent cardiovascular events in the atrial fibrillation patients. The inclusion of studies was 
based on whether their population was free from a previous atrial fibrillation event, or atrial 
fibrillation population followed-up for cardiovascular risk and their populations provided heart 
rate information. Systematic reviews or meta-analytic studies, as well as studies that examined 
heart rate variability associations with atrial fibrillation or CVDs, or their populations contained 
children or adolescent subjects (or fetal subjects) were excluded. 
   69 
 
 
Table 2.5 Search strategy used to identify studies on association between heart rate, incidence of atrial fibrillation and the risk for future CVDs 
Concepts Boolean operator Search Query Items found 
Risk factor 
 #1  ((((((“heart rate"[MeSH Terms] OR pulse rate[Title]) NOT variability[Title]) NOT 
infant*[Title]) NOT fet*[Title])) NOT exercise[Title] 
10,520  
Endpoint Atrial 
Fibrillation 
AND #2 Search atrial fibrillation[Title] 24890 
OR #3 Search atrial fibrillation[MeSH Terms] 36751 
OR #4 Search "atrial fibrillation/epidemiology"[MeSH Major Topic] 2139 
OR #5 Search (onset) AND atrial fibrillation[Title/Abstract] 448 
OR #6  (incidence[Title]) AND atrial fibrillation[Title] 448 
C
a
rd
io
v
a
s
c
u
la
r 
O
u
tc
o
m
e
s
 
 #7  (((prognosis[Title/Abstract]) AND coronary artery disease[Title/Abstract]) OR 
cardiovascular disease*[Title/Abstract]) OR CVD[Title/Abstract] 
116915 
OR #2   (cardiovascular disease[Title/Abstract]) OR CVD[Title/Abstract] 89365  
OR #3  incidence of cardiovascular disease*[Title/Abstract] 40075  
OR #6   ((onset) AND cardiovascular) AND CVD 539  
OR #7   (incidence of cardiovascular disease*) OR incidence of CVD 9274  
OR #8   ((myocardial infarction[Title]) OR stable angina[Title/Abstract]) OR heart 
failure[Title/Abstract] 
178839  
 #9  ((adv rse[Title/Abstract]) AND cardiovascular outcomes[Title/Abstract]) OR 
cardiovascular*[Title/Abstract] 
301501  
  #10  (((((#2) OR #3) OR #4) OR #5) OR #6)  38045  
  #11   (((#7) OR #8) OR #9)  462898  
Final Query used  #12  (((#1) AND #10)OR#11) 4921  
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2.4.2. Existing studies on heart rate and incidence of atrial fibrillation 
 
From the literature search, 4,921 studies were found relevant and their abstracts were 
downloaded. Only 7 of them fulfilled the eligibility criteria. Table 2.6 below shows that 
information on heart rate and atrial fibrillation incidence from observational or experimental 
studies is limited. Recent epidemiological studies are few and have been extensively conducted 
in populations with specific comorbidities already, namely established cardiovascular diseases 
171-175, or hypertensive populations173. None examined sex differences in associations or 
described shapes of associations, potentially due to their limited sample sizes. Additionally no 
study used clinically relevant or sensitive heart rate levels to yield information on “normal” heart 
rate values associations with AF applicable to general practice. No study has previously 
assessed the risk of subsequent non-fatal cardiovascular events risk in patients with atrial 
fibrillation and only two assessed subsequent mortality but with limited sample sizes (Table 
2.7). There is a clear literature gap that would render a new study exploring associations of 
resting heart rate with the incidence of atrial fibrillation and subsequent risk of CVDs, necessary. 
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Table 2.6 Cohort studies reporting association between resting heart rate and incidence of atrial fibrillation 
Author/year 
Y
e
a
r 
o
f 
d
a
ta
 c
o
lle
c
ti
o
n
 
#
 o
f 
p
a
ti
e
n
ts
 
Population 
based cohort 
Baseline CVDs 
excluded 
Gender 
comparison 
Heart rate levels 
N
 o
f 
A
F
 e
v
e
n
ts
 
 
S
h
a
p
e
 o
f 
a
s
s
o
c
ia
ti
o
n
 
Findings 
E
H
R
 
s
u
rv
e
y
/r
e
g
is
tr
y
/ 
tr
ia
l 
Krahn171 
1948-
1992 
3,983 o ● o o <100bpm, >100bpm 299 o 
Reference level: <100bpm 
Findings: For HR>100bpm: RR=1.81 (1.40-
2.34) 
Wilhelmsen172 
1970-
1997 
7,495 o ● o o 
<65bpm, 66-80bpm, 
>89bpm 
754 o 
Reference level: <65bpm 
Findings: For HR>89bpm: RR=0.89 
Okin173 
1995-
1997 
8,828 o ● o ● 
Quintiles (>84bpm), 
per 10bpm 
701 o 
For every 10bpm increase, HazR of 
AF=1.19 (1.13 for men, 1.22 for women) 
Perez176 
1987-
2000 
42,751 o ● N/N o Per 10bpm 1,050 o 
Per 1bpm HR, RR=1.00 
(1.0-1.01) 
Schnabel174 
1968-
1987 
4,764 o ● o o Per 1 bpm 457 o 
Per 1bpm, RR=0.98 
(0.89-1.08) 
Chamberlain175 
1987-
1989 
14,546 o ● o o 
<60bpm, 
60-90 bpm, >90bpm 
515 o 
Reference level: 60-90bpm 
Findings: HR>90bpm, RR=2.03 
(1.34-3.06) 
Grundvold177 
1972-
1975 
2,014 o ● ● o 
Per 1SD of HR 
increase 
270 o 
HR per 1SD: RR=0.98 
(0.86-1.11) 
CALIBER study 
(Present PhD) 
1997-
2010 
196,436 ● o ● ● 
<60bpm, 
60-70bpm, 
70-80bpm, 80-90 
bpm, >90bpm 
6,983 ● 
Reference level: 70-79 bpm 
Findings: For HR>90bpm, AF HazR=1.43 
(1.33-1.54) 
For HR<60bpm, HazR=1.22 (1.11-1.34) 
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Table 2.7 Cohort studies reporting association between resting heart rate and CVDs prognosis in people with atrial fibrillation 
Author/year 
Y
e
a
r 
o
f 
d
a
ta
 c
o
lle
c
ti
o
n
 
#
 o
f 
p
a
ti
e
n
ts
 
Population 
based cohort 
Heart rate levels 
O
u
tc
o
m
e
s
 
 
S
h
a
p
e
 o
f 
a
s
s
o
c
ia
ti
o
n
 
Findings 
E
H
R
 
s
u
rv
e
y
/r
e
g
is
te
r/
tr
ia
l 
Andrade et.al. 
(AFFIRM)178 (pre-pub) 
- 5,164 o ● 90-114bpm, >114bpm Hospitalizations and mortality o 
Reference 90-114bpm 
Findings: For >114bpm, HR for 
hospitalization=1.18.  
No association with mortality  
 
Li et. al.179 (pre-pub) - 7,392 o ● 
<60bpm, 61-70, 71-80, 81-
90, 91-100, >100bpm 
All-cause mortality o 
Reference level <60bpm 
For heart rate>100bpm, HR for all-cause 
mortality=1.29 (p=0.003) 
CALIBER study 
(Present PhD) 
1997-
2010 
196,436 ● o 
<60bpm, 
60-70bpm, 
70-80bpm, 80-90 bpm, 
>90bpm 
HF, SCD, SA, STROKE, MI, PAD, 
CVD & all-cause mortality 
● 
Reference level: <60bpm 
Findings: For HR>90bpm,  
risk of heart failure for HR>90, HazR=1.89 
(1.30-2.75) 
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2.5. Discussion 
 
During the literature search, no meta-analysis was identified related to studies (cohorts or trials) 
assessing the impact of heart rate on cardiovascular outcomes, neither on general healthy 
populations, nor coronary heart disease patients. This is not surprising as the majority of cohort 
studies (and the three trials) showed strong associations of heart rate with mortality outcomes, 
hence there were no controversial findings related to whether or not an established link was 
present. Additionally, studies assessing specific cardiovascular events were scarce so the 
contribution of a meta-analysis would be quite limited. I conducted the literature search without 
language restrictions, with a combination of free text and controlled vocabulary, used and 
assessed cross references from original articles and systematic reviews to identify any grey 
literature evidence. The lack of findings contrasting the strong evidence of heart rate 
associations with mortality outcomes might imply a “file drawer problem”180, in other words a 
sort of publication bias that affects the probability of a study to be published based on whether 
or not the results are statistically significant, practically significant, or agree with the 
expectations of the researcher, editor or funder. In the following chapters I will explore 
associations of heart rate with specific cardiovascular endpoints as well as mortality outcomes 
(cardiovascular and all-cause) that will enable me to make comparisons with existing literature 
findings. 
 
2.6. Conclusions 
 
In this chapter, I present the findings of a thorough literature search concerning resting heart 
rate and its impact on cardiovascular diseases in various populations. We observed that the 
whole literature body is derived by population surveys, clinical trials or registries, that their 
common characteristic is the research specific purpose of their data collection. The 
disadvantages stemming from that are identified in various aspects such as the limited sample 
sizes, the questionable generalizability of the findings or the representativeness. We also saw 
that their findings are mostly related to mortality endpoints or composite phenotypes. 
Furthermore, different trials showed conflicting results in respect to the nature of endpoints 
affected by heart rate increase that triggers mechanistic considerations regarding the 
underlying risk pathways of cardiovascular diseases. Finally, clinically relevant heart rate 
ranges are often ignored from an analytical perspective. Of particular importance is the use of 
linked electronic records to assess these associations, since the large sample size and 
resolution they offer, enable the design and perform of large scale analyses allowing for 
investigation of heart rate associations across a wide range of individual phenotypes. 
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3. CALIBER: A research platform of linked electronic 
health records 
 
In the present chapter I will describe the CALIBER research platform of linked electronic health 
records (EHRs) that I analysed to answer the main research questions that form part of my 
PhD. The central focus of this chapter is to describe in detail heart rate data available in 
CALIBER, from the source of recording and the marker’s initial form to the research ready 
values of heart rate and their characteristics, parameters important for the exploration of the 
marker’s association with CVDs in the following chapters. Additional aims of this chapter are i) 
to describe the raw data that I used to define the populations, risk factors and cardiovascular 
diseases studied in this PhD, ii) to explain how the process of generation of research ready 
data that I used can be applied to the design of my and similar studies and iii) Discuss the 
strengths and weaknesses of CALIBER.  
 
3.1. Introduction 
 
3.1.1. The importance of HER 
 
EHR systems are revolutionizing health research since they have the potential to transform 
health care from a mostly paper-based system to one that utilizes clinical and other pieces of 
information to assist providers in delivering higher quality of care to their patients. Some of the 
basic benefits associated with the use of EHRs include being able to easily access 
computerized records and the elimination of manual processes, which has historically plagued 
the medical chart 181, 182. In 2011 the government published a Strategy for UK Life Sciences183 
which placed EHR research as a central part of the strategy to accelerate health research in 
the UK.  The UK is unique in being the only country with national cardiovascular disease (CVD) 
registries and primary care data (including important information on cardiovascular risk factors 
and their management in the community) as well as more standard sources such as cause-
specific hospitalization and mortality records and census data available at scale for research. 
Patients’ interactions with the healthcare system generate unprecedented amounts of 
structured and unstructured EHR data that are stored in disparate clinical information systems. 
The rich national EHR data sources are increasingly being linked for translational research in 
the US and Europe with the potential to have a positive impact upon medical care and research. 
In the UK, a unique ten digit identifier is assigned to each patient and used at each interaction 
with the NHS allowing the complete patient journey to be traced through EHRs spanning 
primary care, hospitals, disease registries and ultimately death registries.184  
 
3.1.2. The CALIBER platform 
 
CALIBER is a research platform of linked electronic health records (EHR) and administrative 
health data from primary, secondary and tertiary care, that is GP practices, hospital and disease 
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registries that is held and developed at the Farr Institute of Health Informatics Research at UCL. 
Its aim is to provide evidence to inform health care and public health policy for CVDs across 
different stages of translation, from discovery, through evaluation in trials to implementation, 
where linkages to electronic health records provide new scientific opportunities. In England the 
vast majority of the population are registered with a general practice. The majority of symptoms 
and a large part of diseases first present and captured by primary care in GP practices.  
 
Whereas UK general practices have, via the Clinical Practice Research Datalink (CPRD) and 
other initiatives, contributed EHR data that led to a substantial number of publications, use of 
data within hospitals beyond the Hospital Episode Statistics (HES) has led to very limited 
research. One of the reasons for this is that UK hospitals, similarly to Europe’s hospitals, have 
been at a low level of digital maturity, for example according the Healthcare Information 
Management Systems Society classification.185 
 
3.1.3. EHR and heart rate literature 
 
As I showed in Chapter 2, there is a lack of epidemiological studies examining the associations 
between heart rate and CVDs. The wealth of data recorded in primary and hospital care 
remains unexploited. Heart rate is a clinical finding often collected by GPs in daily medical 
practice. These data generated by those frequent measurements, are population-derived and 
largely representative and could potentially contribute majorly to the validation and 
improvement of clinical practice through heart rate examination and the assessment of its place 
in cardiovascular research. EHRs collected within primary and secondary care settings and 
processed and generated by researchers at Farr Institute however, have substantially 
contributed to cardiovascular research, from the onset of cardiovascular diseases 186-190, to the 
progression of CVDs as showed by CALIBER literature (Table 3.1).191 
 
Table 3.1. CALIBER studies 
CALIBER 
studies 
 Study  
Exposure 
and initial 
presentati
on of 
CVDs 
 
Progno
sis of 
CVDs 
in CAD 
 
Model
s 
adjust
ed for 
heart 
rate 
 
Heart 
rate as 
main 
exposu
re 
 
Associati
ons of an 
exposure 
with atrial 
fibrillation 
             
Rapsoma
niki et. 
al.188 2014 
 BP & 
incidence of 
12 CVDs 
 ●  o  o  o  o 
Rapsoma
niki et 
al.191 
 Prognostic 
models for 
CAD 
 o  ●  ●  o  o 
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Pujades-
Rodriguez 
et. al.190 
2014 
 Socioecono
mic 
Deprivation 
and the 
Incidence of 
12 CVDs 
 ●  o  o  o  o 
Pujades-
Rodriguez 
et. al.189 
2015 
 Heterogene
ous 
associations 
between 
smoking 
and a wide 
range of 
initial 
presentation
s of CVDs 
 ●  o  o  o  o 
Shah et 
al.187 2015 
 Type 2 
diabetes 
and 
incidence of 
CVDs 
 ●  o  o  o  o 
George et. 
al.186 2015 
 How does 
CVD first 
present in 
women and 
men? 
 ●  o  o  o  o 
Present 
PhD 
 
●  ●  ●  ●  ●  ● 
 
 
This wealth of information provides a significant source of data towards the assessment of 
important research questions posed by this PhD on heart rate associations with cardiovascular 
diseases onset (chapter 4), prognosis (chapter 5) and rhythm disorders (chapter 6).  
 
3.2. CALIBER data sources 
 
Four sources of electronic health data have been linked to form the CALIBER dataset. These 
data sources spanning primary care records from i) General Practitioner practices (Clinical 
Practice Research Datalink) and secondary care ( ii)myocardial infarction registry (MINAP 
project), iii) hospital episode statistics (HES) and iv) Office of National Statistics (ONS) mortality 
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and social deprivation data) (Figure 3.1). I used these records linked and processed by 
researchers at Farr Ɨ to address and explore the three main research questions posed by this 
PhD. The CALIBER dataset was used to assess the associations of resting heart rate with CVD 
incidence (Chapter 4), CVD progression (Chapter 5) and incidence and progression of atrial 
fibrillation events (Chapter 6).  
 
 
 
 
 
3.2.1.  CPRD data  
 
 
General practices linkage 
The CPRD database is a primary care data source containing anonymised patient records for 
approximately 8% of the UK population (5.2 million patients)192 and is the only source of heart 
rate information available in CALIBER. General practitioners routinely collect heart rate as part 
of their clinical practice. Patients registered with these practices are informed about the data 
extraction and offered the opportunity to opt out of having their personal data extracted.193 Forty 
per cent of the 636 general practices participating in CPRD permit additional data to be 
extracted to allow linkage of individual patient records with other data sources.194 For the 
• Office for 
National 
Statistics (ONS)
• Hospital Episode 
Statistics (HES)
• Myocardial 
Infarction 
National Audit 
Project (MINAP)
• Clinical Practice 
Research 
Database (CPRD)
Heart rate 
Also:Demographics, 
diagnoses, symptoms, 
referrrals, 
investigations. 
prescriptions and 
health behaviours 
(READ codes)
For Acute 
Coronoary 
Syndomes, ECG 
findings, troponins 
etc.
Cause-specific 
mortality and social 
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Figure 3.1. CALIBER platform data sources 
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studies included in this PhD I used data from the 225 practices in England that consented to 
data linkage.  
 
Data quality and implications of QOF on heart rate 
CPRD has its own data quality control and includes only patients whose data is of “acceptable 
research quality”. The GP contract in 2004, introduced the Quality and Outcomes Framework 
which stipulates specific information which must be recorded and levels of preventive treatment 
to be attained.195 This subsequently brought a rise in heart rate value recordings, since 
CALIBER data show an increase of heart rate measurements that reaches 44% (28% of 
CALIBER measurements were recorded any time before 2004 whereas 72% after that date). 
The criteria that CPRD uses for inclusion of practices are listed in Table 3.2.  A data quality 
audit of the patients’ records is also being used. A proportion of 80% of the practices in the 
CALIBER dataset achieved up-to-standard status by 1st January 2000, with the remaining 
achieving it in subsequent years. Financial incentives were provided to general practitioners to 
improve data completeness and quality.  
 
Read codes (NHS Read Clinical Terms Version 3)  
“Read codes” is a hierarchical standard clinical terminology system used by General 
practitioners in the UK to encode data on symptoms, signs, diagnoses, treatments, referrals, 
laboratory test with or without results, hospital admissions, procedures, administrative 
information and health behaviours. (31) GPs use 7-character Read codes and is named after 
Dr James Read who designed it in 1980s for use in his own clinical practice (33). CPRD created 
the “medcodes” system as a more convenient method in addition to save space. The CPRD 
Read dictionary contains the medcode to Read mapping, and only includes the subset of Read 
codes actually used in CPRD. The groupings of diagnoses are approximately similar to ICD-
10, but the hierarchy within chapters is less strict, so it is necessary to search by term text as 
well as by code to ensure that all relevant codes are included in a codelist. With over 100,000 
codes in the Read classification, compared to approximately 20,000 in ICD-10, there are the 
potential for multiple codes for individual diseases and endpoints.  
 
In 1990, the NHS made Read the default scheme for the NHS and general practice, while in 
1994 formally replaced the so far used OXMIS medical codes. The Systematized Nomenclature 
of Medicine - Clinical Terms (SNOMED-CT), an international hierarchical coding system for use 
with electronic health records is the natural successor to Read codes and has been developed 
with the knowledge gained through this terminology.196 It is applicable to all healthcare 
professions in all health care settings and meets the requirements of both primary and 
secondary care in the UK in contrast to Read codes that cannot be extended to support all 
healthcare needs.196 In primary care, where uptake of structured electronic records is already 
advanced, much of the benefit of using SNOMED CT within the patient record will be seen 
through improved sharing of information across care settings, the ability to receive electronic 
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data such as discharge summaries in a coded format, and the ability to aggregate data across 
care settings to support for example quality outcomes analysis.196  
 
 
Table 3.2 Data quality standards used by CPRD193, 197 
Patient-level quality standards: Acceptable 
research quality (ARQ)  
 Practice-level quality standards: Up 
to standard (UTS)  
An empty or invalid 1st registration date  Monthly prescription rate comparable to 
other  practices 
Absence of a record for a year of birth  Percentage of prescriptions with a 
medical indication 
A first registration date prior to birth year  Death rates comparable to other  
practices 
A transferred out reason with no transferred out 
date 
 Cause of death recorded 
A transferred out date with no transferred out 
reason 
 Outcome of pregnancy recorded 
A transferred out date prior to their first 
registration date 
 Referral rate comparable to other 
practices 
A transferred out date prior to their current 
registration date 
 Percentage of referrals with recorded 
clinical speciality 
A current registration date prior to their first 
registration date 
  
A current registration date prior to their birth 
year 
  
A gender other than 
Female/Male/Indeterminate 
  
An age > 115 at end of follow up   
Recorded health care episodes in years prior to 
birth year 
  
Registration status of temporary patients   
 
 
CPRD provides data in several files consisting of unsorted records, which are described in 
Table A3.3 (Appendix 3).The clinical file for instance has 356,446,923 records, 751,165 for 
heart rate and at least one record for each consultation by every patient registered with GPs in 
CPRD over the time frame of the dataset. The records of interest in HES and ONS have to be 
selected from each relevant file and after being combined with other appropriate records if 
necessary, to provide comprehensible information about individual patients, unlike MINAP data 
that are provided in specified variables. In CALIBER, data sources are easily identifiable and 
distinguished since each entry specifies the dataset used in creating each variable. 
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3.2.2.  HES records 
 
Hospital Episodes Statistics (HES) consists of data on admissions since the financial year 
1989/90 and provide no information on heart rate measurements or other anthropometric, 
numerical measurements. These data are recorded by non-clinical trained coders based on the 
discharge summary weeks after discharge.198 The hospital admission data includes private 
patients treated on NHS premises, NHS patients treated by independent providers on behalf of 
the NHS and non-England patients, as well as NHS patients treated in NHS premises.193 HES 
data available in the linked CALIBER dataset covers the period from 1st April 1997 to 31st 
October 2009. In any given year the completeness of HES in recording admissions to NHS 
hospitals is very high. Admissions to or procedures done privately by independent providers 
are not included in HES and therefore not included in my PhD. HES discharge data has nearly 
complete coverage of admissions and procedures performed in NHS hospitals, though 
unmeasured private admissions and procedures may be as high as 10% of the overall number 
for some procedures, particularly in London. 
 
 ICD-10 (International classification of disease, 10th Edition, World Health Organisation) and 
OPCS4.6 (Office for Population Censuses and Surveys codes) 
ICD-10 is used in the UK and many other countries to record morbidity and causes of death. In 
CALIBER, HES and ONS data are coded using ICD-10. ICD-10 has fewer terms than Read, 
and some specific conditions (e.g. ST elevation myocardial infarction) do not have an individual 
code. The record for each episode includes up to 20 diagnoses, coded using the International 
Classification of Disease, Version 10 (ICD-10),199 and up to 24 procedures, coded using the 
Office of Population Censuses and Surveys (OPCS)  Version 4 codes.200Unlike Read, there 
are associated documents detailing when certain codes may be used, and which combinations 
of codes can be used to record conditions affecting more than one body system. For example, 
if an ICD-10 code states '... not otherwise specified', there is an associated list of conditions 
that have to be excluded (or coded more specifically) for this term to be valid. In Read there 
are no such guidelines for GPs, so terms should be taken on face value. OPCS is used by UK 
hospitals to encode procedures. 
 
3.2.3. MINAP records 
 
MINAP is the national registry of patients recording continuous data from every hospital that 
manages acute coronary syndrome (ACS) patients and includes only acute admission health 
records. Information on the timing of symptom onset and admission, clinical features and 
investigations (including ECG results and biomarkers of myocardial necrosis), past medical 
history, hospital treatment and discharge diagnoses collected prospectively at participating 
hospitals, and submitted to the Central Cardiac Audit Database (CCAD). The data is recorded 
usually by an audit nurse, days or weeks after admission, by abstracting data from hospital 
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records.198 These records are regularly linked by CCAD to mortality data from the Office of 
National Statistics and made available in anonymised form to researchers as well as fed back 
to individual hospitals for quality purposes. MINAP was started in 2000, with a limited number 
of hospitals submitting data. The Registry achieved near national coverage in 2009 with 242 
hospitals in 2009, 100% of NHS hospitals in England and Wales.193  
 
Resolution of MINAP phenotypes 
Clinical phenotypes recordings derived my MINAP records are not offered by any other national 
source, and has shown that the reduced rates of heart attack in the early part of this century 
have been largely confined to ST-segment elevation acute myocardial infarction (STEMI) while 
rates of non-ST-segment elevation acute myocardial infarction (NSTEMI) have remained 
static.193 For this PhD, the distinction between the different types of MI was not feasible during 
analyses, due to limited subjects in each individual phenotype and STEMI and non-STEMI 
codes have been merged together. However, this detailed epidemiology is less easily available 
for other manifestations of CVD, such as abdominal aortic aneurysm and ischaemic stroke, 
because disease-specific registries have either not been developed or have only recently 
started recording data. This represents an important gap in our knowledge, and it is not clear 
whether the risk factors and changing epidemiology for CHD can be generalised to other 
manifestations of CVD.193  
 
3.2.4. ONS records 
 
Data on mortality originate from ONS records. Any death occurring within England and Wales 
must be registered with the registrar of births and deaths, generally within 5 days of the death. 
The mortality data for England and Wales is highly complete. Doctor (general practitioner or 
hospital) completes death certificate with cause of death and ICD codes are added by trained 
non-clinical coders.198UK mortality data do not, however, include people either normally or 
formerly resident in the UK who die abroad.  Evidence applicable to the UK suggests that the 
coding on death certificates for IHD is likely to be accurate, although possibly up to 10% of 
cases may be missed. The primary, underlying and up to 14 secondary causes of death are 
recorded using ICD-10. 
 
Besides mortality data, ONS also provided information on the index of multiple deprivation, a 
deprivation index at the small area level. It is a measure of geographical access  used as a 
surrogate for socio-economic status. 
 
The CALIBER variables and coding algorithms were developed through a process of multiple 
clinical speciality review across two institutions (University College London and the London 
School of Hygiene and Tropical Medicine). Professor Harry Hemingway (HH) – Cardiovascular 
Epidemiology, Professor Liam Smeeth (LS) – General Practice, Professor Adam Timmis (AT) 
– Clinical Cardiology, Dr Anoop Shah (AS) – Clinical Pharmacology, Dr Kate Walters (KW) – 
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General Practice, Dr David Osborne (DO) – Psychiatry, all provided clinical expertise in the 
development of the CALIBER code lists. Spiros Denaxas (SD) provided technical advice and 
wrote the programs to extract the relevant records. Emily Herrett (EH) and Julie George (JG) 
wrote the STATA do-files for selecting the Read code lists, further do-files of the mental health 
portion of the CALIBER manual were developed by Ruzan Udumyan (RU). 
 
3.3. From raw data to research-ready data 
 
The manner and reason for the generation, capture, and recording of EHR data vary 
substantially between healthcare settings. Additionally, different medical classification systems 
are used in different data sources and consequently clinical information may be recorded in 
multiple sources but at different levels of clinical detail.  Integrating data from these different 
sources is therefore complex, but doing so is advantageous for research, and consequently for 
clinical, purposes.  
 
3.3.1. Converting raw data to research-ready data: curated common data model 
   
The key stages in creating research-ready data are:  
1) Development of code lists used to define the exposure of interest, risk factors and 
endpoints and select relevant data from each data file. in the case of clinical diagnoses, 
this includes both the identification of diagnosis codes and of other pieces of 
information that can help to support a given diagnosis. 
2) Definition of such variables, i.e. how the records extracted from data files will be used 
to specify the value of research variables  
3) Development of Algorithms for dealing with duplication and contradiction in the 
variables created  
 
In order to select the relevant records from the study population’s data, a code list for each 
variable is needed. At its simplest, a small number of ICD codes are required to select either 
mortality or hospital diagnosis data; much more extensive lists are required to select records 
from CPRD. Exchange and discussion about code lists is an important aspect of making EHR 
research transparent and reproducible.  
 
To generate each code list, initial search terms were agreed by at least two clinicians, and the 
relevant code dictionary searched for matching codes. For ICD-10 codes, OPCS-4 codes and 
entity codes (used by CPRD to specify the content of subsequent fields in the additional and 
test files (Table 3.2), the search was done by hand by researchers at Farr with reference to 
any published studies found. For Read codes, STATA do-files were used to search the 
electronic code dictionary provided by CPRD. Additional codes were identified by hand-
searching the NHS Read code browser, asking for suggestions from colleagues who had 
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produced lists for other studies or, in some cases, identifying code lists in published studies or 
government reports. A preliminary sifting of the identified codes for relevance was completed, 
and then two clinicians rated the resulting lists for relevance and assigned response categories. 
Any disagreements were resolved in face-to-face meetings.  
 
All variable definitions and coding lists used are available through the CALIBER web portal. In 
creating the variable and coding algorithms, an inclusive approach was adopted, but identified 
codes which the researchers thought were less definitive for the assignment of response 
categories. Principles on the ways in which codes would be assigned to the different response 
categories were agreed, to ensure consistency and increase transparency about coding 
decisions. Within CPRD, clinical signs or test results can be recorded either as a Read code 
(e.g. “O/E blood pressure raised”) or as additional data linked to specific entity codes. The 
variable definitions were agreed by both clinical and non-clinical researchers. 
 
The complexities of EHR data mean that a structured method for combining diverse data 
sources and creating EHR “phenotypes” is needed, but no internationally recognised 
framework currently exists.  An EHR phenotyping algorithm translates these clinical 
requirements into queries that leverage multiple linked EHR sources, identify relevant patients 
and extract disease onset, severity and sub-phenotype information.  Defining phenotyping 
algorithms for a study (disease end-points, disease start-points, exclusions, covariates and risk 
factors) consists of identifying relevant codes for diagnosis (e.g. diagnosis of cancer) or risk 
factors (e.g. recording of smoking status) and defining how they should be combined.  However 
these definitions, on which research findings are based, are poorly described in published 
literature with the exception of cases where the curation of phenotyping algorithms occurs 
upstream by the data provider (e.g. eMERGE Network). 
 
Bioinformaticians and other relevant experts including clinicians and epidemiologists based at 
Farr, created and evaluated a framework (Figure 3.2) for transforming raw EHR data into-
research ready phenotypes in a collaborative and transparent manner by involving domain 
experts across disciplines (epidemiology, computer science, public health, health informatics) 
and using a centralized repository for their distribution and curation.  Below are illustrated the 
steps involved in creating a phenotype using the example of myocardial infarction for which 
data is derived by primary (CPRD) and secondary care (HES and MINAP): 
 
The framework consists of multiple iterative steps from initial phenotype definition with domain 
experts to algorithm implementation, validation and distribution to the scientific community.  
 
A large volume of clinical information in primary care is not coded within the EHR but stored as 
freetext, isolating it from researchers. It is often in uncoded freetext that the apparently ‘trivial’ 
presenting symptoms, signs and test results of life-threatening disease are recorded before a 
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coded diagnosis is arrived at. This uncoded freetext is therefore a potentially rich source of 
diagnostic information, and there is considerable interest in methods of accessing it for research 
purposes.  Farr has developed algorithms to extract useful information from freetext fields of 
EHRs, as a step towards identifying early symptoms of CVD before a formal diagnosis is made.  
The linked CPRD record in CALIBER includes coded information but also freetext fields 
containing information recorded by general practitioners or derived from hospital letters.   
 
Figure 3.2 Development of a phenotype algorithm using the Clinical research using LInked Bespoke 
studies and Electronic health Records (CALIBER) programme (Source Morley, K et al.)201 
 
 
 
3.3.2. Population definition 
 
Before I describe the main exposure of this PhD which is resting heart rate, I will explain the 
rationale behind the selection of participants included in each cohort of the individual studies of 
this PhD. CPRD was the only constituent dataset used to define the inclusion criteria for the 
cohorts populations, assembled from the total number of patients registered with CPRD 
practices.  
 
The populations included in the individual studies were restricted to patients who met the 
CPRD’s relevant quality standards of eligibility as described in the previous sub-section. I 
afterwards imposed a period of one year of up-to-standard GP attendance prior to study entry 
to improve the quality of baseline data and allow for sufficient medical history to be captured. 
All cohorts finally structured and implemented by the data manager (Dr S. Denaxas) further 
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consisted of patients aged 30 and above, were of acceptable research quality, gender recorded 
as either male or female, registered with the GP practice on or after 1st January 2000, their 
current registration period contained at least one year of up-to-standard (UTS) observation time 
before each study entry and finally, had at least one heart rate measurement recorded.  
 
For each of the individual studies in this PhD, a further criterion was applied depending on the 
research question. In the first cohort, the purpose was to investigate the onset of different 
specific CVDs in relation to subjects’ resting heart rate, hence I excluded any patient with a 
prior symptomatic atherosclerotic disease (i.e. a record of coronary disease, ischaemic 
cerebrovascular disease, peripheral arterial disease or unspecified atherosclerotic disease) or 
a ventricular arrhythmia event, cardiac arrest or heart failure in any of the constituent data 
sources of CALIBER.  Patients that their endpoint record after study entry indicated a historical 
event were also excluded.  
 
The date of entry in the study (i.e. the date the follow-up started) for all the cohorts of this study, 
was set as the date the patients had their first heart rate measurement after the application of 
the aforementioned criteria. Hence, the date of entry coincides with the baseline heart rate 
measurement. 
 
3.4. Heart rate: From codes to research ready data 
 
This section presents the heart rate marker in CALIBER, from the identification of heart rate 
sources and relevant codes and raw data retrieval, to final research-ready data exploration in 
the different cohorts. 
 
3.4.1. Heart rate coding 
 
A large piece of work on heart rate coding was already done previously by researchers at Farr 
(JG, AS, EH, KM). After the initial retrieving, identification and coding of heart rate that was 
performed prior to the commencement of the PhD, I was responsible to explore the variable 
and its clinical relevance, process it and incorporate it in the necessary research context, 
analyse its associations with adverse cardiovascular events and develop and disseminate the 
results.  
 
To identify all possible data elements related to heart rate the aforementioned researchers, 
agreed on a set of search terms with two clinicians, and the relevant code dictionary searched 
for matching codes. For Read codes, STATA do-files were used to search the electronic code 
dictionary provided by CPRD. For entity codes that are used by CPRD to specify the content of 
subsequent fields in the additional and test CPRD data files (Table A3.3) the search was done 
by hand by the same researchers with reference to any published studies found. Only one entity 
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code for heart rate was identified (Entity 131). Following the process described above, the Read 
codes used to define heart rate variable are listed in Table 3.4 below. It is noteworthy that 
codes characterizing heart rate as tachycardic or bradycardic have been incorporated in the 
variable structure and kept during the variable’s process. However, a very low number of 
measurements has been recorded as bradycardia or tachycardia. In the main cohort, N=4,808 
patients had at least one bradycardia recording and N=2,000 of tachycardia. Since the 
percentage of bradycardia and tachycardia recordings was too low (less than 2%) compared to 
the pulse rate code (98.3%) I incorporated them in the main heart rate variable. These codes 
identified below were used alone or in concert to define heart rate variable and retrieve the 
relevant population with at least one record of these codes.  
 
Table 3.4. Heart rate and its Read terms in CPRD (top percentages) 
Medcode  Read code  Read term  n Percent 
Healthy population (IP cohort) 
6154  242..00  O/E - pulse rate  408,629 
 
98.3 
22442  2431  O/E - pulse rhythm regular  2258 
 
0.54 
23018  2424  O/E - pulse rate normal  2186 
 
0.52 
7128  2426.11  O/E - tachycardia  835 
 
0.20 
1352  2422.11  O/E - bradycardia  721 
 
0.17 
26716  2426  O/E - pulse rate tachycardia  252 
 
0.06 
17413  243..00  O/E - pulse rhythm  130 
 
0.03 
13608  2422  O/E - pulse rate - bradycardia  90 0.02 
26670  2432  O/E - pulse irregularly irreg.  86 
 
0.02 
47594  242Z.00  O/E - pulse rate NOS  31 
 
0.01 
26715  2423  O/E - pulse borderline slow  28 
 
0.01 
26713  2425  O/E - pulse borderline fast  25 
 
0.01 
CAD population 
6154  242..00  O/E - pulse rate  25977 
 
95.05 
23018  2424  O/E - pulse rate normal  1143 
 
4.18 
7128  2426.11  O/E - tachycardia  67 
 
0.24 
17413  243..00  O/E - pulse rhythm  37 
 
0.13 
22442  2431  O/E - pulse rhythm regular  24 
 
0.08 
26716  2426  O/E - pulse rate tachycardia  15 
 
0.05 
1352  2422.11  O/E - bradycardia  10 
 
0.03 
47594  242Z.00  O/E - pulse rate NOS  3 
 
0.01 
13608  2422  O/E - pulse rate - bradycardia  2 0.01 
 
 
3.4.2. Heart rate characteristics  
 
Mean heart rate in CALIBER populations vs consented cohorts-Representativeness of 
CALIBER 
 
Mean heart rate in the CALIBER healthy cohort was found to be 76.5bpm (±14.3). There is 
insufficient literature evidence regarding the overall population mean heart rate of other 
epidemiological studies. In a study conducted in Japan by Fujiura et al. the mean heart rate 
was found to be 68.1 (±11.5) bpm. However, the small sample size restricts comparability with 
CALIBER that its sample size is over 233,900 patients (Table 3.5). Additionally, no report of 
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beta-blockers intake in this Japan population was found in the text. In CALIBER population, 
34.4% of people had a recording of at least one beta-blocker intake during the year before the 
heart rate measurement. Given the values of mean heart rate in each study of the Table 3.5 
below and Figure A3.3 in the Appendix between the two sexes, CALIBER marker’s values are 
presented to be higher than the rest of the healthy population studies. Significant differences 
between CALIBER heart rate mean values and Shaper et al.148 and Mensink et al. studies were 
found. Shaper et al. population was confined to men with a limited sample size, while the data 
was collected the year 1969, hence, secular trends (an increase to heart rate) could be 
responsible for the difference between that population and CALIBER’s mean heart rate. 
Additionally, they found that men under hypertensive treatment (no specification of the type of 
treatment) had a 4bpm lower heart rate than those without (66.7bpm vs 70.5bpm) that could 
have affected the overall men mean heart rate. Mensink et al. that provided no information on 
the baseline beta-blocker (or other hypertension treatment medication) intake, showed a mean 
heart rate in men of 70bpm in men and 73.3bpm in women compared to CALIBER that showed 
74.6bpm and 77.9bpm in men and women respectively (Table 3.5). Only the study of Tverdal 
et al.152 with data collected in 1985 but with a high sample size showed a similar mean heart 
rate in women (77.1bpm) vs 77.9 in CALIBER women.  
 
Heart rate in people with coronary artery disease in CALIBER was approximately 4.3bpm lower 
and its median 4bpm lower (72bpm) than the healthy cohort. Aboyans et al.162 observed an 
overall mean heart rate of 65.8bpm. Its small sample size however might play a role on the 
difference of CALIBER. Further Aboyans et al. study had increased levels of beta-blockers 
intake (60.1%) and a 85.4% revascularization rate that could affect the overall mean HR values. 
Finally, Lonn et al.145 had again lower mean values. The only exception was the study of Kolloch 
et al.166 that showed a mean total heart rate of 75.7bpm, 3.5bpm higher of that of CALIBER 
(Table 3.5). 
 
This difference between mean heart rate values in CALIBER and other epidemiological studies 
with CALIBER values being consistently larger, might be due to other confounders, such as 
acute effects, e.g. acute stress episodes. Other acute events that might have interfered could 
be a fever or pyretial symptoms, however data could not be retrieved due to time restrictions.   
 
In both cohorts the degree of skewness was similar between the two genders. Additionally, in 
both cohorts the kurtosis was closer to 3 (kurtosis=4.6 for both genders in healthy population, 
6.8 in men and 5.3 in women in the CAD population). In Figure A3.4 I present the distribution, 
location and variability features of heart rate in the healthy CALIBER and CAD cohorts. 
3.4.2.1. Mean heart rate in men and women 
 
Women had consistently a mean heart rate approximately 3.3bpm higher than men (77.9 ±14.1 
vs 74.6 ±14.5 respectively) and a median of 4bpm in CALIBER healthy population. Compared 
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to available literature, this difference in means was the same compared to that of Mensink et 
al. that the heart rate mean for men was 70bpm and women 73.3bpm (difference 3.3bpm), and 
Palatini et al. study in which men had a heart rate of 73.1bpm and women 76.3bpm (Figure 
A3.3). These similar findings confirm the representativeness of CALIBER heart rate recordings 
in a greater context of healthy populations and validate our assumption of the resting state of 
patients while these measurements were recorded.  
 
In CALIBER CAD population the difference between sexes reached the 4bpm (74.4 bpm vs 
70.5 bpm respectively) and a median difference of 2bpm. Women had 4bpm higher heart rate 
(74.4 vs 70.5), with an overall mean of 72.2bpm. Separate heart rate values for men and women 
are not reported in the literature, probably due to the small sample sizes that do not allow for 
individual estimations.  
 
 
 
Table 3.5. Mean heart rate in CALIBER populations vs consented cohorts 
   Year of 
study 
N of 
participants 
Age (±SD) Resting heart rate (±SD) 
 
Study  Men Women 
Total 
cohort 
H
e
a
lt
h
y
 c
o
h
o
rt
s
 
CALIBER  2015 233,970 47.5 (±15.7) 
74.6 
(±14.5) 
77.9 
(±14.1) 
76.5 
(±14.3) 
Shaper et 
al. 
 1969 7,735 40-59 (N/A) 
70.7 
(±12.8) 
- - 
Mensink 
et. al. 
 1982 4,756 40-80 (N/A) 
70 
(±11.6) 
73.3 
(±10.6) 
- 
Palatini 
et. al. 
 1999 1,938 
72.7 in men & 
73.3 in women 
73.1 
(±13.6) 
76.3 
(±10.9) 
- 
Fujiura 
et. al. 
 1977 573 50.5 (±6.8) - - 
68.1 
(±11.5) 
Tverdal 
et. al. 
 1985 379,843 40-45 (N/A) 72.6 77.1 - 
         
C
A
D
 c
o
h
o
rt
s
 
CALIBER  2015 51,703 72.3 (±11.4) 
70.5 
(±14.4) 
74.3 
(±14.3) 
72.2 
(±14.5) 
Aboyans 
et. al. 
 
1998-
2002 
1,022 66.9 (±9.2) - - 
65.8 
(±13.5) 
Kolloch 
et. al. 
 1998 22,192 65.9 
75.2 
(±9.7) 
76.2 
(±9.4) 
75.7 
(±9.6) 
Lonn et. 
al. 
 - 31,531 66.5 - - 
68.1  
(±12.2) 
Note: N/A, Mean not available in the text 
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3.4.2.2. Atrial fibrillation and sinus rhythm 
 
The normal regular rhythm of the heart is set by the natural pacemaker of the heart called the 
sinoatrial (sinus) node. It is located in the wall of the right atrium and it is the place where normal 
cardiac impulses start and are transmitted to the atria and down to the ventricles and this type 
of rhythm is called sinus rhythm. Although normally sinus node sends out regular electrical 
impulses, sometimes these impulses are fired off from different places in the atria in a 
disorganised way and this is called atrial fibrillation rhythm. To explore normal heart rate effects, 
it is vital to distinguish between those two types of pulses and make sure that the patients in 
the cohorts have been recorded with the sinus type of rhythm. However, the type of heart rate 
is not easily identifiable and there is a possibility that could be entangled in a complex link with 
atrial fibrillation (AF) rhythm. To investigate whether or not it is possible that AF rhythm often 
represents the normal sinus heart rate rhythm in my data, I checked whether AF events 
diagnoses frequently coincide with the day of heart rate measurement in total AF events on the 
same day or within a month from a heart rate recording, AF events exclusively recorded in 
primary care and secondary care. The results are presented in Table 3.6 below. 
 
  
Table 3.6. Atrial fibrillation events by heart rate level 
AF events  Heart rate categories 
Healthy cohort (excluding 
baseline symptomatic 
CVDs) 
 
<60  60-69  70-79  80-89  >90bpm 
AF total events Ɨ 
 13 
(0.07%) 
 
28 
(0.05%) 
 
57 
(0.08%) 
 
74 
(0.13%) 
 
178 
(0.49%) 
AF total events* 
 126 
(0.69%) 
 
277 
(0.53%) 
 
345 
(0.49%) 
 
418 
(0.74%) 
 
612 
(1.70%) 
AF in Primary careƗ  
 10 
(0.05%) 
 
26 
(0.05%) 
 
40 
(0.06%) 
 
63 
(0.11%) 
 
177 
(0.49%) 
AF in Primary care*  
 74 
(0.45%) 
 
150 
(0,74%) 
 
185 
(0,89%) 
 
150 
(0,73%) 
 
133 
(0,68%) 
AF in secondary careƗ  
 3 
(0.03%) 
 
2 
(0.01%) 
 
17 
(0.00) 
 
11 
(0.01%) 
 
1 
(0.09%) 
AF in secondary care* 
 52 
(0.28%) 
 
127 
(0.24%) 
 
160 
(0.23%) 
 
268 
(0.48%) 
 
479 
(1.33%) 
Ɨ AF event experienced on the same day as heart rate measurement 
*AF event experienced within a month before or after the heart rate measurement 
 
 
The above data show a very low incidence of AF events on the day or within a narrow window 
of one month from a heart rate measurement, in both healthy and CAD populations. Therefore, 
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there is a strong basis to assume that the heart rate nature under investigation of this PhD is 
majorly represented by sinus rhythm. 
  
3.4.2.3. Digit preference 
 
A common phenomenon observed in clinical practice recording is the terminal digit preference 
phenomenon. Measurement of continuous variables is often in practice transformed into 
discrete data, “rounding off to the next multiple of five or 10. 122 Keary et al reported that doctors 
have a 12-fold bias in favour of the terminal digit zero when measuring blood pressure.22 
Terminal digit preference can lead to overestimation or underestimation of actual blood 
pressure and can distort the distribution of observations. This error can potentially reduce the 
power of statistical tests - the chance that the study will find a significant association if one is 
truly present. Therefore, accuracy is important. A recent study done in Quebec202 showed that 
although recommendations have been available for years, a persistent lack of technical and 
practical knowledge in digit preference of blood pressure measurements, is still present. 
Exclusively blood pressure studies have addressed and treated this problem, since in contrast 
to heart rate, is more “objectively” measurable when relies on manual measurement, which is 
a common practice in primary care. The increasing use of digital sphygmomanometers in many 
practices will eventually decrease the errors due to terminal digit preference as well as mercury 
and aneroid device errors, therefore decreasing the sources of variability and increasing the 
quality of BP measurement.203 
Available literature on heart rate has so far failed to explore the digit preference phenomenon. 
As part of my PhD I assessed evidence for this potential systematic bias by examining the 
distribution of recorded heart rate values. Some evidence of digit preference in heart rate 
measurements of CALIBER, which not necessarily end in odd numbers was identified. In the 
CALIBER healthy cohort we observe a higher frequency of recording in values ending in odd 
numbers and multiples of 10 (Figure 3.5(a&b) and Table A3.7 (Appendix 3).  
 
One of the challenges of EHR is the absence of evidence related to the way of specific 
recordings such as heart rate measurements. There are several ways of measuring heart rate, 
e.g. palpation at the wrist, auscultation of the heart or electrocardiogram (ECG) and more 
objective such as sphygmomanometer. Since I am not able to define the way of heart rate 
measurement, hence the accuracy of these recordings, I will use as a proxy of accuracy the 
proportion of heart rate measurements that were taken on the same day as blood pressure 
measurements, given that the latter were recorded using an automated device. This implies 
that heart rate measurements might have been taken using the same device, hence the 
recordings are more accurate. Of the total number of patients, 82.6% of people with a heart 
rate record had a blood pressure measurement on the same day in the healthy cohort and 
100% in the CAD cohort, suggesting a large proportion of heart rate measurements were 
obtained using an automated blood pressure device. In healthy CALIBER, 76.8% (n=179,588) 
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of heart rate measurements end in odd numbers, while 25.2% (n=59,665) end in multiples of 
ten. After restricting to those that had a blood pressure measurement on the same day, 74.91% 
(n=121,691) end in odd numbers and 23.8% (n=38,785) end in multiples of ten. Restricting to 
those with the baseline heart rate measurement not taken on the same day as the blood 
pressure, the difference was not significant as 76.8% (n=178,260) end in odd numbers and 
25.5% (n=59,239) end in zero (Table A3.8). In the CAD CALIBER cohort, returned higher 
percentage of measurements ending in even numbers (81.7%) and a 28.8% ending in multiples 
of zero. The restriction to those with blood pressure measurements on the same day as heart 
rate gave similar results, with 78.1% of measurements end in odd numbers and 25.5% in zeros. 
Restriction to those without heart rate and blood pressure measurements on the same day 
showed a percentage of 81.7% ending in odd numbers and 28.7% end in multiples of ten (Table 
A3.8). 
 
Identifying heart rate recordings taken on the same day as blood pressure that would imply 
measurement of heart rate using an accurate clinical device and not taken on the same day, 
showed little evidence of a difference in heart rate values ending in even numbers or zeros. 
This could be interpreted either as: i) Heart rate measured on the same day as blood pressure 
is not indicative as to what and if a device was used, ii) Possible methods of heart rate 
measurements were palpation at the wrist or auscultation of the heart by clinicians or nursing 
staff, hence questionable accuracy of measurements (although reading errors have clinical 
relevancy when heart rate is near the high risk thresholds (>90bpm), iii) These observed values 
are the true heart rate values in the general population.  
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Figure 3.5 (a)) Histogram of heart rate in CALIBER healthy cohort 
Mean heart 
rate=76.5bpm 
SD=14.3 
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3.4.2.4. Repeated heart rate measurements 
 
Over a mean time of 3.67 years, 41.8% of the population with heart rate measurements had a 
single heart rate measurement, 19.9% had 2 measurements, 24.4% had 3 to 5 and the rest 
13.9% had >5 heart rate measurements (Figure 3.6). To assess the amount of patients that 
had a change in their heart rate it is useful to set heart rate ranges across which any change in 
the rhythm could be identifiable.  
 
To that effect I will use heart rate ranges with clinical relevance that will be also used in the 
following chapters as the main heart rate levels included in my analyses. These ranges are 
defined as: <60bpm, 60-69bpm, 70-79bpm, 80-89bpm, >90bpm. Of 445,510 heart rate 
measurements in total (including repeated measurements), 14.9% remained in the same heart 
rate level in the subsequent measurement. When heart rate of patients showed an increase or 
decrease in a subsequent GP visit, it would not often observed more than one level up or down 
with levels (Figure 3.7). In my PhD, I used the baseline heart rate measurement which was 
Figure 3.5 (b) Histogram of heart rate in CALIBER CAD cohort 
Mean heart 
rate=72.2bpm 
SD=14.5 
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closer to, and right after the date of entry after applying the general eligibility criteria described 
in section 3.4.  
 
 
 
 
 
  
A single HR measurement
2 HR measurements
3/4/5 HR measurements
>5 HR measurements
41.8%
19.9%
24.4%
13.9%
Heart rate measurements frequency
Stable (No HR level change)
HR level change
1 HR level change (downwards)
2 HR levels change (downwards)
3 HR levels change (downwards)
4 HR levels change (downwards)
1 HR level change (upwards)
2 HR levels change (upwards)
3 HR levels change (upwards)
4 HR levels change (upwards)
14.9%
43.1%
7.6%
2.6%
0.6%
0.1%
7.7%
2.5%
0.7%
0.1%
Heart rate changes frequency
Figure 3.6. Frequency of heart rate measurements in CALIBER 
Figure 3.7.Frequency of heart rate changes across GP visitations 
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3.4.2.5. Subjects without heart rate measurements  
 
As I will describe in 3.8.2.1 section, one of the concerns with EHR data is the extent of 
information which is unrecorded for patients and particularly when information on the main 
exposure (i.e. heart rate) is missing. Below in Table 3.9 I have compared in greater detail the 
baseline characteristics of patients with heart rate recordings and without a recording.  
 
It is apparent from the table above that patients with a heart rate measurement included in the 
analysis were 14 years older, more likely to be women and to suffer from diabetes compared 
to patients without heart rate measurements. People with heart rate measurements are also 
more often hypertensive with more frequent systolic blood pressure recordings and higher 
intake of bet and calcium channel blockers. These findings are potentially due to the fact that 
older people visit GPs more often, have additional medical reasons which affect the cardiac 
regulatory system or due to the family history, a more thorough clinical examination is required 
(Table 3.9 above). There is clearly a difference between these two types of patients that could 
potentially lead to important clinical and methodological implications, such as overestimation of 
heart rate effect and reduced generalizability and representativeness of findings. Due to the 
nature of the fraction of population that attended GP practices for various health reasons (either 
they are hypertensive, or diabetic) that had consequently heart rate recordings in primary care, 
the distribution of people’s characteristics is not equal between the two cohorts (with and 
without heart rate recordings). As a consequence, we have to be very careful during the 
interpretation and dissemination part of this PhD results. 
 
3.5. Additional risk factors and cardiovascular diseases  
 
3.5.1. Risk factors 
 
In order to explore associations of heart rate with CVDs, further confounders that might affect 
these associations should be examined. I used additional risk factors to control for in my 
statistical models and these risk factors (or co-variates) are presented below. Sex, age and 
index of multiple deprivation variables were taken as static values from the CPRD patient file. 
All the rests have commonly multiple records per patient. For these records I used the one 
recorded on the date closest to the patient’s study entry up to a year prior to date of entry. 
CALIBER research platform contains the algorithms for research-ready data which incorporate 
data definitions, including meta-data, and the code lists required to produce research-ready 
datasets. This information can be accessed electronically via the CALIBER web data portal at 
https://www.caliberresearch.org/portal. Below, the sources of the most common risk factors 
implemented in this PhD analyses are briefly presented. 
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Table 3.9 Baseline characteristics of people with and without heart rate recoded 
 Heart Rate non recorded Heart rate recorded (all 
levels) 
 
        
 N 
Mean (% 
proportion
) 
sd N 
Mean (% 
proportion
) 
sd 
N% 
recorde
d Demographic factors        
Age at entry 1,701,96
4 
46.2 14.
7 
233,97
0 
58.3 16.
4 
100 
  Female 675,025 (44.8)  11 ,43
6 
( 56.2)  100 
 White ethnicity  534,500 ( 70.3)  98,764 (73.2)  52.5 
IMD score (5th quintile-most 
deprived) 
293,615 (19.6)  44,933 (22.9)  99.5 
Clinical factors        
Systolic blood pressure, 
(mmHg) 
581,414 129.9 18.
4 
125,24
1 
139.8 20.
1 
63.7 
Diastolic blood pressure, 
(mmHg) 
581,414 78.7 10.
0 
125,24
1 
81.6 1 .
0 
63.7 
High density lipoproteins, 
(mmol/L) 
72,060 1.40 0.4
5 
46, 86 1.43 
.43 
6.94 
Low density lipoproteins, 
(mmol/L) 
59,436 3.30 1.0
1 
37,460 3.18 1.0
2 
5.69 
Total cholesterol  (mmol/L) 112,033 5.45 1.1
6 
59,095 5.33 1.1
7 
10.0 
Triglycerides (mmol/L) 80,875 1.69 1.3
7 
45,949 1.64 1.1
2 
7.45 
Creatinine  μmol/L 145,268 85.4 23.
5 
79,752 88.0 27.
7 
13.2 
Haemoglobin (g/dL) 150,980 13.9 1.5
0 
67,849 13.7 1.5
3 
12.8 
Lymphocytes (10^9 / L) 120,836 2.13 1.2
5 
60,506 2.10 1.2
1 
10.6 
Neutrophils (10^9 / L) 120,413 4.07 1.8
2 
60,618 4.25 1.8
6 
10.6 
Diabetes II 18,717 1.24  10,338 5.26   
Behavioural/Environmenta
l factors 
       
Smoking       85.5 
  Non-smokers 758,298 (60.0)  116,72
6 
(60.8)   
  Ex-smoker 173,235 (13.7)  30,262 (15.7)   
  Current smoker 332,070 ( 26.2)  44,836 ( 23.3)   
BMI ( kg / m2) 432,269 26.3 5.1
6 
68,548 28.2 6.1
2 
29.4 
Family history of CHD 51,548 ( 3.42)  3,744 (1.91)  100 
Medication        
Beta blockers 62,098 (4.12)  28,245 (14.3)   
Calcium channel blockers 35,404 (2.35)  23,456 ( 11.9)   
Statins 26,904 ( 1.79)  22,385 ( 11.4)   
Aspirin 24,031 ( 1.60)  16,916 ( 8.61)   
Diltiazem 1,990 ( 0.13)  1,384 (0.70)   
Verapamil 1,638 (0.11)  742 (0.38)   
Hypertensives 58,434 (3.88)  22,871 ( 11.6)   
Other cardiac and rhythm 
conditions 
       
Atrial fibrillation 3,116 ( 0.18)  4,785 (2.05)   
Valve disease 16,819 ( 0.97)  7,452 (3.19)   
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Gender  
Gender was recorded in the patient file in CPRD. Patients with indeterminate gender were 
excluded from the study. Gender was used in my analyses as a covariate in the standard Cox 
models or as a binary classification for exploration of absolute differences in hazards during 
subgroup analyses. 
 
Smoking  
Smoking status was routinely recorded by GPs in their daily practice, practices nurse, 
healthcare assistants or administrative staff either in the context of new patient questionnaires 
or individual consultations. This data is provided by CPRD, using Read codes. In the present 
thesis, smoking status was classified as ex-smoker, current smoker or non-smoker. Where a 
patient’s last smoking status prior to study entry was non-smoker, their status was changed to 
ex-smoker if there was any previous record of being a smoker at any point in the patient’s 
history.  
 
Blood pressure 
The blood pressure measurements used in this study were recorded as part of routine care in 
general practice. The measurements were made by a wide variety of staff, including GPs and 
practice nurses, using different machines under a variety of conditions, ranging from GP 
consultations for potentially unrelated illnesses to new patient checks to hypertension clinics. 
The data was provided by CPRD. No information on the circumstances under which the 
measurements were taken was available for this study. Systolic blood pressure (SBP) at 
baseline was defined as the mean SBP over the two years prior to study entry. Diastolic blood 
pressure (DBP) at baseline was similarly defined.  
 
Age  
Age at study entry was derived from the year of birth recorded in CPRD, assuming a date of 
birth of 1st January of that year. The actual date of birth is not available in pseudo-anonymised 
data to protect patient identities.  
 
Social deprivation  
The index of multiple deprivation (IMD), was used to measure social deprivation. For analytic 
purposes of this PhD, IMD was divided into quintiles with the lowest quintile indicating the 
greatest deprivation.  
 
Lipids  
Total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) 
cholesterol, and triglycerides in mmol/L were recorded in the CPRD test file. Records with unit 
in mmol/L or those with none were extracted, but there were significant differences in the 
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distribution of those with units recorded and those with none, so only those with mmol/L 
specified were used.  
 
Use of statins  
Use of statins was derived from a minimum of a single prescription of a statin recorded in CPRD 
during one year before study entry.  
 
Body mass index  
Patients’ body mass index (BMI) in kg/m2 recorded in the CPRD additional file was used for 
this variable. 
 
Diabetes mellitus  
Patients with diabetes mellitus were identified by any record in CPRD prior to study entry of:  
 A diagnosis of Type I, Type II or not further specified;  
 A monitoring or treatment which specifically identified diabetes;  
 Complications of diabetes; or  
 One or more prescriptions for insulin or oral anti-diabetic medication.  
 
This approach to defining diabetes did not take into account any measurements of blood 
glucose (although these are available in limited patients in CPRD) and may have under-
estimated diabetes. Although the date of onset of diabetes is generally difficult to determine, 
the approach to analysis used in this thesis did not treat diabetes as a time-varying co-variate, 
so the timing of onset of diabetes did not pose a problem for these particular set of analyses. 
 
Use of anti-hypertension medication  
Use of anti-hypertensive medication was derived from at least two successive prescriptions for 
commonly used agents [beta-blockers, angiotensin-converting-enzyme (ACE) inhibitors, 
angiotensin receptor blockers (ARBs), thiazides] as well as other less common preparations.  
 
3.5.2. Cardiovascular diseases 
 
Sources and description of the cardiovascular diseases used by this PhD to investigate whether 
specific vascular, cerebral or peripheral phenotypes are affected by resting heart rate are 
presented below. An overview of codes used to define these endpoints along with their 
information sources are showed in Table A3.10 in Appendix. 
 
Stable angina (SA) 
 Sources: CPRD, HES and MINAP 
 
Patients with stable angina were identified by a record of:  
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 A diagnosis of stable angina or angina pectoris not further specified (ICD-10 I20, 
excluding I20.0);  
 A coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI) 
not within 30 days of an admission for myocardial infarction or unstable angina;  
 Two or more subsequent prescriptions for nitrates or other specific anti-anginal 
medication; or  
 An abnormal result following an exercise ECG, stress echocardiogram, radioisotope 
scan, or an invasive, computed tomography (CT), magnetic resonance imaging (MRI) 
or unspecified angiogram.  
 
 
 
Acute myocardial infarction (AMI) 
 Sources: Acute myocardial presentations are derived from three data sources; CPRD, 
HES & MINAP.  
 
Acute myocardial infarction includes three subtypes; ST elevation myocardial infarction 
(STEMI), non-ST elevation myocardial infarction (nSTEMI) and myocardial infarction not 
otherwise specified (MI NOS). Patients with STEMI were identified by a combination of ST-
elevation on ECG, raised troponins and clinical findings indicative of MI in MINAP data, as 
defined by the internationally agreed definition of STEMI.204 A record of diagnosis of STEMI in 
CPRD was also included, on the basis that this would reflect information from a discharge letter 
from an acute admission.193 Similarly, patients with nSTEMI were identified by no ST-elevation 
on ECG, raised troponins and clinical findings indicative of MI in MINAP data and diagnosis 
code alone from CPRD.193 All other records which did not specify type of myocardial infarction 
(MI), including AMI codes from HES (ICD-10 I21, I22, & I23), were included in MI not otherwise 
specified (NOS). Patients with unheralded fatal MI were included in the unheralded coronary 
death category. Due to sample size restrictions, in the present PhD individual studies (chapters 
4, 5, 6) STEMI, nSTEMI and MI NOS endpoints were merged into a single cardiovascular event, 
MI. 
 
Unstable angina (UA) 
 Sources: CPRD, HES and MINAP 
 
Patients with unstable angina were identified in MINAP by clinical findings of acute coronary 
syndrome but no raised ST elevation on ECG and no raised troponin levels.193UA was further 
identified by diagnosis of unstable angina (ICD10 I20.0) or acute ischaemic heart disease (I24, 
I 24.0, I24.8 & I24.9) in HES or unstable/worsening angina or acute coronary syndrome in 
CPRD.  
Coronary heart disease not otherwise specified (CHD NOS)  
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 Sources: CPRD, HES 
 
Patients with coronary heart disease not otherwise specified (CHD NOS) were those with a 
variety of non-specific diagnoses such as CHD NOS, chronic ischaemic heart disease and 
silent myocardial ischaemia (I25 excluding I25.2, old myocardial infarction) in either CPRD or 
HES.  
 
Heart failure (HF) 
 Sources: CPRD, MINAP, HES, ONS 
 
Patients with heart failure were identified by a record of:  
 A diagnosis of heart failure in HES (I50, I26.0, I11.0, I13.0 & I13.2) or CPRD; or  
 A result of left ventricular hypertrophy on a resting ECG in CPRD; or  
 An underlying cause of death (UCOD) of HF in mortality data as the first presentation 
of atherosclerotic disease after study entry.  
 
Unheralded coronary death (UCD) 
 Source: ONS 
 
UCD was exclusively identified by mortality records of ONS. Patients with unheralded coronary 
death were identified by an UCOD from coronary heart disease (ICD-10 I20-I25) which was not 
preceded by any other atherosclerotic code.  
 
Sudden cardiac death, ventricular arrhythmias, cardiac arrest (SCD, V/A, CA) 
 Sources: CPRD, MINAP, HES, ONS 
 
Patients with ventricular arrhythmias, cardiac arrest or sudden cardiac death were identified by:  
 A diagnosis of ventricular tachycardia (I47.2) or fibrillation (I47.0); or  
 Asystole, cardiac arrest (I46, I46.0 & I46.9), cardiac resuscitation, electro-mechanical 
dissociation; or  
 Implanted cardiac defibrillation device; or  
 A diagnosis of sudden cardiac death in HES or CPRD; or  
 Mortality from cardiac arrest, sudden cardiac death or ventricular arrhythmia.  
 
Ischaemic stroke  
 Sources: CPRD, HES and ONS 
 
Patients with stroke were identified by:  
 A record of ischaemic stroke (I63); or  
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 A record of stroke not otherwise specified (I64, G46.3-G46.7); or  
 Mortality from any of the above as the first presentation of CVD.  
 
Patients with stroke not otherwise specified (NOS) were included since the large majority of 
such unspecified strokes are commonly ischaemic.  Under ischaemic category however, fall 
also some patients with haemorrhagic stroke. Ischaemic stroke will be used as an independent 
endpoint in chapter 4 for the assessment of heart rate on 12 CVDS and as a part of a composite 
stroke endpoint in chapter 5 where I will explore heart rate relationships and prognosis of CVDs 
in patients with CAD. 
 
Subarachnoid haemorrhage  
 Sources: CPRD, HES and ONS 
 
Subarachnoid haemorrhage events were identified as: 
 Subarachnoid haemorrhage from carotid siphon and bifurcation (G601.00) 
 Subarachnoid haemorrhage from middle cerebral artery (G602.00) 
 Subarachnoid haemorrhage from intracranial artery, unspecified (G60X.00) 
 A record of subarachnoid haemorrhage (I60) 
 Mortality from any of the above as the first presentation of CVD.  
 
Similarly as ischaemic stroke, subarachnoid haemorrhage will be used as an independent 
endpoint in chapter 4, whereas as a part of a composite stroke endpoint in chapter 5. 
 
Intracerebral haemorrhage 
 Sources: CPRD, HES and ONS 
 
Intracerebral haemorrhage events were identified as: 
 A record of subarachnoid haemorrhage (I61) 
 Mortality from any of the above as the first presentation of CVD or 
 A record of haemorrhage not otherwise specified (I64, G46.3-G46.7) 
 
Intracerebral haemorrhage, similarly to ischaemic stroke and subarachnoid haemorrhage, will 
be used as an individual endpoint in chapter 4 and as a part of the composite stroke endpoint 
in chapter 5. 
 
Transient ischaemic attack (TIA) 
 Sources: CPRD, HES and ONS 
 
TIA events were identified as: 
 A record of transient ischaemic attack (G458) 
   102 
 
 Mortality from any of the above as the first presentation of CVD  
 
Abdominal aortic aneurysm event (AAA) 
 Sources: CPRD, HES and ONS 
 
Patients with AAA were identified by:  
 A diagnosis of AAA (I71), other than thoracic AAA ; or  
 An abnormal results on abdominal ultrasound or CT indicating AAA; or  
 A procedure for AAA; or  
 Mortality from AAA as the first presentation of CVD.  
 
Peripheral arterial disease (PAD) 
 Sources: CPRD, HES, MINAP and ONS 
 
Patients with PAD were identified by:  
 A diagnosis of PAD (I73, I73.1, I73.8, I73.9) including peripheral complications of 
diabetes, peripheral ischaemia, peripheral vascular disease, gangrene and intermittent 
claudication; or  
 An abnormal results on abdominal ultrasound or CT indicating PAD; or  
 A procedure for PAD; or  
 Mortality from PAD as the first presentation of CVD.  
 
 
3.6. CALIBER strengths and weaknesses 
 
The most important CALIBER strengths and limitations are: 
 
Strengths 
 Large sample size, hence great resolution in exposures 
 Clinical phenotypes resolution 
 Data readily updateable- Absence of any manual effort of investigators spanning from 
recruitment process to data recording 
 Efficiency- Recruitment, baseline and follow up phenotypic assessment zero cost to 
research funder 
 Flexible opportunities to define disease follow-up (start point and endpoints), based on 
availability in the clinical record of ‘Phenome wide’ information 
 Flexibility in cohorts definition 
 Flexibility in inclusion criteria of individual cohorts-diverse population that allows for 
investigation of various research questions applicable to different populations 
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Weaknesses:  
 Missing information at a practice, patient and data level 
 Linkage process difficulties 
 Difficult to handle and curate, demand high degree of expertise-large datasets to 
handle. 
 
3.6.1. CALIBER strengths 
 
The CALIBER platform is a part of a greater vision to provide evidence across different stages 
of translation, related to cardiovascular research using linked electronic health records. Its 
strengths are stemming from a combination of primary and secondary care and disease registry 
data that cover the whole spectrum of clinical phenotyping in a large UK population. For 
research purposes of the present PhD, linked electronic health records offered a vast resource 
of diverse clinical data that allowed the exploration of research questions regarding heart rate 
and its impact on CVDs to be performed with accuracy, high resolution and completeness. 
 
Large sample sizes-High statistical power 
By consenting 225 GP practices with the subsequent linkage of additional sources not only at 
the follow-up phase but also at the baseline level (which is defined by the requirements of each 
individual study), that yielded >3 billion records of raw data, >700 clinical terms and 106 cohort 
sample sizes and makes it one of the biggest clinical information sources of real world data 
worldwide. Higher sample is also translated into sufficient power and accuracy to explore 
differential effects across different subgroups, for instance gender or age, etc. that without it 
epidemiological studies have failed to produce clinically important findings such as differential 
effects of heart rate on CVD phenotypes172 or null effects in women e.g. on heart failure by 
Nanchen et al.159 In clinical research this is of crucial importance since personalised care 
promotes the delivery of a more effective and sustainable health care. 
 
 Resolution of clinical phenotypes  
This substantial body of research data further allows for an in depth exploration of a massive 
pool of diverse risk factors and clinical phenotypes, and also a high degree of resolution which 
covers the detection of an array of specific, severe and non-severe, fatal and non-fatal 
diseases. The majority of investigator led (bespoke) studies treat cardiovascular diseases as 
pooled, unified phenomena implying a common root, while this aggregation of endpoints 
renders findings unclear and potentially inaccurate. A typical example of this is the heart rate 
and CVD existing literature that addresses the hazard of increased resting heart rate on 
coronary artery disease and cardiovascular or non-cardiovascular mortality which commonly 
treats these endpoints in a composite form. In that way, constituent phenotypes or disorders of 
the heart conduction system and muscle such as atrial fibrillation and heart failure have not 
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been properly explored. CALIBER enables the disaggregation of complex phenotypes into 
distinct cardiovascular endpoints of coronary, cerebral, abdominal and vascular beds. Besides 
outcomes’ accuracy, flexibility in exposure investigation is also provided with large numbers of 
risk factors measured and recorded in primary care.  
 
Data readily updateable  
All information of clinical research interest such as clinical variables, lab test values, treatments, 
procedures and medication records are available for studying and readily updatable. It is an 
automated recording process not only for data gathering at a baseline level, but also allows a 
“low effort” follow-up monitoring for events recording. 
 
Efficiency 
Furthermore, one of the significant advantages of this linkage lies on the practical aspect of 
data gathering and information collection. Unlike clinical cohorts or surveys, the recruitment 
process of patients is eliminated, since after GP practices opt in, automatically all patients’ data 
that attended these practices between 2001-2010 becomes available for research purposes in 
our dataset. Hence, there is no research cost of data collection to the research funders. Since 
the whole stage of participants’ recruitment and data collection as I described in chapter 7 was 
both tedious and time consuming especially with the manual component incorporated in the 
process, the value of the electronic patients’ collection process in CALIBER proved extremely 
valuable.        
 
Temporal resolution and follow-up time flexibility 
Additionally, long follow-up times highly contribute towards accuracy achievement, since the 
time windows to observe cardiovascular events which might not be chronic but more acute, are 
sufficient for safe inferences. Flexibility in observational start point and endpoint timelines is 
one of the many benefits of EHR that enables investigators to adapt the time frames and follow-
up to their personal research preferences. Furthermore, the platform that mainly aims at CVD 
investigation provides additional information for further pathophysiological disorders and 
diagnoses such as cancer, musculoskeletal and genetic disorders, etc. An additional benefit is 
temporal resolution which allows disentangling the sequential issue of events. CPRD data 
capture amongst others mild non-fatal manifestations of diseases that are not recorded at 
secondary health care level. Consequently, first events of diseases in CALIBER are easier to 
distinguish whether or not they were initial manifestations (e.g. unheralded coronary death) or 
were preceded by any symptoms or events.  
 
Inclusion criteria flexibility 
The flexible inclusion criteria of CALIBER (all patients regardless age, gender, etc.) without any 
clinical or health status restriction allows for various research questions’ investigations that the 
results can be applicable and representative of different populations. It offers the possibility of 
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bespoke research that it is not restricted to specific risk factors collected exclusively for 
research purposes, or narrow diagnosed outcomes. To that effect, chapter 4 which is focus on 
the impact of resting heart rate on CVDs in a healthy population, differs in the cohort design 
from chapter 5 that investigates heart rate and CVD prognosis in people with CAD, hence the 
inclusion criteria fundamentally differs, while the underlying sources of data remain the same.  
 
Population based design-Generalisability 
That particular characteristic of CALIBER, the non-selective nature of the population included 
in the dataset, hence the inclusion of healthy population or population with diverse health 
background, enhances the applicability and generalizability of the findings outside this study or 
even outside UK population and strengthens its external validity. This platform provides a 
knowledge pool that can be used to investigate gaps identified in clinical research, flexible 
enough to investigate questions from different clinical backgrounds. In the individual studies of 
this PhD that examine associations of heart rate with CVDs, I was able to define with flexibility 
the baseline populations without applying specific clinical criteria, unlike published 
epidemiological studies that a restricted by rigid patients’ characteristics or procedures (e.g. in 
prognosis research, inclusion exclusively of patients that belong to specific registries and have 
undergone cardiovascular procedures such as cardioversion, etc.). 
 
3.6.2.  CALIBER weaknesses 
 
3.6.2.1. Reasons for missing clinical information 
One of the main challenges of EHR and subsequently CALIBER, is the large numbers of 
missing information stemming from various sources and spanning general practices, patients 
numbers, missing measurement values, or not collected clinical information unavailable in 
general practice. The variability in completeness of data across practices, patients and across 
clinical measurements requires careful consideration. An illustration of this hierarchy is showed 
in Figure 3.8 below.  
 
3.6.2.1.1. Missing practices 
Of the total 592 practices in the CPRD in November 2010, 465 are based in England, and 244 
practices participated in the linkage (52% of English practices, 41% of all CPRD practices).194 
Roughly 45% of 592 CPRD practices in the UK consented to linkage of their registered patients, 
hence CALIBER uses data from only 225 practices in England. For these participating 
practices, all patients registered at the practice were included. Nowadays, CPRD database has 
reached the 674 practices in the UK with a coverage of 11.3 million patients.205 
 
 
3.6.2.1.2. Missing patients 
Apart from information missing due to limited number of GP practices participating in CPRD 
and hence lower number of GP practices consented to CALIBER participation, there is 
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information missing due to patients’ failure to register with GPs. Of the 6,623,382 CPRD 
patients with follow-up post 2000, 3,892,042 (58.8%) were eligible for linkage (of those, 
3,854,106 (99.0%) had a valid NHS number as indicated by the trusted third party).194 At the 
mid-year date of 2 July 2013, the dataset held information on 11.3 million patients who were 
deemed acceptable for research based on data quality checks. The population of active 
patients (alive and currently registered) on 2 July 2013 was 4.4 million, representing 6.9% of 
the total UK population (based on the UK 2013 mid-year population of 64.1 million). The 
remaining 6.9 million records represent inactive patients who have died or are no longer 
registered with a participating practice.205 
 
 
Figure 3.8 Missing clinical information sources 
 
 
This problem is further enhanced by the fact that even if patients are registered with the GP 
practices, they fail to attend, which leads to important information missingness. CPRD patients 
are broadly representative of the UK population in terms of age and sex. Patients are also 
comparable to the UK census in terms of ethnicity206 and comparable to the Health Survey for 
England for body mass index distribution in most patient subgroups.207 However, the CPRD 
may not be representative of all practices in the UK based on geography and size, which is 
something that one has to take into careful consideration when draw inferences on 
generalizability regarding particularly socio-economic research.205, 208 However, given the 
nature of my PhD aims related to heart rate, the possibility of systematic bias stemming from 
missing patients is rather relatively limited. 
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3.6.2.1.3. Missing values of variables  
Missing values in EHR are very common and their extent varies across different variables 
mainly due to different frequencies of recordings. Not all information is captured during GP 
visits and even if it is reported by patients, it is unknown what percentage of that information 
was used and what was discarded during the information recording process, or if this 
information was prompted by the GP. Moreover, possibly biomarkers and other factors were 
requested and collected by GPs only when considered needed. As a result, a potential pattern 
behind specific variables’ recording might be hidden (i.e. missing non randomly values). In this 
case, significant systematic biases (e.g. reporting bias) might interfere with the data and 
conceal true associations with risk factors, whereas overestimate others non-significant. 
Various statistical techniques have been implemented for the treatment of that phenomenon, 
however one must be very careful not to miss any potential biases systematic or sampling that 
might interfere with the results. An example of missing values in my CALIBER cohort is shown 
in Table 3.11. It is a common practice for researchers to address missing data by including in 
the analysis only complete cases, i.e. those individuals who have no missing data in any of the 
variables required for that analysis. However, results of such analyses can still be biased.209 
Furthermore, the cumulative effect of missing data in several variables often leads to exclusion 
of a substantial proportion of the original sample, which in turn causes a substantial loss of 
precision and power.209 
 
The risk of bias due to missing data depends on the reasons why data are missing. Reasons 
for missing data are commonly classified as: missing completely at random (MCAR), missing 
at random (MAR), and missing not at random (MNAR), where missing values are systematically 
different from the observed values and the reason for missingness is directly related to the 
factor being observed.210 When it is plausible that data are missing at random, but not 
completely at random, analyses based on complete cases may be biased. Such biases can be 
overcome using methods such as multiple imputation that allow individuals with incomplete 
data to be included in analyses. Unfortunately, it is not possible to distinguish between missing 
at random and missing not at random using observed data. For example, it could be more 
possible for women in reproductive age to attend GP practices potentially due to disorders of 
menstrual cycle and hence have their heart rates measured more often than men. In the present 
PhD I used multiple imputation techniques to overcome the missing values phenomenon. 
However, it is possible to identify how many people did not have a heart rate recording, but it 
is not equally easy to capture people that while suffer from thyroid disease have actually a 
record of thyroid disease. In this missingness category, I will also include another challenge 
related to recording, as the absence of a Read code for disease must be interpreted as an 
absence of the disease itself, or when GPs record information as free text, valuable information 
is ultimately missing despite being recorded. 
 
3.6.2.1.4. Not clinically collected data 
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Another aspect of data missingness lies on the lack of codes that would allow clinicians to 
capture phenotypic details although it is observable. Specific forms of research questions that 
need qualitative parameters to get explored, such as quality of life scales to assess 
psychological or behavioural functioning, or specific symptomatic descriptions (such as degree 
of pain severity) are unable to be addressed, since this kind of data is scarce in CALIBER 
dataset and if there is any, it is difficult to handle during the curation process. Another drawback 
present at data recording is the absence of information related to the techniques, devices or 
methods used to measure biomarkers and other clinical parameters. (e.g. whether or not a 
blood pressure device or palpation was used to measure heart rate).  
 
3.6.2.2. Lack of genetic information 
 
The growth of EHRs has been recognized as a viable and efficient model for genetic research. 
The absence of genetic information in CALIBER limits at the moment its research power and 
demands alternative sources of genetic information. By overcoming that obstacle, CALIBER 
will have the ability to respond with accuracy and credibility to any research question that 
emerges from contemporary clinical science with extension to causal mechanisms. Genome 
wide association studies have highly contributed towards giving insight into complex 
relationships between biomarkers and adverse cardiovascular events such as the work of Den 
Hoed et al. 140 which identified important information on heart rate and CAD outcomes by 
overcoming the reverse causality issues inserted by pure observational studies. Now that linked 
electronic health records are on the rise, further work on heart rate loci and specific 
cardiovascular phenotypes using EHR is feasible and crucial. As a matter of fact, the eMERGE-
PGx project aims at the initiation of a multi-site test of the concept that sequence information 
can be coupled to electronic health records (EHRs) for use in healthcare. For sequencing data, 
the workgroup uses the PGRN-Seq platform, developed by the Pharmacogenomics Research 
Network (PGRN). The long-term goal of the eMERGE-PGx project is to begin to develop 
strategies for the optimal implementation of genetic sequence data into the clinical environment, 
something that will shed further light into important clinical questions.211 Moreover, the 
Genomics England 100,000 Genomes Project, an ambitious discovery project involving the 
sequencing of 100,000 genomes and linkage of genomic information to EHR data, makes this 
a priority area. The Research Program for Genes Environment and Health in Kaiser,212 and the 
“precision” medicine initiatives213 all place a major emphasis on specific disease types and 
follow-up through health records.  
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Table 3.11 Percentages of recordings in baseline cohort characteristics 
 N N% recorded 
Demographic factors   
Age at entry 233,970 100 
  Female 110,436 100 
 White ethnicity  98,764 52.5 
IMD score (5th quintile-most deprived) 44,933 99.5 
Clinical factors   
Heart rate (bpm) 233,970  
Systolic blood pressure, (mmHg) 125,241 63.7 
Diastolic blood pressure, (mmHg) 125,241 63.7 
High density lipoproteins, (mmol/L) 46,186 6.94 
Low density lipoproteins, (mmol/L) 37,460 5.69 
Total cholesterol  (mmol/L) 59,095 10.0 
Triglycerides (mmol/L) 45,949 7.45 
Creatinine  μmol/L 79,752 13.2 
Haemoglobin (g/dL) 67,849 12.8 
Lymphocytes (10^9 / L) 60,506 10.6 
Neutrophils (10^9 / L) 60,618 10.6 
Diabetes II 10,338 * 
Behavioural/Environmental factors   
Smoking  85.5 
  Non-smokers 116,726  
  Ex-smoker 30,262  
  Current smoker 44,836  
BMI ( kg / m2) 68,548 29.4 
Family history of CHD 3,744 100 
Medication   
Beta blockers 28,245 * 
Calcium channel blockers 23,456 * 
Statins 22,385 * 
Aspirin 16,916 * 
Diltiazem 1,384 * 
Verapamil 742 * 
Hypertensives 22,871 * 
Other cardiac and rhythm conditions   
Atrial fibrillation 4,785 * 
Valve disease 7,452 * 
*Diagnosis or medication 
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3.6.2.3. Linkage issues 
 
The linkage of different data sources, which is the cornerstone of the CALIBER platform along 
with the post-collection data curation and its transformation into research ready data results to 
big challenges that one comes across when dealing with linked records. Starting from the latter, 
the obstacle that prevails in the use of linked electronic health records is the form of data itself 
as recorded by the different sources and particularly as recorded in primary care. Linkage 
process is prone to several inconsistencies that are observed across the different datasets. 
Some examples of these inconsistencies are the differences in values of measurements or 
even types of diseases between datasets, the differences in the dates of recording for risk 
factors, or events. Information linked to the wrong patients has also been observed, as well as 
discrepancies in the way information is recorded which stems from the diverse data sources is 
also a quite common phenomenon, e.g. levels and categories of variables that overlap. 
However the latter is easily treatable after appropriate decisions are made by researchers 
depending on the study aim, while data derived exclusively by primary care is not affected by 
inconsistencies. Hence, a thorough exploration of the data and careful cleaning combined with 
necessary clinical decisions is vital to overcome discrepancies across different data sources. 
 
3.6.2.4. Too large datasets-Occasional lack of accuracy 
 
Finally, I would like to highlight that at the last stage of data handling, cohort data cleaning in 
such large datasets plays an important part of the process to ensure data quality. In this Big 
Data paradigm it is easy to overlook that concept given that it is expected that when dealing 
with vast volumes of data and that can come from a multitude of sources, “messiness” is to be 
expected. As Mayer-Schönberger & Cukier 214 note, “What we lose in accuracy at the micro 
level we gain in insight at the macro level.” This common conception can often be misleading. 
Data quality and its provenance do matter and the question is important in establishing 
generalizability of the Big Data findings. 
 
3.7. Conclusions 
 
In this chapter I presented and described the CALIBER platform, its data sources, processes 
from raw to research ready data, as well as HER weaknesses and strengths. I finally presented 
the characteristics of heart rate marker collected by GP practices in both healthy and CAD 
populations investigated in the present PhD. Electronic health record (EHR) have the potential 
to transform the health care system from a mostly paper-based industry to one that utilizes 
clinical and other pieces of information to assist providers in delivering higher quality of care to 
their patients. CALIBER dataset, a platform that connects four sources of electronic health data 
spanning primary care records from General Practitioner practices and secondary and mortality 
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data and these data were used to address and explore the three main research questions 
posed by this PhD. The manner and reason for the generation, capture, and recording of EHR 
data vary substantially between these healthcare settings.  Additionally, different medical 
classification systems are often used for different data sources and consequently clinical 
information may be recorded in multiple sources but at different levels of clinical detail.  “Read 
codes” clinical terminology system used by General practitioners in UK to encode combined 
with ICD-10 codes to record morbidity and causes of death provided the raw platform that after 
necessary process produces research ready data. The key stages in this process are: i) 
Development of code lists used to define the exposures, risk factors and endpoints, ii)Definition 
of such variables and iii)Algorithms for dealing with duplication and contradiction in the 
variables. In CALIBER, heart rate was somewhat higher than values recorded in literature with 
no significant deviations. Among the important strengths of CALIBER are large sample sizes, 
Clinical phenotypes resolution, efficiency, flexible time-scales, flexible cohort definitions, 
whereas among its weaknesses belong missing information at practice, patient and data level 
and linkage process difficulties. 
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4. Specificity of associations of heart rate in the normal 
range with the incidence of a wide range of 
cardiovascular diseases in 233,970 women and men: a 
linked electronic health records CALIBER study1 
 
 
The aim of this chapter is to identify potential correlations of heart rate with initial presentations 
of 12 specific cardiovascular diseases. Intrinsically, the term “initial presentation” refers to the 
first manifestation of these diseases (first symptomatic presentation), hence the analysis will 
exclusively include population free of any cardiovascular disease, or prior manifestation or 
history.   
 
4.1.  Introduction 
 
Resting heart rate is a readily accessible biomarker that is routinely measured by clinicians and 
increasingly, with wearable sensors,215 by patients themselves. In healthy population cohorts, 
resting heart rate is associated with mortality from coronary heart disease (CHD)216 and all-
causes9, 151, 152, 157, 216 but there are no established thresholds for public health education or 
clinical practice defining a “normal” HR at which risk of cardiovascular events is at its lowest. 
About a third of the adult population has a resting heart rate of 70-79 beats per minute, yet only 
a few, small, studies have evaluated the risk of cardiovascular events at this level.  
 
Furthermore, little is known about the specificity of the associations between resting HR and 
the incidence of different CVDs. To date studies have examined either mortality only, or at most 
2 incident non-fatal diseases, including myocardial infarction, stroke and heart failure. Some 
studies reporting sudden cardiac death, coronary mortality or aggregated cardiovascular 
disease (CVD) have suggested that an effect is present for SCD but not for MI as we presented 
in chapter 2 (Table 2.2).  There have been no studies that have disaggregated CVD and 
examined associations of heart rate with the incidence of a wide range of cardiac, 
cerebrovascular or peripheral vascular diseases.  It is well known that women have higher 
resting heart rates than men,152, 156 but there is a lack of sufficiently large studies powered to 
reliably detect gender differences. Existing studies report either that women have no 
associations of heart rate with CVD 153, 159 or that associations are weaker compared with 
men.21, 85, 154 
 
The objectives therefore of our research were i) to determine the extent to which heart rate, 
adjusted for conventional risk factors, is associated with the incidence of 12 different cardiac, 
                                                          
1 The present piece of work was submitted and orally presented at the ESRC Multi-disciplinary Health & Biomarkers 
Conference, ISER, University of Essex, 2015  
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coronary, cerebrovascular and peripheral vascular diseases, ii) to determine the extent to which 
women and men show similar associations and iii) to determine the shape of any associations, 
in particular whether there is evidence of a threshold and whether risk extends into “normal 
ranges”. We used large scale, population based linked primary-secondary care electronic 
health records in the CALIBER (ClinicAL disease research using LInked Bespoke studies and 
Electronic health Records) resource,217 We have previously demonstrated that the validity of 
these data for a wide range of cardiovascular risk factors (age, and sex,129 systolic and diastolic 
blood pressure,218 type II diabetes187 and smoking189) and have discovered novel, associations 
across a wide range of CVDs.129, 218  
 
4.2. Methods 
 
4.2.1.  Data resource 
 
The Cardiovascular disease research using Linked Bespoke studies and Electronic Records 
(CALIBER) e-health database was the data resource for this study. CALIBER links patient 
records from four different data sources: Clinical Practice Research Database (CPRD)192 
MINAP (Myocardial Ischaemia National Audit Project registry)219 Hospital Episodes Statistics 
(HES)220, the Office for National Statistics (ONS).221 CPRD data were used to obtain heart rate 
measurements, demographic variables and other risk factors. Primary care practices and the 
subset of linked practices used in the present study analysis are representative of the UK 
primary care setting194 and have been validated for epidemiological research.222 A detailed 
description of CALIBER has been presented elsewhere.198 
 
4.2.2.  Study population 
 
An open cohort of 2,23 million people was drawn from registrants between January 1997 and 
March 2010 with 225 primary care practices who consented to data linkage. People included 
in the final study cohort were aged ≥30 years at study entry (‘index date’), with ≥1 year 
registration prior to the index date, no prior diagnosis of CVD and with at least one recorded 
heart rate measurement during the study period. Follow-up started from the date of their first 
heart rate measurements after applying the above eligibility criteria. Participants were censored 
on the dates of leaving the practice, or last submission of data, or death, or endpoint 
occurrence. The study flow diagram is shown in Figure 4.1.  
 
4.2.3.  Heart rate 
 
Heart rate was prospectively collected by general practice staff Although the method of 
measurement is not recorded in the EHR, 82.6% of people with a heart rate record had a blood 
pressure measurement the same day, suggesting a large proportion of heart rate 
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measurements were obtained using an automated blood pressure device. However, 
distributions of heart rate measurements showed some evidence of digit preference suggesting 
also more subjective measurement techniques (e.g. palpation at the wrist) (Figure A3.7 (a)). 
 
4.2.4.  Cardiovascular risk factors 
 
Information on risk factors was obtained from CPRD, as recorded during consultations in 
primary care. The most recent measurement (or prescription) recorded in CPRD up to one year 
before or on the date of study entry (index date, coinciding with first heart rate measurement) 
was used to define baseline covariates. Socioeconomic status was derived from ONS using 
the Index of Multiple Deprivation (IMD) 2007.223 It was divided into five categories (quintiles), 
the 1st quintile corresponding to the least deprived and the 5th quintile to the most deprived 
groups. The most recent smoking record before the index date was used to classify participants 
as never, ex or current smokers. Phenotyping algorithms combining Read, ICD-10, drug and 
procedure codes to define risk factors and endpoints are available at 
http://www.caliberresearch.org/portal/.  
 
4.2.5.  Endpoints 
 
The onset of CVD with specific initial presentations was defined as the recording of a specific 
diagnosis on first recorded date that would prevent for evolvement of a disease and its 
conversion into another CVD phenotype. To disable misclassification of phenotypes, the data 
used from both HES and the Myocardial Ischaemia National Audit Project (MINAP) are based 
on discharge rather than admission diagnosis. Additionally, the time elapsed between the first 
recorded diagnosis and the subsequent one for a sample of patients from CALIBER; was 
investigated and found that the mean number of days between different types of events was 
over 60 days for all presentations, suggesting that using the first recorded diagnosis is a robust 
approach to studying onset of CVD.224 Where more than one diagnosis was recorded on one 
day, the most specific and serious presentation was used. Endpoints are allocated a priority 
order so if a more severe or advanced form of the disease occurs on the same day as a milder 
form the more severe form is counted. This hierarchy is presented in Table A4.1 in Appendix 
4. 
 
All four constituent data sources (CPRD, MINAP, HES, ONS) were used to define the 
cardiovascular phenotypes used in this study. Both historical and incident codes were used to 
exclude patients from the cohort, but only incident codes were used to identify initial 
presentation of CVD. Both fatal and non-fatal presentations are included, with the exception of 
stable angina, which does not include fatal presentations, and unheralded coronary death which 
does not include non-fatal presentations. 
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The primary endpoints were the initial presentation of non-fatal or fatal CVDs across the four 
data sources. The CVD outcomes analysed entailed stable angina (SA), acute coronary 
diseases (unstable angina (UA), myocardial infarction (MI)); heart failure (HF), unheralded 
coronary death; a composite of cardiac arrest, ventricular fibrillation and sudden cardiac death 
(SCD); abdominal aortic aneurysm (AAA); peripheral arterial disease PAD and cerebrovascular 
diseases including transient ischaemic attack (TIA), ischaemic stroke, subarachnoid 
haemorrhage (SAH) and intracerebral haemorrhage. Additional composite endpoints analysed 
were Coronary artery disease events (CAD), total CVD events and mortality outcomes (i.e. 
CVD deaths and all-cause mortality). Diagnoses were identified using codes from the 
International Classification of Diseases 10th Revision (ICD 10)  for the hospital data (HES) and 
mortality data (ONS), from Read Codes for primary care data and bespoke variables in the 
ACS registry (MINAP). All ICD-10 and Read codes used to define each cardiovascular endpoint 
and data sources were presented in chapter 3 (Table A3.9). 
 
4.2.6.  Statistical analysis 
 
For analytic purposes, heart rate was divided into levels (<60, 60-69, 70-79, 80-89, >90) 
(<60bpm reference level) and outliers (<30 and >150bpm) were removed. Additionally, to 
explore whether digit preference might affect the results, we divided it into quintiles (30-65 bpm, 
66-72 bpm, 73-79 bpm, 80-87 bpm, 88-150bpm) (Figure A4.2). We also used heart rate as a 
continuous variable per 10 bpm increase. Differences in risk factors by level of heart rate were 
tested using the F statistic from analysis of variance or its non-parametric version (Kruskal 
Wallis test) and the chi-square statistic, as appropriate. The association between heart rate and 
each disease was assessed using Cox proportional hazard models with time since study entry 
as the timescale, adjusting for baseline age and sex as the first step and then for established 
cardiovascular risk factors (age, sex, social deprivation, smoking, systolic blood pressure, BP 
lowering medication, total cholesterol, HDL, LDL, type 2 diabetes and BMI) and stratified by 
primary care practice. For covariate adjustments the missing at random covariate values were 
imputed using multiple chained equations.225 To assess the shape of association between heart 
rate and the different CVD endpoints we used restricted cubic splines with 4 knots and the 
reference value of 70bpm (Figure 4.10).226 
 
In sensitivity analyses, we excluded i) cardiovascular events that occurred within the first year 
of follow-up to account for potential reverse causality effect, ii) events that were diagnosed in 
primary care to validate the diagnostic accuracy of cardiovascular events and then iii)  all 
patients that reported beta-blockers or blood pressure medication intake (Figures A4.3-A4.6). 
Additionally, we restricted the analysis to those that had their heart rate and blood measurement 
recorded on the same date (consequently probably measured by the same device). To further 
explore associations of severe stable angina events with increased heart rate we restricted the 
analysis to patients who underwent a Coronary Artery Bypass Graft (CABG) before after a 
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stable angina event. Statistical analyses were performed using Stata statistical software 
(StataSe v13 and R version 3.0.3). 
 
4.3. Results 
 
4.3.1.  Baseline characteristics 
 
We included 233,970 patients (58% women) with heart rate measurements available at 
baseline (mean (SD) HR in men 74.6bpm,( ±14.5) and in women 77.9bpm (±14.0)) who 
experienced 28,381 events during 641,843.5 person-years of follow-up (mean follow-up per 
patient 3.26 years). Cohort characteristics by heart rate are shown in Table 4.1. Higher heart 
rates were associated with female sex, social deprivation, current smoking and type 2 diabetes 
and lower use of beta-blockers.  
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Table 4.1. Baseline characteristics of patients by heart rate level 
 <60 bpm 
(N=18,278) 
60-69bpm 
(N=52,630) 
70-79 bpm 
(N=70,549) 
80-89bpm 
(N= 56,235) 
90-150bpm (N=36,098) N total (%) 
 Mean (%) SD Mean (%) SD Mean (%) SD Mean (%) SD Mean (%) SD N total (%) 
Demographic factors            
Age at entry (years) 59.7 15.5 58.2 16.1 58.0 16.4 58.9 16.9 57.2 16.3 233,970 (100%) 
Women 41.3  50.9  57.2  60.9  61.0  135,599 (57.9%) 
White Ethnicity 75.5  73.6  73.7  73.5  73.7  126,650 (54.2%) 
Deprivation (most deprived 
quintile) 
18.7  20.9  22.0  24.4  26.6  52,541 (22.5%) 
Clinical biomarkers and risk factors            
Heart rate (continuous) (bpm) 53.4 4.81 64.5 3.07 73.8 2.83 83.0 3.10 101.1 11.3 233,970 
Systolic blood pressure, (mmHg) 143.1 21.3 139.5 20.2 138.6 19.5 139.4 19.8 141.4 20.8 225,766 
Diastolic blood pressure, (mmHg) 80.8 11.4 80.9 10.8 81.1 10.7 81.8 10.8 83.5 11.6 225,766 
High density lipoproteins, (mmol/L) 1.41 0.39 .39 1.43 0 .4 1.44 0.4 1.43 0.4 1.44 0.4 71,902 
Low density lipoproteins, (mmol/L) 3.20 0.99 3.20 0.99 3.21 1.0 3.17 1.0 3.12 1.0 37,460 
Total cholesterol  (mmol/L) 5.30 1.10 5.31 1.1 5.35 1.2 5.34 1.1 5.34 1.3 63,412 
Triglycerides (mmol/L) 1.55 0.92 1.56 0.9 1.62 1.1 1.69 1.2 1.76 1.3 45,949 
Creatinine  (μmol/L) 93.1 25.4 89.3 25.9 87.5 26.2 86.8 29.4 86.5 30.5 79,752 
BMI (kg/m2 ) 27.9 5.3 27.8 5.6 28.2 5.7 28.5 6.1 28.5 6.4 68,548 
Smoking            
Non-smokers 63.5  61.6  60.2  57.8  55.1  107,346 (45.9%) 
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Ex-smoker 17.8  16.0  15.2  15.0  14.1  53,872 (23.0%) 
Current smoker 16.8  20.1  22.3  24.2  28.0  68,630 (29.3%) 
Diabetes type  II 4.83  4.48  4.77  5.74  6.77  23,006 (9.84%) 
Medication            
Beta-blockers 39.7  21.1  11.1  8.71  8.07  80,525 (34.4%) 
Calcium channel blockers 15.3  11.8  10.8  11.3  13.5  67,533 (28.8%) 
BP medication 48.5  39.1  38.7  39.0  41.7  131,937 (56.4%) 
Statins 14.1  11.6  10.8  10.7  11.8  45,280 (19.3%) 
Aspirin 11.38  8.78  7.90  8.47  8.66  45,560 (19.5%) 
Note: Blood pressure (BP) medication includes diuretics, b-blockers, calcium channel blockers and ACE inhibitors intake; N total % latest recording within a year before baseline (HR measurement) 
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4.3.2. Specificity of associations across different incident CVDs  
 
The age and sex adjusted Cox analysis (Fig A4.8-Appendix 4) showed significantly increased 
hazard of unheralded coronary death, heart failure, sudden cardiac death, myocardial infarction 
and peripheral arterial disease in >90bpm values compared with <60bpm.  
 
However, in the fully adjusted model, heart rate was specifically, strongly associated with the 
incidence of three cardiac diseases: heart failure, sudden cardiac death and unheralded 
coronary death, The fully adjusted hazard ratios comparing a heart rate of >90bpm vs <60bpm 
were for unheralded coronary death (UCD) (HR=1.93, 95%CI 1.46-2.55), sudden cardiac death 
(SCD) (HR=2.41, 95% CI 1.79-3.24) and heart failure (HF) (HR=1.92, (95%CI 1.60-2.29) 
(Figure 4.9, Table 4.2). Heart rate was not in adjusted analyses associated with the incidence 
of coronary diseases (stable angina, unstable angina, myocardial infarction), cerebrovascular 
diseases (transient ischaemic attack, subarachnoid haemorrhage, ischaemic stroke, 
intracerebral haemorrhage), peripheral arterial disease or abdominal aortic aneurysm. For 
lower heart rate values 70-79bpm compared to <60bpm an increased risk of UCD (HR= 1.35, 
95% CI 1.03-1.77) and all-cause mortality (1.48, 95% CI 1.35-1.63) was found, while for 80-
89bpm heart rate, an increased risk for HF was also observed (HR=1.64, 95% CI 1.37-1.95). 
The composite total CVD events endpoint, showed an increase in risk of 1.40 and 1.65 times 
in 80-89bpm and >90bpm respectively. 
 
The shapes of the associations showed no strong evidence of a threshold with the hazard of 
unheralded coronary death, heart failure and cardiovascular mortality increasing progressively 
with heart rates that would usually be regarded as normal (Figure 4.10).  
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Figure 4.9. Multivariable adjusted hazard ratios for the association between heart rate and the initial presentation of 12 cardiovascular 
diseases and mortality outcomes 
 
Note: CI, confidence interval; HR, hazard ratios adjusted for age, sex, social deprivation, smoking, systolic blood pressure, BP 
medication, total cholesterol, HDL, LDL, diabetes II and BMI; CA, Cardiac Arrest; CV, Cardioversion 
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Figure 4.10.  Restricted cubic splines of heart rate and 12 cardiovascular diseases 
    
 
   
    
.Note: Adjustments include age, quadratic age, and stratification by sex and primary care practice 
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Table 4.2. Adjusted hazard ratio of heart rate with 12 CVDs   
Outcomes N of events  <60bpm  60-69bpm  70-79bpm  80-89bpm  >90bpm  P-value 
HR#sex 
CARDIAC     HR (95% CI)  HR (95% CI)  HR (95% CI)  HR (95% CI)  HR (95% CI) 
Stable Angina              
Men 823  1.00(ref) 
1.00(ref) 
 1.12 
[0.86-1.46] 
 
 1.28[0.99-1.66] 
 
 1.48 [1.14-1.93] 
 
 1.17 [0.87-1.58] 
 
 
0.067 
Women 750   0.65 [0 8-0.87]  0.65[0.49-0.86]  0.73 [0.56-0.97]  0.60 [0.44-0.81]  
Unstable Angina              
Men 429  1.00(ref) 
1.00(ref) 
 0.69 [0.49-0.98]  0.96[0.69-1.33]  0.89[0.63-1.26]  1.09 [0.76-1.57]  
0.210 
Women 528   0.93 [0.64-1.36]  0.85[0.59-1.23]  0.97[0.67-1.40]  0.76[0.51-1.14]  
Myocardial infarction              
Men 1,113  1.00(ref) 
1.00(ref) 
 1.16[0.92-1.46]  1.20[0.96-1.51]  1.29[1.02-1.63]  1.39 [1.08-1.79]  
0.047 
Women 908   1.01[0.74-1.37]  1.07[0.79-1.44]  1.10[0.82-1.49]  1.01 [0.74-1.39]  
Unheralded coronary death              
Men 530  1.00(ref) 
1.00(ref) 
 1.05 
[0.70-1.57] 
 1.65[1.13-2.41]  2.14[1.46-3.13]  3.06[2.07-4.52]  0.000 
Women 555   0.86[0.58-1.29]  0.97[0.66-1.41]  1.08[0.74-1.58]  1.32[0.89-1.96]   
Heart Failure              
Men 1,038  1.00(ref) 
1.00(ref) 
 1.18[0.89-1.56]  1.65[1.26-2.16]  2.11[1.61-2.76]  3.26[2.48-4.30]  0.005 
Women 1,502   0.81[0.63-1.04]  0.85[0.67-1.07]  1.23[0.97-1.55]  1.62[1.28-2.06]   
Sudden cardiac death/ 
Cardioversion/Cardiac arrest 
             
Men 442  1.00(ref) 
1.00(ref) 
 0.93[0.64-1.33]  1.05[0.73-1.50]  1.25[0.87-1.80]  2.69[1.89-3.83]  0.683 
Women 285   0.87[0.47-1.58]  1.07[0.61-1.88]  1.28[0.73-2.25]  2.52[1.45-4.40]   
Coronary heart disease (NOS)              
Men  1,038  1.00(ref) 
1.00(ref) 
 0.78[0.63-0.97]  0.92[0.75-1.13]  0.84[0.68-1.05]  0.94[0.74-1.20]  
0.226 
Women 883   0.93[ 0.70-1.24]  0.96[0.73-1.26]  0.81[0.62-1.08]  0.76[0.57-1.03]  
CEREBRAL              
Transient Ischaemic Attack             
0.325 
Men 659   0.890.67-1.17]  0.85 
[0.65-1.12] 
 1.17 
[0.89-1.55] 
 1.03 
[0.75-1.42] 
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Women 1,010  1.00(ref) 
1.00(ref) 
 0.97[0.73-1.29]  1.01[0.77-1.33]  0.92[0.70-1.22]  1.04[0.78-1.40]   
Subarachnoid Haemorrhage               
Men 30  1.00(ref) 
1.00(ref) 
 0.55[0.14-2.11]  1.03[0.31-3.43]  1.14[0.33-3.97]  0.68[0.14-3.19]  0.964 
Women 97   0.60[0.22-1.59]  0.86[0.35-2.12]  1.13[0.47-2.75]  0.71[0.27-1.88]   
Intracerebral Haemorrhage              
Men 136  1.00(ref) 
1.00(ref) 
 0.91[0.48-1.75]  0.95[0.50-1.80]  1.26[0.66-2.42]  1.78[0.91-3.48]  
0.422 
Women 194   0.95[0.48-1.90]  1.19[0.62-2.29]  1.29[0.67-2.48]  1.17[0.58-2.36]  
Ischaemic Stroke              
Men 489  1.00(ref) 
1.00(ref) 
 0.79[0.57-1.09]  1.05[0.77-1.42]  1.02[0.74 -1.41]  0.92[0.64-1.34]  
0.851 
Women 780   0.92[0.68-1.24]  0.85[0.63-1.14]  0.77[0.57-1.04]  1.04[0.76-1.42]  
PERIPHERAL              
Peripheral Arterial Disease             
0.182 Men 685  1.00(ref) 
1.00(ref) 
 1.50[1.09-2.06]  1.45[1.06-1.99]  1.76[1.28-2.42]  1.45[1.03-2.06]  
Women 802   0.86[0.62-1.19]  0.99[0.73-1.35]  0.92[0.67-1.26]  1.09[0.79-1.50]  
Abdominal Aortic Aneurysm              
Men 320  1.00(ref) 
1.00(ref) 
 0.86[0.57-1.29  0.98[0.66-1.47]  1.22[0.81-1.83]  1.12[0.70-1.78]  
0.938 
Women 150   0.68[0.33-1.40]  0.82[0.42-1.62]  0.71[0.35-1.42]  1.01[0.48-2.09]  
COMPOSITES              
Total CVD events              
Men 12,439  1.00(ref) 
1.00(ref) 
 1.23[1.16-1.30]  1.21[1.14-1.28]  1.52[1.44-1.61]  1.79[1.70-1.89]  
0.055 
Women 15,942   1.10[1.04-1.16]  1.03[0.97-1.09]  1.25[1.18-1.31]  1.45[1.38-1.53]  
CVD mortality              
Men  1,613  1.00(ref) 
1.00(ref) 
 1.11[0.96-1.30]  1.25[1.05-1.48]  1.58[1.36-1.84]  1.77[1.52-2.06]  0.059 
Women  2,369   1.12[0.98-1.28]  0.89[0.76-1.03]  1.16[1.02-1.32]  1.23[1.07-1.40]   
All-cause mortality              
Men 3,968  1.00(ref) 
1.00(ref) 
 1.17[1.02-1.34]  1.55[1.36-1.77]  1.99[ 1.74-2.28]  2.90[2.52-3.33]  
0.000 
Women 7,023   0.86[0.58-1.29]  0.97[0.66-1.41]  1.08[0.74-1.58]  1.32[0.89-1.96]  
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4.3.3.  Effects of gender and age 
 
Interactions with sex were found to be significant for heart failure, unheralded coronary death, 
myocardial infarction and composite mortality outcomes. There was a profound risk at average 
heart rate values in men. Specifically, the increased hazard of unheralded coronary death with 
a heart rate >70bpm was particularly marked in men but in women was eliminated. The 
increased hazard of heart failure was also greater in men and evident at heart rates >70bpm 
compared with women in whom the hazard was confined to heart rates >90bpm (Table 4.2, 
Fig A4.11, A4.12). An increased risk of all-cause mortality was found in men starting from lower 
heart rate values (>70bpm) but no risk at all was present in women at any level, while 
cardiovascular mortality was strongly associated with heart rate >70bpm in men, whereas in 
women was barely evident. Stable angina risk was slightly high increased in men for heart rate 
values 80-89bpm, whereas a protective effect was observed in women with HR 60-69bpm, 70-
79bpm and >90bpm heart rate levels. We observed no other gender differences in the 
associations between heart rate and hazard of CVDs. In the age group analysis the increased 
hazard of the majority of outcomes (unheralded coronary death, heart failure, sudden cardiac 
death and cerebrovascular outcomes) for >90bpm compared with <60bpm appeared less 
pronounced in people aged >80 compared with younger age groups while the increased hazard 
of heart failure and UCD was more prominent in people aged <60 (Figure A.4.13). 
 
4.4.  Discussion 
 
4.4.1.  Main findings 
 
This is the first study to demonstrate the specificity of the heart rate associations across a wide 
range of pathologically diverse incident cardiovascular diseases. In by far the largest healthy 
population cohort of women and men of representative age (>30 years of age) we show that 
heart rate is strongly specifically associated with cardiac diseases (unheralded coronary death, 
sudden cardiac death, heart failure) but not associated with coronary, peripheral diseases or 
stroke. We found strong associations at heart rate levels that would be commonly considered 
“normal” with no strong evidence of a threshold. We found that men had stronger associations 
with diseases than women and at lower heart rate levels. Resting heart rate of 70-79bpm, seen 
in 29.1% of men, should not be considered normal, whereas for women risk was largely 
confined to >90bpm rates. 
 
4.4.2.  Associations of HR with myocardial and arrhythmic disorders 
 
The specificity of associations of heart rate with specific CVDs contrasts with findings for BP 
which showed linear associations of systolic and diastolic blood pressure with each of the same 
12 CVD presentations.188 The graded association between resting heart rate and incident heart 
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failure, with hazard doubling for rates >90bpm compared with rates <60bpm, is consistent with 
previous reports.159, 227 Certainly, in established heart failure, rate reduction with beta-blockers 
and with ivabradine, improves prognosis regardless of gender.228, 229 Nevertheless, 
contemporary guidelines continue to classify heart rate as a minor risk factor for heart failure, 
making no recommendations for rate-lowering preventive treatment in the absence of 
randomised trials to support such a strategy.230 Associations between heart rate with 
unheralded coronary death, that is a fatal myocardial infarction event unheralded by prior 
symptomatic disease and have not been previously explored, were also found for lower than 
conventionally considered heart rate of 70-79bpm and above. 
 
The association we found between heart rate and sudden cardiac death is also consistent with 
previous reports but unlike heart failure there appeared to be a steeper risk increase, hazard 
ratios increasing when heart rate exceeded 90bpm.21, 85, 147, 148, 231 Only one previous large study 
of 379,843 people aged 40-45 years included an adjusted gender analysis but its finding of no 
association between heart rate and sudden cardiac death in either men or women may be 
explained by the age-range of the study participants.152 Associations of heart rate with sudden 
cardiac death may also be consistent with experimental data showing diminishing ventricular 
fibrillation thresholds as heart rate is increased in stimulation studies and increasing thresholds 
when heart rate is lowered with ivabradine.232 Further evidence of a mechanistic link of heart 
rate with cardiomyopathy and sudden death comes from genome-wide association studies that 
have identified single nucleotide polymorphisms influencing heart rate regulation in genes also 
involved in the pathophysiology of dilated cardiomyopathy, congestive heart failure and sudden 
cardiac death.233 
 
4.4.3.  Why do men and women differ? 
 
In the present study, we found an increased hazard of heart failure that was greater in men and 
evident at heart rates >70bpm compared with women in whom the hazard was confined to heart 
rates >90bpm. Epidemiological studies on resting heart rate and heart failure have shown 
weaker associations in women and in other smaller studies it was confined to men perhaps 
reflecting under-powering rather than a true gender difference.227 Unlike heart failure risk that 
showed a progressive increase starting at lower rates in men, sudden cardiac death appeared 
with a steeper risk that was increasing when heart rate exceeded 90bpm in both men and 
women.21, 85, 147, 148, 231 Average heart rate of 70-79bpm, showed strong associations with 
unheralded coronary death but only men, whereas for women the risk was not present. Finally, 
associations with stable angina showed a protective effect in 60-69bpm, 70-79bpm and 
>90bpm in women, whereas in men associations were of the opposite direction. Although 
women have a higher resting heart rate than men, the weaker association of heart rate with 
outcome in women might arise from a greater variability of heart rate within female individuals. 
However, a trial of Palatini et al.234 showed that the reproducibility of measured heart rate either 
at the clinic or by using ambulatory device was similar in the two genders. The higher heart rate 
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and volume contraction in female populations could also be the result of a higher sympathetic 
outflow.235 Alternatively, oestrogens, like digitalis, may exert a direct positive inotropic effect, 
thereby increasing cardiac output236 and in healthy young women, oral contraceptives increase 
cardiac output, produce little change in arterial pressure, and decrease total peripheral 
resistance.237 
 
4.4.4.  Lack of associations between HR and CAD, PAD, stroke or AAA 
 
An important finding in the present study was that heart rate associations were specific to 
diseases of heart muscle and were not detected for atherosclerotic disorders. Small 
associations of heart rate with acute myocardial infarction and peripheral arterial disease were 
found, in sex and age adjusted >90bpm versus <60bpm comparisons that were eliminated in 
the fully adjusted model. Associations with stable angina were weak and a further sensitivity 
analyses restricted to more severe cases of angina and to those without beta-blockers intake 
recorded, did not alter the results. A non-specific effect of increased heart rate on mortality 
outcomes was also observed. Moreover, there was no association of heart rate with the other 
manifestations of coronary or cerebrovascular disease or with abdominal aortic aneurysm. 
These observations may have mechanistic implications, suggesting that damages of the 
myocardium and the electrical stability of the conduction system are more associated with 
higher heart rate and its autonomic drivers than to disease progression in the arterial wall, 
despite data relating increased heart rates to endothelial dysfunction and accelerated 
atherosclerosis.238 Adjustment for conventional atherogenic risk factors had little effect on our 
risk estimates. Observational studies in general populations showed a lack of association of 
HR with fatal MI, however the sample was restricted to male subjects147, while findings from a 
clinical trial, the Study Assessing the Morbidity-Mortality Benefits of the If Inhibitor Ivabradine 
in Patients with Coronary Artery Disease (SIGNIFY) trial showed that heart rate reduction with 
ivabradine does not affect the risk of myocardial infarction in patients with stable coronary artery 
disease.239 Mendelian randomization studies show that the genetic loci that are associated with 
HR are not with CAD or MI,240 suggesting that these diseases and heart rate are not causally 
associated. 
 
4.4.5.  Clinical and research implications  
 
Heart rate is one of the most ubiquitous clinical measurements and is increasingly recorded by 
healthy people monitoring personal fitness with mobile devices and phone applications.241, 242 
Our findings can be used to help establish normal values for men and women. Approximately 
74% of women and 63% of men have heart rates >70bpm and are at risk of cardiac events, 
with a risk for HF, UCD, CVD mortality and all-cause death more pronounced in men. In other 
words, average heart rate values particularly in men, cannot be considered normal any more 
and further attention should be given to those males with heart rates lower than those so far 
considered as “normal” rhythm values. Trials are required of heart rate lowering in high risk 
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groups, e.g. in patients with resting tachycardia (≥90bpm) present in 17% of women and 13% 
in men. Remarkably there are no guidelines to inform clinical decision-making regarding 
behavioural, pharmacological, etc. for these patients. Heart rate may contribute to the 
identification of patients at high risk of severe outcomes such as sudden cardiac and 
unheralded coronary death. Finally, our findings require re-evaluation of the contribution that 
heart rate makes to risk prediction, taking account of specific outcomes of interest and 
recognizing that existing tools such as SCORE and Framingham include disorders with weak 
or absent associations with heart rate in their aggregate CVD endpoints.243  
 
4.4.6.  Strengths and limitations 
 
The main strength of this study lies in a population based large scale cohort of 233,970 men 
and women with clinical resolution of 12 different CVD presentations. It is the first study to use 
clinical heart rate measurements recorded using Electronic Health Records and therefore has 
intrinsic clinical relevance. We have recently demonstrated the validity of using electronic health 
record cohorts in high resolution cardiovascular epidemiology by replicating and extending 
associations from smaller studies for BP, type 2 diabetes, sex and smoking.186-189 Robustness 
of results for this paper, was assessed by excluding endpoints exclusively recorded in primary 
care (Figure A4.4).  
Limitations include the digit preference in the heart rate measurements that were not taken 
under standard conditions (Figure 3.5(a) in chapter 3.). Although associations between heart 
rate and CVDs are not influenced by variation of resting values over time or by the 
measurement method used152 we can assume that more accurate measurements would likely 
show stronger associations. Additionally, we were unable to adjust for physical activity which 
was recorded in only 50,069 patients. However, this is unlikely to have affected our findings 
based on previous studies where adjustment for exercise had little effect on heart rate 
associations with CVD.148, 153, 154 Moreover, the possibility that heart rate might be acting as a 
surrogate for physical fitness in these associations is not supported by recent physiological 
data.158 The potential for imbalance between baseline beta-blocker prescription rates to distort 
our findings was excluded in a sensitivity analysis (Figure A4.5). Finally, patients with a resting 
heart rate recorded within CALIBER were an average of 14 years older than those without a 
heart rate record. These findings are potentially due to the fact that older people visit GPs more 
often, have additional medical reasons which affect the cardiac regulatory system and a more 
thorough clinical examination is required. However, mean heart rate values in men and women 
(74bpm in men and 77bpm in women) were fairly similar to subjects of observational studies of 
similar characteristics. 
 
4.5.  Conclusions 
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Resting heart rate shows specific associations with myocardial and arrhythmic disorders, but 
not with coronary disease, stroke or PAD. Average resting heart rate of >70bpm in the general 
population increases the hazards of specific cardiovascular diseases and mortality particularly 
in men and should not be considered as normal. No substantial effect on the hazard of vascular 
events in the coronary, cerebrovascular and peripheral arterial beds was found. Disaggregation 
of CVD into its constituent phenotypes can help our understanding of disease mechanisms with 
implications for clinical practice and the design and interpretation of clinical trials. 
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5. Heart rate and the risk of a wide range of cardiovascular 
events in 51,703 people with stable coronary artery 
disease (sCAD): a CALIBER study2 
 
This chapter will attempt to estimate the prognostic ability of heart rate on people with 
established stable coronary artery disease using data from the general primary and secondary 
care in UK and will allow for more precise investigations with higher resolution not only among 
different CVDs but also between the two genders 
 
5.1.  Introduction 
 
The relationship between resting heart rate (RHR) and cardiovascular diseases (CVDs) and 
total and cardiovascular mortality, has been investigated in patients with stable coronary artery 
disease (CAD)169 and in the general population (IP HR paper). However, associations between 
heart rate and specific cardiac phenotypes and rhythm disorders are unclear. Recent clinical 
trials on heart rate lowering medications direct their focus on composite endpoints consisting 
of combinations of non-fatal myocardial infarction with CVD outcomes and subsequently fail to 
establish any associations between those and RHR while the invest large amounts of 
sources.128  
 
Contemporary data regarding the association between higher heart rate and CVD events of 
CAD patients is derived from clinical trials or angiographic registries that is collected solely for 
research purposes and is majorly focused on high risk patients125  or people admitted to hospital 
for acute coronary syndromes168, 244, referred for specific cardiovascular procedures or 
hospitalized and not to the general population.125, 169 However, the selective nature of the 
populations studied might compromise the external validity of the findings. Composite 
cardiovascular endpoints do not allow for investigations of associations with specific types of 
cardiovascular events that can provide insights into the pathophysiological mechanisms of 
disease progression in a stable CAD population. These mechanisms can be further explored 
through the assessment of resting heart rate associations with rhythm disorders such as atrial 
fibrillation in populations with stable coronary artery disease that so far remain under-examined. 
Available observational studies that assessed specific endpoints present old findings, hence 
the update of evidence is crucial. Additionally, gender differences in heart rate effects on 
cardiovascular events have not been sufficiently examined as the majority of findings 
particularly derived by clinical trials include male participants.163, 168 A summary of the available 
studies was presented in chapter 2 (Table 2.4). 
 
                                                          
2 The present piece of work was submitted and presented orally at the Farr Institute Conference, St Andrews, 
Scotland, 2015  
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Using linked electronic health records we will investigate the prognosis of CAD in relation to 
heart rat3e levels that are relevant in clinical practice. We have previously demonstrated the 
validity of these data by developing prognostic models that incorporate clinical measures 
recommended in guidelines and target patients with SCAD.245 The associations and shape of 
the relationships with a large range of recurrent cardiovascular diseases previously unexplored 
will be studied in a large population of patients with stable CAD, and evidence for gender 
interactions will be assessed. Specifically our objectives entail: i) The identification across a 
large range of CVDs of those important for the design of clinical trials on heart rate lowering 
medication, ii) examine potential differences in CVDs prognosis between men and women with 
sCAD. 
 
5.2. Methods 
 
5.2.1.  Data resource 
 
The Cardiovascular disease research using Linked Bespoke studies and Electronic Records 
(CALIBER) e-health database was analysed. CALIBER links patient records from four different 
data sources: the Clinical Practice Research Datalink (CPRD)192, the Myocardial Ischaemia 
National Audit Project registry (MINAP)219, Hospital Episodes Statistics (HES)220, and the Office 
for National Statistics (ONS)221. The primary care practices and the subset of 225 linked 
practices consenting to data linkage are representative of UK primary care settings194 and have 
been validated for epidemiological research.222 Primary care data were used to obtain heart 
rate measurements, demographic variables and other risk factors.  
 
5.2.2.  Study population 
 
An open cohort of 2,23 million people covering approximately 5% of the UK population was 
drawn from patients registered between January 1997 and March 2010. People eligible for 
study inclusion were aged ≥30 years at study entry (‘index date’), had ≥1 year registration prior 
to the index date and being diagnosed with stable coronary artery disease, that is at least 1 
year prior to index date a diagnosis of one of the following CVDs: stable/unstable angina, 
myocardial infarction (at least 6 months after a MI or UA event to be stable) and finally at least 
one recorded heart rate measurement after the index date.  CVD events that ensured eligibility 
should have been experienced any time prior to the index date or in case of its absence, any 
time after that date. In case of existence of an event prior to and after the eligibility index date, 
the date used for analysis was the former one. Participants were censored on the earliest of 
the following dates: leaving the practice, last collection date of the practice, death, or endpoint 
occurrence. The study flow diagram is shown in Figure A5.1 (Appendix 5). 
                                                          
 
   131 
 
 
5.2.3.  Heart rate 
 
Heart rate was prospectively collected by general practice staff and values ranged from 20-240 
bpm. The method of measurement is not recorded in the database but it is likely to have been 
obtained through palpation at the wrist, auscultation of the heart and readings from an 
automated blood pressure device or electrocardiogram (ECG). Because 100% of people with 
a heart rate record at baseline had a blood pressure measurement the same day. However, 
digital preference was identified in heart rate distributions as we observed in chapter 3 (Figure 
3.5(b) and Table A3.7) and consequently I cannot infer with certainty that heart rate was 
recorded using the same device as in blood pressure measurements. 
 
5.2.4.  Cardiovascular risk factors 
 
Information on risk factors was obtained from CPRD, as recorded during consultations in 
primary care. The most recent measurement (or prescription) recorded in CPRD up to one year 
before or on the date of study entry (first heart rate measurement after the index date) was 
used to define baseline covariates. Socioeconomic status was derived from ONS using the 
Index of Multiple Deprivation (IMD) 2007.223 It was divided into five categories (quintiles), the 
1st quintile corresponding to the least deprived and the 5th quintile to the most deprived groups. 
The most recent smoking record before the index date was used to classify participants as 
never, ex or current smokers. Phenotyping algorithms combining Read, ICD-10, drug and 
procedure codes to define risk factors are available at 
http://www.caliberresearch.org/portal/.  
 
5.2.5.  Endpoints 
 
The primary endpoints were the first presentation of a new non-fatal or fatal CVDs after the 
date of entry across the four data sources: acute coronary diseases (myocardial infarction (MI)); 
heart failure); a composite of cardiac arrest, ventricular fibrillation and sudden cardiac death 
(CA-SCD); a composite of cerebrovascular diseases including ischaemic stroke, subarachnoid, 
and intracerebral haemorrhage and unknown stroke type; and peripheral arterial disease. 
Additionally, two mortality outcomes were assessed, CVD and all-cause mortality, and atrial 
fibrillation. Diagnoses were identified using codes from the International Classification of 
Diseases 10th Revision (ICD 10)  for the hospital data (HES) and mortality data (ONS), from 
Read Codes for primary care data (CPRD) and bespoke variables in MINAP).  
 
5.2.6.  Statistical analysis 
 
In primary analyse heart rate was grouped into clinically relevant categories (<60 bpm, 60-70 
bpm, 70-80, 80-90, >90bpm) and the lowest level (considered as sinus bradycardia in adults 
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246) was used as the reference category. In secondary analyses heart rate was analysed as a 
10 bpm increase continuous variable. Analyses were also conducted separately for patients 
with different types of pre-existing CHD (i.e. stable angina, unstable angina and myocardial 
infarction). And evidence for interaction by age, sex and hypertensive status (sbp/dbp>140/90) 
was assessed. The association between heart rate and each endpoint was assessed using Cox 
proportional hazard models with time since study entry as the timescale and stratified by 
primary care practice.. Covariates were added in the models in two steps for estimated 
adjustment: 1) Sex and age adjusted; 2) additionally by established cardiovascular risk factors 
(index of multiple deprivation, systolic blood pressure, smoking status, body mass index (BMI), 
diabetes type II, high density lipoprotein cholesterol and total serum cholesterol). 
 
For covariate adjustments the missing at random covariate values were imputed using multiple 
chained equations225 with a similar process as described in chapter 4. To assess the shape of 
associations between heart rate and CVD endpoints I used restricted cubic splines with 4 
knots.226 Several sensitivity analyses were performed. First, repeating the analyses after 
excluding CVD events occurring during the first year after the heart rate measurement (Figure 
A5.7). Second, performing analyses restricted to patients without baseline prescription of beta-
blockers, blood pressure lowering medication or warfarin/digoxin medication (Figures A5.8, 
A5.9, A5.10). Third, conducting separate analyses for patients who had pre-existing CHD prior 
or after their index date (Figures A5.11, A5.12) and normotensive/hypertensive people 
(Figures A5.13, A5.14). Finally, after excluding patients with history of heart failure and after 
ignoring CVD events recorded in primary care data (Figures A5.15, A5.16). Statistical analyses 
were performed using Stata statistical software (StataSE 13) and R (v3.0.3). 
 
5.3. Results 
 
5.3.1.  Baseline characteristics 
 
I included 51,703 patients (44.1% women) who experienced 9,043 cardiovascular events 
during 132,359.7 person-years of follow-up (mean follow-up per patient 2.6 years). Patient 
characteristics by heart rate level are shown in Table 5.1. Compared with patients with heart 
rate <60 bpm, those with >90 bpm were more commonly females, socioeconomically deprived, 
current smokers, hypertensive and diabetic. Proportions of beta-blocker, aspirin and statin 
users decreased with higher heart rate levels, while the proportions of warfarin, digoxin and 
verapamil increased with higher heart rate levels. Baseline prevalence of pre-existing heart 
failure, stroke and atrial fibrillation also increased with higher heart rate levels. People with 
history of unstable angina were more likely women, of white ethnicity, have hypertension and 
diabetes and receive anti-arrhythmic and blood pressure lowering medication, compared to 
people with pre-existing stable angina or myocardial infarction (Table A5.2-Appendix 5).
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Table 5.1. Baseline characteristics of people with stable coronary artery disease by heart rate level 
 L1  
(<60 bpm) 
L2  
(60-69 bpm) 
L3  
(70-79 bpm) 
L4  
(80-89 bpm) 
L5  
(>90 bpm) 
Total (%) 
 Mean (%) SD Mean (%) SD Mean (%) SD Mean (%) SD Mean (%) SD N Total (%) 
Demographic factors            
Age (years) 71.7 10.3 71.5 11.1 72.6 11.6 73.1 11.7 72.2 11.9 51,703 (100%) 
Female 31.5  39.4  46.9  52.0  53.1  22,809 (44.1%) 
White Ethnicity 79.8  79.7  80.2  80.6  80.4  37,980 (80.1%) 
Socioeconomic 
deprivation (most 
deprived quintile) 
16.5  18.2  20.3  22.3  24.4  10,300 
(19.98%) Clinical biomarkers and 
risk factors 
           
Heart rate (continuous) 
(bpm) 
52.7 4.97 63.7 3.11 73.5 2.85 82.7 3.08 101.1 12.6 51,703 
Systolic blood pressure, 
(mmHg) 
139.0 20.3 137.3 19.5 138.2 19.8 138.8 19.8 138.8 21.1 44,297 
Diastolic blood pressure, 
(mmHg) 
75.4 10.9 76.1 10.5 77.0 10.5 77.8 10.6 78.9 11.7 44,297 
High density lipoprotein 
cholesterol, (mmol/L) 
81.3 36.9 82.8 38.5 86.3 40.4 89.0 42.6 91.6 43.1 26,461  
Low density lipoprotein 
cholesterol, (mmol/L) 
2.39 0.83 2.46 0.88 2.53 0.93 2.56 0.96 2.60 1.02 21,381  
Total cholesterol  
(mmol/L) 
42.8 9.89 44.0 10.5 45.3 11.0 46.0 11.2 46.5 11.6 35,078  
Triglycerides (mmol/L) 1.52 0.84 1.57 1.02 1.60 1.04 1.62 1.00 1.67 1.40 26,382  
Creatinine  (μmol/L) 103.3 34.0 102.1 40.8 102.9 108.4 102.0 41.5 101.9 43.5 37,083  
BMI (kg/m2 ) 27.9 4.77 28.1 5.20 28.1 5.47 28.4 5.95 28.5 6.30 23,928  
Smoking            
Non-smokers 37.9  39.3  41.1  42.1  38.4  19,713 (95.2%) 
Ex-smoker 51.6  47.7  44.6  42.5  43.3  22,670 (95.2%) 
Current smoker 9.7  11.8  12.7  13.5  16.4  6,177 (95.2%) 
Type 2 Diabetes 10.0  10.9  11.9  12.5  14.8  51,703 (100%) 
Current alcohol drinker 60.6  57.9  54.7  54.1  51.9  9,367 (18%) 
Hypertension diagnosis 5.68  5.07  6.35  6.97  9.47  2,791 (6.3%) 
Medication            
Beta-blockers 79.7  63.1  43.1  31.8  28.2  26,212 (50.7%) 
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Antianginal medication* 69.1  65.5  64.6  64.9  66.5  34,040 (65.8%) 
Blood pressure lowering 
medication 
79.8  76.1  73.9  72.3  74.2  38,871 (75.2%) 
Warfarin 6.56  7.52  8.47  9.65  11.47  4,365 (8.44 %) 
 Digoxin 2.91  3.65  5.23  6.48  8.66  2,594 (5.02 %) 
 Verapamil 0.66  1.39  1.74  2.24  3.04  884 (1.71%) 
 Diltiazem 
10.4  10.7  12.1  13.0  11.8  6,007 (11.6%) 
 Aspirin 76.6  71.3  65.9  62.1  58.7  34,975  (67.6%) 
 Statins 75.9  68.6  60.2  54.0  52.9  32,611 (63.1%) 
 CVD comorbidities & 
sCAD diagnosis at 
baseline 
 
           
Heart failure 
 
12.2  12.7  15.2  17.4  20.6  7,769 (15.0%) 
 Stable angina 
 
47.8  50.1  53.6  56.5  58.0  44,370 (37.7%) 
 Myocardial infarction 
 
25.2  24.2  22.5  21.1  20.3  5,597 (16.5 %) 
Stroke 4.61  5.32  6.15  6.67  6.80  3,023 (5.85%) 
 Peripheral arterial 
disease 
 
0.75  0.90  1.24  1.50  1.78  607 (1.17%) 
 Atrial fibrillation 
 
14.1  14.7  17.0  19.2  23.9  8,820 (17.1%) 
 
Note: Blood pressure (BP) medication consists of BNF codes that refer to diuretics, b-blockers, calcium channel blockers and ACE inhibitors intake.  
For categorical variables the means represent % proportions. *Antianginal medication consists of: Ca channel blockers, nitrates, vasodilators and other angina medication  
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5.3.2.  Heart rate and CVDs prognosis 
 
In multivariable models, the hazard of heart failure, atrial fibrillation, CVD and total mortality 
increased with increasing levels of heart rate. These associations were present regardless of 
the type of pre-existing coronary event (Table A5.3-Appendix 5). Hazards of sudden cardiac 
death and stroke were also higher in patient with >=90 vs. <60 bpm (HR=2.23, 95%CI 1.41-
3.51 and HR=1.30, 95%CI 1.10-1.55) (Figure 5.2, Table 5.4) although the risk of stroke was 
found attenuated compared to the analysis adjusted just for sex and age (Figure A5.3-
Appendix 5).  However, no evidence of association with stroke was found for people with pre-
existing MI or UA (Table A5.3-Appendix 5). The heart rate level was not associated with 
subsequent occurrence of myocardial infarction or peripheral arterial disease.  
 
5.3.3. Interactions with age and gender 
 
Overall, interactions with sex were found to be significant for PAD, AF and cardiovascular death 
(Table 5.5). Separate analysis for men and women are presented in Figures A5.4 and A5.5). 
For every 10bpm heart rate increase, the risk for mortality (CVD and all-cause) was attenuated 
in people >80 years of age. Mild but consistent decrease of HF and AF was also found >80 
age, with the risk for heart failure getting lower for ages >60 years (Figure A5.6-Appendix 5).  
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Table 5.4. Multivariable adjusted hazard ratios for the association between heart rate levels and the subsequent fatal and non-fatal events among  people with 
stable coronary artery disease 
 N of events  
Level1 
(<60 bpm) 
(N= 12,147) 
 
Level2 
(60-69 bpm) 
(N= 10,199) 
 
Level 3 
(70-79 bpm) 
(N= 9,188) 
 
Level 4 
(80-89 bpm) 
(N= 10,501) 
 
Level 5 
(>90 bpm) 
(N= 9,668) 
 Heat rate/sex Interactions  Per 10 bpm 
     
HR (95% CI) 
 
HR (95% CI) 
 
HR (95% CI) 
 
HR (95% CI) 
 
p-value 
 
HR (95% CI) 
Cardiac outcomes          
Myocardial infarction 1,041  REF  0.99(0.82-1.19)  
1.07(0.88-1.29) 
 
 1.01 (0.82-1.24)  1.20(0.95-1.51)  0.71  
1.02  
(0.98-1.07) 
Atrial fibrillation 9,960  REF  1.05(0.98-1.12)  1.19(1.11-1.28)  1.46(1.35-1.56)  2.04(1.88-2.21)  0.01  
1.15  
(1.13-1.16) 
Heart Failure 3,465  REF  1.30(1.15-1.48)  1.65(1.46-1.86)  2.29(2.02-2.59)  2.69(2.59-3.39)  0.17  
1.21  
(1.19-1.23) 
CA-SCD 237  REF  1.55(1.05-2.28)  1.41(0.95-2.11)  0.93(0.58-1.50)  2.23(1.41-3.51)  0.95  
1.07  
(0.99-1.16) 
Peripheral arterial 
disease 
1,181  REF  1.06(0.88-1.28)  1.17(0.97-1.42)  1.19(0.97-1.46)  1.13(0.88-1.45)  0.03  
1.03  
(0.99-1.07) 
All cause stroke 1,746  REF  0.99(0.86-1.15)  1.10(0.96-1.27)  1.27(1.10-1.47)  1.30(1.10-1.55)  0.26  
1.06  
(1.03-1.10) 
CVD death 1,477  REF  1.19(0.99-1.43)  1.28(1.06-1.54)  1.63(1.36-1.97)  2.02(1.64-2.48)  0.05  
1.14  
(1.10-1.17) 
Total mortality 3,098  REF  1.26(1.11-1.43)  1.58(1.40-1.79)  1.73(1.52-1.97)  2.34(2.04-2.69)  0.00  
1.15  
(1.13-1.18) 
Note: CVD, cardiovascular; SCD-CA, Sudden cardiac death-Cardiac arrest;  CI, confidence interval; HR, hazard ratios from Cox proportional hazard model stratified by general practice  and adjusted for sex, age, index of 
multiple deprivation, smoking, systolic blood pressure, type 2 diabetes, total cholesterol, HDL cholesterol and body mass index 
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Note: CI, confidence interval; HR, hazard ratios from Cox proportional hazard model stratified by general practice and 
adjusted for sex, age, index of multiple deprivation, smoking, systolic blood pressure, diabetes type II, total cholesterol, HDL 
cholesterol and body mass index 
 
 
 
 
 
Figure 5.2. Multivariable adjusted hazard ratios for the association between heart rate (top vs bottom 
level) and the subsequent fatal and non-fatal events among  people with stable coronary artery 
disease 
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Table 5.5. Adjusted hazard ratios for the association between heart rate levels and the subsequent fatal and non-fatal events in men and women with stable 
coronary artery disease 
 
N of events 
 Level1 
(<60 bpm) 
 Level2 
(60-69 bpm) 
 Level 3 
(70-79 bpm) 
 Level 4 
(80-89 bpm) 
 Level 5 
(>90 bpm) 
 
Heat rate/sex Interactions 
     
HR (95% CI) 
 
HR (95% CI) 
 
HR (95% CI) 
 
HR (95% CI) 
 
p-value 
Cardiac outcomes         
Myocardial Infarction              
Men 720 
 
1  
0.95 
(0.75-1.19) 
 
1.02 
(0.80-1.28) 
 
0.99 
(0.76-1.28) 
 
1.22 
(0.90-1.64) 
 
0.71 
Women 521 
 
  
1.08 
(0.77-1.53) 
 
1.14 
(0.81-1.59) 
 
1.03 
(0.73-1.46) 
 
1.23 
(0.83-1.81) 
 
Atrial Fibrillation              
Men 5,396 
 
1  
1.06 
(0.97-1.16) 
 
1.25 
(1.15-1.37) 
 
1.65 
(1.50-1.81) 
 
2.18 
(1.96-2.43) 
 
0.01 
Women 4,564 
 
  
1.01 
(0.90-1.13) 
 
1.09 
(0.97-1.22) 
 
1.25 
(1.11-1.40) 
 
1.84 
(1.62-2.08) 
 
Heart Failure              
Men 2,178 
 
1  
1.28 
(1.10-1.49) 
 
1.60 
(1.37-1.87) 
 
2.41 
(2.07-2.82) 
 
2.94 
(2.47-3.49) 
 
0.17 
Women 1,769 
 
  
1.30 
(1.05-1.62) 
 
1.70 
(1.38-2.10) 
 
2.13 
(1.72-2.64) 
 
2.96 
(2.37-3.70) 
 
CA-SCD              
Men 235 
 
1  
1.71 
(1.11-2.63) 
 
1.49 
(0.95-2.35) 
 
1.09 
(0.64-1.86) 
 
2.38 
(1.41-4.01) 
 
0.95 
Women 64 
 
  
0.94 
(0.37-2.38) 
 
1.08 
(0.44-2.65) 
 
0.52 
(0.17-1.56) 
 
1.84 
(0.70-4.83) 
 
Peripheral Arterial Disease              
Men 739 
 
1  
0.95 
(0.75-1.19) 
 
1.21 
(0.96-1.52) 
 
1.20 
(0.93-1.54) 
 
1.31 
(0.96-1.77) 
 
0.03 
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Women 442 
 
  
1.34 
(0.93-1.91) 
 
1.14 
(0.79-1.64) 
 
1.20 
(0.83-1.74) 
 
0.99 
(0.64-1.55) 
 
All-cause stroke              
Men 1,108 
 1  0.98 
(0.82-1.19) 
 
1.15 
(0.95-1.39) 
 
1.31 
(1.06-1.61) 
 
1.09 
(0.83-1.42) 
 
0.26 
Women 1,267 
   1.05 
(0.84-1.31) 
 
1.10 
(0.88-1.37) 
 
1.31 
(1.05-1.64) 
 
1.47 
(1.15-1.88) 
 
CVD death              
Men 912 
 1  1.23 
(0.98-1.54) 
 
1.35 
(1.07-1.70) 
 
1.72 
(1.35-2.20) 
 
2.23 
(1.70-2.93) 
 
0.05 
Women 730 
   1.08 
(0.79-1.48) 
 
1.21 
(0.89-1.65) 
 
1.49 
(1.09-2.03) 
 
1.78 
(1.27-2.50) 
 
Total mortality              
Men 1,840 
 1  1.26 
(1.08-1.49) 
 
1.63 
(1.38-1.91) 
 
1.87 
(1.58-2.22) 
 
2.65 
(2.21-3.19) 
 
0.00 
Women 1,685 
   1.23 
(1.00-1.52) 
 
1.50 
(1.22-1.84) 
 
1.56 
(1.27-1.93) 
 
2.03 
(1.63-2.54) 
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5.4. Discussion 
 
5.4.1.  Main findings 
 
In this prospective study, we report an association between elevated heart rate and the risk of 
cardiovascular endpoints and morbidity in patients with stable coronary artery disease. Our 
study confirms previous reports that elevated heart rate is a predictor of mortality and heart 
failure in CAD patients.125, 166, 169 However, our results also extend these observations to 
cerebrovascular and atrial fibrillation events. In line with recent trials findings we found no 
association between increased heart rate with subsequent coronary events, i.e. myocardial 
infarction.   
  
5.4.2. Choice of primary outcomes in trials 
 
We dissected the primary endpoint used in a number of trials that commonly incorporates a 
mortality (cardiovascular or non) combined with ischaemic events mainly represented by 
myocardial infarction into separate specific cardiac outcomes and we further explored a number 
of other cardiac phenotypes including atrial fibrillation. We observed a strong association of 
increased HR with CVD mortality but not with MI, which puts trials’ findings in a clinical context 
and largely explains their findings.  
 
Specifically, a recent large clinical trial, SIGNIFY by Fox et.al. of 19,102 patients with CAD and 
no clinical heart failure on ivabradine, failed to show a significant difference between the 
ivabradine group and the placebo group in the incidence of the primary end point (a composite 
of death from cardiovascular causes or nonfatal MI) nor did they show significant differences in 
the incidences of death from cardiovascular causes and nonfatal myocardial infarction 
separately. In beta-blocker trials such TIBET (Total Ischaemic Burden European Trial),247 
atenolol resulted to no reduction in the primary endpoint (a composite of cardiac mortality, MI, 
UA, CABG) compared with placebo and just a greater HR reduction. In the Angina and Silent 
Ischaemia Study (ASIS), patients with RHR >80 bpm were twice as likely to develop ischemia 
as those with rates <60 bpm.102 Furthermore, the INternational VErapamil-SR/trandolapril 
Study (INVEST)166 of hypertensive patients with stable CHD, showed a modest linear 
association with risk of death, MI, or stroke from 55 to 100 bpm, which did not retain significance 
in the multivariate analysis. Further evidence found by observational studies such as the TNT 
study (CAD-patients),248 the study of Bemelmans et al, 144the 3C study (elderly subjects from 
the population)249 also supported the absence of significant relation between RHR and risk for 
MI. Genome Wide Association Studies (GWAS) support these findings as they failed to identify 
associations of heart rate loci with coronary artery disease (CAD) or MI.240 The lack of 
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association between heart rate and coronary artery disease found in the above studies, 
contrasts with results from previous post hoc analyses of 5,438 CAD patients with reduced 
LVEF of the BEAUTIfUL trial, in which ivabradine was reported to be associated with a 24% 
reduction in the primary endpoint and a 42% reduction in hospitalization for MI  in patients with 
limiting angina.125 
 
5.4.3.  Further cardiovascular outcomes 
 
Associations between resting heart rate values (without the mediation of heart rate medication 
in analyses) and other specific cardiovascular endpoints outside the coronary disease 
spectrum, are not clear. In the present study we found a strong and consistent increase in 
hazard in L5 compared with L1 for heart failure, sudden cardiac death, AF and CVD mortality 
independent of blood pressure, beta-blockers and arrhythmia medication (Fig A5.8-10) or past 
heart failure events (Fig A5.15) and a mild association with stroke events, while we failed to 
show any associations with coronary heart disease manifestations.  
 
In our study, associations of heart rate with heart failure, CVD and total mortality, AF and stroke 
was strong not only in the general CAD population but also in a subset of patients after the 
exclusion of those with heart failure diagnosed at baseline (Figure A5.15). In patients with heart 
failure, the reduction in heart rate with ivabradine has been shown to improve clinical outcomes, 
beyond the improvements observed with beta-blockers.229 The benefit observed with lowering 
the heart rate in patients with heart failure but not in those with stable coronary artery disease 
may reflect the fact that an elevated heart rate is due to different pathophysiological 
mechanisms in these two conditions90 such as neurohormonal activation in patients with heart 
failure and further ventricular remodelling.  
 
A significantly increased risk of AF was also found for heart rate values >70bpm above which 
the hazard increased progressively. Sympathetic activation and progressive disruption of 
autonomic balance may also be important in the pathogenesis of atrial fibrillation after CABG.250 
White and his colleagues found a significant increase in the incidence of AF in patients in whom 
administration of b-adrenoceptor antagonists was ceased when compared with those whose 
drug treatment was continued after surgery.251 Tachycardia can shorten the atrial effective 
refractory period and make the atrium more susceptible to atrial fibrillation,252 however the 
majority of studies available have been conducted on animal models.  Further evidence of a 
mechanistic link of heart rate with atrial fibrillation comes from genome-wide association studies 
that have identified heart rate increasing alleles of five loci that are associated with both 
increased and decreased risk of atrial fibrillation.240 
 
Whether the effects of an increased RHR on CVDs are a reflection of the harmful effects of an 
increased sympathetic tone or of an increase in heart rate itself is unclear. However, in our 
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exploratory analyses we adjusted for some determinants of sympathetic activity (BMI, type 2 
diabetes mellitus) and another measure of present sympathetic tone (systolic blood pressure). 
Correction for these variables did not lead to substantial differences in the results, suggesting 
that is it not only sympathetic activity, but increased RHR itself that plays a role in the increased 
risk of mortality and heart failure.  
 
5.4.4. Gender differences  
 
Additionally, a gender-related difference in the association between heart rate and mortality has 
been found in some studies conducted either in subjects from general populations or in patients 
with MI.253 In particular, in most studies high heart rate appeared to be a weak predictor of 
death from coronary artery disease in the female gender with the exception of CASS study by 
Diaz et al.169, which indicated that tachycardia can be deleterious also in the female gender. In 
our study we found a slightly higher increase in risk of stroke in women in L5 (HR: 1.47, 95% 
CI: 1.15-1.88) compared to men (HR: 1.09, 95% CI: 0.83-1.42), while a higher risk for atrial 
fibrillation was found in men in L3, L4 and L5 compared to women that the risk was restricted 
to heart rate values >80bpm. 
 
5.4.5.  Shape of associations 
 
Our study provides evidence for a steep increase in risk for heart failure and cardiovascular 
mortality above 70bpm, a threshold significantly lower than the majority of the available studies. 
Quite steep is also the increase to atrial fibrillation events above 70bpm, while the risk of sudden 
cardiac death shows an increase in higher heart rate values above 90bpm (Figure A5.17). 
Published studies have suggested a threshold effect of heart rate on mortality outcomes, above 
which the risk increases steeply. Data from the Coronary Artery Surgery Study (CASS) registry 
suggested an increased risk of all-cause mortality for a heart rate >77 beats/ min and of CV 
death at a HR>83 beats/min.169 In contrast, other studies have supported a slightly lower 
threshold of >70 beats/min15,18,19 while others have demonstrated an increased risk at relatively 
low HRs, suggesting a J-shaped, rather than a linear, relation.18,20,21 In line with our findings, 
data from the BEAUTIFUL study, however, has suggested that the increase in death and heart 
failure outcomes rose continuously ≥70 bpm, whereas the relationship was less pronounced 
for MI and revascularization.125  
 
5.4.6. Main implications of linked electronic health records 
 
Heart rate is one of the most easily accessible biomarkers that recent studies have given 
impetus to its examination. Private companies and academic institutes have invested significant 
amount of financial, scientific and infrastructural sources to design and conduct clinical trials 
investigating the effect of heart rate lowering medication such as ivabradine or beta-blockers 
on specific coronary disease phenotypes such as MI that as showed by our study are not linked. 
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These quantitative (money) and qualitative (investigators’ or patients’ time) investments could 
have been avoided if the application of linked electronic health records had preceded the actual 
trial, while these sources could have been   allocated towards investigation of heart rate links 
with other cardiac diseases such as people at early stages of heart failure and resting 
tachycardia. The design of such trials should take into account of the selective associations of 
heart rate with the non-vascular disease presentations identified in our study.  
 
5.4.7. Strengths 
 
The main strengths of this study lies in its large scale population based prospective design and 
our use of CALIBER’s linked electronic health records to assemble a population based cohort 
of sufficient size, clinical resolution and follow-up to power the analysis of resting heart rate and 
its associations with different components that may influence the design and composition of 
primary endpoints in clinical trials.  
 
5.4.8. Main limitations 
 
Although associations between heart rate and CVDs are not influenced by variation of resting 
values over time or by the measurement method used152 we can assume that more accurate 
measurements would likely show stronger associations with CVDs. Additionally, we were 
unable to adjust for physical activity which was recorded in only 10,137 patients. However, this 
is unlikely to have affected our findings based on previous studies where adjustment for 
exercise had little effect on heart rate associations with CVD.169 The non-reporting of heart rate 
measurement techniques led to a digit preference (Figure 3.5(b) and Table A3.7). The 
potential for imbalance between baseline beta-blocker or blood pressure medication 
prescription rates to distort our findings was excluded in a sensitivity analysis (Figures A5.8 & 
A5.9).  
 
5.5. Conclusions  
 
Resting heart rate was strongly associated with outcomes not included so far in trials primary 
endpoints such as heart failure, and not associated with outcomes commonly used by trials as 
main endpoint or a part of composite primary endpoints such as myocardial infarction. Higher 
resting heart rates above 70bpm increase the hazard of heart failure events, stroke in women 
and atrial fibrillation, without substantially affecting the hazard of vascular events in the coronary 
arterial beds. Our findings show how disaggregation of CVD into specific phenotypes can help 
to disentangle the underlying disease mechanisms with implications for clinical practice and the 
design and interpretation of clinical trials. 
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6. Heart rate and the onset and prognosis of atrial 
fibrillation in 196,436 initially healthy men and women: a 
CALIBER study 
 
The purpose of this chapter is dual. Initially, I will explore associations of resting heart rate with 
the incidence of atrial fibrillation in a healthy cohort using linked electronic health records. The 
nested cohort of patients with atrial fibrillation that I will identify will then be followed-up to 
estimate the risk of subsequent cardiovascular diseases. Further analysis by genders will shed 
light to the previously unexplored area of atrial fibrillation incidence differences between men 
and women.  
 
6.1. Introduction 
 
Resting heart rate is a powerful marker in a broad range of subjects in sinus rhythm (SR), with 
or without cardiovascular disease.21,254 Various experimental and clinical observations suggest 
that sympathetic and vagal neural regulatory mechanisms play a critical role in altering cardiac 
electrical properties and in promoting the occurrence of arrhythmic events255-257 and heart rate 
is an important marker of sympathetic tone. Genome-wide association studies (GWAS) have 
identified associations between genetic variants in the region of the gene HCN4, which codes 
for the main ion channel responsible for the If current, and both heart rate and atrial fibrillation 
(AF),258, 259 while observational studies have shown that the pulmonary venous myocardium, 
which is an important source of AF initiation and maintenance,260 demonstrates an If current 
which is affected by ivabradine (a pure heart rate lowering agent).261  
 
Despite the evidence available from GWAS on the underlying genetic association between 
heart rate and atrial fibrillation, information from observational or experimental studies from a 
clinical and health care practice perspective of this association is limited. Specific links between 
resting heart rate and the incidence and prognosis of AF in healthy population without prior 
CVDs at baseline have not been addressed so far using large scale data. Epidemiological 
studies are few, old and have been extensively conducted in populations with specific 
comorbidities already at baseline, namely established cardiovascular diseases 171-175, or 
hypertensive populations.173 Additionally, available studies have very low sample sizes and 
hence are of limited power to secure sufficient events number and follow-up to accommodate 
both an assessment of AF incidence and subsequent CVD events, while those exploring 
prognosis of CVD outcomes in AF populations are restricted to mortality outcomes.178, 179 
Additionally, no study so far has examined the impact of low heart rate on AF, since the 
reference levels commonly taken in available studies are pooled heart rate ranges of higher 
HR values (i.e. reference HR category: <100bpm171 or 60-80bpm175). None examined sex 
differences in associations or described shapes of associations, potentially due to their limited 
sample sizes (chapter 2- Tables2.6, 2.7). 
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I will investigate the association of resting heart rate and incidence of atrial fibrillation and its 
links to subsequent cardiac, vascular and mortality events using real-world linked electronic 
health data. These data provides me the opportunity to i) explore the long-term course of 
patients initially free from prior atherosclerotic disease or arrhythmic disorder that experienced 
an atrial fibrillation event and ii) follow them up until the subsequent experience of a subsequent 
cardiovascular event while ensuring internal validity, as well as iii) to explore potential 
differences in risk between the two genders, in relation to their heart rate.  
 
6.2. Methods 
 
6.2.1.  Data resource 
 
The Cardiovascular disease research using Linked Bespoke studies and Electronic Records 
(CALIBER) e-health database was the data resource for this study. CALIBER links patient 
records from four different data sources: Clinical Practice Research Database 
(CPRD)192MINAP (Myocardial Ischaemia National Audit Project registry)219 Hospital Episodes 
Statistics (HES)220, the Office for National Statistics (ONS)221 and the Office of the Population 
Censuses and Surveys Classification of Interventions and Procedures262 (4th revision). 
CPRD data were used to obtain heart rate measurements, demographic variables and other 
risk factors. The primary care practices and the subset of linked practices used in the present 
study analysis are representative of the UK primary care setting194 and have been validated for 
epidemiological research.222  
 
6.2.2.  Study population 
 
An open cohort of 2,23 million people covering approximately 5% of the UK population was 
drawn from registrants between January 1997 and March 2010 with 225 primary care practices 
who consented to data linkage. People included in the final healthy cohort were aged ≥30 years 
at study entry (‘index date’), with ≥1 year registration prior to the index date, no prior diagnosis 
of CVD and with at least one recorded heart rate measurement during the study period. This 
population was initially followed-up to assess the risk of AF onset. At the second stage of the 
study, people that had at least one AF event and a heart rate measurement on the day of this 
event or up until a year after it, were further followed-up for subsequent CVD events (Figure 
A6.1). Participants were censored on the dates of leaving the practice, or last submission of 
data, or death, or endpoint occurrence. The study flow diagram is shown in Figure A6.2. 
 
6.2.3.  Heart rate 
 
Heart rate was prospectively collected by general practice staff and ranged from 20-240 bpm. 
The method of measurement is not recorded in the database and recorded heart rate values 
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are likely to have been obtained through palpation at the wrist, auscultation of the heart and 
readings from an electrocardiogram (ECG) or automated blood pressure device. Since 
approximately 90% of the heart rate measurements were recorded on the same day as blood 
pressure, the most likely method of heart rate measurement is the latter. 
 
6.2.4.  Cardiovascular risk factors 
 
Information on risk factors was obtained from CPRD, as recorded during consultations in 
primary care. The most recent measurement (or prescription) recorded in CPRD up to one year 
before or on the date of study entry (first heart rate measurement after the index date for the 
initially healthy population and the most recent heart rate measurement up to one year after a 
first AF event for people who consecutively experienced a AF event) was used to define 
baseline covariates for AF onset and prognosis respectively. Socioeconomic status was 
derived from ONS using the Index of Multiple Deprivation (IMD) 2007.223 It was divided into five 
categories (quintiles), the 1st quintile corresponding to the least deprived and the 5th quintile 
to the most deprived groups. The most recent smoking record before the index date was used 
to classify participants as never, ex or current smokers.  
 
6.2.5.  Endpoints 
 
The primary endpoint in the healthy population was the first presentation of atrial fibrillation after 
the baseline heart rate measurement date across the four data sources and its record was 
provided by primary and secondary care sources. The codes used to construct atrial fibrillation 
algorithm consist of i. a diagnosis of AF (first record of AF) without preference for primary versus 
secondary care and ii. inferred AF, in which no diagnosis code is present, but the patient record 
includes a warfarin prescription in the absence of prior deep vein thrombosis or pulmonary 
embolism, or a digoxin prescription in the absence of HF.263 Details on the AF algorithm codes 
are presented in Table A6.1. 
For the progression of AF events, the CVD outcomes analysed entailed acute coronary 
diseases (myocardial infarction (MI)); heart failure (HF)); a composite of cardiac arrest, 
ventricular fibrillation and sudden cardiac death (CA-SCD); a composite of cerebrovascular 
diseases including ischaemic stroke, subarachnoid haemorrhage (SAH), transient ischaemic 
attack (TIA) and intracerebral haemorrhage; and finally peripheral arterial disease (PAD). 
Additionally, two mortality outcomes were assessed (CVD and all-cause mortality). Diagnoses 
were identified using codes from the International Classification of Diseases 10th Revision (ICD 
10)  for the hospital data (HES) and mortality data (ONS), from Read Codes for primary care 
data (CPRD) and bespoke variables in the ACS registry (MINAP). Codes used to define atrial 
fibrillation and each cardiovascular endpoint and data source are presented in Tables A6.1, 
A3.10. 
 
6.2.6.  Statistical analysis 
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In the final analysis heart rate was analysed in five categories (<60 bpm, 60-69 bpm, 70-79, 
80-89, >90bpm) in order to be more clinically relevant taking as reference level the lower heart 
rate range of <60bpm for the AF incidence examination and the range of 70-79bpm at the stage 
of CVD prognosis. Differences in risk factors by level of heart rate were tested using the F 
statistic from analysis of variance or its non-parametric version (Kruskal Wallis test) and the 
chi-square statistic, as appropriate. The association between heart rate and each endpoint was 
assessed using Cox proportional hazard models to model cause-specific hazards, with time 
since study entry as the timescale. Separate analysis for AF incidence was performed using as 
reference level the lowest heart rate range of <60bpm for clinical relevance reasons and 
comparability with previous findings (Figure A6.4). 
 
For covariate adjustments the missing at random covariate values were imputed using multiple 
chained equations225. To assess the shape of association between heart rate and atrial 
fibrillation incidence and prognosis, we used restricted cubic splines with 4 knots and the 
reference value of 70bpm226 (Figures A6.5, A6.6). In sensitivity analyses, we repeated the 
analyses of atrial fibrillation incidence separately for those that had at least a CVD event before 
the atrial fibrillation event and those who did not to exclude the possibility of AF events that are 
post CVDs manifestations. Separate analysis was conducted restricted to those that had an AF 
event at least 6 months after an MI event and after exclusion of AF events up to a year after 
the heart rate measurement to account for reverse causality effects. Further analyses were 
performed restricted to those with beta-blockers and warfarin/digoxin prescriptions and those 
without thyroid disorder (Figures A6.7(a-f)). Statistical analyses were performed using Stata 
statistical software (StataSE 13) and R (v3.0.3). 
 
6.3. Results 
 
6.3.1. Baseline characteristics of initially healthy population and population with atrial 
fibrillation 
 
We included 196,436 patients (56.2% women) with heart rate measurements available at 
baseline who experienced 6,983 atrial fibrillation events during 508,769.24 person-years of 
follow-up (median follow-up 2.59 years). Healthy cohort characteristics by heart rate level are 
shown in Table 6.2. Compared with a HR of <60 bpm, patients with >90 bpm were more 
commonly female, current smokers, diabetic, with higher diastolic blood pressure and greater 
proportions in the top deprivation quintile, while systolic blood pressure was particularly 
increased at <60bpm rates. Proportions on cardiovascular medications, particularly beta-
blockers, were lower in the highest HR level compared with the lower or “normal” HR values of 
70-79bpm. Few CVDs were experienced prior to the AF events with lower rates of stroke in 
>90bpm compared to <60bpm or 70-79bpm. In the second part of this study, baseline 
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characteristics of people that experienced an atrial fibrillation event showed similar traits only 
lower systolic blood pressure (Table 6.3).  
 
 
Table 6.2. Baseline participant characteristics by heart rate (healthy population) 
 <60 bpm 
(N=14,284) 
60-69 bpm 
(N=43,326) 
70-79 bpm 
(N=60,105) 
80-89bpm 
(N=47,869) 
>90 bpm 
(N=30,852) 
N total 
(%) 
 Mean 
(%) 
SD Mean 
(%) 
SD Mean 
(%) 
SD Mean 
(%) 
SD Mean 
(%) 
SD N total 
(%) 
Demographic factors            
Age at entry (years) 59.7 15.5 58.2 16.1 58.0 16.4 58.9 16.9 57.2 16.3 196,436 
(100%) 
Female 41.3  50.9  57.2  60.9  61.0  110,436 
(56.2%) 
White Ethnicity 74.4  72.7  73.2  73.4  73.4  98,764 
(73.2%) 
Deprivation (most deprived 
quintile) 
18.7  20.9  22.0  24.4  26.6  44,933 
(22.9%) 
Clinical biomarkers and 
risk factors 
           
Heart rate  (bpm) 53.4 4.81 64.5 3.07 73.8 2.83 83.0 3.10 101.1 11.3 196,436 
Systolic blood pressure, 
(mmHg) 
143.1 21.3 139.5 20.2 138.6 19.5 139.4 19.8 141.4 20.8 125,241 
(63.7%) 
Diastolic blood pressure, 
(mmHg) 
80.8 11.4 80.9 10.8 81.1 10.7 81.8 10.8 83.5 11.6 125,241 
(63.7%) 
High density lipoproteins, 
(mmol/L) 
1.41 0.39 
.39 
1.43 0 .4 1.44 0.4 1.43 0.4 1.44 0.4 46,186 
Low density lipoproteins, 
(mmol/L) 
3.20 0.99 3.20 0.99 3.21 1.0 3.17 1.0 3.12 1.0 37,460 
Total cholesterol  (mmol/L) 5.30 1.10 5.31 1.1 5.35 1.2 5.34 1.1 5.34 1.3 59,095 
Triglycerides (mmol/L) 1.55 0.92 1.56 0.9 1.62 1.1 1.69 1.2 1.76 1.3 45,949 
Creatinine  (μmol/L) 93.1 25.4 89.3 25.9 87.5 26.2 86.8 29.4 86.5 30.5 79,752 
BMI (kg/m2 ) 27.9 5.3 27.8 5.6 28.2 5.7 28.5 6.1 28.5 6.4 68,548 
Smoking            
Non-smokers 63.5  61.6  60.2  57.8  55.1  116,726 
(60.8%) Ex-smoker 
17.8  16.0  15.2  15.0  14.1  30,262 
(15.7%) 
Current smoker 16.8  20.1  22.3  24.2  28.0  44,836 
(23.3%) 
Diabetes type  II 4.83  4.48  4.77  5.74  6.77  10,338 
(5.26%) 
Medication            
Beta-blockers 39.7  21.1  11.1  8.71  8.07  28,245 
(14.3%) 
BP medication 48.5  39.1  38.7  39.0  41.7  97,073 
(41.4%) 
Calcium channel blockers 15.3  11.8  10.8  11.3  13.5  23,456 
(11.9%) 
Statins 14.1  11.6  10.8  10.7  11.8  22,385 
(11.4%) 
Aspirin 11.38  8.78  7.90  8.47  8.66  16,916 
(8.61%) 
CVD events developed after 
baseline and before atrial 
fibrillation onset 
           
Heart failure 
 
3.5  5.44  5.55  7.04  5.7  402 
(5.75) 
Stable angina 
 
7.94  8.23  6.83  6.92  5.07  485 
(6.94) 
Myocardial infarction 
 
5.29  7.17  6.73  7.86  4.44  458 
(6.55) 
Stroke 8.87  7.70  8.06  6.34  4.44  488 
(6.98) 
Peripheral arterial disease 
 
2.80  3.12  3.04  2.75  2.45  200 
(2.86) 
Note: Blood pressure (BP) medication: diuretics, b-blockers, calcium channel blockers, hypertension and heart failure 
medication and ACE inhibitors  
 
 
 
 
 
 
 
 
Table 6.3. Characteristics of patients with new diagnosis of  atrial fibrillation by heart rate 
level by heart rate level  
 <60 bpm 
(N=401) 
60-69 bpm 
(N=920) 
70-79 bpm 
(N=1,075) 
80-89 bpm 
(N=1,093) 
>90 bpm 
(N=1,271) 
N total 
(%) 
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 Mean 
(%) 
SD Mean 
(%) 
SD Mean 
(%) 
SD Mean 
(%) 
SD Mean 
(%) 
SD N total 
(%) 
Demographic factors            
Age at entry (years) 74.3 10.7 75.4 11.6 76.2 11.2 77.2 11.3 75.1 11.6 4,760(100) 
Female 41.4  49.4  54.6  58.2  57.2  2,573 
(54.0) 
White Ethnicity 74.0  77.1  77.9  77.3  73.9  3,630 
(76.2) 
Deprivation (most 
deprived quintile) 
16.9  18.5  20.2  22.6  23.8  1,007 
(21.1) 
Clinical biomarkers and 
risk factors 
           
Heart rate (bpm) 52.4 5.41 64.0 3.25 73.7 2.87 83.1 3.15 108.3 18.4 4,760  
Systolic blood pressure, 
(mmHg) 
145.2 22.6 142.4 20.1 141.0 19.4 142.0 20.5 141.0 21.2 3,988  
Diastolic blood pressure, 
(mmHg) 
78.1 11.5 78.8 11.6 78.8 11.2 79.7 11.7 80.7 12.3 3,988  
High density lipoproteins, 
(mmol/L) 
1.38 0.39 1.50  0.41 1.43 0.43 1.54 0.47 1.47 0.43 1,615  
Low density lipoproteins, 
(mmol/L) 
2.66  0.92 2.89     0.94 2.88 1.02 2.89 0 
.96 
2.96 1.02 1,299  
Total cholesterol  
(mmol/L) 
4.72 1.04 4.97 1.13 4.94 1.14 5.00 1.13 5.08 1.15 2,112  
Triglycerides (mmol/L) 1.42 0.83 1.33 0 
.64 
1.43 0 
.74 
1.36 0.69 1.46 0.79 1,564  
Creatinine  (μmol/L) 103.6 36.4 96.7 28.3 97.6 42.5 100.5 62.3 97.9 44.5 3,119  
BMI (kg/m2 ) 27.9 6.16 27.8 5.92 27.5 5.62 27.5 6.62 28.3 7.14 1,952  
Smoking            
Non-smokers 64.8  63.8  62.6  61.6  60.1  2,959 
(62.1) Ex-smoker 
20.7  19.3  20.5  19.1  19.9  945 (19.8) 
Current smoker 12.4  14.6  13.9  16.3  16.8  728 (15.2) 
Diabetes type  II 10.4  10.1  10.3  10.8  11.9  517 (10.8) 
Current alcohol drinker 19.4  17.6  15.0  13.1  14.1  726 (15.2) 
Hypertensives 14.7  14.1  11.7  12.2  14.2  630 (13.2) 
Medication            
Beta-blockers 52.1  42.5  31.2  24.0  22.6  1,487 
(31.2) 
Nitrates 35.6  33.7  31.4  29.7  29.0  1,485 
(31.1) 
Ca-Channel blockers 28.6  27.1  27.7  26.5  26.5  1,291 
(27.1) 
BP medication 73.0  63.8  62.4  60.0  63.8  3,018 
(63.4) 
Warfarin 6.48  7.50  8.00  6.95  4.56  315 (6.62) 
Digoxin 3.99  4.57  6.98  8.87  6.45  312 (6.55) 
Aspirin 38.4  35.5  32.0  32.7  29.7  1,561 
(32.7) 
Statins 33.6  26.5   23.1  19.8  21.2  1,115 
(23.4) 
Note: Blood pressure (BP) medication: diuretics, b-blockers, calcium channel blockers, hypertension and heart failure 
medication and ACE inhibitors.  
For categorical variables the means represent % proportions.  
 
6.3.2.  Heart rate and atrial fibrillation onset in initially healthy subjects 
 
The age and sex adjusted Cox analysis (Table 6.4) showed significantly increased hazard of 
atrial fibrillation in both >90bpm (L5) (HR: 1.44, 95% CI: 1.34-1.55) and <60bpm (L1: HR=1.30, 
95% CI: 1.19-1.43) compared with 70-79bpm (L3). In adjusted analysis for sex, age, smoking, 
systolic blood pressure, diabetes, cholesterol, hdl, bmi and imd (Table 6.4, Figure 6.3), these 
associations remained. After restricting to AF events not preceded by a CVD, the association 
between heart rate (L5 vs L3) and atrial fibrillation became stronger with a HR=1.53 (CI 95% 
1.41-1.66). The association between L1 and L3 of heart rate event though attenuated was still 
significant with HR=1.18 (95% CI: 1.06-1.31). 
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Table 6.4. Multivariable analysis of heart rate (by heart rate level) with atrial fibrillation incidence (healthy population) 
Atrial Fibrillation N of events  
Level1 
(<60 bpm) 
 (N=401) 
 
Level2 
(60-69 bpm) 
(N= 920) 
 
Level 3 
(70-79 bpm) 
 (N= 1,075) 
 
Level 4 
(80-89 bpm) 
(N= 1,093) 
 
Level 5 
(>90 bpm)  
(N= 1,271) 
     
HR (95% CI) 
 
HR (95% CI) 
 
HR (95% CI) 
 
HR (95% CI) 
Total persons        
Adjusted for sex/age 
  
1.30 (1.19-
1.43) 
 1.10 (1.03-1.18)  REF  1.08 (1.01-1.16)  1.44 (1.34-1.55) 
Multivariable adjusted model 
6,983  
1.22 (1.11-
1.34) 
 1.08 (1.00-1.15)  REF  1.09 (1.02-1.16)  1.43 (1.33-1.54) 
Men 
3,091  
1.12 (0.99-
1.28) 
 0.99 (0.89-1.10)  REF  1.11 (1.00-1.24)  1.50 (1.33-1.68) 
Women 
3,892  
1.35 (1.18-
1.54) 
 1.14 (1.04-1.25)  REF  1.07 (0.98-1.17)  1.40 (1.27-1.54) 
With preceded (first manifestation)  CVDs 1,488  
1.27 (1.05-
1.54) 
 1.14 (0.98-1.32)  REF  0.96 (0.83-1.11)  1.11 (0.93-1.32) 
Men 
682  
1.17 (0.88-
1.54) 
 1.02 (0.82-1.28)  REF  0.96 (0.77-1.20)  1.05 (0.80-1.38) 
Women 
806  
1.49 (1.12-
1.98) 
 1.24 (1.01-1.53)  REF  0.95 (0.78-1.16)  1.20 (0.95-1.51) 
Without preceded (first manifestation) CVDs 
5,495  
1.18 (1.06-
1.31) 
 1.06 (0.98-1.15)  REF  1.12 (1.04-1.21)  1.53 (1.41-1.66) 
Men 
2,409  
1.11 (0.95-
1.29) 
 0.97 (0.86-1.09)  REF  1.15 (1.02-1.30)  1.65 (1.45-1.87) 
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Women 
3,086  
1.27 (1.08-
1.48) 
 1.13 (1.01-1.25)  REF  1.10 (1.00-1.22)  1.45 (1.30-1.62) 
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Note: CI, confidence interval; HR, hazard ratios adjusted for age, sex, social deprivation, smoking, systolic blood pressure, BP medication, total cholesterol, HDL, LDL, diabetes II and BMI 
 
Figure 6.3. Multivariably adjusted hazard ratios for the association between heart rate (70-79bpm vs >90bpm) and the risk of atrial fibrillation 
Men 
(b) 
Women 
(c) 
Total 
(a) 
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6.3.3.  The age and sex analysis  
 
Subgroup gender analysis showed a strong association between heart rate >90bpm (vs 70-
79bpm) and atrial fibrillation in both men (HR=1.50, 95% CI: 1.33-1.68) and women (HR=1.40, 
95% CI: 1.27-1.54). The associations were particularly strong in cases that no CVD event 
preceded that of atrial fibrillation in men and women (HR=1.65, 95% CI: 1.45-1.87 and 
HR=1.45, 95% CI: 1.30-1.62, respectively) (Table 6.4). Risk of AF at lower heart rate range 
(<60 vs 70-79bpm) was found to be strong in women (HR=1.35, 95% CI: (1.18-1.54) but not 
significant in men (Table 6.4, Figure 6.3). Compared to men, heart rate range of 70-90bpm vs 
<60bpm (70-79bpm and 80-89bpm vs >90bpm) showed a protective effect for atrial fibrillation 
in women. Finally, atrial fibrillation risk was higher in people aged >80 that belonged to >90bpm 
heart rate range (HR=1.32, 95% CI: 1.10-1.59) (data not shown). 
 
6.3.4.  Heart rate and CVDs prognosis in patients with atrial fibrillation 
 
In total, 2,474 of 4,760 patients with atrial fibrillation had a subsequent CVD event after a 
median time of 1.95 years. Strong associations were found between higher heart rate (70-
79bpm, 80-89bpm, >90bpm) and the hazard of heart failure (70-79bpm HR=1.86, 95% CI: 1.29-
1.68), (80-89bpm HR=2.00, 95% CI: 1.39-2.89), (>90bpm HR=1.89, 95% CI: 1.30-2.75) (Table 
6.5). The risk increased above 70bpm and became stable but high above 85bpm. A positive 
but insignificant association was found between MI events and 60-69bpm, 70-79bpm and 80-
89bpm heart rate levels but not >90bpm. Associations between heart rate and stable angina, 
sudden cardiac death, stroke or PAD were weak or imperceptible.   
 
 
6.4. Discussion 
 
6.4.1.  Main findings on AF incidence 
 
By linking electronic health records this is the first study to report associations of resting heart 
rate with onset of atrial fibrillation in a large healthy population cohort. We have shown that 
while increased heart rate is strongly associated with atrial fibrillation in men and women, lower 
HR ranges are linked with an increased AF risk which is confined to women (Table 6.4, Figure 
6.3, Figure A6.8).  
  
6.4.2.  Findings on AF prognosis  
 
People that at the first stage developed atrial fibrillation, subsequently showed a significant 
increase in heart failure and all-cause mortality risk (Table 6.5) when heart rate exceeded a 
threshold level of 70bpm that so far has been regarded as normal. A sensitivity analysis 
performed after exclusion of heart failure events experienced within 6 months after the baseline 
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heart rate measurement of the atrial fibrillation cohort yielded similar results, however 
insignificant due to the low number of events. 
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Table 6.5. Multivariable analysis of heart rate (by heart rate level) with prognosis of 10 CVDs in an atrial fibrillation population 
 
N of events 
 Level1 
(<60 bpm) 
 (N=401) 
 Level2 
(60-69 bpm) 
(N= 920) 
 Level 3 
(70-79 bpm) 
 (N= 1,075) 
 Level 4 
(80-89 bpm) 
(N= 1,093) 
 Level 5 
(>90 bpm)  
(N= 1,271) 
 
 
    
Cardiovascular endpoints in follow-up     
HR (95% CI) 
 
HR (95% CI) 
 
HR (95% CI) 
 
HR (95% CI) 
        
Stable Angina 626  REF  1.06 (0.78-1.44)  0.98 (0.72-1.33)  1.05 (0.77-1.43)  0.83 (0.59-1.15) 
Myocardial infarction 402  REF  1.27 (0.83-1.94)  1.32 (0.87-2.02)  1.35 (0.88-2.07)  1.00 (0.63-1.58) 
Heart Failure 670  REF  1.46 (1.00-2.12)  1.86 (1.29-2.68)  2.00 (1.39-2.89)  1.89 (1.30-2.75) 
SCD 65  REF  0.40 (0.15-1.05)  0.48 (0.20-1.17)  0.61 (0.24-1.54)  0.46 (0.17-1.24) 
Stroke 528  REF  0.86 (0.59-1.23)  1.15 (0.82-1.63)  0.90 (0.62-1.30)  0.83 (0.57-1.23) 
Peripheral Arterial Disease 183  REF  1.04 (0.57-1.88)  1.30 (0.74-2.30)  1.03 (0.56-1.89)  0.88 (0.47-1.67) 
CVD mortality 380  REF  1.10 (0.72-1.70)  1.33 (0.87-2.02)  1.59 (1.04-2.43)  1.45 (0.94-2.23) 
All-cause mortality 1,179  REF  1.19 (0.88-1.59)  1.32 (0.99-1.76)  1.60 (1.21-2.12)  1.60 (1.21-2.11) 
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6.4.3. Findings in the context of previous research 
 
Associations of heart rate and AF incidence were found significant in only 2 previous studies 
that were both conducted more than 20 years ago, examined populations with established 
cardiovascular diseases,171, 175 where one of them was solely focused on men171 and neither 
examined low heart rates. Atrial fibrillation occurs in congestive heart failure and in myocardial 
infarction264, 265 and has been related to the severity of infarction.266, 267 We showed that atrial 
fibrillation occurs without these comorbidities and heart rate is -although not causally-, 
independently associated with it regardless other cardiovascular events. In a previous 
epidemiological study, 24% of heart failure hospitalizations occurred before or at diagnosis of 
atrial fibrillation and 17% after it. Atrial fibrillation is well known to cause or aggravate congestive 
heart failure, related to loss of systolic filling or rapid ventricular rate, but heart failure may also 
promote atrial fibrillation.172 In our study, only 5.75% of people that developed atrial fibrillation 
had experienced heart failure and in a sensitivity analysis after excluding all CVD events, the 
risk of atrial fibrillation for people with heart rates >90bpm became higher (HR=1.53, 95% CI: 
1.41-1.66). It has been also found that ischemic heart disease often precedes atrial fibrillation, 
and is an independent risk factor. This suggests that ischemic heart disease produces changes, 
particularly acutely, in the atria that predispose to the development of atrial fibrillation268, and 
that atrial fibrillation infrequently precedes clinical ischemic heart disease. 
 
A history of myocardial infarction or heart failure, high BMI and blood pressure have been 
shown to be strong predictors of atrial fibrillation.172 However, after adjusting for these factors 
with the addition of blood pressure medication and lipids, heart rate remained an independent 
marker of AF incidence prediction. In the present study 6.55% of people that experienced AF 
had previously an MI event.  
 
In follow-up, we showed that there is an association between heart rate and MI but for the 60-
69bpm, 70-79bpm, 80-89bpm heart rate, however this risk was statistically insignificant. Strong 
associations were found between resting heart rate and subsequent heart failure events and 
total mortality. Only two recent studies examined the prognosis of AF patients but were limited 
to all-cause mortality outcomes.  
 
6.4.4. Shape of associations 
 
We also showed that atrial fibrillation risk has a U shape and increases steeply above 74bpm 
(Figures A6.5). This shape was particularly pronounced in women that their lower levels of 
heart rate showed a high increase of AF incidence. In follow-up of people that subsequently 
experienced an atrial fibrillation event we showed an increase in risk of heart failure above 
70bpm (Figure A6.6), similar to the one we previously showed in people with CHD whereas in 
healthy population this risk is more obvious in heart rates above 75bpm. 
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6.4.5. Mechanistic considerations 
 
Genome-wide associations studies (GWAS) showed that five of heart rate loci in human 
genome are associated with both increased and decreased risk of atrial fibrillation.140 Three 
large studies in 2010 used a GWAS to analyze variability in PR interval. In one of these, Pfeufer 
et al 269 performed a meta-analysis of GWASs of PR interval that included 28,517 European 
subjects. They found 9 loci associated with PR interval (including SOX5), of which 5 were also 
associated with AF. Kolek et al270 conducted a separate GWAS of PR interval in 2,334 subjects 
drawn from BioVU and replicated the finding that SCN10A variants are associated with 
variability in the PR interval.271 The vast majority of subjects in these studies had no history of 
AF, the finding that genetic variants play a role in heart rate at rest and AV nodal conduction 
which might imply that they might also modify the response to rate control therapy in AF. For 
example, genetic variants in adrenergic receptor genes are associated with response to b 
blockers in patients with hypertension and heart failure272 and also modify heart rate response 
to b blockade in healthy subjects.273 In addition, more recent studies have suggested that there 
is no difference in outcomes between a strict and lenient target heart rate response during 
AF.274 The common variant, rs6795970, in SCN10A has been also associated with PR interval 
duration in both healthy populations and those with atrial fibrillation. This variant may also be 
associated with heart rate response in atrial fibrillation, indicating its role in modulating 
atrioventricular conduction. 275 A meta-analysis in 2014 which identified an association between 
If current inhibition and AF supported by the associations recently found between genetic 
markers near HCN4,  provide further evidence for the role of HCN4 and the If current in the 
pathophysiology of AF.276 
 
6.4.6.  Clinical and research implications 
 
Although we cannot assume a causal link between heart rate and AF incidence and prognosis, 
identifying individuals at the highest risk for AF and then aggressively addressing a modifiable 
risk marker of developing AF such as heart rate in these individuals may be beneficial with 
respect to prevention of atrial fibrillation and subsequent heart failure, mortality and cost. 
Temporal trends suggest that by 2050, the ageing population could result in as many as 15.9 
million cases of atrial fibrillation in the USA, with similar projected increases in prevalence for 
other developed countries,277 while the lifetime risk of atrial fibrillation is about one in four 
individuals.278  
 
Common CHD risk scores are not effective at predicting AF risk. CHD and AF share some 
common risk factors, such as hypertension, diabetes, and obesity, but heart rate has been 
shown to be a risk factor of development of AF only and not of CHD. This highlights the 
importance of a separate risk score to predict AF, and potentially, the need to develop different 
preventive interventions by incorporation of heart rate in such scores. Some AF risk prediction 
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models have been proposed which were based on single US-cohorts.175 However, these 
models have not been validated thoroughly or included risk factors which are not routinely 
available in primary care such as heart rate (e.g. Framingham Heart Study).174 Recently the 
CHARGE-HF consortium published a simple risk model derived from three US cohorts using 
variables readily available in a primary care setting (age, race, height, weight, blood pressure, 
smoking, antihypertensive medication, diabetes, myocardial infarction and heart failure) which 
showed good risk prediction. However this model was performed in elderly cohorts with the 
majority of people aged more than 65 years. We showed differences between genders with a 
focus in lower heart rates and hence potential differences in pathophysiologies of AF that 
should lead to a personalized clinical care. 
 
In the light of these findings, targeting of drug interventions in routine clinical practice should 
be examined with caution. In a recent meta-analysis it was found that ivabradine has not been 
shown to limit the ventricular rate in patients in AF, and so authors concluded that those patients 
who develop AF are likely to have higher heart rates, thus negating any benefits of ivabradine 
as a rate-lowering therapy in treating either angina or heart failure.276 Our findings that support 
that the increase of AF incidence is higher among men and women with higher baseline heart 
rate and in women with low heart rate, raise the possibility that the contribution of ivabradine in 
these patient groups could be possibly proved to be trivial if not adverse. In another clinical trial, 
it was provided solid preclinical evidence that ivabradine and ranolazine, alone or in 
combination, have roles in AF rate control.279 A post hoc joint analysis of primary source data 
from 2 multicentre RCTs (AFFIRM and AF-CHF) showed that baseline heart rate of patients in 
sinus rhythm was independently associated with mortality in contrast with people’s heart rate 
in atrial fibrillation rhythm which showed no evidence of an association.280 In view of the lack of 
associations of heart rate in patients with atrial fibrillation rhythm as showed here and supported 
by previous literature findings, clinical practice professionals should be targeting medications 
for AF primary prevention with a personalized health care perspective and communicating of 
risk for individuals cautiously. Additionally, both short-term and long-term clinical trials in 
patients with AF will need to be conducted to determine appropriate doses and to measure 
changes in heart rate.281 
 
6.4.7.  Strengths and limitations 
 
The main strength of this study lies in the size of the cohort of 196,436 men and women 
compared to the available studies with sizes in the low thousands. Our study further has large 
resolution and follow-up to power the analysis of resting heart rate and its association with atrial 
fibrillation incidence and the investigation of associations with subsequent CVD events in the 
sub-population of atrial fibrillation patients. The nature of the data recorded in clinical practice 
enhances the clinical relevance of our findings and their representativeness in the general 
population. 
 
   159 
 
Limitations include the lack of accurate reporting regarding the device or technique used to 
record heart rate. However, it has been found that associations between heart rate and AF or 
CVDs are not influenced by variation of resting values over time or by the measurement method 
used.152 The possibility of baseline beta-blocker intake different rates across heart rate levels 
distorting our findings was excluded in a sensitivity analysis (Fig A6.7(d)). Finally, LV 
dysfunction, early heart failure or even acute coronary events as a reason for higher heart rate 
over time may also impact directly on the risk of developing AF282-284 via increases in left atrial 
pressure and stretch that can promote AF and act as a source of reverse causality bias.285 This 
possibility was examined by excluding all CVD events prior to AF incidence and the AF events 
that were experienced within 6 months after an MI event, where in the first case associations 
were found to be stronger whereas the latter showed a slight attenuation but strong significance 
(Fig A6.7(b),(f)). 
 
6.5. Conclusions  
 
This is the first study to report associations of resting heart rate with onset of atrial fibrillation in 
a large healthy population cohort and follow-up the patients for subsequent cardiovascular 
diseases. We have shown that while heart rate is strongly associated with atrial fibrillation in 
men, its association in women is not established. Rates across heart rate levels show a 
constant increase of hazard of subsequent heart failure events compared to low heart rate 
values (<60bpm) in people with diagnosed atrial fibrillation. Further investigation of heart rate 
mechanisms is needed, with particular focus in underlying differences between men and 
women and sex-adjusted medication treatments, in addition to a more focused approach 
towards patients with atrial fibrillation and early stages and heart failure development.  
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7. Methodology of a clinical biobanked cohort (4C study) 
 
7.1. Abstract 
 
Background  
Consented cohorts recruited in clinical settings make important contributions towards 
addressing translational research questions in prognosis research.  Few large, well-
characterised cohorts that collect genetic material, imaging diagnostics and quality of life data 
are available to support research in people with suspected or confirmed coronary artery 
disease. 
 
Objectives 
The general objective of 4C was to establish a contemporary, prospective clinical cohort of 
patients with linked phenotypic, genetic and biomarker data as a resource. The individual 
objectives set initially for the purposes of this PhD were to explore heart rate associations with 
i)  diagnoses based on functional imaging and invasive coronary angiography results, e.g. 
number of diseased vessels, ii) Quality of life parameters and mental health, iii) Single 
nucleotide polymorphisms (SNPs) that are related to coronary heart disease. 
 
Methods 
Consecutive patients undergoing investigation for new-onset, non-acute chest pain were 
recruited between 2009-2014 from four UK NHS hospitals.  Participants provided blood 
samples for biomarker and DNA analysis and completed a health questionnaire at baseline.  
Detailed clinical information was manually extracted from hospital electronic databases.  
Participants are being followed-up for CVD events, and health-related quality of life was 
assessed using a postal questionnaire (mean follow-up 469 days).   
 
Results 
3345 consecutive patients (63.1% men; mean age±SD 58.0±12.5 years) were enrolled.  Blood 
samples were collected for 84%, baseline questionnaire data for 89% and clinical data for 99% 
of patients. Heart rate was recorded for 83.3% of patients of which 20% of people belonged to 
the lowest heart rate range (<60bpm) and 12% to the highest (>90bpm). So far, during a median 
follow-up of 326 days, 839 patients were sent for matching and finally were matched to a record. 
Total number of deaths coming from ONS are 110 (3.2%). These low numbers of events that 
have been recorded so far render the exploration of associations between heart rate and CAD 
prognosis unfeasible in the current period of follow-up.   
 
Conclusions  
The Clinical Cohorts in Coronary disease Collaboration (4C) is a contemporary consented DNA 
bio-resource linked to hospital electronic health records (EHRs), questionnaire data and health 
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outcomes.  Significant challenges remain for automatically extracting the entire patient EHR 
from health information systems and as a result a wealth of data remains inaccessible for 
research.  The design, development and provision of common infrastructure, data standards 
and services that will allow researchers to access and exploit such data are crucial for 
expanding 4C in the future.  Related initiatives such as the NIHR Health Informatics 
Collaborative will provide best practices and guidelines for doing so. 
 
This chapter will describe the design and methodology of a clinical cohort (4C) of patients with 
coronary artery disease and chest pain symptoms that I recruited from a clinical settings in UK 
(The Heart Hospital London). This prospective cohort was assembled from 4 different hospitals 
in UK and was conducted to establish a resource of genetic, clinical and biomarker data that 
are associated with the onset of stable angina pectoris and its progression to acute fatal/non-
fatal events. 
 
7.2. Introduction 
 
In the previous chapter it was noted that linked electronic health records fail to capture in depth 
parameters of the patients’ perceptions on their health such the implementation of quality of life 
scales to assess psychological or behavioural functioning, or diagnostic imaging tests and other 
visual tools. Their observational nature and subsequently their confinement to associations or 
correlation pathways that are not causal was further pinpointed. As a consequence, the need 
for a consented cohort to yield both clinical and genetic information to address translational 
research questions in prognosis was crucial. High quality prognosis research in clinical 
populations can improve understanding of how biomarkers or genes interact with environmental 
factors associated with disease by linking imaging, genomic and bespoke phenotypic data with 
rich clinical information held in the patients EHR. However, despite their potential advantages, 
large, prospective clinical cohorts are lacking across all disease areas, with a limited number 
focused on coronary artery disease (CAD).5-8 
 
For this purpose, a new clinical cohort of people with suspected or established coronary artery 
disease was designed and launched in 2009 as a resource in which DNA and biomarker 
samples were obtained at time of presentation with chest pain linked to detailed phenotypic 
data obtained from EHRs and participant self-completed questionnaires. This new cohort which 
aimed at finding new ways of diagnosing symptoms, offers information related to specific chest 
pain symptoms and the well-being of patients using self-reported questionnaires and vital 
genetic information through the use of biobanked data that would enable me to explore new 
perspectives of heart rate and coronary artery disease. The study recruitment phase finished 
in 2014 and its follow-up is ongoing.  
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The initial purpose of this PhD study was to explore further associations of heart rate with the 
prognosis of cardiovascular diseases in people with CAD and chest pain. It has been previously 
shown that chest pain is a more frequent initial presentation of CAD than an unheralded AMI11 
thus new-onset chest pain may represent a potential intervention point that could facilitate the 
identification of those at risk of acute cardiac events. Links between heart rate and chest pain 
have not yet to be examined and studies looking into associations of heart rate with CAD need 
to be updated and focused on clinically relevant endpoints that would further inform clinical 
practice and large trial investigations. However, the low number of events did not allow for 
associations between heart rate and chest pain and/or symptomatic coronary artery disease 
exploration.  
 
A further initial objective of this PhD was to use the genetic pool accrued from the recruitment 
of patients’ biological specimens to assess genetic variants role on the association between 
heart rate and CAD prognosis. Genome-wide association studies (GWAS) have failed to 
identify associations of heart rate loci with coronary artery disease or MI.140 Furthermore, 
despite markedly different underlying pathophysiology, symptomatic presentation, clinical 
management and prognosis, most genetic case collections measure CAD and AMI in 
aggregate. GWAS of CAD and AMI published to date use the same single nucleotide 
polymorphism (SNP) platform in multiple patient samples and suggest that there may be 
different associations for CAD-only versus CAD and AMI collectively.286, 287 Hence, 
distinguishing specific coronary phenotypes may provide specific causal mechanistic insights 
relevant to public health. The high genetic resonance of this consented cohort would allow for 
the examination of the relationship of resting heart rate and the prevalence and prognosis of 
CAD. However, due to time limitations these explorations will not be performed within the time 
frame of this PhD.   
 
A summary of my responsibilities during the first year of my PhD conducting field clinical 
research are presented in Table 7.1 below. 
 
7.3. Aims 
 
The aim of the 4C study was to explore and assess the current potential of setting up a 
comparable consented research platform by collecting DNA samples and to quantify the extent 
to which diverse NHS hospital information systems are accessible for extracting secondary care 
data (structured and unstructured) for research purposes at scale. This pool of genetic and 
clinical information would then be used to identify and evaluate genetic and environmental 
factors associated with the onset of suspected or confirmed stable coronary artery disease, the 
stable angina pectoris syndrome and its progression to acute fatal and non-fatal events. 
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Table 7.1 Personal responsibilities during 4C field research 
Study setup in Heart hospital 
Contribution to study forms design and piloting 
Organization of study's site and equipment 
Liaison with different clinical professionals for more efficient study conduct 
Patients' approach and recruitment 
Consenting patients 
Questionnaires administration 
Blood samples collection 
Bloods processing (centrifugation/ aliquoting) 
Clinical data collection from referral and discharge letters 
 Diagnostic imaging collection using hospital electronic systems 
Insert data to case record forms 
Questionnaires coding and data transfer to excel and access databases 
Training of new staff 
Co-ordination of meetings at tended by all research teams based at Heart Hospital 
 
 
7.4. Methods 
 
7.4.1.  Source population 
 
The 4C study is an ongoing clinical prospective cohort which was set out to explore the 
prognosis of people with suspected or established CAD. Patients were recruited from four 
centres in England: the Bristol Royal Infirmary (Bristol Heart Institute, Bristol), Newham 
University hospital (London), the Heart hospital (London) and the London Chest hospital 
(London). I recruited and collected information from 600 patients attended the Heart Hospital 
in London. Overall, 3,345 patients were recruited from all the four 4C centres. 
 
7.4.2.  Inclusion and exclusion criteria 
 
Since the aim of 4C study was to identify factors related to stable CAD phenotype, the 
appropriate eligibility criteria were applied to ensure good quality and representative data 
(Figure 7.1-Appendix 7.4). Consecutive patients undergoing evaluation for stable angina 
being assessed at the Rapid Access Chest Pain Clinics (RACPC) or undergoing coronary 
angiography within cardiac catheter laboratories at participating hospitals were approached for 
inclusion in the study. Patients were not eligible for inclusion if they were diagnosed with non-
cardiac chest pain, previous history of admission with acute coronary syndrome (ACS), Q wave 
or left bundle branch block on resting electrocardiogram or previous coronary angiography. On 
the basis of age or coexisting conditions, no patients were excluded. Trained researchers 
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identified eligible patients by checking clinic appointment databases and angiogram procedure 
lists on a daily basis.  
 
7.4.3. Participant consent  
 
Patients were approached directly by a researcher at the hospital at the time of their clinic 
appointment.  Informed consent was sought for: a) completion of a baseline health 
questionnaire; b) provision of a blood sample for long-term storage and analysis of DNA and 
biomarkers; c) extraction of patient hospital data; and d) linkage of patient data with national 
EHR data sources (e.g. coded hospitalizations and procedures, emergency admissions and 
cause-specific mortality). A sample of the consent form is in Appendix 7.1.  
 
7.4.4. Patients referred for coronary angiogram to pre-assessment clinics 
 
The study’s target population was people referred by their GPs to angiogram clinics for coronary 
angiography or percutaneous coronary interventions. Prior to their admission to the angiogram 
wards, patients had to go through a process that included an appointment to a pre-assessment 
clinic for blood collection and a brief clinical interview. In addition to the pre-assessment clinics 
I was attending coronary angiogram wards daily to identify potentially suitable patients for the 
study on the day of their angiogram procedure. Where possible, potential participants were 
recruited to the study and the baseline assessment was carried out right before the time of their 
procedure or in rare cases after the angiogram as soon as the patient fully recovered. I was 
checking the clinic appointments database daily (Mon-Fri) for details of new referrals to identify 
potentially suitable patients for the study. As soon as the potential participants arrived for their 
appointment, I was approaching and inviting them to take part after screening for inclusion 
criteria. At the same time, an information sheet and a sample consent form was administered 
by me and a second research staff member. After a few minutes I was approaching them again 
to discuss the requirements of the study in detail, its significance and purpose and consented 
those who finally accepted to participate. Patients were given a minimum of 15 minutes to read 
through the consent and study information sheet (see Appendix) and consider whether to 
participate in the study and an extra 15-20 minutes to fill in the questionnaire. All patients had 
the opportunity to discuss the study and any concerns regarding the upcoming angiography 
process they had with me. In cases of language or other problems related to reading and 
understanding the questions, I was responsible to go through the forms and make the 
appropriate interpretations. 
 
7.4.5. Patients undergoing coronary angiography 
 
Where possible, potential participants were recruited to the study and the baseline assessment 
carried out at the time of their angiogram preadmission appointment. However, a significant 
number of patients were transferred as emergencies from different hospitals. In this event, 
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patients were recruited to the study on the day of their coronary angiogram and their approach, 
consent and baseline assessment were conducted before or after the procedure as appropriate. 
Patients were allowed a minimum of 15 minutes to consider their decision to consent to 
participate in the 
study. 
 
7.4.6. Baseline assessment 
 
Measures were piloted and refined prior to commencement of the study. Three sources of risk 
factors were used during patients’ scheduled hospital appointments.  Research measures 
(biological specimens) included blood samples for DNA and biomarker analysis and a short 
health questionnaire completed by participants. Clinical measures obtained as part of the usual 
clinical investigation collected for research purposes constituted detailed clinical information 
extracted from the hospital EHR up to six months after the date of patients’ attendance.  
 
7.4.6.1. Baseline health questionnaire 
 
The questionnaires captured detailed information at entry to the study on education, ethnicity, 
general health functioning (EQ-5D),288 functional chest pain (Rose angina questionnaire),289 
angina severity (Canadian Cardiovascular Society classification (CCS class),290 and symptoms 
of anxiety (Generalised Anxiety Disorder 7-item scale (GAD-7))291 and depression (Patient 
Health Questionnaire (PHQ-9))292 at baseline. A sample questionnaire is attached in Appendix 
7.2. 
 
7.4.6.2. Research blood sampling 
 
In order to collect genetic information on heart rate loci and relevant SNPs that would allow me 
to investigate links of heart rate with CAD prognosis using an instrumental variable apporach, 
I collected research blood samples from the majotity of participants approached and consented 
within the study. I followed detailed operation protocols for sampling, processing, logging and 
storage of samples, including adverse event standard procedure and reporting. I obtained 
research bloods from all consented individuals, including those in whom a diagnosis of angina 
was subsequently ruled out. Afterwards, I was transferring and processing the collected 
samples in a different site (Centre for cardiovascular Biology and Medicine, UCL) by 
centrifuging and aliquoting them. All the blood cryovials then were stored in a secure location 
from where the samples were collected and transported for long term storage at a biobank. A 
summary of the blood processing procedure is provided in Figure II below (Figure 7.3.3.2.2). A 
total 20 ml of blood was drawn from the antecubital vein (vein of the inside elbow) into several 
vacutainers in the following order (2x 4.0ml EDTA, 1x 4.5ml PST, 1x 5.0ml STT/gel, 1x 2.5ml 
PAXgene for RNA) to enable a wide range of research measures to be obtained. into 0.5ml 2-
D bar coded cryovials as follows: EDTA (plasma) to 9 cryovials, EDTA (white cells) to 2 
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cryovials, LH (PST) to 4 cryovials, SST to 4 cryovials, PAXgene RNA to 5 cryovials. I logged 
each cryovial individually into the sample logging database by using a single-tube bar-code 
reader and then I stored them in a secure location in the basement of the same centre within a 
96 position rack in a -20oC freezer. Samples were collected on a quarterly basis by secure 
courier and transported on dry ice for long term storage at a biobank where they were stored 
at -80oC until they are retrieved for analysis, which may be up to 30 years after sampling 
(Figure 7.2, Appendix 7.4). 
 
7.4.6.3. Extraction of data as part of standard clinical care 
 
I reviewed hospital databases and recorded detailed clinical information onto standardized case 
report forms (Appendix 7.3).  Depending on the clinic or hospital, different clinical systems 
were searched to manually extract data that could not be downloaded or exported as a data 
file (Table 7.2-Appendix 7.4).  Information included reason(s) for referral, history of chest pain, 
physician-recorded risk factors for CAD, previously diagnosed medical history and test results. 
The resting ECG and exercise treadmill test had to be removed from the notes or ordered from 
medical records and photocopied.   Manual extraction of clinical biochemistry results from the 
hospital systems proved burdensome and was abandoned. Data were then manually entered 
onto a research database at the study co-ordinating centre, cleaned and coded ready for 
analysis.    
 
7.4.6.3.1. Routine biochemistry results 
Previous blood  results collected as part of routine hospital care are recorded on local hospital 
clinical systems. I carried out individual patient searches using the hospital system to which I 
had access after logging in with a secure password. I removed any patients identifiers and 
replaced them with the unique participant study identifier after I downloaded all the relevant 
data from the hospital electronic database and stored onto encrypted media. Additionally, 
Reports were anonymised at source. 
 
7.4.6.3.2. Routine cardiac imaging results 
I gathered all the available invasive, CT and MR angiography results (reports and raw data) 
from the hospital electronic record using the hospital program TOMCAT. Reports are 
anonymised at source. Digitised images were transferred to a core laboratory in the iMAC suite 
within the Advanced Centre for Cardiac Imaging at the London Chest hospital using the Image 
Exchange Portal (IEP) where they will be further anonymised. All the available information from 
every consented patient (biochemistry results and imaging) was recorded into specific forms, 
the case record forms, which they were then transferred back to the co-ordinating centre (See 
Appendix). Extraction of data from the Primary Care record. With appropriate permissions (e.g. 
from NHS Primary Care Trusts) I had access to the primary care records for consented 
participants to record data including risk factors, medication, previous medical investigations 
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and treatment and comorbid medical conditions. Data were downloaded onto an encrypted data 
stick and printed and after proper anonymization I transferred the complete patients files to the 
study coordinating centre. 
 
7.4.7. Heart rate measurement sources 
 
Baseline heart rate in 4C was obtained (in some of the centres) from resting ECGs performed 
on the day of the participants’ appointment, while in the Heart hospital ECGs were collected 
from the angiography labs that had performed them at the time of patients’ arrival at the day 
units of the labs. In case that patients’ ECGs had been performed at a later than recruitment 
time, ECGs were sent to another UCL centre (Maple House) and then collected from there. In 
the 4C dataset, heart rate values are available for 67.5% of the participants. Women had a 
significantly higher heart than men (74.5±13.6 versus 71.6±14.6, p<0.001). 
 
7.4.8. Pseudo-anonymization of patients records 
 
Patient identifiable data or information refers to information that can be used to identify an 
individual either on its own or in combination with other sources of information. In the context 
of this study, patient identifiable data is defined as a participants name, date of birth, full address 
or postcode, other contact details including email address, NHS number and any hospital-
specific identifiers such as hospital record number or hospital name. In addition, several fields 
are defined as sensitive and will only be disclosed to members of the research team if there is 
a valid reason to do so. Sensitive fields include ethnicity, employment status and referring GP 
name. A unique participant study identifier was assigned to individual participants at the point 
of enrolment to the study. Study IDs were generated by the data manager at the study 
coordinating centre, and were consist of a randomly generated ID (unique to each research site 
and patient). All electronic data and case record forms, apart from the participant consent form 
and study administration form (containing patient contact details for follow up purposes), were 
anonymised using the unique study ID number (i.e. for example setting the patient name to the 
pseudo-identifier in the software application that generates it). When this was not possible, 
anonymization was carried out by complete removal of identifiers by cutting identifiers out with 
scissors (preferred) or using a combination of the provided black permanent marker and 
provided stickers. This was done in a manner which ensures all affected areas are entirely 
covered without overrunning clinical information. 
 
7.4.9. Participant follow-up 
 
7.4.9.1. Clinical outcomes 
 
The primary endpoint of interest in the larger concept of 4C was a pre-specified composite of 
cardiovascular mortality, non-fatal AMI, non-fatal stroke and peripheral arterial disease. The 
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secondary outcomes are angina status and general health functioning. Unlike CALIBER, the 
power that stems from this smaller dataset does not allow for disaggregation of CVDs.  
 
7.4.9.2. Electronic Sources of data (EHR) 
 
We linked consented individuals with secondary care data from Hospital Episode Statistics, a 
national data warehouse of administrative data containing ICD-10 coded hospital diagnoses 
and OPCS4-coded procedures.  We additionally linked participants with mortality data from the 
Office of National Statistics that provided ICD10-coded cause-specific mortality data. The 
linkages were conducted via the NHS Health and Social Care Information Centre (formerly 
known as the NHS Information Centre) and patients were identified using their NHS number (a 
unique ten digit numeric identifier for the healthcare system), gender, date of birth and 
postcode. Unlike CALIBER, linkages were not performed by the mediation of a third trusted 
party, due to the direct consent practice (right from the source/patients). Notifications for 
admission to hospital and death and are downloaded onto a secure server via a secure web-
link from the NHS Information Centre for Health and Social Care on a quarterly basis by the 
study coordinator. Data are anonymised by removing patient identifiers and replacing them with 
the participant unique study identifier. In the UK, there is currently no centralized conduit, with 
national coverage, for linking and extracting primary care data at scale for research. We 
attempted to link consented participants with primary care resources but that involved going to 
individual GP practices and performing manual queries and data extraction operations – a route 
that is both unscalable and cost inefficient.  As a result, we were unable to obtain primary care 
EHR data in this study, although proposed substantial investment in this area (e.g. the Clinical 
Practice Research Datalink) will make this feasible in the future.  
 
7.4.9.3. Questionnaires 
 
A postal (or online) follow-up questionnaire was sent to study participants after recruitment 
(mean follow-up 469 days) to assess general health status, functional status, symptoms of 
depression and anxiety and use of nitrate medication, consistent to the first questionnaire that 
was administered to the participants’ on the day of their clinic attendance. Details of participant 
survival will be checked against quarterly notifications for death before sending invitations for 
follow-up. Participants are also being invited to consent to being contacted some years in the 
future with a further short follow-up questionnaire to determine their health status. 
 
7.5. Results 
 
7.5.1. Baseline data (Table 7.3-Appendix 7.4)  
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Between 9 July 2009 and 9 January 2014, 3345 participants (63.1% men; mean±SD age 
58.0±12.5 years) were enrolled in the study.  Detailed clinical information was manually 
extracted from hospital EHRs six months after the baseline assessment, to allow time for 
procedure and test results to be uploaded.  Approximately half (52%) were recruited from 
RACPCs and 48% from angiography pre-assessment clinics and cardiac catheter laboratories. 
Heart rate was available in 2,841 patients (83.3%). For clinical relevancy reasons, I present the 
baseline characteristics by heart rate of the following levels : <60bpm, 60-69bpm, 70-79bpm, 
80-89bpm and >90bpm. 20% of people belonged to the lowest heart rate range (<60bpm) and 
12% to the highest (>90bpm). People that belonged to the highest heart rate level were more 
commonly younger (mean age= 56.8 years compared to 62 years of age in people with <60bpm 
heart rate). They were also more commonly men, current smokers and with lower diabetes type 
II proportions. They also had lower beta-blockers, blood pressure medication, statins and 
antiplatelet prescriptions.  Of the 3345 participants recruited into the study, 99.1% granted full 
access to their medical records.   
 
7.5.2. Diagnoses and angiography findings 
 
The initial diagnosis provided by the clinician or nurse assigned to the patient was stable angina 
in 51.5% of the cohort for which this information was recorded.  Surprisingly, of the total 4C 
population, 41.4% of the participants were initially diagnosed as non-CAD chest pain, of which 
a higher percentage were women (51.7% versus 36.0% for men).  However, only 56.1% of our 
cohort had information available on initial diagnosis.  The overall assessment, obtained for 
61.3% of the total cohort, was based on the description of severity or percentage of luminal 
diameter stenosis made available on the angiogram report (coronary angiogram or coronary 
CT angiogram), with number of diseased vessels classified according to vascular territory of 
the three major coronaries.  The following criteria were then applied: (1) no evidence of disease 
in any of the territories was classified as normal; (2) some evidence of disease (e.g. mild 
disease or irregularities, “no significant disease”, “no flow limiting disease”) classified as less 
than moderate (obstruction ≤50%) in severity, was considered non-obstructive CAD; (3) 
evidence of moderate (50-69%) or worse (severe: ≥70%) disease in any one of the three 
territories was classified as 1 diseased vessels; (4) evidence of moderate or worse disease in 
any 2 territories or the left main stem (LMS) was classified as 2 diseased vessels; (5) evidence 
of moderate or worse in all 3 territories was classified as 3 diseased vessels.  Applying these 
criteria, 12.4% of our cohort was classified as having a normal angiogram, 28.1% as non-
obstructive CAD, 21.2% as 1 diseased vessel, 23.4% as 2 diseased vessels and 14.9% as 3 
diseased vessels.  Of people with higher heart rate (>90bpm) only 19.6% had an ischaemic or 
CAD history and 6.92% of a previous acute MI event, compared to patients with heart rate 
<60bpm that had 37.5% and 21.4% respectively. Additionally, people with heart rate >90bpm 
reported more often shortness of breath (37.3% vs 30.5% in people with <60bpm heart rate. 
Finally, people with >90bpm rate had less often a normal angiogram (14.5%), whereas were 
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more often diagnosed with 3 diseased vessels (66.6% vs 41.1% in people with <60bpm).  These 
diagnoses are presented in Table 7.4-A7.4. 
 
7.5.3. Symptoms and quality of life (Table 7.5-A7.4) 
 
Three-quarters (76.4%) of participants reported pain/discomfort problems (73.6% men versus 
81.3% women), and nearly half (45.6%) reported problems with anxiety/depression (42.3% 
men versus 51.6% women).  However, only 14.4% of participants reported problems with self-
care (14.5% men versus % 16% women). People with heart rate >90bpm consistently reported 
more often problems with mobility, self-care, performing usual activities, pain and anxiety or 
depression. They also reported higher in the Canadian Cardiovascular Society (CCS) (class 
IV) which corresponds to severe limitation in performing any activity without angina or angina 
at rest. In the PHQ-9 scale of mental health they also reported slightly higher percentages of 
depression (6.92%). 
 
7.5.4. Interim follow-up data for hospital admissions and procedures and mortality  
 
A high proportion of consented participants were successfully linked to hospital admission and 
procedure data in HES (96.7% of patients sent for matching to date).  Additionally, 99% of 
participants were linked successfully with the ONS national death registry and 110 incident 
deaths were recorded (with 25 recorded as CHD-related deaths (ICD-10 codes I20-25) as the 
underlying cause of death) (Table 7.6-A7.4). The nature of population (CAD patients) as well 
as the sample size restricts our power to explore specific subsequent cardiovascular events.  
 
7.6. Strengths and weaknesses of a consented clinical cohort 
 
4C principle strengths consist of: 
 Research measures systematically recorded, on information that is virtually never 
available in the EHR, including quality of life, DNA, biomarkers. 
 Direct generation of research ready data 
 Higher quality information and research reinforcement 
 Qualitative factors recorded such as quality of life, psychological symptoms and 
diagnostic imaging 
 A pool of genetic information 
 
4C principal weaknesses: 
 Manually performed data collection processes and personal time investment for 
recruitment 
 Difficulties in consenting 
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 Findings have limited applicability and are restricted to populations that resembles the 
clinical characteristics of cohort participants 
 Small sample size 
 
7.6.1. Strengths of 4C 
 
7.6.1.1. Systematic way of data collection 
 
The 4C study is an example of a clinical cohort that consists of 4 different individual cohorts 
representing 4 socioeconomically diverse areas of UK. Since it seeks to explore potential risk 
factors associated with the onset of stable coronary artery disease (angina pectoris) and chest 
pain, it has clear strategy and protocol to collect it according to the study needs. It is a research 
question driven cohort with a structured protocol and clear guidelines for conducting research 
in a standard and rigorous way. All the necessary data is collected in a clear and systematic 
way while we were able to adjust the techniques we used for its collection according to data 
nature or population characteristics, visiting back and revising our information gathering tools. 
The systematic way of data recording is also reflected on the clear accounts we have 
concerning biomarkers data collection, such as the one investigated in the PhD at hand. Heart 
rate measurements (recorded for 67.5% of participants) were collected through ECGs. The 
contribution of the systematic way followed by the researchers, had an additional benefit. 
Common problems in linked electronic health records stemming from the diverse sources 
recording such as data duplication or mislinkage, are not present in this clinical cohort. Each 
patient is recruited once by each centre and after regular communication with the other centres 
we made sure that the same patient would not be recruited twice or more. 
 
7.6.1.2. Generation of research-ready data 
 
Compared to the CALIBER platform and linked electronic data in general, one great advantage 
stands out. After the data collection and a brief process and cleaning that it might need 
depending to its nature, it is in a readily accessible form. As a result, the investigator could 
analyse the data without the need of extensive data manipulation.   
 
7.6.1.3. Research methods reinforcement 
 
A significant strength of 4C is the nature of data collected. Since the recruitment and data 
collection process required direct involvement of the investigator with patients and their data, I 
had the opportunity to thoroughly explain the needs and characteristics of the study to eligible 
participants and yield more accurate responses on the questions included in the questionnaires. 
Additionally, my personal time and involvement resulted to a better control of the responses 
rates (approximately 95% at Heart Hospital). Another benefit coming out of it is the low missing 
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values that is a result of the persistence and thoroughness of the researcher-recruiter. With my 
personal approach to the patients, I made sure that no question (hence variable) is left blank.  
 
7.6.1.4. Qualitative parameters 
 
Without questionnaires, parameters such as quality of life, psychological symptoms and 
specific chest pain descriptions wouldn’t be measurable, unlike primary care practice and linked 
electronic health records that this information is not usually recorded. Having access to the 
hospitals electronic systems, offered as a wide pool of diagnostic imaging data necessary for 
in depth recording of patients procedures, findings and diagnoses. 
 
7.6.1.5. Genetic information 
 
However, the main indisputable advantage of 4C cohort remains the collection and linkage with 
genetic data of the participants. For reliable assessment of parameters relevant to diagnostics 
and therapy a study’s subjects must be characterized both with respect to phenotype and 
genotype. The incorporation of genome parameter in clinical data will shed light into the 
complex nature of cardiovascular diseases causal pathways.  
 
7.6.2. Limitations of 4C study 
 
7.6.2.1. Manual processes 
 
The main weakness of field research while I participated in 4C was the manual component that 
prevails in all clinical cohorts and surveys gathered for research purposes. From daily 
preparation of biomarkers collection equipment, collecting anthropometric measurements, 
processing blood samples (centrifugation, aliquoting) and preparing them for transference to 
Biobank, to collection of clinical information using different hospital systems, manual 
anonymization, data manually entered in different programs and coding, as well as manually 
entered in clinical information forms, etc. Data in the hospital systems were often missing or 
were incomplete requiring further manual adjudication and validation by the researchers and 
that translated into a significant investment of qualitative and quantitative sources. 
 
7.6.2.2. Consent obstacles 
 
A great part of this time spent in hospital and recruiting was taken up by the fact that recruitment 
relied exclusively on a voluntary basis, with eligible participants derived from diverse 
socioeconomic backgrounds. The language barriers that we had to overcome, along with the 
hesitant attitude of patients towards researchers enhanced by their concern about their health 
and the imminent angiographic procedures, made the process extremely challenging. One half 
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of patients approached between all 4 centres for inclusion in the study were either ineligible or 
declined to participate, and low response rates were more marked in hospitals serving an 
ethnically diverse population, so selection bias is likely. Continuous direct contact with different 
gatekeepers to ensure access to participants’ medical records was further required, or to gain 
permission to approach patients and collect their biomarkers, without hinder their daily clinical 
routine.  
 
7.6.2.3. Generalisability 
 
A further weakness of 4C concerns the nature of population recruited. Since the aim was a 
cohort of CAD people with angina symptoms and chest pain, specifically recruited for research 
purposes, the generalisability of the findings is limited. Due to restricted representativeness of 
the CAD subjects into a general population, the inferences could not be interpreted in a wider 
clinical or epidemiological context.  
 
7.6.2.4. Small sample size 
 
Additional limitations that stemming from the nature of the study design, is the small sample 
size and hence the limited potential number of exposures and event types. The main outcome 
that will be explored to serve the main 4C purpose is a composite of cardiovascular mortality, 
non-fatal AMI, non-fatal stroke and peripheral arterial disease, while  the investigation of more 
specific cardiac endpoints in relation to resting heart rate, was unfeasible. 
 
7.7. Conclusions 
 
4C is a resource of genetic, biomarker, clinical and questionnaire data among patients with 
new-onset established or suspected stable CAD. This source of genetic and clinical information, 
can be used to identify and evaluate genetic and environmental factors associated with the 
onset of a specific expression of stable coronary artery disease, the stable angina pectoris 
syndrome and its progression to acute fatal and non-fatal events. Despite the fact that its limited 
sample size does not allow for specific cardiovascular phenotypes investigation, the highly 
consistent clinical data collection with the large completeness along with the valuable genomics 
pool will provide insights to the links between clinical biomarkers such as heart rate and genetic 
variance in CAD populations using an instrumental variable approach.  
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8. A comparison of clinical cohort methods: conventional 
consented study (4C study) vs Linked electronic health 
records (CALIBER)  
 
As presented in chapters 3 and 7, this PhD illustrates two alternative approaches to establishing 
clinical cohorts: the first, a conventional clinical research study involved consenting patients 
and manually extracting data from chart review, and obtaining and processing research blood 
samples (4C).  The second, involved linked electronically recorded linked health records 
(CALIBER). Each of these two approaches offers methodological strengths and limitation: 
 
CALIBER 
Strengths 
 Large sample size, hence great resolution in exposures 
 Clinical phenotypes resolution 
 Data readily updateable- Absence of any manual effort of investigators spanning from 
recruitment process to data recording 
 Efficiency- Recruitment, baseline and follow up phenotypic assessment zero cost to 
research funder 
 Flexible opportunities to define disease follow-up (start point and endpoints), based on 
availability in the clinical record of ‘Phenome wide’ information 
 Flexibility in cohorts definition 
 Flexibility in inclusion criteria of individual cohorts-diverse population that allows for 
investigation of various research questions applicable to different populations 
 
Weaknesses:  
 Missing information at a practice, patient and data level 
 Linkage process difficulties 
 Difficult to handle and curate, demand high degree of expertise-large datasets to 
handle. 
 
4C 
Strengths 
 Research measures systematically recorded, on information that is virtually never 
available in the EHR, including quality of life, DNA, biomarkers. 
 Direct generation of research ready data 
 Higher quality information and research reinforcement 
 Qualitative factors recorded such as quality of life, psychological symptoms and 
diagnostic imaging 
 A pool of genetic information 
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Weaknesses: 
 Manually performed data collection processes and personal time investment for 
recruitment 
 Difficulties in consenting 
 Findings have limited applicability and are restricted to populations that resembles the 
clinical characteristics of cohort participants 
 Small sample size 
 
This chapter highlights the main differences concerning information governance, study design 
(population and data), follow-up techniques and practical data linkage issues between 
CALIBER linked electronic health records study and the conventional clinical cohort 4C. Those 
differences are summarized in Table 8.1.  
 
8.1.   Information governance 
 
A medical record (in paper or electronic format) provides a written account of a patient's medical 
history, containing information about diagnosis, treatment, chronological progress notes and 
discharge recommendations. A whole raft of legislation, standards and guidance on what has 
become known as 'Information Governance' has been produced in the last few years to cover 
issues of access, confidentiality and disclosure293 The legal framework governing the use of 
personal confidential data in health care is complex. It includes the NHS Act 2006, the Health 
and Social Care Act 2012, the Data Protection Act, and the Human Rights Act. This framework 
allows personal data to be shared between those offering care directly to patients but it protects 
patients’ confidentiality when data about them are used for other purposes, for instance 
improving the quality of care provided, planning and commissioning public health services, 
research purposes, etc. CALIBER complies to 251 of the NHS Act 2006. Section 251 allows 
the Secretary of State for Health to make regulations to lift temporarily the common law duty of 
confidentiality for defined medical purposes and is a result of the realization that certain NHS 
activities and important medical research could be conducted through the use of identifiable 
patient information. In CALIBER similarly to other linked electronic health record databases, 
individual patients’ consent was not feasible to obtain for the collection of sensitive confidential 
information. Therefore, section 251 secured the law basis of the disclosure of confidential 
information that was not easily anonymized and consent seeking was unpractical in terms of 
cost, technology and other sources. In 4C study, on the other hand, a smaller scale clinical 
hospital-based cohort that required genetic material collection, this act was not necessary. 
Study’s participants were individually approached and consented and permission to provide 
personal and clinical information, blood samples and future contact for follow-up purposes was 
asked.  
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The manual dimension of 600 patients approach and consent that I personally did, made the 
process particularly tedious and time-consuming, something that CALIBER and linked 
electronic health records conducted automatically within a trivial amount of time to around 5 
million patients of GP practices. These practices participated by giving consent for inclusion in 
the study without individual consent having been seeking. Anonymization of sensitive 
confidential information was also made manually in 4C. Important identifiers were stripped 
manually during a pseudo-anonymization process (individual records could be identified by the 
researcher). These identifiers that were present at all stages of data collection, from patients 
clinical records collection (GP referrals, hospital discharge letters, blood samples collection and 
electronic databases creation for genetic material recording and storage to the Biobank, were 
removed and replaced with a unique participant study number assigned at the point of 
enrolment to the study. 
 
8.2.  Populations synthesis 
 
4C study was created to “serve” a specific clinical purpose. To explore patients with suspected 
or established coronary artery disease. The very nature of this purpose implies a specific high 
amount of rigidness regarding the cohort synthesis and the population that is under 
examination. Hence, the structure of 4C cohort is fixed as opposed to the CALIBER cohort that 
due to the wide coverage of population and the lack of specificity in terms of the research 
purposes that enables a wide range of research questions explored, render the cohort more 
flexible and adjustable to researchers’ specific scientific questions.  
 
This lack of flexibility of 4C population is also reflected on the health status of the participants.  
To answer the specific research question posed at the conception and design of the cohort, 
patients suffering from specific disease or symptomatic of coronary artery disease were 
requited. In contrast to that, CALIBER population that was collected from GP practices that 
people attended for various reasons did not necessarily mean that they are diagnosed with a 
disorder or disease and a large part of this population did not provide evidence for a past 
cardiovascular disease event, that allowed the exploration of CVDs incidence in the present 
PhD. Healthy population was used in chapter 4 to explore associations of resting heart rate with 
CVDs onset that could not be conducted using data from a coronary disease registry similar to 
4C cohort. 
 
Since the aim of 4C study was to identify factors related to stable CAD and especially angina 
pectoris phenotype, the appropriate eligibility criteria were applied to ensure good quality and 
representative data. Therefore, patients were not eligible for inclusion if they were diagnosed 
with structural heart disease, cardiomyopathy or arrhythmia or were referred for ablation or 
placement of devices (e.g. pacemaker). On the basis of age or coexisting conditions, no 
patients were excluded. On the other hand, CALIBER study, which majorly focuses on an 
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advanced quality database of various clinical data sources and not on specific populations, set 
three main inclusion criteria; age <30 years at study entry, with at least 1 year registration prior 
to entry, during which up-to-standard quality data has been collected. The wide inclusion of 
eligible patients without any clinical restriction allows for various research questions’ 
investigations that the results can be applicable and representative of different populations.  
 
An additional difference lies on the magnitude of the sample sizes. CALIBER cohort, by 
consenting 225 GP practices with the subsequent linkage of additional sources yielded > 106 
cohort sample size making it one of the biggest clinical information sources of real world data 
worldwide. This enables an in depth exploration of a massive pool of diverse risk factors and 
clinical phenotypes, but also a high degree of resolution which covers the detection of an array 
of specific, severe and non-severe, fatal and non-fatal diseases. In contrast to CALIBER, 4C 
cohort has a limited sample size that is sufficient for the examination of a specific research 
question but does not provide the degree of resolution or the coverage of a large amount of 
information that could extend further outside the narrow path of coronary artery disease patients 
with chest pain symptoms. 
 
Finally, an important difference between CALIBER and 4C is the nature of patients’ participation 
approach and response rates. 4C study relied exclusively on a voluntary participation approach 
that resulted to a response rate of 47% when compared to CALIBER that by design the patients 
participated automatically (after application of relevant quality criteria explicitly presented in 
Chapter 3) after their registration to GP practices without giving individual consents (response 
rate 100%).  
 
8.3.  Baseline data 
 
4C cohort in reality is a combination of 4 different clinical cohorts, each of them derived from a 
different hospital setting in UK. Data was collected from rapid access chest pain clinics, cardiac 
catheter laboratories and coronary angiogram pre-assessment clinics in four ethnically diverse 
UK National Health Service (NHS) hospitals (see chapter 7), all parts of the secondary care 
setting in UK, that required direct access from the investigators. CALIBER baseline data on the 
other hand, was derived mainly from primary care system that was 225 GP practices consenting 
to data linkage in UK, while secondary health care data provided follow-up data and diagnoses 
information. The primary care system of GP practices contribution was one major difference 
between the clinical cohort and the linked electronic records data that used this linkage of GP 
to provide baseline risk factor and clinical variables information in contrast to 4C which required 
anthropometric characteristics measured by researchers and questionnaires administration in 
addition to hospital records and procedures on the day of clinic attendance manual recording 
and file. In UK, there is currently no centralized conduit, with national coverage, for linking and 
extracting primary care data at scale for research. The secondary care information coming from 
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the clinics in 4C consisted of discharge letters, and procedure on the day of attendance results, 
while in CALIBER, the linkage of MINAP, HES and ONS data provided a wealth of secondary 
care information. 
 
However time-consuming the manual collection of 4C data was, offered access to information 
difficult to retrieve when you deal with linked health records, such as diagnostic imaging 
information. A major contribution of 4C was the blood samples and genetic information 
collection that made the cohort valuable as acts as a pool of genetic and clinical information, 
that could then enable it to identify and evaluate genetic and environmental factors associated 
with the onset of a specific expression of stable coronary artery disease. The lack of genetic 
information in CALIBER however, can be overcome by the linkage of external electronic 
datasets such as UK Biobank. To maximise the utility of this DNA collection bank, marrying the 
DNA to the electronic health records is essential. The United Kingdom is unique in maintaining 
a single set of primary care-based medical records containing all medical interactions involving 
a patient, whether in primary, secondary or tertiary care. Apart from CALIBER, there are further 
electronic databases that enrich the landscape of studies focused on cardiovascular diseases 
and more such as the Secure Anonymised Information Linkage (SAIL) database that uses ICD-
10 secondary care diagnoses of CAD linked to primary care datasets. Future work on validation 
of associations of heart rate with CVDs by these initiatives will offer insights into the clinical 
marker of millions of patients registered in primary care, have large geographical coverage and 
good quality of records. 
 
Additionally, behavioural and psychological information such as quality of life parameters were 
more thoroughly explored in 4C after the incorporation of well-being assessment scales (e.g. 
EQ-5D scale) in the questionnaires.  
 
The flexibility of data recordings that differs among the data collection tools varies between the 
two studies. 4C on the one hand through the use of adjustable clinical case record forms for 
data collection, offers flexibility to ensure the highest efficiency and to match pre-specified 
research needs unlike CALIBER that data collection and nature varies uncontrollably 
depending the GP (free text use, etc.), which is another difference that contrasts with the 
investigator personal involvement in data collection process of 4C. 
 
The number of risk factors and outcomes differs largely between the two studies with CALIBER 
being able to offer massive numbers of potentially available exposures collected without 
knowledge of research hypothesis tested as opposed to the limited number of risk factors that 
4C collects after a purposively designed protocol. The form of variables however in 4C is a 
readily usable type of information that needs no further process to use, unlike CALIBER that 
the variables need to be curated by developing and using established meta-data standards.  
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Finally, heart rate measurements differ in regards to the way of recording, or more precisely to 
the information that we have on how the marker was recorded. ECGs were the main source of 
heart rate recordings in 4C that were performed on the day of patients’ angiography clinic 
attendance. Heart rate is one of the most widely observed measurements in hospitals and is 
included in early warning scores and risk prediction for standard observations made by every 
nurse. However, currently hospitals still are at an early stage of digitisation (low HIMS score) 
and such data are commonly not available electronically, only on paper. In some individual 
hospitals (e.g. University Hospitals Birmingham) heart rate might be recorded electronically, 
but these data have not yet been combined across hospitals or linked to national primary care 
datasets, although this is feasible and undoubtedly will happen in the near future. The critical 
care theme of the NIHR Health Informatics Collaboration is collecting detailed clinical 
information including heart rate from patients admitted to critical care units in 5 hospitals. 
Hence, in CALIBER this kind of information is absent with the only information available being 
the value of heart rate and the date of measurement by the GP in primary care recorded used 
Read codes (see Chapter 3 for coding details) without specific reporting of the technique or 
device of measurement, while heart rate data from secondary care (HES/ONS) is entirely 
missing. I will present the main descriptive statistics of people with coronary artery disease 
recruited in 4C and those retrieved by CALIBER linkage. Their comparison is presented in 
Figure 8.3.1 and Table 8.3.2.  
 
A higher percentage of men were recruited in 4C, raising questions on whether there are gender 
differences on health seeking behaviour that could partially account for more severe obstructive 
sCAD cases among men or if there are in fact underlying differences in aetiology, diagnosis, 
management and treatment of CAD between men and women that are not yet fully understood. 
4C heart rate data has a skewness of 0.6 and a kurtosis of 3.8. The mean is 71.7 (±14.2) and 
median is 70 bpm. Heart rate shows a more symmetrical, less skewed shape, without rough 
peaks (Fig 8.1 (a)). Differences between men and women are smoother than in CALIBER data 
with a mean heart rate difference of 3bpm (Figure 8.1 (a) and Table 8.2. People with higher 
heart rate (>90bpm) tended to have higher blood pressure, less likely to be women or of white 
ethnicity (data not shown).  
 
In CALIBER, heart rate is skewed right (skewness=1.0), a peaked distribution with a 6.4 kurtosis 
with heavier tails. The distribution is relatively symmetrical with moderate skewness and 
kurtosis. The mean is 72.2 (±14.5) and median 71. Men have rougher peaks (kurtosis=7.1 vs 
5.8 in women) and their distributions are more skewed to the right (Fig 8.1 (b)). Mean heart 
rate of women is 4bpm higher than men (74.4 vs 70.5). Overall, in 4C dataset, heart rate was 
recorded in 64.7% of participants, while in CALIBER in only 11.9%. 
 
8.4.  Follow-up and outcomes 
 
   180 
 
Follow up in 4C is being conducted using a two-step approach. A postal follow-up questionnaire 
(Chapter 7) was sent to study participants 2 years after recruitment to assess health status. 
The subsequent linkage of the consented patients to data from HES and ONS, will yield 
important information on potential future diagnoses and procedures they might undertake, or 
even death events respectively. However, no primary care data have been linked in 4C, 
therefore any future GP visit is not recorded in contrast to CALIBER that the linkage with GP 
practices and myocardial infarction registry in addition to HES and ONS provide a complete 
picture of a patient’s clinical course.  
 
The follow-up in CALIBER is performed automatically and exclusively using electronic methods, 
by linking secondary care, disease registry and ONS data, while the manual aspect is still 
involved in the follow-up process with questionnaires sent, recorded and coded by researchers.   
 
Follow-up duration is a parameter highly different between the 4C clinical cohort and linked 
electronic health records. The median observation time from study entry date in CALIBER is 
5.5 years in the study assessed in the present PhD, while for 4C it is just 469 days, with 
implications on methodological and analytical aspects. 
 
Differences further lie on the outcomes of the studies. The primary endpoint of interest in 4C 
was pre-specified at baseline stage and aimed at a composite of cardiovascular mortality, non-
fatal AMI, non-fatal stroke and peripheral arterial disease assessment. CALIBER endpoints on 
the other hand, due to various reasons such as the statistical power to handle individual specific 
cardiovascular endpoints, or the high degree of resolution that is provided by the wide coverage 
of primary and secondary care sources are numerous and flexible, with different outcomes 
explored by different studies depending on the research question or researcher’s preferences.  
 
Due to the short follow-up duration in 4C that resulted in a limited number of events, longitudinal 
analysis was not advisable, nor feasible. Cross-sectional analyses was exclusively the only 
robust methodological pathway that would lead to reliable inferences between risk factors and 
the composite outcome, compared to CALIBER and its large follow-up duration that allowed for 
risk factors effects on incidence and prognosis of future cardiovascular events (chapters 4, 5, 
6).  
 
Finally, interpretation and dissemination of results of 4C should be done cautiously as the 
findings due to the highly specific population might not representative on the general population 
and hence with limited generalizability. CALIBER on the other hand, produces results and 
presents findings applicable to various populations, regardless the severity of diseases, 
including healthy population without a history of a cardiovascular disease. 
 
8.5. Generating research ready data 
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Data linkage is a crucial part of the studies design and performance. In 4C all participants’ 
records and data are linked through a sequence number assigned by the investigator to every 
patient, hence the investigator has direct access to participants’ identifiers (pseudo-
anonymization) before the anonymization process. In CALIBER, the linkage is performed 
through NHS, date of birth, sex and post code by a third party, which prevents investigators 
from any kind of control over data identifiers. 
 
Since 4C study recruits patients and collects data guided by a more specific research idea and 
a targeted population in addition to the personal direct involvement of the investigator during 
the data collection process, the data completeness is quite high at baseline. In contrast to linked 
electronic data that the data gathering relies on GP data collection preferences at every visit, 
the reason of practice attendance, etc. that produce high missing numbers. The fact that 
different sources and not a single researcher collect the data, as well as the fact that patients 
can be captured more than once by different source, leads apart from a partial completeness 
to data inconsistencies such as duplication of data by patients registered in several practices, 
inconsistencies in diagnoses or data recording dates or values. Therefore, the need for good 
documentation of decisions during data preparation and specification of relevant sensitivity 
analyses to test the robustness of the definitions is of utmost importance in CALIBER. However, 
the recruitment of participants only once by investigators in 4C has an important drawback that 
is eliminated in CALIBER. Data validation in 4C is not easily performed, since the lack of 
repetitive patients’ recruitment and further information recorded by more than one source does 
not allow for crosschecks in contrast to linked records that provide extra information beneficial 
for data comparisons. 
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Table 8.1. Comparison of a consented clinical cohort (4C) and EHR cohort (CALIBER) 
Research stage  Clinical cohort (4C study)  Linked Electronic Health Records (CALIBER) 
Information Governance 
Legal and ethical basis  
 
London City Road & Hampstead National Research 
Ethics Committee, local NHS Research & 
Development committees 
 
General and PIAG (Patient Information Advisory Group) 
approvals for use of CALIBER: Compliance to section 251 of 
the NHS Act 2006 (which allows  medical research, when 
individual patient consent not feasible) 
 
For CPRD access: 
 
Study specific approvals of the protocols from ISAC 
(Independent Scientific Advisory Committee)  
A signed licence outlining scope and data confidentiality of use 
of CPRD data 
 
For MINAP, HES, ONS data: 
 
Applications are made to the MINAP Academics 
Group, and to the NHS Information Centre 
Identification of participants 
 Patients identified manually using daily appointment 
lists at the pre-assessment clinics and schedules for 
angiogram procedures. Patients’ history files in pre-
 Inclusion of all patients attended the consented GPs 
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assessment clinics were available for a screening 
prior to approach to assess eligibility   
Written informed patient 
consent 
 Research staff seek consent from each patient 
individually 
 N/A 
Practitioner consent  N/A  
Yes and All patients of a GP practice are included in consenting 
practices 
Confidentiality measures: 
handling of  strong identifiers 
(NHS no, name, dob, address, 
postcode)  
 Retained by data manager and study co-ordinator 
only.  Identifiers manually removed by researchers 
from all sources and replaced with a unique 
participant study number assigned at the point of 
enrolment 
 
None released to research team 
Data are anonymized and all personal identifiers are removed 
by the data provider.  
Population     
Cohort structure  Fixed  Flexible 
Population selection  Selection for research specific purposes  All patients attended GP practices in UK from 1997-2010 
Population health status   Diseased or symptomatic  General populations (healthy included) 
Population inclusion criteria 
 Specific common criteria on population health status 
and symptoms 
 
No health status restrictions for entry to the general CALIBER 
cohort 
Population exclusion criteria 
 Diagnosed with heart disease, cardiomyopathy or 
arrhythmia or were referred for ablation or placement 
of devices (e.g. pacemaker) 
 
Age <30 years at study entry, with <1 year registration prior to 
the study entry (depending on study requirements) 
Sample size  Limited ( N=3,345 patients)  Large (N=~2M patients without prior CVDs) 
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Patients participation 
 
Voluntary participation. Lower response rates (47%)  
All patients included given they are registered with a GP 
consented practice (100% response rate at patients level) 
Populations’ generalisability of 
findings 
 Might not be representative of the general 
population*  
 Data dissemination and findings can be applicable to various 
populations regardless severity of disease, etc. 
Baseline data 
 
Patients recruitment sites 
 Rapid access chest pain clinics, cardiac catheter 
laboratories and coronary angiogram pre-
assessment clinics in four ethnically diverse UK 
National Health Service (NHS) hospitals 
 
225 GP practices consenting to data linkage in UK 
Baseline risk factor sources 
 Anthropometric characteristics measured by 
researchers, questionnaires 
 
Linkage of primary care records 
Baseline risk factor sources 
(e.g. behavioural, 
environmental) 
 
Questionnaires, GP referral letters 
 
CPRD data 
Baseline clinical variables’ 
sources (e.g. heart rate, BP, 
etc.) 
 
Hospital records, Patients’ files on the day of the 
procedure, measurements by investigators 
 
Linkage of CPRD, HES records 
Baseline clinical variables 
sources 
 Hospital records and procedures on the day of clinic 
attendance and recruitment 
 Linkage of primary care records 
Primary Care sources  Not able to link-scarce evidence from GP referrals  GP practices linkage 
Secondary Care sources  Discharge Letters, Hospital attendance  Linkage with HES, MINAP and ONS 
Data extraction ways 
 Data recorded both electronically and in paper and 
collected for research purposes 
 Electronically recorded for clinical purposes. 
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Clinical notes 
 Behavioural/environmental factors, prior procedures 
and medication 
 Biomarkers, environmental/behavioural factors 
Imaging reports  
 Clinical characteristics such as heart rate, N of 
diseased vessels, biomarkers  
 N/A 
Blood samples   Genetic info  No genetic material collected 
Data collection protocols 
 Standardized data collection and recording with 
definitions and reporting commonly used by 
recruiters 
 
Codified using standardised classifications systems (Read 
codes, ICD10, OPCS). Information also entered as free text but 
not available for research, No protocol 
Data collection tools 
 Flexibility provided by clinical case record forms 
adjustable to ensure the highest efficiency and to 
match pre-specified research needs 
 
Data collection and nature varies uncontrollably depending the 
GP (free text use, etc.) 
Data collectors 
 Research staff (directly or through extraction from GP 
referrals letters or hospital records) 
 GPs 
Biomarkers collection 
 Bloods, saliva (buccal swabs) specimens collected 
from all subjects at specified times (RACPC visits) 
 
 No biomarkers collection 
Biomarkers processing 
 Centrifugation, aliquoting, transfer and storage as per 
protocol 
 Non applicable 
Self-reported variables (chest 
pain description, quality of life 
and psychological 
parameters) and symptoms 
 
Questionnaires standardized  
Self-reported symptoms not standardised (not known if 
information was prompted by GP, what was recorded from what 
patient reported) 
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Mode of heart rate 
measurement 
 
Resting ECGs, computed from R-R intervals  Usually not recorded, includes palpation, BP monitor and ECG 
Exposures (risk factors) 
numbers 
 
Limited number of exposures pre-defined in protocol  
Large numbers of potentially available exposures collected 
without knowledge of research hypothesis tested 
Variable responses  Standardised and pre-defined  Response categories wide and merged accordingly 
Diagnostic imaging 
tests(e.g. angiograms, 
echocardiograms) 
 
Available but unstructured, recorded in a text and 
imaging form, manually extracted information 
 
Inconsistently recorded. Sometimes test recorded but not 
result. Multiple coding of results frequently available  
Electrocardiograms 
 Extraction of heart rate, QT wave, PR intervals, QRS 
axis, etc.  
 Read codes for heart rate no further characteristics of pulse 
Coronary angiography 
 Extraction of number of diseased vessel, arterial 
heart rate (used as substitute when heart rate 
missing), number of previous stents/grafts (history 
contribution), diseased territory or proximity to heart, 
LVEF 
 
Poorly recorded LVEF in HES, no recording of a large piece of 
information regarding clinical characteristics or coronary 
disease in primary care. 
QoL 
 
Quality of life assessment using standardised scales 
(Euro QOL) 
 
Rarely administered in clinical practice, and thus are not 
available in the HER. In case of recording QoL data, difficult 
curation, or identification of relevant codes time consuming  
Follow-up and outcomes 
Follow-up data sources 
 
HES/ONS data linkage. Not primary care 
 Primary care, HES, ONS, MINAP. Longitudinal to identify 
endpoints. 
Follow-up duration 
 Limited by re-application for refresh of follow up data 
to HES, ONS 
 Potentially long follow up duration (e.g. until death, practice 
deregistration or last collection date).  
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Endpoints 
 
Limited to those which are hospitalised or deaths..  
Large numbers of potential endpoints (e.g. recorded diagnoses 
including those in primary care) 
Data Linkage and research ready data generation 
Data linkage method 
 Data linked through a sequence number assigned to 
every participant (prefix centre-specific) by 
investigators 
 
Data linked through NHS number, date of birth, sex and post 
code by a third party, so no control by investigators  
Data coding and transfer 
 Responses manually coded and entered into excel 
and access databases 
 
Electronically coded, curated. Algorithms applied to form  final 
form of variables 
Variables form 
 
Readily available  
Variables curated developing and using established meta-data 
standards 
Data duplication and 
inconsistencies 
 
Limited inconsistencies if properly conducted. Each 
patient recruited once. Rare data duplication. 
 Potential for data duplication (e.g. patients registered in several 
practices), Inconsistencies across datasets (e.g. differences in 
dates or values). Need for good documentation of decisions 
during data preparation and specification of relevant sensitivity 
analyses to test the robustness of the definitions) 
Data completeness  
High completeness (at baseline): thus e.g. if smoking 
status missing in one part of the notes, researcher 
can search for in another part of notes, or ask the 
patient. Additionally, purposively collected variables 
recorded across patients by researchers 
 
Recordings of information depending on GPs or reason for 
attendance. Low completeness on biomarkers 
Data validation 
 Each patient recruited individually, hence no 
alternative source of information for each patient (e.g. 
by duplicated recordings) to validate and crosscheck. 
 Same patient recorded in different data sources- Allows 
longitudinal crosscheck, however no further access to patients’ 
medical history. 
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However, information related to medication, prior 
diagnosis or procedures can be obtained and 
crosschecked via GP referral letters, angiography 
procedure results or patients’ hospital files 
 
*Hospitals may admit patients with more comorbidities or be of different racial mix if they are located in areas that are systematically different from 
not participating hospitals. The degree to which a registry/study centre of a clinical cohort is representative of the general population will depend 
on the selection of enrolment sites and the use of consecutive or random sampling. 
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Table 8.2 Comparison of baseline characteristics of people with CAD using clinical cohort 
data or linked electronic health records  
  
4C research study 
(people with established CAD and HR 
measurement) 
(N=2,841) 
 
CALIBER study 
(prognosis cohort) 
(N=51,703) 
Baseline 
characteristics 
    
     
Clinical factors     
Heart rate (bpm)  71.7 (±14.3)  72.2 (±14.5) 
Systolic blood pressure 
(mmHg) 
 135.4 (±24.1)  138.2(±19.9) 
Hypercholesterolemia  52.5  22.7 
Type 2 diabetes  22.4  11.7 
BMI (kg/m2 )  29.5  28.2 (5.5) 
Smoking status     
Current smoker  19.1  11.9 
Ex-smoker  26.0  43.8 
Non-smoker  28.9  38.13 
Demographic 
characteristics 
    
Age  58.6(±12.6)  72.2(±11.4) 
Female  36.9  44.1 
White ethnicity  45.8  73.4 
Education (finished at 
15yo) 
 31.4  - 
     
Medication     
Beta-blockers  14.5  50.7 
Aspirin/antiplatelet  19.8  67.6 
ACE-inhibitors  12.6  39.5 
Nitrates  6.2  47.6 
Statins  23.2  63.0 
Endpoints     
Primary 4C composite 
endpoint (cardiovascular 
mortality, non-fatal AMI, 
non-fatal stroke and 
 27   
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peripheral arterial 
disease) (HES) 
CVD death  -  1,642 
Heart failure  -  3,947 
Myocardial infarction  -  1,241 
Stroke  -  2,375 
Peripheral arterial 
disease 
 -  1,181 
Note: Means for continuous variables (SD), (%) for categorical; cohorts total population after 
exclusion of those without heart rate measurements 
 
 
8.6. Conclusions 
 
In this chapter I tried to point out the dual nature of this PhD, compares the two largely different 
studies and their data that I used to explore my research questions. Overall, CALIBER platform 
provides a knowledge pool of large sample size that can be variously used depending on gaps 
identified in clinical research, flexible enough to investigate questions from different clinical 
backgrounds, whereas 4C cohort, aims specifically to a coronary artery disease population 
investigation, gathering data from a research (diseased) population that serves that particular 
purpose, while its findings will be applicable only to a population with similar characteristics. 
The manual nature of processes in 4C made the participants’ recruitment stage and the data 
collection handling time-consuming, however it provided a high completeness of data among 
which genetic information valuable for mendelian associations exploration. Finally, CALIBER 
cohort that was designed and created using electronic techniques and automatic 
methodologies, saved valuable time but required a higher degree of expertise. 
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9. Conclusions 
 
9.1. Introduction 
 
Summary of thesis 
In this thesis, I have described the clinical marker of heart rate and the factors that affect or are 
affected by higher values (Chapter 1). I then went on to explore published literature on resting 
heart rate and adverse cardiovascular outcomes association (Chapter 2). In Chapter 3 I briefly 
described the field of electronic health record (EHR) research and I specifically focused on the 
research platform CALIBER that I used to assess potential associations of heart rate with 
cardiovascular diseases. In chapter 4, using the aforementioned platform’s data, I examined 
the onset of specific fatal and non-fatal cardiovascular diseases with regards to resting heart 
rate of healthy individuals (free from atherosclerotic diseases) that attended GP practices. In 
chapter 5 my aim was to explore similar associations as in chapter 4, in a coronary heart 
diseased population using CALIBER data. Chapter 6 aimed at the assessment of the initial 
presentation of atrial fibrillation in a healthy population. However this time, people that 
eventually experienced an atrial fibrillation event were followed for subsequent cardiovascular 
events associated with the patients’ heart rate levels. In chapters 7 and 8, I presented the 
methodology used in a consented cohort study of patients with established or suspected 
coronary heart disease (4C), that I participated in recruiting from clinical settings in UK and then 
compared and contrasted the weaknesses and advantages offered by CALIBER platform which 
represented digital era and various automatic processes, with the consented cohort 4C that is 
characterized by manual components and personal involvement with data collection. In this 
chapter I will give a summary of the findings of this PhD, describe the implications of these 
findings in a broader clinical, research and public health context and finally present the overall 
strengths and limitations of the cohorts produced and analysed by this PhD followed by 
recommendations for future research. 
 
Research context 
In the literature search, we observed that the whole literature body is derived by population 
surveys, clinical trials or registries, that their common characteristic is the research specific 
purpose of their data collection. Among further weaknesses it was the limited sample sizes, the 
questionable generalizability of the findings or the representativeness. We also found that their 
findings are mostly related to mortality endpoints or composite phenotypes. Finally, clinically 
relevant heart rate ranges are often ignored from an analytical perspective. No previous study 
used linked electronic records to assess associations between heart rate data yielded by 
primary care and cardiovascular events experience. This is the first attempt to explore these 
associations using EHR, since the large sample size and resolution they offer, enable the 
design and perform of large scale analyses allowing for investigation of heart rate associations 
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across a wide range of individual phenotypes. To that effect, the present PhD had the following 
objectives: 
 
 
i) Explore published literature on resting heart rate and adverse cardiovascular 
outcomes association. 
ii) Examine the onset of specific fatal and non-fatal cardiovascular diseases with 
regards to resting heart rate of healthy individuals using linked electronic health 
records (EHR) 
iii) Examine associations of heart rate with the prognosis of specific CVDs in people 
with coronary artery disease (CAD) using EHR 
iv) Assess the association of HR with the onset and prognosis of atrial fibrillation using 
HER 
v) Describe a consented clinical cohort of patients with CAD (4C) and explore 
associations of resting heart rate with parameters not recorded by primary care 
and EHR, such as genetic variants and quality of life 
vi) Compare EHR processes and data with the 4C consented clinical cohort (4C) 
 
9.2. Major findings 
 
This PhD set out to explore associations between resting heart rate and incidence and 
prognosis of cardiovascular diseases in healthy, coronary artery diseased and atrial fibrillation 
populations. Of eminent position in this thesis that largely contributed to address and answer 
of the research questions posed, has been EHR and particularly the CALIBER platform that 
was developed by colleagues at Farr (prev. The Clinical Epidemiology Group at UCL). 
CALIBER links primary care data from GP practices, hospital and registry data and data from 
ONS that provide the mortality parameters of the studies. Using these data, I constructed and 
analysed two different cohorts, one included healthy population (N=233,970) and one patients 
with stable coronary artery disease (SCAD) (N=51,703). The former cohort was also used to 
explore the onset of atrial fibrillation in a healthy population that subsequently led to 
cardiovascular events.  
The major findings observed from these 3 cohorts were: 
 
 Study of resting heart rate and incidence of CVDs in healthy individuals 
 Resting heart rate showed specific associations with myocardial and 
arrhythmic disorders, but not with coronary disease, stroke or PAD.  
 Average resting heart rate of >70bpm in the general population is associated 
with increased hazard of specific cardiovascular diseases and mortality 
particularly in men and should not be considered as normal.  
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 Women and men differed in their heart rate-CVD associations, with 
associations being weaker or absent in women 
 
 Resting heart rate and prognosis of patients with CAD 
 Increased resting heart rate (RHR) was strongly associated with higher risk of 
cardiovascular outcomes not included so far in the primary endpoints of trials 
such as heart failure. Additionally, RHR was not found to be associated with 
outcomes commonly used by trials as main endpoint or a part of composite 
primary endpoints such as myocardial infarction.  
 Higher resting heart rates above 70bpm increase the hazard of heart failure 
events, stroke in women, and atrial fibrillation, without substantially affecting 
the hazard of events in the coronary arterial beds.  
 
 Resting heart rate and atrial fibrillation onset with subsequent CVD events 
 Higher heart rate is strongly associated with atrial fibrillation in men 
 This association in women was not found.  
 Cardiovascular event rates across heart rate levels show a constant increase 
of hazard of subsequent heart failure events compared to low heart rate values 
(<60bpm) in people with diagnosed atrial fibrillation.  
 
9.2.1.  Heart rate and CVDs in men and women 
 
In the present PhD, we found an increased hazard of heart failure that was greater in healthy 
men and evident at heart rates >70bpm compared with healthy women in whom the hazard 
was confined to heart rates >90bpm. Epidemiological studies on resting heart rate and heart 
failure have shown weaker associations in women and in other smaller studies it was confined 
to men perhaps reflecting under-powering rather than a true gender difference. Average heart 
rate of 70-79bpm, showed strong associations with unheralded coronary death but only men, 
whereas for women the risk was not present. Finally, associations with stable angina showed 
a protective effect in 60-69bpm, 70-79bpm and >90bpm in women, whereas in men 
associations were of the opposite direction, however imperceptible and insignificant.  
 
A strong association between heart rate >90bpm (vs 70-79bpm) and atrial fibrillation onset was 
observed in both healthy men (HR=1.50, 95% CI: 1.33-1.68) and women (HR=1.40, 95% CI: 
1.27-1.54). The associations were particularly strong in cases that no CVD event preceded that 
of atrial fibrillation in men and women (HR=1.65, 95% CI: 1.45-1.87 and HR=1.45, 95% CI: 
1.30-1.62, respectively). Risk of AF at lower heart rate range (<60bpm vs 70-79bpm) was found 
to be strong in women (HR=1.35, 95% CI: (1.18-1.54) but not significant in men. Compared to 
men, heart rate range of 70-90bpm vs <60bpm showed a protective effect for atrial fibrillation 
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in women. Finally, atrial fibrillation risk was higher in people aged >80 that belonged to the 
>90bpm heart rate range (HR=1.32, 95% CI: 1.10-1.59). 
 
Finally, I found a slightly higher increase in risk of stroke in women with CAD in heart rate 
>90bpm (HR: 1.47, 95% CI: 1.15-1.88) compared to men (HR: 1.09, 95% CI: 0.83-1.42), while 
a higher risk for atrial fibrillation was found in men with CAD in 70-79bpm, 80-89bpm and 
>90bpm compared to women that the risk was restricted to heart rate values >80bpm. Gender-
related difference in the association between heart rate and mortality was also found in some 
studies conducted in subjects in patients with MI. In particular, in most studies high heart rate 
appeared to be a weak predictor of death from coronary artery disease in the female gender, 
which indicated that tachycardia can be deleterious also in women.  
 
9.2.2. Shapes of associations between heart rate and CVDs 
 
This PhD also provides evidence for a steep increase in risk for heart failure and cardiovascular 
mortality above 70bpm, a threshold significantly lower than the majority of the available studies. 
Quite steep is also the increase to atrial fibrillation events above 70bpm, while the risk of sudden 
cardiac death shows a steep increase at higher heart rate values above 90bpm in both men 
and women. Published studies have suggested a threshold effect of heart rate >77bpm on 
mortality outcomes, above which the risk for all-cause mortality increases steeply and for CV 
death at a heart rate >83 beats/min. In contrast, other studies have found a slightly lower 
threshold of >70 beats/min while others have demonstrated an increased risk at relatively low 
heart rates, suggesting a J-shaped, rather than a linear, relation. In line with our findings, data 
from the BEAUTIFUL study, which suggested that the increase in death and heart failure 
outcomes rose continuously for values of ≥70 bpm, whereas the relationship was less 
pronounced for MI and revascularization. I also showed that atrial fibrillation risk has a U shape 
and increases steeply above 74bpm. This shape was particularly pronounced in women that 
their lower levels of heart rate showed a high increase of AF incidence. In follow-up of people 
that subsequently experienced an atrial fibrillation event we showed an increase in risk of heart 
failure above 70bpm, similar to the one we previously showed in people with CHD whereas in 
healthy population this risk is more obvious in heart rates above 75bpm. 
 
9.2.3. Heart rate monitoring-challenges 
 
Apart from the measurement during clinical routine by medical professionals, heart rate is now 
also recorded by individuals, athletes or people trying to measure their fitness levels and are 
interested in monitoring their heart rate to gain maximum efficiency from their training, using 
various devices such as activity trackers (fitbits), smartphones, pedometers, accelerometers, 
etc. The ubiquity of cheap technology and an attendant abundance of phone applications now 
allow a growing number of people to track their heart beat in a 24/7 basis. Large health 
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databases such as UK BIOBANK, invite participants to wear a wrist worn activity monitor, and 
have already undertaken repeated measures on 20,000 participants. 
 
Limitations 
A key challenge for this is that a huge amount of personal data can be collected from many of 
these devices. The aforementioned health and fitness gadgets can capture sensitive details 
about a person’s markers and consequently health, and send it automatically for processing to 
tech vendors, who may then wish to share it with third parties for 'big data' profiling. 
Organizations and companies will soon start offering wearables to employees aiming at 
improving productivity. Although the size of data yielded particularly on markers such as heart 
rate will be vast, individuals must be given clear and transparent information about what data 
is collected about them and how it will be used, in addition to rights to manage their personal 
data. Additionally, data security is another important issue. Without the proper security and 
precaution measures, some wearables could expose a huge amount of intimate and extensive 
personal health data (not only limited to health) about an individual. Urgent reforms that give 
wearers of fitness devices the right to have all personal data erased, and in case these personal 
data are given for processing by private companies and industry, a consent before that should 
be required and obtained.  
 
9.2.4. Mechanistic implications 
 
An important finding in the present study were the relatively trivial associations of heart rate 
with acute myocardial infarction, intracerebral haemorrhage and peripheral arterial disease, the 
lower confidence intervals for increased risk of these outcomes never exceeding 10% in 
adjusted >90bpm versus <60bpm comparisons.  Moreover, there was no association of heart 
rate with the other manifestations of coronary or cerebrovascular disease or with abdominal 
aortic aneurysm. These observations may have mechanistic implications, and suggest that 
tachycardia and its autonomic drivers are more damaging to the myocardium and the electrical 
stability of the conduction system than to disease progression in the arterial wall, despite trial 
data relating increased heart rates to endothelial dysfunction and accelerated atherosclerosis. 
238 However, an alternative explanation could be the longer atherosclerotic process that leads 
to delayed clinical manifestations, hence studies with longer follow-up might be potentially more 
appropriate to capture these effects. 
 
Additionally, Genome Wide Association Studies (GWAS), failed to identify associations of heart 
rate loci with coronary artery disease (CAD) or MI.140 Consistent to these findings our study 
enhances the theory of lack of atherogenic and endothelial dysfunction mechanisms behind 
increased heart rate effect. Certainly, adjustment for conventional atherogenic risk factors had 
little effect on our risk estimates and there are now clinical data from the Study Assessing the 
Morbidity-Mortality Benefits of the If Inhibitor Ivabradine in Patients with Coronary Artery 
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Disease (SIGNIFY) trial showing that heart rate reduction with ivabradine does not affect the 
risk of myocardial infarction in patients with stable coronary artery disease.128 The association 
between sustained tachycardia and cardiomyopathy, however, is well established based on 
experimental studies of rapid cardiac pacing and on clinical presentations of patients with 
tachyarrhythmias. The potential for complete reversal of LV dysfunction following correction of 
the arrhythmia emphasizes the central role of heart rate in generating these disorders. 
Associations of heart rate with sudden cardiac death may also be consistent with experimental 
data showing diminishing ventricular fibrillation thresholds as heart rate is increased in 
stimulation studies and increasing thresholds when heart rate is lowered with ivabradine. 
Further evidence of a mechanistic link of heart rate with cardiomyopathy and sudden death 
comes from genome-wide association studies that have identified single nucleotide 
polymorphisms influencing heart rate regulation in genes also involved in the pathophysiology 
of dilated cardiomyopathy, congestive heart failure and sudden cardiac death.233 
 
9.2.5. Clinical implications 
 
9.2.5.1. People with normal heart rates at risk 
 
Heart rate is one of the most ubiquitous clinical measurements and is increasingly recorded by 
healthy people monitoring personal fitness with mobile devices and phone applications. The 
findings of this PhD can be used to help establish normal values for men and women. 
Approximately 74% of women and 63% of men have heart rates >70bpm and are at increased 
risk of cardiac events, with a risk for heart failure, unheralded coronary death, CVD mortality 
and all-cause death more pronounced in men. In other words, average heart rate values 
particularly in men, cannot be considered normal and further attention should be given even to 
those males with heart rates lower than those so far considered as “normal” rhythm values. 
Trials are required of heart rate lowering in high risk groups, e.g. in patients with resting 
tachycardia (≥90bpm) present in 17% of women and 13% in men. Remarkably there are no 
guidelines to inform clinical decision-making regarding behavioural, pharmacological, etc. for 
these patients. Heart rate may contribute to the identification of patients at high risk of severe 
outcomes such as sudden cardiac and unheralded coronary death.  
 
9.2.5.2. Risk prediction  
 
Finally, our findings require re-evaluation of the contribution that heart rate makes to risk 
prediction, taking account specific outcomes of interest and recognizing that existing tools such 
as SCORE and Framingham include disorders with weak or absent associations with heart rate 
in their aggregate CVD endpoints. Common CHD risk scores are not effective at predicting AF 
risk. CHD and AF share some common risk factors, such as hypertension, diabetes, and 
obesity, but heart rate has been shown to be a risk factor of development of AF only and not of 
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CHD. This highlights the importance of a separate risk score to predict AF, and potentially, the 
need to develop different preventive interventions by incorporation of heart rate in such scores.  
 
9.2.5.3. Patient management and guidelines 
 
We showed differences between genders with a focus in lower heart rates and hence potential 
differences in pathophysiologies of AF that should lead to a personalized clinical care. 
Additionally, targeting of drug interventions in routine clinical practice should be examined with 
caution. In a recent meta-analysis it was found that ivabradine has not been shown to limit the 
ventricular rate in patients in AF, and so authors concluded that those patients who develop AF 
are likely to have higher heart rates, thus negating any benefits of ivabradine as a rate-lowering 
therapy in treating either angina or heart failure. Our findings support that the increase of AF 
incidence is more prominent among men and women with higher baseline heart rate, as well 
as in women with low heart rate. This raises the possibility that the contribution of ivabradine in 
these patient groups could be possibly proved to be trivial if not adverse. In another clinical trial, 
it was provided solid preclinical evidence that ivabradine and ranolazine, alone or in 
combination, have roles in AF rate control. Therefore, clinical practice professionals should be 
targeting to medications for AF prevention and treatment as well as for its prognosis with a 
personalized health care perspective and communicating of risk for individuals cautiously. 
 
9.2.6.  Research implications 
 
Heart rate is one of the most easily accessible biomarkers that recent studies have given 
impetus to its examination. Private companies and academic institutes have invested significant 
amount of financial, scientific and infrastructural sources to design and conduct clinical trials 
investigating the effect of heart rate lowering medication such as ivabradine or beta-blockers 
on specific coronary disease phenotypes such as MI that as showed by our study are not linked. 
These quantitative (money) and qualitative (investigators’ or patients’ time) investments could 
have been avoided if the application of linked electronic health records had preceded the actual 
trial, while these sources could have been   allocated towards investigation of heart rate links 
with other cardiac diseases such as people at early stages of heart failure and resting 
tachycardia. The design of such trials should take into account of the selective associations of 
heart rate with the non-vascular disease presentations identified in this PhD.  
 
9.2.7. Heart rate in 4C 
 
As we noticed, the linked electronic health records fail to capture in depth parameters of the 
patients’ perceptions on their health such the implementation of quality of life scales to assess 
psychological or behavioural functioning, or diagnostic imaging tests and other visual tools. 
Their observational nature and subsequently their confinement to associations or correlation 
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pathways that are not causal was further pinpointed. Consequence a consented cohort to yield 
both clinical and genetic information to address translational research questions in prognosis 
was required. Therefore, the 4C clinical cohort of people with suspected or established coronary 
artery disease was launched in 2009 as a resource in which DNA and biomarker samples were 
obtained at time of presentation with chest pain linked to detailed phenotypic data obtained 
from EHRs and participant self-completed questionnaires.  
 
I personally recruited and consented 600 patients from a single centre (overall cohort including 
the other centres was 3,345), collected and processed their blood samples in addition to 
questionnaires that yielded important information related to specific chest pain symptoms and 
their well-being. People that belonged to the highest heart rate level were more commonly 
younger (mean age= 56.8 years compared to 62 years of age in people with <60bpm heart 
rate). They were also more commonly men, current smokers and with lower diabetes type II 
proportions. They also had lower beta-blockers, blood pressure medication, statins and 
antiplatelet prescriptions.  Of the 3345 participants recruited into the study, 99.1% granted full 
access to their medical records.   
 
Among my initial objectives were to explore associations of heart rate with i)  diagnoses based 
on functional imaging and invasive coronary angiography results, e.g. number of diseased 
vessels, ii) Quality of life parameters and mental health, iii) Single nucleotide polymorphisms 
(SNPs) that are related to coronary heart disease. However, due to time limitations and 
significant lack of cardiovascular events due to limited follow-up time as this is still in an on-
going process, I was unable to pursuit these aims.  
 
9.3. Conclusion 
 
With the use of heart rate data recorded in clinical care by general practitioners or other clinical 
professionals, this PhD sought to examine associations of resting heart rate and incidence and 
prognosis of CVD events in healthy and CAD populations. This is the first time that that primary 
care data is used to provide answers related to heart rate links with cardiovascular diseases 
and by the large number and high resolution information I was able to shed light into these links. 
These complex relationships are hard to disentangle in terms of direction and causality. Further 
work on the true causality of these associations is needed where the accuracy of mendelian 
randomization studies combined with the specificity and clinical wealth of linked electronic 
health records data will yield more scientifically robust answers on underlying mechanisms and 
causal effects. Nowadays, this will be soon feasible through the linkage of CALIBER datasets 
with UK Biobank, a major national health resource of 500,000 people recruited across UK that 
will complete the translational route of research in linked electronic health records. 
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10. Appendix 3§ 
 
Table A3.3 Selected constituent data files used for PhD, † including description and number of rows in full CALIBER research platform Constituent Data 
files193 
 Description Records Used for 
CPRD files  
Heart rate  
Record of heart rate measurement, 
patient identifier, heart rate value 
751,165 Main PhD exposure 
Patient  
Year of birth, gender, marital status, 
registration details and other 
administrative information  
5,372,790 Demographic co-variates 
Practice  
Region of practice, date practice met 
data quality standards and last data 
collection date  
226 
Modelling data clustered at general 
practice level 
Clinical  
Record of each consultation including 
practice, patient and consultation 
identifiers, date of data entry, date of 
consultation, and medcode (CPRD 
synonym for Read codes)  
356,446,923 
Specifying cohort, and defining 
ethnicity, clinical co-variates, and 
endpoints 
Additional  
Information, such as measurements 
(e.g. blood pressure measurement or 
BMI) or categories (e.g. smoking 
status – current, ex, non) which are 
not captured by Read code.  
97,244,627 Defining clinical co-variates 
Test  
Type of test performed, values, units 
of measure and normal range for 
laboratory.  
227,075,743 Defining clinical co-variates 
                                                          
 § Appendices numbering correspond to chapter numbers and start from the chapter that we encounter an appendix reference for the first time 
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Therapy  
Prescriptions issued included British 
National Formula (BNF) code, CPRD 
product code, total quantity 
prescribed, pack type, number of 
packs, numeric daily dose, total 
quantity and number of repeats.  
400,859,645 
Defining clinical co-variates and 
specifying endpoints (stable angina) 
HES files  
Patient  
Patient identifier, birthyear, gender, 
ethnicity, ethnicity, HES data 
collection start and end, and 
matching quality data  
2,026,520 
Defining demographic co-variate 
(ethnicity only) 
Diagnosis (Admissions)  
Patient identifier, admission identifier, 
date of discharge, ICD10 code, 
primary diagnosis flag  
7,983,022 
Specifying cohort, and defining 
clinical co-variates and endpoints 
ONS files  
Mortality  
Patient identifier, date of death, 
under-lying cause of death, cause of 
death (1-10)  
278,088 
Specifying cohort and defining 
endpoints 
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Figure A3.3. Histograms of heart rate in, healthy and CAD cohorts (by sex) 
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Figure A3.4.  Boxplots of mean heart rate in healthy populations identified in literature (by sex) 
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Table A3.7. Digit preference exploration in heart rate data in both healthy and CAD 
population of CALIBER 
 Healthy individuals CAD population 
Heart rate (bpm) Frequency Percent Frequency Percent 
     
30 11 0.00 3 0.01 
32 11 0.00 2 0.00 
33 7 0.00 3 0.01 
34 11 0.00 6 0.01 
35 23 0.01 6 0.01 
36 42 0.02 10 0.02 
37 22 0.01 23 0.04 
38 35 0.01 5 0.01 
39 38 0.02 25 0.05 
40 238 0.10 14 0.03 
41 71 0.03 117 0.23 
42 168 0.07 32 0.06 
43 114 0.05 79 0.15 
44 404 0.17 41 0.08 
45 252 0.11 212 0.41 
46 319 0.14 127 0.25 
47 313 0.13 147 0.28 
48 968 0.41 122 0.24 
49 356 0.15 2 0.00 
50 1,189 0.51 163 0.32 
51 582 0.25 583 1.13 
52 1,573 0.67 220 0.43 
53 694 0.30 815 1.58 
54 1,553 0.66 259 0.50 
55 1,207 0.52 675 1.31 
56 2,947 1.26 433 0.84 
57 1,352 0.58 1,337 2.59 
58 2,232 0.95 425 0.82 
59 1,546 0.66 869 1.68 
60 10,769 4.61 413 0.80 
61 1,887 0.81 4,461 8.64 
62 3,711 1.59 491 0.95 
63 2,183 0.93 1,044 2.02 
64 8,674 3.71 498 0.96 
65 3,138 1.34 2,910 5.63 
66 5,074 2.17 701 1.36 
67 2,822 1.21 1,196 2.32 
68 11,422 4.89 483 0.94 
69 2,950 1.26 2,863 5.54 
70 12,759 5.46 471 0.91 
71 3,032 1.30 2,879 5.57 
72 16,479 7.05 447 0.87 
73 2,873 1.23 3,467 6.71 
74 5,965 2.55 376 0.73 
75 3,821 1.63 975 1.89 
76 11,846 5.07 558 1.08 
77 3,018 1.29 2,360 4.57 
78 8,103 3.47 404 0.78 
79 2,653 1.13 1,525 2.95 
80 21,983 9.40 357 0.69 
81 2,364 1.01 4,774 9.24 
82 4,419 1.89 292 0.57 
83 2,251 0.96 770 1.49 
84 8,080 3.46 265 0.51 
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85 2,482 1.06 1,523 2.95 
86 3,282 1.40 341 0.66 
87 1,804 0.77 490 0.95 
88 8,062 3.45 215 0.42 
89 1,508 0.65 1,465 2.84 
90 4,980 2.13 190 0.37 
91 1,209 0.52 822 1.59 
92 3,086 1.32 133 0.26 
93 1,046 0.45 494 0.96 
94 1,343 0.57 131 0.25 
95 1,123 0.48 195 0.38 
96 3,105 1.33 118 0.23 
97 718 0.31 470 0.91 
98 1,392 0.60 82 0.16 
99 715 0.31 200 0.39 
100 4,664 1.99 69 0.13 
101 615 0.26 745 1.44 
102 819 0.35 70 0.14 
103 552 0.24 102 0.20 
104 1,277 0.55 62 0.12 
105 550 0.24 169 0.33 
106 532 0.23 64 0.12 
107 380 0.16 66 0.13 
108 777 0.33 45 0.09 
109 360 0.15 123 0.24 
110 1,132 0.48 33 0.06 
111 296 0.13 163 0.32 
112 699 0.30 26 0.05 
113 213 0.09 80 0.15 
114 274 0.12 23 0.04 
115 201 0.09 29 0.06 
116 284 0.12 28 0.05 
117 184 0.08 29 0.06 
118 194 0.08 18 0.03 
119 136 0.06 25 0.05 
120 1,477 0.63 10 0.02 
121 78 0.03 229 0.44 
122 105 0.04 7 0.01 
123 83 0.04 14 0.03 
124 138 0.06 5 0.01 
125 106 0.05 16 0.03 
126 99 0.04 15 0.03 
127 47 0.02 16 0.03 
128 118 0.05 7 0.01 
129 50 0.02 14 0.03 
130 211 0.09 3 0.01 
131 36 0.02 26 0.05 
132 99 0.04 4 0.01 
133 33 0.01 13 0.03 
134 32 0.01 1 0.00 
135 42 0.02 2 0.00 
136 55 0.02 10 0.02 
137 15 0.01 8 0.02 
138 22 0.01 3 0.01 
139 8 0.00 3 0.01 
140 191 0.08 3 0.01 
141 10 0.00 34 0.07 
142 16 0.01 3 0.01 
143 7 0.00 1 0.00 
144 34 0.01 6 0.01 
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145 22 0.01 2 0.00 
146 19 0.01 2 0.00 
147 3 0.00 2 0.00 
148 24 0.01 2 0.00 
149 1 0.00 1 0.00 
150 61 0.03 16 0.03 
Total 233,790 100.00 51,703 100 
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Table A3.8 Digit preference exploration in heart rate data in measurements recorded 
on the same day as blood pressure and not recorded on the same day 
 HR measured on the same day as 
BP 
 HR not measured on the same day as 
BP 
Heart 
rate 
Frequency Percent  Frequency Percent 
30 7 0.00  11 0.00 
31 0 0.00  0 0.00 
32 3 0.00  11 0.00 
33 2 0.00  7 0.00 
34 5 0.00  11 0.00 
35 14 0.01  23 0.01 
36 26 0.02  42 0.02 
37 15 0.01  22 0.01 
38 19 0.01  35 0.02 
39 18 0.01  38 0.02 
40 122 0.08  237 0.10 
41 48 0.03  69 0.03 
42 95 0.06  167 0.07 
43 78 0.05  112 0.05 
44 236 0.15  401 0.17 
45 148 0.09  252 0.11 
46 192 0.12  319 0.14 
47 227 0.14  309 0.13 
48 594 0.37  964 0.42 
49 234 0.14  352 0.15 
50 747 0.46  1,182 0.51 
51 401 0.25  576 0.25 
52 1,005 0.62  1,561 0.67 
53 485 0.30  688 0.30 
54 1,009 0.62  1,544 0.67 
55 822 0.51  1,200 0.52 
56 1,909 1.18  2,928 1.26 
57 996 0.61  1,342 0.58 
58 1,511 0.93  2,222 0.96 
59 1,129 0.70  1,536 0.66 
60 6,606 4.07  10,700 4.61 
61 1,370 0.84  1,871 0.81 
62 2,600 1.60  3,674 1.58 
63 1,617 1.00  2,165 0.93 
64 5,743 3.54  8,608 3.71 
65 2,285 1.41  3,112 1.34 
66 3,591 2.21  5,040 2.17 
67 2,177 1.34  2,789 1.20 
68 7,993 4.92  11,309 4.87 
69 2,277 1.40  2,929 1.26 
70 8,673 5.34  12,653 5.45 
71 2,306 1.42  3,011 1.30 
72 11,124 6.85  16,355 7.05 
73 2,199 1.35  2,848 1.23 
74 4,355 2.68  5,910 2.55 
75 2,894 1.78  3,787 1.63 
76 8,375 5.16  11,765 5.07 
77 2,316 1.43  2,996 1.29 
78 5,733 3.53  8,059 3.47 
79 2,050 1.26  2,632 1.13 
80 14,336 8.83  21,826 9.41 
81 1,805 1.11  2,350 1.01 
82 3,195 1.97  4,391 1.89 
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83 1,739 1.07  2,229 0.96 
84 5,523 3.40  8,024 3.46 
85 1,837 1.13  2,456 1.06 
86 2,362 1.45  3,257 1.40 
87 1,375 0.85  1,787 0.77 
88 5,489 3.38  7,999 3.45 
89 1,157 0.71  1,498 0.65 
90 3,364 2.07  4,941 2.13 
91 928 0.57  1,198 0.52 
92 2,182 1.34  3,066 1.32 
93 804 0.49  1,036 0.45 
94 991 0.61  1,333 0.57 
95 846 0.52  1,113 0.48 
96 2,073 1.28  3,079 1.33 
97 548 0.34  713 0.31 
98 1,006 0.62  1,379 0.59 
99 550 0.34  712 0.31 
100 3,004 1.85  4,634 2.00 
101 481 0.30  613 0.26 
102 598 0.37  814 0.35 
103 430 0.26  550 0.24 
104 897 0.55  1,267 0.55 
105 397 0.24  547 0.24 
106 396 0.24  526 0.23 
107 285 0.18  380 0.16 
108 524 0.32  766 0.33 
109 283 0.17  357 0.15 
110 750 0.46  1,125 0.48 
111 229 0.14  291 0.13 
112 467 0.29  693 0.30 
113 165 0.10  212 0.09 
114 208 0.13  271 0.12 
115 146 0.09  201 0.09 
116 217 0.13  282 0.12 
117 144 0.09  184 0.08 
118 144 0.09  193 0.08 
119 110 0.07  133 0.06 
120 902 0.56  1,468 0.63 
121 56 0.03  77 0.03 
122 76 0.05  104 0.04 
123 62 0.04  82 0.04 
124 101 0.06  137 0.06 
125 66 0.04  106 0.05 
126 70 0.04  97 0.04 
127 34 0.02  47 0.02 
128 79 0.05  117 0.05 
129 40 0.02  50 0.02 
130 125 0.08  210 0.09 
131 34 0.02  35 0.02 
132 64 0.04  99 0.04 
133 21 0.01  32 0.01 
134 23 0.01  32 0.01 
135 26 0.02  42 0.02 
136 31 0.02  55 0.02 
137 13 0.01  15 0.01 
138 13 0.01  22 0.01 
139 7 0.00  8 0.00 
140 115 0.07  191 0.08 
141 7 0.00  10 0.00 
142 11 0.01  16 0.01 
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143 2 0.00  7 0.00 
144 19 0.01  34 0.01 
145 12 0.01  22 0.01 
146 12 0.01  19 0.01 
147 2 0.00  3 0.00 
148 17 0.01  24 0.01 
149 0 0.00  1 0.00 
150 34 0.02  61 0.03 
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Table A3.10. Overview of codes used to define each cardiovascular endpoints and data sources 
 
Endpoint CPRD – Read codes 
MINAP – specific 
disease registry 
HES – OPCS 4 
hospital 
procedures 
HES – ICD 10 hospital 
diagnoses† 
ONS – ICD 10 causes of 
death‡ 
Stable angina G33..00: Stable Angina. 
G33z.00: Angina pectoris 
NOS + 25 other codes for 
diagnosis of stable angina 
pectoris. 
30 codes for evidence of 
coronary artery disease at 
angiography (CT,MR, 
invasive or not specified). 
151 Read codes for 
evidence of myocardial 
ischaemia (Resting ECG, 
exercise ECG, stress echo, 
radioisotope scan). 
Two or more successive 
prescriptions for anti-
anginals. 
 
nu K40-K46: Coronary 
artery bypass graft. 
K49,K50 and K75: 
Percutaneous 
coronary 
intervention, not 
within 30 days of an 
acute coronary 
syndrome. 
I20: Stable angina pectoris 
excluding unstable angina 
(I20.0). 
nu 
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Unstable angina G311.13/G311100: 
Unstable angina. 
G233200: Angina at rest. 
G311400: Worsening angina 
+ 13 other codes. 
 
Discharge diagnosis 
of unstable angina, no 
raised ST elevation. 
No raised troponin 
levels. 
nu I20.0: Unstable or worsening 
angina. 
I24: Acute ischaemic heart 
disease.  
I24.0: Coronary thrombosis 
not resulting in MI. 
 
 
 
  
 
I24.8: Other forms of 
ischaemic heart disease. 
I24.9: Acute ischaemic heart 
disease, unspecified. 
nu 
Coronary heart disease not 
otherwise specified 
G3…00: Ischaemic heart 
disease + 90 other codes 
including CHD NOS, chronic 
ischaemic heart disease, 
silent myocardial infarction. 
 
nu nu CHD NOS, chronic 
ischaemic  heart disease, 
silent MI (I25) 
excluding.I25.2, old MI. 
nu 
Acute Myocardial Infarction 
(MI) 
 
G30X000: Acute ST 
segment elevation 
myocardial infarction. 
G307100: Acute non-ST 
segment elevation 
myocardial infarction. 
G30..14: Heart attack. 
G30..15: MI Acute 
myocardial infarction + 60 
other codes as Acute MI not 
otherwise specified. 
MI with or without ST 
elevation based on 
initial 
electrocardiogram 
findings, raised 
troponins and clinical 
diagnosis. 
nu I21: Acute myocardial 
infarction. 
I23: Current complications of 
acute MI. 
nu 
Unheralded coronary death Any CVD excluded. Any CVD excluded. Any CVD excluded. Any CVD excluded. I20: Angina Pectoris. 
I21: Acute MI. 
I22: Subsequent MI. 
I23: Certain current 
complications following acute 
MI. 
I24: Other acute ischaemic 
heart diseases. 
I25: Chronic ischaemic heart 
disease. 
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Heart failure  G58..00: Heart Failure + 92 
other Read codes for heart 
failure diagnosis. 
nu Nu I50: Heart failure.   
I11.0: Hypertensive heart 
disease with (congestive) 
heart failure.  
I13.0: Hypertensive heart 
and renal disease with 
(congestive) heart failure. 
I13.2: Hypertensive heart 
and renal disease with both 
(congestive) heart failure 
and renal disease. 
I50 Heart failure. 
I11.0 Hypertensive heart 
disease with (congestive) 
heart failure. 
I13.0: Hypertensive heart and 
renal disease with 
(congestive) heart failure.  
I13.2: Hypertensive heart and 
renal disease with both 
(congestive) heart failure and 
renal disease 
Ventricular arrhythmias, 
cardiac arrest and sudden 
cardiac death 
G574.00: Ventricular 
fibrillation and flutter. 
G757.00: Cardiac arrest + 35 
other Read codes for 
ventricular fibrillation, 
asystole, cardiac arrest, 
cardiac resuscitation, 
electro-mechanical 
dissociation. 
G575100: Sudden cardiac 
death. 
 
nu X50: Implanted 
cardiac defibrillation 
device. 
K59: Implantation, 
revision and renewal 
of cardiac 
defibrillator. 
I46: Cardiac arrest. 
I47.0: Re-entry ventricular 
arrhythmia. 
I47.2: Ventricular 
tachycardia. 
 
 
I46: Cardiac arrest. 
I47.0: Re-entry ventricular 
arrhythmia. 
I47.2: Ventricular 
tachycardia. 
Transient ischaemic attack Fyu5500: [X]Other transient 
cerebral ischaemic attacks + 
related symptoms + 5 other 
Read codes. 
nu Nu G458: Other transient 
cerebral ischaemic attacks 
and related syndromes. 
G459: Transient cerebral 
ischaemic attack, 
unspecified. 
 
nu 
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Ischaemic stroke G64..11: CVA – cerebral 
artery occlusion, G64..13 
Stroke due to cerebral 
arterial occlusion. 
G6W..00: Cerebral infarction 
due to unspecified 
occlusion/stenosis of 
precerebral arteries. 
G6X..00: Cerebral infarction 
due to unspecified 
occlusion/stenosis of 
cerebral arteries plus 8 other 
codes. 
nu Stroke NOS with 
carotid 
endarterectomy or 
stenting within 90 
days (OPCS codes 
L294, L295, L311, 
L314; Read codes 
7A20300 + 4 others). 
I63: Cerebral infarction.   
 
 
 
 
I63: Cerebral infarction. 
Subarachnoid 
haemorrhage 
G601.00:Subarachnoid 
haemorrhage from carotid 
siphon and bifurcation. 
G602.00: Subarachnoid 
haemorrhage from middle 
cerebral artery. 
G60X.00: Subarachnoid 
haemorrhage from 
intracranial artery, 
unspecified. 
 
nu  I60: Subarachnoid 
haemorrhage. 
I60: Subarachnoid 
haemorrhage. 
Intracerebralhaemorrhage Gyu6F00: [x] Intracerebral 
haemorrhage in hemisphere, 
unspecified + 16 other 
codes. 
nu  I61: Intracerebral 
haemorrhage. 
I61: Intracerebral 
haemorrhage. 
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Stroke not otherwise 
specified 
G66..11: Cerebrovascular 
accident unspecified + 14 
other Read codes. 
nu U54.3: Delivery of 
rehabilitation for 
stroke. 
I64: Stroke not specified as 
haemorrhage or infarction. 
G463-G467: Stroke 
syndromes. 
I64: Stroke not specified as 
haemorrhage or infarction. 
I672: Cerebral 
atherosclerosis. 
I679: Cerebrovascular 
disease, unspecified. 
 
 
 
Peripheral arterial disease 63 codes for lower limb 
peripheral arterial disease 
diagnosis (including diabetic 
PAD, gangrene, arterial 
thrombosis of the leg and 
intermittent claudication). 
Evidence of atherosclerosis 
of iliac and lower limb 
arteries based on 
angiography or Dopplers. 
nu L50-L54: Bypass, 
reconstruction and 
other open 
operations on iliac 
artery. 
 L58-L60, L62: 
Bypass, 
reconstruction, 
transluminal 
operations or other 
open operations of 
femoral artery. 
 L65: Revision of 
reconstruction of 
artery. 
 
I70.2: atherosclerosis of 
arteries of extremities. 
I73.9: Peripheral vascular 
disease intermittent 
claudication  
E10.05,E11-E14: Peripheral 
complications of diabetes 
including gangrene, insulin 
dependent diabetes mellitus, 
non-insulin-dependent 
diabetes mellitus, 
malnutrition-related diabetes 
mellitus, other specified 
diabetes mellitus,  
unspecified diabetes 
mellitus. 
I70.2: Atherosclerosis of 
arteries of extremities. 
I73.9: Peripheral vascular 
disease intermittent 
claudication. 
Peripheral complications of 
diabetes including gangrene 
0.5 suffix of E10: Insulin 
dependent diabetes mellitus, 
E11: Non-insulin-dependent 
diabetes mellitus, E12: 
Malnutrition-related diabetes 
mellitus, E13: Other specified 
diabetes mellitus,  E14: 
Unspecified diabetes mellitus 
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Abdominal aortic 
aneurysm 
G714.00: AAA without 
mention of rupture + 12 more 
codes for AAA diagnosis. 
42 codes for AAA 
procedures. 
nu L16: Extra anatomic 
bypass of aorta. 
L18-L23: 
Replacement of 
aneurysmal segment 
of aorta, bypass of 
segment of aorta, 
plastic repair of 
aorta. 
L25-L28: 
Transluminal or 
endovascular 
insertion of stent on 
aneurysmal segment 
of aorta. 
I71.3: Ruptured AAA. 
171.4: AAA without rupture. 
I71.5: Ruptured thoraco-
abdominal aortic aneurysm. 
I71.6: Thoracoabdominal 
aortic aneurysm without 
mention of rupture. 
I71.8: Aortic aneurysm of 
unspecified site, ruptured. 
I71.9: Aortic aneurysm of 
unspecified site, without 
mention of rupture. 
I71.3: Ruptured AAA. 
I71.4: AAA without rupture. 
I71.5: Ruptured thoraco-
abdominal aortic aneurysm. 
I71.6: Thoracoabdominal 
aortic aneurysm without 
mention of rupture. 
I71.8: Aortic aneurysm of 
unspecified site, ruptured. 
I71.9: Aortic aneurysm of 
unspecified site, without 
mention of rupture. 
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11. Appendix 4 
 
Table A4.1 Hierarchy of endpoints severeness 
1 Sudden cardiac death / ventricular fibrillation / cardiac arrest 
2 Heart failure 
3 Unheralded coronary death 
4 Myocardial infarction 
5 Unstable angina 
6 Stable angina 
7 Coronary disease, not otherwise specified 
8 Abdominal aortic aneurysm 
9 Peripheral arterial disease 
10 Subarachnoid haemorrhage 
11 Haemorrhagic stroke 
12 Ischaemic stroke 
13 Transient Ischaemic Attack 
14 Other deaths (Cancer, COPD, Liver disease) 
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Figure A4.2. Hazard ratios (95% CIs) for the association between heart rate quintiles (vs. reference 1st Q) in 12 cardiovascular diseases and mortality  
 
Note: Hazard ratios adjusted for sex, age, quadratic age, interaction between heart rate and sex, social deprivation, smoking, systolic blood pressure, BP 
medication, total cholesterol, HDL, LDL, diabetes II and BMI and stratification by primary care practice (data imputed); CI, confidence interval; HR, 
hazard ratios; CA, Cardiac Arrest; CV, Cardioversion 
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Figure A4.3 Multivariable ajusted  hazard ratios between heart rate (top vs bottom level) and the initial presentation of 12 
cardiovascular diseases after exclusion of cardiovascular events during the first year after heart rate measurement 
 
Note: Hazard ratios adjusted for sex, age, quadratic age, interaction between heart rate and sex, social deprivation, smoking, 
systolic blood pressure, BP medication, total cholesterol, HDL, LDL, diabetes II and BMI and stratification by primary care 
practice (data imputed); CI, confidence interval; HR, hazard ratios; CA, Cardiac Arrest; CV, Cardioversion 
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Figure A4.4 Hazard ratios for the association of heart rate with 12 CVDs using only secondary care data (after exclusion of 
CPRD data) 
 
Note: Hazard ratios adjusted for sex, age, quadratic age, interaction between heart rate and sex, social deprivation, smoking, 
systolic blood pressure, BP medication, total cholesterol, HDL, LDL, diabetes II and BMI and stratification by primary care 
practice (data imputed); CI, confidence interval; HR, hazard ratios adjusted for sex and age; CA, Cardiac Arrest; CV, 
Cardioversion  
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Figure A4.5 Multivariable adjusted hazard ratios for the association between heart rate (top vs bottom quintile) and the initial 
presentation of 12 cardiovascular diseases in patients without beta-blockers intake reports 
 
Note: Hazard ratios adjusted for sex, age, quadratic age, interaction between heart rate and sex, social deprivation, smoking, 
systolic blood pressure, BP medication, total cholesterol, HDL, LDL, diabetes II and BMI and stratification by primary care 
practice (data imputed); CI, confidence interval; HR, hazard ratios; CA, Cardiac Arrest; CV, Cardioversion 
   222 
 
Figure A4.6 Multivariable adjusted hazard ratios for the association between heart rate (top vs bottom level) and the initial 
presentation of 12 cardiovascular diseases in patients without blood pressure medication intake reports 
 
Note: Hazard ratios adjusted for sex, age, quadratic age, interaction between heart rate and sex, social deprivation, smoking, 
systolic blood pressure, BP medication, total cholesterol, HDL, LDL, diabetes II and BMI and stratification by primary care 
practice (data imputed); CI, confidence interval; HR, hazard ratios; CA, Cardiac Arrest; CV, Cardioversion  
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Figure A4.7 Hazard ratios for the association between heart rate (top vs bottom level) and the initial presentation of 12 
cardiovascular diseases in patients with heart rate and systolic blood measurements reported on the same day 
 
Note: Hazard ratios adjusted for  sex, age and BP medication and stratification by primary care practice; CI, confidence interval; 
HR, hazard ratios; CA, Cardiac Arrest; CV, Cardioversion 
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Figure A4.8 Age and sex adjusted hazard ratios (95% CIs)  for the association between heart rate and the initial presentation of 
12 cardiovascular diseases  and 3 composite mortality outcomes 
 
Note: CI, confidence interval; HR, hazard ratios adjusted for sex and age; CA, Cardiac Arrest; CV, Cardioversion 
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Figure A4.11 Multivariable ajsuted hazard ratios (95% CIs) for the association between heart rate levels (vs. reference L1) in 
12 cardiovascular diseases in men 
 
Note: Hazard ratios adjusted for sex, age, quadratic age, interaction between heart rate and sex, social deprivation, smoking, 
systolic blood pressure, BP medication, total cholesterol, HDL, LDL, diabetes II and BMI and stratification by primary care 
practice (data imputed); CI, confidence interval; HR, hazard ratios; CA, Cardiac Arrest; CV, Cardioversion 
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Figure A4.12 Multivariable ajsuted hazard ratios (95% CIs) for the association between heart rate levels (vs. reference L1) in 
12 cardiovascular diseases in women 
 
Note: Hazard ratios adjusted for sex, age, quadratic age, interaction between heart rate and sex, social deprivation, smoking, 
systolic blood pressure, BP medication, total cholesterol, HDL, LDL, diabetes II and BMI and stratification by primary care 
practice (data imputed); CI, confidence interval; HR, hazard ratios; CA, Cardiac Arrest; CV, Cardioversion 
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Figure A4.13. Multivariable ajsuted hazard ratios (95% CIs) for the for the association between heart rate and 12 cardiovascular 
diseases (by age group) 
 
Note: Heart rate measured in 10 bpm increments. Hazard ratios adjusted for sex, interaction between heart rate and sex, social 
deprivation, smoking, systolic blood pressure, BP medication, total cholesterol, HDL, LDL, diabetes II and BMI and 
stratification by primary care practice (data imputed); CI, confidence interval; HR, hazard ratios; CA, Cardiac Arrest; CV, 
Cardioversion 
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12. Appendix 5 
 
 
A5.1. Study Flow diagram 
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Table A5.2. Baseline characteristics of stable CAD patients by previous coronary artery disease event (cause of study entry) 
  
All stable patients 
(Ν=51,703) 
 
Stable angina 
(Ν=44,370) 
 
Stable after unstable 
angina 
 (Ν=1,736) 
 
Stable after MI 
(Ν=5,597) 
 % recorded 
           
Demographic factors           
Age at entry (years)  72.3 (11.4)  72.1 (11.4)  71.5 (12.3)  73.6 (11.1)  100% 
Female  22,809 (44.1%)  20,141 (45.39)  812 (46.7)  1,856 (33.2)  100 % 
White Ethnicity  37,980 (80.1%)  32,529 (73.3)  1,369 (78.8)  4,082 (72.9)  91.66% 
Deprivation (most deprived quintile)  10,300 (19.98%)  8,941 (20.1)  351 (20.2)  1,008 (18.0)  99.72% 
Clinical factors           
Heart rate (continuous) (bpm)  72.2 (14.5)  72.2 (14.4)  72.7 (14.7)  71.6 (14.5)  100% 
Systolic blood pressure, (mmHg)  138.3 (19.9)  138.5 (20.7)  136.7 (20.3)  137.2 (20.7)  85.6% 
Diastolic blood pressure, (mmHg)  76.8 (10.8)  76.9 (10.7)  76.5 (11.4)  76.3 (11.1)  85.6% 
High density lipoproteins, (mmol/L)  85.3 (40.0)  85.5 (40.1)  84.2 (38.7)  83.9 (39.8)  53.5% 
Low density lipoproteins, (mmol/L)  2.5 (0.92)  2.50 (0.92)  2.43 (0.94)  2.44 (0.86)  41.3% 
Total cholesterol  (mmol/L)  44.7 (10.8)  44.9 (10.9)  43.6 (11.0)  43.9 (10.1)  71.0% 
Triglycerides (mmol/L)  1.59 (1.04)  1.60 (1.05)  1.57 (0.90)  1.53 (0.95)  51.0% 
Creatinine  (μmol/L)  102.5 (64.8)  101.7 (67.3)  105.6 (59.8)  107.4 (41.5)  19.0% 
Haemoglobin (g/dL)  13.5 (1.64)  13.5 (1.62)  13.3 (1.76)  13.5 (1.75)  54.3% 
Lymphocytes (109 /L)  2.03 (1.26)  2.04 (1.26)  2.05 (1.08)  1.98 (1.29)  48.7% 
Neutrophils (109 /L)  4.60 (1.89)  4.58 (1.87)  4.78 (2.14)  4.68 (1.98)  48.7% 
Behavioural/Environmental factors           
Non-smokers  19,713 (38.1)  17,260 (40.8)  645 (38.8)  1,808 (34.0)  
95.2% Ex-smoker  22,670 (43.8)  19,260 (45.5)  778 (46.9)  2,632 (49.6)  
Current smoker  6,177 (11.9)  5,179 (12.2)  217 (13.0)  781 (14.7)  
BMI (kg/m2 )  28.2 (5.48)  28.3 (5.49)  28.8 (5.76)  27.3 (5.17)  46.3% 
Family history of CHD  1,013 (1.96)  916 (2.06)  18 (1.04)  79 (1.41)  100% 
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Diabetes type  II  6,087 (11.7)  5,190 (11.7)  230 (13.2)  667 (11.9)  100% 
Current alcohol drinker  9,367 (18.1)  8,114 (18.3)  264 (15.2)  989 (17.7)  32.1% 
Hypertensives  2,791 (6.30)  2,399 (5.41)  112 (6.45)  280 (5.00)  85.6% 
Medication           
Beta-blockers  26,212 (50.7)  22,400 (50.5)  908 (52.3)  2,904 (51.8)  100% 
Antianginal medication*  34,040 (65.8)  30,375 (68.5)  1,123 (64.7)  2,542 (45.4)  100% 
BP medication   38,871 (75.2)  33,308 (75.1)  1,376 (79.3)  4,187 (74.8)  100% 
Anti-arrhythmic medication   4,241 (8.20)  3,583 (8.08)  186 (10.7)  472 (8.43)  100% 
Statins           
Aspirin           
Note: Blood pressure (BP) medication consists of BNF codes that refer to diuretics, b-blockers, calcium channel blockers, hypertension and heart failure medication and ACE inhibitors intake.  
For categorical variables the means represent % proportions. *Antianginal medication consists of: Ca channel blockers, nitrates, vasodilators and other angina medication. Mean (SD) for continuous measurements, 
N(%) for categorical data 
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Table A5.3 Multivariable adjusted hazard ratios for the association between heart rate levels and the subsequent fatal and non-fatal events among  people with stable coronary artery disease (by coronary disease 
type at baseline) 
Prior stable angina              
Primary outcomes              
Myocardial infarction 999  REF  0.98(0.79-1.21)  1.13(0.91-1.39)  1.06(0.84-1.33)  1.26(0.97-1.63)  1.04 (0.99-1.08) 
Heart Failure 3,235  REF  1.29(1.13-1.49)  1.63(1.42-1.87)  2.32(2.02-2.66)  3.02(2.61-3.50)  1.22 (1.19-1.24) 
SCD-CA 227  REF  1.21(0.79-1.86)  1.21(0.78-1.89)  0.94(0.56-1.56)  1.86(1.12-3.08)  1.08 (0.99-1.18) 
Peripheral arterial disease 1,009  REF  1.08(0.88-1.33)  1.15(0.93-1.42)  1.18(0.95-1.47)  1.08(0.83-1.42)  1.02 (0.97-1.06) 
All cause stroke 2,010  REF  1.02(0.87-1.19)  1.11(0.95-1.30)  1.29(1.10-1.52)  1.33(1.10-1.61)  1.07 (1.04-1.10) 
CVD death 1,339  REF  1.16(0.94-1.41)  1.24(1.01-1.52)  1.62(1.31-1.99)  2.05(1.63-2.58)  1.14 (1.10-1.18) 
Total mortality 2,940  REF  1.23(1.07-1.42)  1.52(1.32-1.74)  1.71(1.48-1.97)  2.26(1.94-2.63)  1.15 (1.12-1.18) 
Secondary outcomes              
Atrial fibrillation 8,365  REF  1.04(0.97-1.12)  1.17(1.08-1.26)  1.45(1.34-1.57)  2.00(1.84-2.18)  1.15 (1.13-1.16) 
Prior MI              
Primary outcomes              
Myocardial infarction 194  REF  1.05(0.66-1.65)  0.80(0.49-1.30)  0.91(0.54-1.52)  1.15(0.63-2.10)  1.01 (0.91-1.12) 
Heart Failure 583  REF  1.32(0.95-1.81)  1.79(1.31-2.46)  2.17(1.56-3.00)  2.85(1.97-4.11)  1.19 (1.13-1.26) 
SCD-CA 64  REF  7.75(1.91-31.46)  5.20(1.22-22.07)  1.55(0.28-8.61)  8.22(1.69-40.01)  0.97 (0.80-1.18) 
Peripheral arterial disease 146  REF  0.82(0.46-1.47)  1.19(0.67-2.09)  1.26(0.69-2.32)  1.21(0.57-2.55)  1.10 (0.98-1.24) 
All cause stroke 283  REF  1.02(0.67-1.53)  1.09(0.71-1.65)  1.30(0.84-2.00)  1.32(0.78-2.25)  1.04 (0.95-1.13) 
CVD death 247  REF  1.26(0.79-2.01)  1.34(0.84-2.14)  1.55(0.96-2.51)  1.75(0.97-3.13)  1.12 (1.02-1.23) 
Total mortality 465  REF  1.69(1.16-2.46)  2.09(1.44-3.04)  2.09(1.41-3.09)      2.84(1.83-4.38)  1.14 (1.07-1.21) 
Secondary outcomes              
Atrial fibrillation 1,183  REF  1.03(0.83-1.27)  1.28(1.04-1.58)  1.42(1.14-1.76)  2.34(1.84-2.98)  1.13 (1.09-1.17) 
Prior unstable angina              
Primary outcomes              
Myocardial infarction 48  REF  0.76(0.23-2.45)  1.04(0.35-3.06)  0.47(0.13-1.76)  0.32(0.05-1.85)  0.81 (0.61-1.08) 
Heart Failure 129  REF  1.78(0.80-3.93)  1.78(0.79-3.96)  2.43(1.07-5.51)  3.30(1.37-7.95)  1.17 (1.03-1.33) 
SCD-CA 8  REF  -  -  -  -  - 
Peripheral arterial disease 26  REF  1.50(0.24-9.46)  2.64(0.43-16.24)  1.58(0.21-11.97)  2.21(0.31-16.02)  1.13 (0.85-1.49) 
All cause stroke 82  REF  0.85(0.37-1.94)  1.03(0.46-2.31)  0.94(0.39-2.28)  0.67(0.21-2.20)  0.97 (0.81-1.18) 
CVD death 56  REF  5.88(0.72-48.14)  11.05(1.32-92.50)  6.19(0.73-52.58)  11.62(1.26-107.25)  1.18 (0.95-1.46) 
Total mortality 120  REF  0.81(0.38-1.70)  1.38(0.68-2.82)  0.62(0.27-1.42)  2.64(1.21-5.78)  1.14 (1.02-1.29) 
Secondary outcomes              
Atrial fibrillation 412  REF  1.15(0.78-1.72)  1.19(0.80-1.79)  1.45(0.96-2.20)  2.02(1.27-3.20)  1.14 (1.06-1.23) 
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Note: CVD, cardiovascular; SCD-CA, Sudden cardiac death-Cardiac arrest;  CI, confidence interval; HR, hazard ratios from Cox proportional hazard model stratified by general practice  and adjusted for sex, age, 
index of multiple deprivation, smoking, systolic blood pressure, diabetes type II, total cholesterol, HDL cholesterol and body mass index 
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Figure A5.3. Age and sex adjusted hazard ratios for the association between heart rate (top vs bottom level) and the incidence 
of 7 cardiovascular diseases and mortality outcomes in people with sCAD 
 
Note: CI, confidence interval; HR, hazard ratios from Cox proportional hazard model stratified by general practice  and adjusted 
for sex and age 
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Figure A.5.4. Multivariable adjusted hazard ratios for the association between heart rate (top vs bottom level) and the subsequent 
fatal and non-fatal events among  men with stable coronary artery disease 
 
Note: CI, confidence interval; HR, hazard ratios from Cox proportional hazard model stratified by general practice  and 
adjusted for sex, age, index of multiple deprivation, smoking, systolic blood pressure, diabetes type II, total cholesterol, HDL 
cholesterol and body mass index 
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Figure A5.5. Multivariable adjusted hazard ratios for the association between heart rate (top vs bottom level) and the subsequent 
fatal and non-fatal events among women with stable coronary artery disease 
 
Note: CI, confidence interval; HR, hazard ratios from Cox proportional hazard model stratified by general practice  and 
adjusted for sex, age, index of multiple deprivation, smoking, systolic blood pressure, diabetes type II, total cholesterol, HDL 
cholesterol and body mass index 
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Figure A5.6. Multivariable hazard ratios for the association between heart rate and the initial presentation of  cardiovascular 
diseases in people with stable coronary artery disease stratified by age group 
 
Note: Heart rate measured in 10 bpm increments.  CI, confidence interval; HR, hazard ratios from Cox proportional hazard 
model stratified by general practice  and adjusted for sex, age, index of multiple deprivation, smoking, systolic blood 
pressure, diabetes type II, total cholesterol, HDL cholesterol and body mass index 
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Figure A.5.7 Multivariable adjusted hazard ratios for the association between heart rate (5th vs 1st level) and the subsequent 
fatal and non-fatal events among  people with corornary artery disease after exclusion of events occurring during the first year 
of study follow-up 
 
Note: CI, confidence interval; HR, hazard ratios from Cox proportional hazard model stratified by general practice  and 
adjusted for sex, age, index of multiple deprivation, smoking, systolic blood pressure, diabetes type II, total cholesterol, HDL 
cholesterol and body mass index 
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Figure A5.8 Multivariable adjusted hazard ratios for the association between heart rate (5th vs 1st level) and the subsequent 
fatal and non-fatal events among  people with stable corornary artery disease but no baseline beta-blockers prescription 
 
Note: CI, confidence interval; HR, hazard ratios from Cox proportional hazard model stratified by general practice  and 
adjusted for sex, age, index of multiple deprivation, smoking, systolic blood pressure, diabetes type II, total cholesterol, HDL 
cholesterol and body mass index 
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Figure A5.9 Multivariable adjusted hazard ratios for the association between heart rate (5th vs 1st level) and the subsequent 
fatal and non-fatal events among  people with stable corornary artery disease but no baseline blood pressure lowering medication 
prescription 
 
Note: CI, confidence interval; HR, hazard ratios from Cox proportional hazard model stratified by general practice  and 
adjusted for sex, age, index of multiple deprivation, smoking, systolic blood pressure, diabetes type II, total cholesterol, HDL 
cholesterol and body mass index 
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Figure A5.10. Multivariable adjusted hazard ratios for the association between heart rate (5th vs 1st level) and the subsequent 
fatal and non-fatal events among  people with stable corornary artery disease but no baseline warfarin/digoxin prescription 
 
Note: CI, confidence interval; HR, hazard ratios from Cox proportional hazard model stratified by general practice  and 
adjusted for sex, age, index of multiple deprivation, smoking, systolic blood pressure, diabetes type II, total cholesterol, HDL 
cholesterol and body mass index 
 
  
   241 
 
Figure A5.11 Multivariable adjusted hazard ratios for the association between heart rate (5th vs 1st level) and the subsequent 
fatal and non-fatal events among  people with coronary artery disease and the entry eligibility CVD event occurred prior to 
the date of entry in the study 
 
Note: CI, confidence interval; HR, hazard ratios from Cox proportional hazard model stratified by general practice  and 
adjusted for sex, age, index of multiple deprivation, smoking, systolic blood pressure, diabetes type II, total cholesterol, HDL 
cholesterol and body mass index 
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Figure A5.12 Multivariable adjusted hazard ratios for the association between heart rate (5th vs 1st level) and the subsequent fatal and non-fatal events among  
people with coronary artery disease and the entry eligibility CVD event occurred after the date of entry in the study 
 
Note: CI, confidence interval; HR, hazard ratios from Cox proportional hazard model stratified by general practice  and adjusted for sex, age, index of 
multiple deprivation, smoking, systolic blood pressure, diabetes type II, total cholesterol, HDL cholesterol and body mass index 
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Figure A5.13  Multivariable adjusted hazard ratios for the association between heart rate (5th vs 1st level) and the subsequent 
fatal and non-fatal events among  people with stable coronary artery disease and baseline normal blood pressure values 
 
 
Note: CI, confidence interval; HR, hazard ratios from Cox proportional hazard model stratified by general practice  and 
adjusted for sex, age, index of multiple deprivation, smoking, systolic blood pressure, diabetes type II, total cholesterol, HDL 
cholesterol and body mass index 
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Figure A5.14  Multivariable adjusted hazard ratios for the association between heart rate (5th vs 1st level) and the subsequent 
fatal and non-fatal events among  people with hypertension 
 
Note: CI, confidence interval; HR, hazard ratios from Cox proportional hazard model stratified by general practice  and 
adjusted for sex, age, index of multiple deprivation, smoking, systolic blood pressure, diabetes type II, total cholesterol, HDL 
cholesterol and body mass index 
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Figure A5.15Multivariable adjusted hazard ratios for the association between heart rate (5th  vs 1st level) and the subsequent 
fatal and non-fatal events among  people with stable coronary artery disease after exclusion of patients with recorded heart 
failure before study entry 
 
Note: CI, confidence interval; HR, hazard ratios from Cox proportional hazard model stratified by general practice  and 
adjusted for sex, age, index of multiple deprivation, smoking, systolic blood pressure, diabetes type II, total cholesterol, HDL 
cholesterol and body mass index 
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Figure A5.16 Age and sex adjusted hazard ratios for the association between heart rate (5th vs 1st level) and the subsequent fatal and non-fatal events among  people with stable coronary artery disease after exclusion 
of primary care data 
 
Note: CI, confidence interval; HR, hazard ratios from Cox proportional hazard model stratified by general practice  and adjusted for sex and age 
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Figure A5.17 Restricted cubic splines of heart rate and CVD events in people with stable coronary artery disease 
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13. Appendix 6 
 
Figure A6.1. Cohorts design  
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A6.2. Study Flow diagram 
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Table A6.1. Categories and codes of atrial 
fibrillation variable 
 
GPRD Read codes 
1. History of atrial fibrillation or flutter     
 
14AN.00:H/O: atrial fibrillation 
14AR.00: History of atrial flutter 
212R.00: Atrial fibrillation resolved 
2. Atrial fibrillation monitoring                
 
662S.00:Atrial fibrillation monitoring 
6A9..00:Atrial fibrillation annual review 
9Os..00:Atrial fibrillation monitoring administration 
9Os0.00:Atrial fibrillation monitoring first letter 
9Os1.00:Atrial fibrillation monitoring second letter 
9Os2.00:Atrial fibrillation monitoring third letter 
9Os3.00:Atrial fibrillation monitoring verbal invite 
9Os4.00:Atrial fibrillation monitoring telephone invite 
9hF..00:Exception reporting: atrial fibrillation quality 
indicators 
9hF1.00:Excepted from atrial fibrillation qual indic: 
Inform dissent 
3. Paroxysmal atrial fibrillation                G573200:Paroxysmal atrial fibrillation 
4. Persistent or permanent atrial fibrillation   
 
G573400:Permanent atrial fibrillation 
G573500:Persistent atrial fibrillation 
5. Atrial fibrillation, not otherwise specified  
 
3272:ECG: atrial fibrillation 
G573000:Atrial fibrillation 
G573300:Non-rheumatic atrial fibrillation 
6. Atrial fibrillation or flutter                
 
G573.00:Atrial fibrillation and flutter 
G573z00:Atrial fibrillation and flutter NOS 
7. Atrial flutter                                
 
3273:ECG: atrial flutter 
G573100:Atrial flutter 
HES Icd codes 
All the above I48: Atrial fibrillation and flutter 
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Figure A6.4 Multivariably adjusted hazard ratios for the association between heart rate (5L vs 1L) and the risk of atrial fibrillation 
  
 
 
  
Note: CI, confidence interval; HR, hazard ratios adjusted for age, sex, social deprivation, smoking, systolic blood pressure, BP medication, total cholesterol, HDL, LDL, diabetes II and BMI 
  
Total 
Men Women 
(a) 
(b) (c) 
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Figure A6.5. Restricted cubic splines of heart rate and atrial fibrillation incidence in general population and by gender 
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Figure A.6.6. Restricted cubic splines of heart rate and cardiovascular diseases and mortality 
   
   
  
 
Note: Adjustments include sex, age, quadratic age, and stratification by primary care practice 
0.5
1.0
1.5
2.0
2.5
3.0
H
az
ar
d 
R
at
io
 o
f S
A
42 52 62 72 82 92 102 112
Heart rate, bpm
0.5
1.0
1.5
2.0
2.5
3.0
H
az
ar
d 
R
at
io
 o
f M
I
42 52 62 72 82 92 102 112
Heart rate, bpm
0.5
1.0
1.5
H
az
ar
d 
R
at
io
 o
f H
F
42 52 62 72 82 92 102 112
Heart rate, bpm
0.5
2.5
4.5
6.5
8.5
H
a
za
rd
 R
a
tio
 o
f 
S
C
D
42 52 62 72 82 92 102 112
Heart rate, bpm
0.5
1.0
1.5
2.0
H
a
za
rd
 R
a
tio
 o
f 
S
tr
o
ke
42 52 62 72 82 92 102 112
Heart rate, bpm
0.5
1.0
1.5
H
a
za
rd
 R
a
tio
 o
f 
P
A
D
42 52 62 72 82 92 102 112
Heart rate, bpm
0.5
1.0
1.5
H
az
ar
d 
R
at
io
 o
f a
ll-
ca
us
e 
m
or
ta
lit
y
42 52 62 72 82 92 102 112
Heart rate, bpm
0.5
1.0
1.5
H
az
ar
d 
R
at
io
 o
f C
V
D
 d
ea
th
42 52 62 72 82 92 102 112
Heart rate, bpm
Heart Failure Stable angina Myocardial infarction 
Sudden cardiac death Stroke PAD 
All-cause mortality CVD death 
   254 
 
 
Figure A6.7 Heart rate and atrial fibrillation incidence in healthy population 
  
  
  
Note: a. Restricted to those without warfarin/digoxin intake, b. Exclusion of AF events for 6 months after an MI event, c. Exclusion of AF events during the first year after the heart rate measurement., d. No beta-
blockers medication intake, e. No thyroid disease diagnosis at baseline, f. No prior CVD event (before the AF incident) 
a b 
c d 
e f 
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Figure A6.8 Kaplan-Meier curves of AF cumulative hazard (by heart rate level and overall) 
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14. Appendix 7.1 
 
Participant consent form used in the Clinical Cohorts in Coronary 
disease Collaboration (4C) study  
 
  
My Healthy Heart 
Participant consent form 
Chief investigator:  Professor Harry Hemingway  
 
Thank you for reading the information sheet about the ‘My Healthy Heart’ study examination.  
Please read this consent form carefully and put your initials in the boxes by the items to 
which you agree or give your consent. Please put a line through the box if you do not wish to 
give your consent to a particular item.  
 
 
         <Affix patient unique study  
         identifier label here> 
 
 
1. I have read and understand the information sheet dated 10th July 2012 (version 1.2A), and  
and have had the opportunity to ask questions.       
 
  
2. I understand that my participation is voluntary and that I am free to withdraw at any time  
without giving any reason.  
 
  
3. I understand that I may be contacted again by the study team (e.g. to answer some more 
questions and/or attend another assessment visit), but this is optional. 
 
  
4. I give permission for long-term storage and use of my blood samples for health-related research 
purposes (even after my incapacity or death), and relinquish all rights to these samples which I 
am donating to the My Healthy Heart study. 
 
  
5. I give permission for full access to my past, present and future medical and other health-related 
records, and for long-term storage and use of this and other information about me, for health-
related research purposes (even after my incapacity or death).  I understand that information held 
and managed by The Health and Social Care Information Centre and other central UK NHS 
bodies may be used in order to help contact me or provide information about my health status. 
 
  
6. I understand that all research data will be anonymised in a form that will preclude me from being 
identified personally, and all data will be stored securely at the study co-ordinating centre.  
 
  
7. I understand that none of my results will be given to me including my blood results.   
  
  
  
8. I agree to take part in this study. 
 
 
 
 
 
___________________________    __________________       __________________________ 
Name of participant (CAPITALS)        SIGNATURE                         Date (dd/mm/yyyy)      
 
__________________________       __________________     ______________________ 
Name of person taking consent     SIGNATURE                          Date (dd/mm/yyyy)       
(CAPITALS) 
 
 
 
Please initial boxes. Example: 
 
 
 
Correct                   Incorrect 
NF 
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15. Appendix 7.2 
 
Clinical Cohorts in Coronary disease Collaboration (4C) participant 
baseline health questionnaire 
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17. Appendix 7.4 
 
Figure 7.1 Clinical Cohorts in Coronary disease Collaboration (4C) study flow 
diagram. 
 
 
 
 
ECG: electrocardiogram; HES: Hospital Episode Statistics; ONS: Office for National Statistics 
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Figure 7.2. Summary of the standard operating procedure for processing and storage of research blood samples 
 
 
 
Screen and consent patient  
Blood sample via venepuncture: total 21.5mls 
2x EDTA (9mls); 1x SST (5mls); 1x PST (5mls); 1x RNA (2.5mls)  
Invert each vacutainer 10x 
PST and EDTA samples centrifuge 
immediately at 2500g for 10 min 
Allow SST sample to clot for 25-30 mins at room temperature. 
Then centrifuge at 2500g for 10 mins 
PAXgene RNA tube 
 
Aliquot samples into 0.5ml 2-D labelled cryovials 
EDTA (plasma) to 9 cryovials 
EDTA (buffy coat and remaining cells) to 2 cryovials 
PST to 4 cryovials 
SST to 4 cryovials 
PAXgene RNA to 5 cryovials 
Log each cryovial into the sample logging database using the single-tube bar-code reader 
Store all cryovials in a 96 position rack at -20
o
C 
At quarterly intervals all samples will be collected from each hospital for storage by Fisher Bioservices. Samples will be 
transported in dry ice 
Using a flat-bed bar-code system the racks and sample positions will be identified and logged prior to storage at -80
o
C 
For analysis samples will be retrieved by Fisher Bioservices, logged out and sent to the appropriate laboratory(ies) 
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Table 7.2 Methods of extracting clinical data and extent to which data could be accessed 
electronically in Heart Hospital of London  H art Hospital of Lond n 
 Data available for 
electronic 
download 
Method of collection 
Clinical 
biochemistry 
results  
Yes 
Not done 
Resting 
electrocardiogram 
No 
Manual photocopying of paper ECG from notes or 
manual extraction of data from clinical database  
Exercise treadmill 
test  
No 
Not done 
Clinical risk 
factors 
No 
Manual extraction of information from the GP 
referral letter  
Medical history 
No 
Manual extraction of information from the GP 
referral letter  
Symptoms and 
clinical 
examination  
No 
Manual extraction of information from discharge 
letter and database 
Diagnosis  
No 
Manual extraction of information from discharge 
letter and database 
Coronary 
angiogram results  
No 
Manual extraction of information from clinical 
system 
Cardiac 
investigations/ 
imaging  
No 
Manual extraction from clinical systems and 
imaging reports 
Medical 
management  
No 
Manual extraction from discharge summary 
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Table 7.2. Baseline characteristics of patients by heart rate level 
 <60 bpm 
(N=570) 
60-69bpm 
(N=807) 
70-79 bpm 
(N=696) 
80-89bpm 
(N= 421) 
90-150bpm 
(N=347)  Mea
n 
(%) 
SD Mea
n 
(%) 
SD Mea
n 
(%) 
SD Mea
n 
(%) 
SD Mea
n 
(%) 
SD 
Demographic 
factors 
          
Age at entry (years) 62.1 12.
3 
59.9 12.
3 
57.0 12.
6 
55.0 12.
4 
56.8 12.
2 Women 72.7  62.7  62.5  58.0  56.6  
White Ethnicity 65.5  63.0  60.0  59.2  59.9  
Age of education 
completion 
18.3 7.3
8 
18.0 6.8
7 
19.3 9.2
4 
19.0 7.4
9 
17.8 5.4
3 Clinical biomarkers 
and risk factors 
          
Heart rate 
(continuous) (bpm) 
54.0 4.4
7 
64.6 2.7
9 
74.1 2.8
6 
83.7 2.7
9 
97.9 9.4
0 Systolic lood 
pressure, (mmHg) 
132.
6 
22.
3 
132.
3 
20.
4 
128.
5 
18.
6 
139.
4 
19.
3 
131.
9 
20.
2 Dia tolic blood 
pressure, (mmHg) 
73.9 11.
8 
78.1 11.
4 
78.5 11.
2 
80.1 10.
3 
80.8 11.
3 Hypercholesterole
mia  
58.2  54.8  48.2  46.5  53.6  
BMI (kg/m2 ) 28.8 4.9
6 
29.1 5.5
6 
29.4 5.2
0 
30.7 5.6
5 
30.2 6.0
6 Smoking           
Non-smokers 30.2  39.9  43.6  47.8  40.7  
Ex-smoker 47.1  35.1  30.8  25.6  29.0  
Current smoker 22.6  24.9  25.5  26.5  30.2  
Diabetes type  II 20.6  28.3  22.1  14.1  14.7  
Medication           
Beta-blockers 24.9  15.4
9 
 10.0  6.65  8.36  
Calcium channel 
blockers 
11.0  8.80  9.48  9.03  12.9  
BP m dication 32.9  27.8  23.2  20.4  24.7  
Statins 30.3  23.1  19.1  19.2  22.1  
Antiplatelets 26.4  8.78  20.8  16.2  14.2  
Note: Values are means ± standard deviation or % in categorical variables 
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Table 7.2 Clinical symptoms and assessment of CAD patients by heart rate level 
 <60bpm 
N=3315 
60-
69bpm 
n=2089 
70-79bpm 
n=1226  
80-89bpm >90bpm 
Symptoms on 
presentation  
     
     Shortness of breath 30.5 33.1 34.9 27.6 37.3 
Cardiac history      
     Ischaemic/coronary 
heart disease 
37.5 30.9 23.9 16.15 19.6 
     Acute myocardial 
infarction (AMI) 
21.4 11.7 6.75 4.04 6.92 
     Unstable angina 1.75 0.74 0.72 0.24 0.29 
     Heart failure 3.33 2.11 1.72 1.19 2.02 
Investigations 
performed (index 
procedure) 
     
Invasive coronary 
angiogram 
77.4 55.27 45.4 33.5 40.0 
Coronary computed 
tomography (CT) 
     angiogram 
3.33         6.07 7.90 9.74 6.92 
Angiogram 
assessment 
     
     Nor al angiogram  19.7 25.0 25.0 15.7 14.5 
     Non-obstructive 
CAD 
20.6 29.1 25.8 17.3 7.04 
     1 diseased vessel  23.5 19.5 14.2 0.00 16.6 
     2 diseased vessels 35.2 34.1 39.2 66.6 16.6 
     3 diseased vessels 41.1 46.3 46.4 33.3 66.6 
Note:  CAD: coronary artery disease; Values are % 
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Table 7.4 Baseline health questionnaire responses of the Clinical Cohorts in Coronary disease 
Collaboration (4C) study cohort.  
Questionnaire Heart rate 
 <60bpm 
N=519 
 
60-
69bpm 
N=719 
70-
79bpm 
N=610 
80-
89bpm 
N=358 
>90bpm 
N=292 Functional health status (EQ-
5D)181 
     
Mobility      
No problem reported 61.27 60.64 60.98 63.69 53.77 
Any problem reported 38.73 39.36 39.02 36.31 46.23 
Self-care:          
No problem reported  87.09 86.15 87.07 85.83 82.53 
Any problem reported 12.91 13.85 12.93 14.17 17.47 
Usual activities:          
No problem reported  61.92 66.25 65.52 69.36 54.45 
Any problem reported  38.08 33.75 34.48 30.64 45.55 
Pain/discomfort       
No problem reported  25.92 23.78 20.50 21.88 17.99 
Any problem reported  74.08 76.22 79.50 78.13 82.01 
Anxiety/depression:       
No problem reported  59.30 53.38 51.75 56.29 48.04 
Any problem reported 40.70 46.62 48.25 43.71 51.96 
Rose angina182      
   Chest pain  89.30 86.00 85.06 80.05 81.27 
   Non-cardiac chest pain  7.84 7.84 20.03 25.85 18.52 
Canadian Cardiovascular Society 
(CCS) classification183   
     
      I  15.63 32.29 27.08 11.46 13.54 
      II 26.47 32.35 14.71 16.18 10.29 
      III 11.89 25.26 27.90 19.82 15.12 
      IV  18.18 9.09 27.27 9.09 36.36 
Mental health      
Depression (PHQ-9)185 2.98 5.20 4.74 4.28 6.92 
Note: Values are (%); PHQ-9: Patient Health Questionnaire 
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Table 7.5 Follow-up for hospitalisations and mortality in the Clinical Cohorts in Coronary disease 
Collaboration (4C) cohort. 
 Office for 
National 
Statistics 
(ONS) 
(mortality) 
Hospital Episode 
Statistics (HES) (non-
fatal diagnoses and 
procedures)* 
Patients who consented to follow-up (of 
3345 recruited to 4C) 
3315 (99.1%) 3315 (99.1%)  
N (%) patients sent for matching  3315 (100%)  867 (26.2%)*  
N (%) patients matched to record 3311 (99.9%) 839 (96.7%)* 
Follow-up (months): Median (inter-
quartile range)  
20 (14-26) 326 (155-563) 
Observed N (%) participants with 
endpoint from ONS 
  
All-cause deaths 110 (2.5%)  - 
Cause of death registered 54 (64.3%) - 
CHD-related deaths (ICD-10 codes 
I20-25**) 
25 (46.3%) - 
Non-CHD CVD-related deaths (ICD-10 
codes: I010 to 99, excluding I200 to 
259***) 
9 (16.7%) - 
Non-CVD deaths 20 (37.3%) - 
Awaiting cause of death registration 30 (35.7%) - 
Observed N (%) participants with 
endpoint from HES: 
  
Non-fatal AMI + non-fatal stroke + 
peripheral arterial disease  
- 27 (3.2%) 
Approxim te annual ri k (%) 1.3 3.6 
AMI: acute myocardial infarction; CHD: coronary heart disease; CVD: cardiovascular disease 
*Updated HES data are awaiting release by the NHS Information Centre  
** International Classification of Diseases (ICD-10) codes I20 angina pectoris; I21 ST elevation 
myocardial infarction (STEMI) and non-ST elevation myocardial infarction (NSTEMI); I22 
Subsequent STEMI and NSTEMI; I23 Certain current complications following STEMI and 
NSTEMI (within 28 day period); I24 Other acute ischaemic heart diseases; and I25 Chronic 
ischaemic heart disease ***I010 to I99, excluding I200 Unstable Angina to I259 Chronic 
ischaemic heart disease, unspecified 
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